SE|1||ti|1|text|14|78|Formate assay in body fluids: application in methanol poisoning.
SE|1||ti|1|entity|C0016572|Formates|orch|||Formate|||0|888|14|21
SE|1||ti|1|entity|C1510438|Assay|lbpr|||assay|||0|888|22|27
SE|1||ti|1|entity|C0005889|Body Fluids|bdsu|||body fluids|||0|1000|31|42
SE|1||ti|1|entity|C0392621|Methyl alcohol poisoning|inpo|||methanol poisoning|||0|1000|59|77
SE|1||ti|1|relation|3|3|C1510438|Assay|lbpr|lbpr|||assay|||0|888|22|27|PREP|DIAGNOSES||56|58|1|1|C0392621|Methyl alcohol poisoning|inpo|inpo|||methanol poisoning|||0|1000|59|77


SE|2||ti|1|text|14|132|Delineation of the intimate details of the backbone conformation of pyridine nucleotide coenzymes in aqueous solution.
SE|2||ti|1|entity|C1522508|Details|qlco|||details|||0|861|42|49
SE|2||ti|1|entity|C0037949|Vertebral column|bpoc|||backbone|||0|694|57|65
SE|2||ti|1|entity|C0597331|pyridine nucleotide|nnon|||pyridine nucleotide|||0|901|82|101
SE|2||ti|1|entity|C0009235|Coenzymes|bacs,orch|||coenzymes|||0|901|102|111
SE|2||ti|1|entity|C0599956|Aqueous|qlco|||aqueous|||0|888|115|122
SE|2||ti|1|entity|C0037633|Solutions|sbst|||solution|||0|888|123|131


SE|3||ti|1|text|14|81|Metal substitutions incarbonic anhydrase: a halide ion probe study.
SE|3||ti|1|entity|C0025552|Metals|inch|||Metal|||0|566|14|19
SE|3||ti|1|entity|C1555721|Substitution|idcn|||substitutions|||0|566|20|33
SE|3||ti|1|entity|C0457555|Halide|inch|||halide|||0|833|58|64
SE|3||ti|1|entity|C0022023|Ions|elii|||ion|||0|833|65|68
SE|3||ti|1|entity|C0182400|Probes|medd|||probe|||0|833|69|74
SE|3||ti|1|entity|C0008972|Clinical Research|resa|||study|||0|833|75|80
SE|3||ti|1|relation|0|0|C0008972|Clinical Research|resa|resa|||study|||0|833|75|80|MOD/HEAD|USES||69|80|0|0|C0182400|Probes|medd|medd|||probe|||0|833|69|74


SE|4||ti|1|text|14|124|Effect of chloroquine on cultured fibroblasts: release of lysosomal hydrolases and inhibition of their uptake.
SE|4||ti|1|entity|C1280500|Effect|qlco|||Effect|||0|1000|14|20
SE|4||ti|1|entity|C0008269|Chloroquine|orch,phsu|||chloroquine|||0|1000|24|35
SE|4||ti|1|entity|C0010453|Anthropological Culture|idcn|||cultured|||0|853|39|47
SE|4||ti|1|entity|C0016030|Fibroblasts|cell|||fibroblasts|||0|853|48|59
SE|4||ti|1|entity|C0521450|Lysosomal|blor|||lysosomal|||0|888|72|81
SE|4||ti|1|entity|C0020289|Hydrolase|aapp,enzy|||hydrolases|||0|888|82|92
SE|4||ti|1|entity|C0243144|uptake|phsf|||uptake|||0|1000|117|123
SE|4||ti|1|relation|0|0|C0020289|Hydrolase|aapp,gngm,enzy|gngm|||hydrolases|||0|888|82|92|MOD/HEAD|PART_OF||72|92|0|0|C0521450|Lysosomal|blor|blor|||lysosomal|||0|888|72|81
SE|4||ti|1|relation|6|1|C0008269|Chloroquine|orch,phsu|orch|||chloroquine|||0|1000|24|35|NOM|AFFECTS||14|20|6|2|C0016030|Fibroblasts|cell|cell|||fibroblasts|||0|853|48|59


SE|5||ti|1|text|14|92|Atomic models for the polypeptide backbones of myohemerythrin and hemerythrin.
SE|5||ti|1|entity|C0567415|Atom|elii|||Atomic|||0|623|14|20
SE|5||ti|1|entity|C1305923|Polypeptides|aapp|||polypeptide|||0|872|36|47
SE|5||ti|1|entity|C0037949|Vertebral column|bpoc|||backbones|||0|872|48|57
SE|5||ti|1|entity|C0067056|myohemerythrin|aapp|||myohemerythrin|||0|1000|61|75
SE|5||ti|1|entity|C0018976|Hemerythrin|aapp,bacs|||hemerythrin|||0|1000|80|91


SE|6||ti|1|text|14|70|Studies of oxygen binding energy to hemoglobin molecule.
SE|6||ti|1|entity|C0008972|Clinical Research|resa|||Studies|||0|966|14|21
SE|6||ti|1|entity|C0030054|Oxygen|elii,phsu|||oxygen|||0|802|25|31
SE|6||ti|1|entity|C0424589|Vitality|fndg|||energy|||0|802|40|46
SE|6||ti|1|entity|C0019046|Hemoglobin|aapp,bacs|||hemoglobin|||0|888|50|60
SE|6||ti|1|entity|C0567416|Molecule|sbst|||molecule|||0|888|61|69


SE|7||ti|1|text|14|53|Maturation of the adrenal medulla--IV.
SE|7||ti|1|entity|C0001629|Adrenal Medulla|bpoc|||adrenal medulla|||0|1000|32|47

SE|7||ti|2|text|53|73|Effects of morphine.
SE|7||ti|2|entity|C1280500|Effect|qlco|||Effects|||0|966|53|60
SE|7||ti|2|entity|C0026549|Morphine|orch,phsu|||morphine|||0|1000|64|72


SE|8||ti|1|text|14|119|Comparison between procaine and isocarboxazid metabolism in vitro by a liver microsomal amidase-esterase.
SE|8||ti|1|entity|C0033218|Procaine|orch,phsu|||procaine|||0|1000|33|41
SE|8||ti|1|entity|C0022154|Isocarboxazid|orch,phsu|||isocarboxazid|||0|888|46|59
SE|8||ti|1|entity|C0025519|Metabolism|orgf|||metabolism|||0|888|60|70
SE|8||ti|1|entity|C1533691|in vitro|qlco|||in vitro|||0|1000|71|79
SE|8||ti|1|entity|C0026030|Microsomes, Liver|celc|||liver microsomal|||0|843|85|101
SE|8||ti|1|entity|C0051581|amidase|aapp,enzy|||amidase|||0|843|102|109
SE|8||ti|1|entity|C0014894|ESTERASE|aapp,enzy|||esterase|||0|843|110|118
SE|8||ti|1|relation|4|1|C0033218|Procaine|orch,phsu|orch|||procaine|||0|1000|33|41|NOM|compared_with||14|24|4|2|C0022154|Isocarboxazid|orch,phsu|orch|||isocarboxazid|||0|888|46|59


SE|9||ti|1|text|14|129|Radiochemical assay of glutathione S-epoxide transferase and its enhancement by phenobarbital in rat liver in vivo.
SE|9||ti|1|entity|C0599914|radiochemical|chvf|||Radiochemical|||0|888|14|27
SE|9||ti|1|entity|C1510438|Assay|lbpr|||assay|||0|888|28|33
SE|9||ti|1|entity|C0014630|Epoxy Compounds|orch|||epoxide|||0|916|51|58
SE|9||ti|1|entity|C0017837|Glutathione S-Transferase|aapp,enzy|||glutathione S-epoxide transferase|||0|916|37|70
SE|9||ti|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital|||0|1000|94|107
SE|9||ti|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|888|111|114
SE|9||ti|1|entity|C0023884|Liver|bpoc|||liver|||0|888|115|120
SE|9||ti|1|entity|C1515655|in vivo|spco|||in vivo|||0|1000|121|128
SE|9||ti|1|relation|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|888|115|120|MOD/HEAD|PART_OF||111|120|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|888|111|114
SE|9||ti|1|relation|2|1|C0023884|Liver|bpoc|bpoc|||liver|||0|888|115|120|PREP|LOCATION_OF||108|110|4|1|C0031412|Phenobarbital|orch,phsu|orch|||phenobarbital|||0|1000|94|107


SE|10||ti|1|text|15|60|Digitoxin metabolism by rat liver microsomes.
SE|10||ti|1|entity|C0012258|Digitoxin|bacs,carb,phsu,strd|||Digitoxin|||0|888|15|24
SE|10||ti|1|entity|C0025519|Metabolism|orgf|||metabolism|||0|888|25|35
SE|10||ti|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|901|39|42
SE|10||ti|1|entity|C0026030|Microsomes, Liver|celc|||liver microsomes|||0|901|43|59
SE|10||ti|1|relation|0|0|C0026030|Microsomes, Liver|celc|celc|||liver microsomes|||0|901|43|59|MOD/HEAD|PART_OF||39|59|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|901|39|42


SE|11||ti|1|text|15|131|Identification of adenylate cyclase-coupled beta-adrenergic receptors with radiolabeled beta-adrenergic antagonists.
SE|11||ti|1|entity|C0001492|Adenylate Cyclase|aapp,enzy|||adenylate cyclase|||0|853|33|50
SE|11||ti|1|entity|C0034785|beta-adrenergic receptor|aapp,rcpt|||beta-adrenergic receptors|||0|853|59|84
SE|11||ti|1|entity|C1527121|Radiolabeled|qlco|||radiolabeled|||0|908|90|102
SE|11||ti|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-adrenergic antagonists|||0|908|103|130


SE|12||ti|1|text|15|166|The effect of adrenaline and of alpha- and beta-adrenergic blocking agents on ATP concentration and on incorporation of 32Pi into ATP in rat fat cells.
SE|12||ti|1|entity|C1280500|Effect|qlco|||effect|||0|1000|19|25
SE|12||ti|1|entity|C0014563|Epinephrine|horm,nsba,orch,phsu|||adrenaline|||0|1000|29|39
SE|12||ti|1|entity|C0439095|Alpha|inpr|||alpha|||0|1000|47|52
SE|12||ti|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-adrenergic blocking agents|||0|1000|58|89
SE|12||ti|1|entity|C1366628|ATP8A2 gene|gngm|51761|ATP8A2|ATP|||0|694|93|96
SE|12||ti|1|entity|C0243126|incorporation|ftcn|||incorporation|||0|1000|118|131
SE|12||ti|1|entity|C1366628|ATP8A2 gene|gngm|51761|ATP8A2|ATP|||0|1000|145|148
SE|12||ti|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|901|152|155
SE|12||ti|1|entity|C0206131|Adipocytes|cell|||fat cells|||0|901|156|165
SE|12||ti|1|relation|0|0|C0206131|Adipocytes|cell|cell|||fat cells|||0|901|156|165|MOD/HEAD|PART_OF||152|165|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|901|152|155
SE|12||ti|1|relation|1|1|C0206131|Adipocytes|cell|cell|||fat cells|||0|901|156|165|PREP|LOCATION_OF||149|151|8|1|C1366628|ATP8A2 gene|gngm,aapp|aapp|51761|ATP8A2|ATP|||0|1000|145|148


SE|13||ti|1|text|15|128|Action of propranolol on mitochondrial functions--effects on energized ion fluxes in the presence of valinomycin.
SE|13||ti|1|entity|C0033497|Propranolol|orch,phsu|||propranolol|||0|1000|25|36
SE|13||ti|1|entity|C0521451|Mitochondrial|ftcn|||mitochondrial|||0|888|40|53
SE|13||ti|1|entity|C0542341|Function|ftcn|||functions|||0|888|54|63
SE|13||ti|1|entity|C1280500|Effect|qlco|||effects|||0|966|65|72
SE|13||ti|1|entity|C0022023|Ions|elii|||ion|||0|660|86|89
SE|13||ti|1|entity|C0042287|Valinomycin|aapp,antb|||valinomycin|||0|1000|116|127
SE|13||ti|1|relation|5|4|C0033497|Propranolol|orch,phsu|orch|||propranolol|||0|1000|25|36|NOM|COEXISTS_WITH||104|112|1|1|C0042287|Valinomycin|aapp,gngm,antb|aapp|||valinomycin|||0|1000|116|127


SE|14||ti|1|text|15|60|Malathion A and B esterases of mouse liver-I.
SE|14||ti|1|entity|C0024547|Malathion|hops,opco,phsu|||Malathion|||0|1000|15|24
SE|14||ti|1|entity|C0054741|carboxylesterase|aapp,enzy|||B esterases|||0|983|31|42
SE|14||ti|1|entity|C0025914|House mice|mamm|||mouse|||0|888|46|51
SE|14||ti|1|entity|C0023884|Liver|bpoc|||liver|||0|888|52|57
SE|14||ti|1|relation|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|888|52|57|MOD/HEAD|PART_OF||46|57|0|0|C0025914|House mice|mamm|mamm|||mouse|||0|888|46|51
SE|14||ti|1|relation|2|1|C0054741|carboxylesterase|aapp,gngm,enzy|aapp|||B esterases|||0|983|31|42|PREP|PART_OF||43|45|1|1|C0023884|Liver|bpoc|bpoc|||liver|||0|888|52|57


SE|15||ti|1|text|15|88|Increase in acetyl CoA synthetase activity after phenobarbital treatment.
SE|15||ti|1|entity|C0442805|Increase|ftcn|||Increase|||0|1000|15|23
SE|15||ti|1|entity|C0001028|Acetate-CoA Ligase|aapp,enzy|||acetyl CoA synthetase|||0|916|27|48
SE|15||ti|1|entity|C0747568|PHENOBARBITAL TREATMENT|topp|||phenobarbital treatment|||0|1000|64|87


SE|16||ti|1|text|15|93|Inhibition of aldehyde reductase by acidic metabolites of the biogenic amines.
SE|16||ti|1|entity|C0002003|Aldehyde Reductase|aapp,enzy|||aldehyde reductase|||0|1000|29|47
SE|16||ti|1|entity|C0001128|Acids|chem|||acidic|||0|853|51|57
SE|16||ti|1|entity|C0870883|Metabolites|bacs|||metabolites|||0|853|58|69
SE|16||ti|1|entity|C0005496|Biogenic Amines|horm,nsba,orch,phsu|||biogenic amines|||0|1000|77|92


SE|17||ti|1|text|15|131|Effects of 5,6-dihydroxytryptamine on tyrosine-hydroxylase activity in central catecholaminergic neurons of the rat.
SE|17||ti|1|entity|C1280500|Effect|qlco|||Effects|||0|966|15|22
SE|17||ti|1|entity|C0012338|Dihydroxytryptamines|orch,phsu|||dihydroxytryptamine|||0|861|30|49
SE|17||ti|1|entity|C0041491|Tyrosine 3-Monooxygenase|aapp,enzy|||tyrosine-hydroxylase|||0|901|53|73
SE|17||ti|1|entity|C0682701|central neuron|cell|||central catecholaminergic neurons|||0|896|86|119
SE|17||ti|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|1000|127|130
SE|17||ti|1|relation|2|1|C0682701|central neuron|cell|cell|||central catecholaminergic neurons|||0|896|86|119|PREP|LOCATION_OF||83|85|3|1|C0041491|Tyrosine 3-Monooxygenase|aapp,gngm,enzy|aapp|||tyrosine-hydroxylase|||0|901|53|73
SE|17||ti|1|relation|4|1|C0012338|Dihydroxytryptamines|orch,phsu|orch|||dihydroxytryptamine|||0|861|30|49|NOM|INTERACTS_WITH||15|22|4|2|C0041491|Tyrosine 3-Monooxygenase|aapp,gngm,enzy|aapp|||tyrosine-hydroxylase|||0|901|53|73
SE|17||ti|1|relation|4|1|C0682701|central neuron|cell|cell|||central catecholaminergic neurons|||0|896|86|119|PREP|PART_OF||120|122|1|1|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|1000|127|130


SE|18||ti|1|text|15|82|Inhibition of aldehyde reductase isoenzymes in human and rat brain.
SE|18||ti|1|entity|C0002003|Aldehyde Reductase|aapp,enzy|||aldehyde reductase|||0|901|29|47
SE|18||ti|1|entity|C0022173|Isoenzymes|aapp,enzy|||isoenzymes|||0|901|48|58
SE|18||ti|1|entity|C0020114|Human|humn|||human|||0|1000|62|67
SE|18||ti|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|888|72|75
SE|18||ti|1|entity|C0006104|Brain|bpoc|||brain|||0|888|76|81
SE|18||ti|1|relation|0|0|C0006104|Brain|bpoc|bpoc|||brain|||0|888|76|81|MOD/HEAD|PART_OF||72|81|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|888|72|75
SE|18||ti|1|relation|2|1|C0020114|Human|grup,humn|humn|||human|||0|1000|62|67|PREP|LOCATION_OF||59|61|2|1|C0002003|Aldehyde Reductase|aapp,gngm,enzy|aapp|||aldehyde reductase|||0|901|29|47
SE|18||ti|1|relation|2|1|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|888|72|75|PREP|LOCATION_OF||59|61|2|1|C0002003|Aldehyde Reductase|aapp,gngm,enzy|aapp|||aldehyde reductase|||0|901|29|47


SE|19||ti|1|text|15|59|Antidepressant drugs affect dopamine uptake.
SE|19||ti|1|entity|C0003289|Antidepressive Agents|phsu|||Antidepressant drugs|||0|1000|15|35
SE|19||ti|1|entity|C0013030|Dopamine|nsba,orch,phsu|||dopamine|||0|888|43|51
SE|19||ti|1|entity|C0243144|uptake|phsf|||uptake|||0|888|52|58
SE|19||ti|1|relation|1|1|C0003289|Antidepressive Agents|phsu|phsu|||Antidepressant drugs|||0|1000|15|35|VERB|AFFECTS||36|42|1|1|C0243144|uptake|phsf|phsf|||uptake|||0|888|52|58


SE|20||ti|1|text|15|75|Aggregation of blood platelets by adrenaline and its uptake.
SE|20||ti|1|entity|C0332621|Aggregation|ftcn|||Aggregation|||0|1000|15|26
SE|20||ti|1|entity|C0005821|Blood Platelets|cell|||blood platelets|||0|1000|30|45
SE|20||ti|1|entity|C0014563|Epinephrine|horm,nsba,orch,phsu|||adrenaline|||0|1000|49|59
SE|20||ti|1|entity|C0243144|uptake|phsf|||uptake|||0|1000|68|74


SE|21||ti|1|text|15|155|[Biochemical studies on camomile components/III. In vitro studies about the antipeptic activity of (--)-alpha-bisabolol (author's transl)].
SE|21||ti|1|entity|C0205474|Biochemical|ftcn|||Biochemical|||0|872|16|27
SE|21||ti|1|entity|C0008972|Clinical Research|resa|||studies|||0|872|28|35
SE|21||ti|1|entity|C0752226|Chamomile|plnt|||camomile|||0|813|39|47
SE|21||ti|1|entity|C1524073|Component, LOINC Axis 1|clas|||components|||0|813|48|58
SE|21||ti|1|entity|C0439070|III|inpr|||III|||0|813|59|62
SE|21||ti|1|entity|C1533691|in vitro|qlco|||In vitro|||0|813|64|72
SE|21||ti|1|entity|C0008972|Clinical Research|resa|||studies|||0|813|73|80
SE|21||ti|1|entity|C0439095|Alpha|inpr|||alpha|||0|888|119|124
SE|21||ti|1|entity|C0053774|bisabolol|orch,phsu|||bisabolol|||0|888|125|134
SE|21||ti|1|entity|C0221192|Author|idcn,prog|||author's|||0|694|136|144

SE|21||ab|1|text|161|289|(--)-alpha-Bisabolol has a primary antipeptic action depending on dosage, which is not caused by an alteration of the pH-value.
SE|21||ab|1|entity|C0439095|Alpha|inpr|||alpha|||0|888|166|171
SE|21||ab|1|entity|C0053774|bisabolol|orch,phsu|||Bisabolol|||0|888|172|181
SE|21||ab|1|entity|C0178602|Dosages|qnco|||dosage|||0|1000|227|233
SE|21||ab|1|entity|C1518422|Not|ftcn|||not|||0|1000|244|247
SE|21||ab|1|entity|C1515926|Alteration|idcn|||alteration|||0|1000|261|271

SE|21||ab|2|text|289|402|The proteolytic activity of pepsin is reduced by 50 percent through addition of bisabolol in the ratio of 1/0.5.
SE|21||ab|2|entity|C0030946|Endopeptidases|aapp,enzy,phsu|||proteolytic|||0|888|293|304
SE|21||ab|2|entity|C0442796|Additive|qlco|||addition|||0|928|357|365
SE|21||ab|2|entity|C0053774|bisabolol|orch,phsu|||bisabolol|||0|1000|369|378
SE|21||ab|2|entity|C0456603|Ratio|inpr|||ratio|||0|1000|386|391
SE|21||ab|2|entity|C0450316|1/5|qnco|||1/0.5|||0|913|395|400

SE|21||ab|3|text|402|476|The antipeptic action of bisabolol only occurs in case of direct contact.
SE|21||ab|3|entity|C0053774|bisabolol|orch,phsu|||bisabolol|||0|1000|427|436

SE|21||ab|4|text|476|556|In case of a previous contact with the substrate, the inhibiting effect is lost.
SE|21||ab|4|entity|C0205156|Previous|tmco|||previous|||0|694|489|497
SE|21||ab|4|entity|C0311403|Inhibited|qlco|||inhibiting|||0|872|530|540
SE|21||ab|4|entity|C1280500|Effect|qlco|||effect|||0|872|541|547


SE|22||ti|1|text|15|332|[Demonstration of tumor inhibiting properties of a strongly immunostimulating low-molecular weight substance. Comparative studies with ifosfamide on the immuno-labile DS carcinosarcoma. Stimulation of the autoimmune activity for approx. 20 days by BA 1, a N-(2-cyanoethylene)-urea. Novel prophylactic possibilities].
SE|22||ti|1|entity|C0027651|Neoplasm|neop|||tumor|||0|829|33|38
SE|22||ti|1|entity|C0311403|Inhibited|qlco|||inhibiting|||0|829|39|49
SE|22||ti|1|entity|C0871161|Property|qlco|||properties|||0|829|50|60
SE|22||ti|1|entity|C1521991|Molecular|qlco|||molecular|||0|839|97|106
SE|22||ti|1|entity|C0041667|Underweight|fndg|||low-molecular weight|||0|839|93|113
SE|22||ti|1|entity|C0439861|Substance|sbst|||substance|||0|839|114|123
SE|22||ti|1|entity|C0009491|comparative study publication|inpr|||Comparative studies|||0|839|125|144
SE|22||ti|1|entity|C0020823|Ifosfamide|opco,phsu|||ifosfamide|||0|1000|150|160
SE|22||ti|1|entity|C0007140|Carcinosarcoma|neop|||carcinosarcoma|||0|736|185|199
SE|22||ti|1|entity|C0443146|Autoimmune|patf|||autoimmune|||0|888|220|230
SE|22||ti|1|entity|C0439228|day|tmco|||days|||0|827|255|259
SE|22||ti|1|entity|C0969767|BA 1|orch,phsu|||BA 1|||0|1000|263|267
SE|22||ti|1|entity|C0041942|Urea|bacs,orch,phsu|||urea|||0|608|291|295
SE|22||ti|1|entity|C0679622|novel|inpr|||Novel|||0|608|297|302
SE|22||ti|1|relation|5|3|C0969767|BA 1|orch,phsu|orch|||BA 1|||0|1000|263|267|NOM|AUGMENTS||201|212|5|1|C0443146|Autoimmune|patf|patf|||autoimmune|||0|888|220|230

SE|22||ab|1|text|338|498|A report is given on the recent discovery of outstanding immunological properties in BA 1 [N-(2-cyanoethylene)-urea] having a (low) molecular mass M = 111.104.
SE|22||ab|1|entity|C0332185|Recent|tmco|||recent|||0|694|363|369
SE|22||ab|1|entity|C0205470|immunologic|ftcn|||immunological|||0|773|395|408
SE|22||ab|1|entity|C0871161|Property|qlco|||properties|||0|773|409|419
SE|22||ab|1|entity|C0969767|BA 1|orch,phsu|||BA 1|||0|1000|423|427
SE|22||ab|1|entity|C0041942|Urea|bacs,orch,phsu|||urea|||0|1000|449|453
SE|22||ab|1|entity|C0205251|low|qlco|||low|||0|1000|465|468
SE|22||ab|1|entity|C0598892|Molecular Mass|qnco|||molecular mass|||0|901|470|484

SE|22||ab|2|text|498|786|Experiments in 214 DS carcinosarcoma bearing Wistar rats have shown that BA 1, at a dosage of only about 12 percent LD50 (150 mg kg) and negligible lethality (1.7 percent), results in a recovery rate of 40 percent without hyperglycemia and, in one test, of 80 percent with hyperglycemia.
SE|22||ab|2|entity|C0681814|research study|resa|||Experiments|||0|1000|498|509
SE|22||ab|2|entity|C0007140|Carcinosarcoma|neop|||carcinosarcoma|||0|756|520|534
SE|22||ab|2|entity|C0034716|Rats, Wistar|mamm|||Wistar rats|||0|756|543|554
SE|22||ab|2|entity|C0969767|BA 1|orch,phsu|||BA 1|||0|1000|571|575
SE|22||ab|2|entity|C0178602|Dosages|qnco|||dosage|||0|1000|582|588
SE|22||ab|2|entity|C0023378|Lethal Dose 50|qnco|||LD50|||0|804|614|618
SE|22||ab|2|entity|C0332269|Negligible|ftcn,qlco|||negligible|||0|838|635|645
SE|22||ab|2|entity|C1031740|Lethe|invt|||lethality|||0|838|646|655
SE|22||ab|2|entity|C0237820|Recovery|orgf|||recovery|||0|888|684|692
SE|22||ab|2|entity|C1521828|Rate|qnco|||rate|||0|888|693|697
SE|22||ab|2|entity|C0020456|Hyperglycemia|dsyn|||hyperglycemia|||0|1000|720|733
SE|22||ab|2|entity|C0205447|One|qnco|||one|||0|888|742|745
SE|22||ab|2|entity|C0039593|Testing|resa|||test|||0|888|746|750
SE|22||ab|2|entity|C0020456|Hyperglycemia|dsyn|||hyperglycemia|||0|1000|771|784

SE|22||ab|3|text|786|1075|Under otherwise unchanged conditions the reference substance ifosfamide (IF) -- a further development of cyclophosphamide -- applied without hyperglycemia in its most efficient dosage of 47 percent LD50 (150 mg kg) brought about a recovery rate of 25 percent at a lethality of 18 percent.
SE|22||ab|3|entity|C1514811|Reference|idcn|||reference|||0|851|827|836
SE|22||ab|3|entity|C0439861|Substance|sbst|||substance|||0|851|837|846
SE|22||ab|3|entity|C0020823|Ifosfamide|opco,phsu|||ifosfamide|||0|851|847|857
SE|22||ab|3|entity|C1517331|Further|spco|||further|||0|888|868|875
SE|22||ab|3|entity|C1527148|Development|ftcn|||development|||0|888|876|887
SE|22||ab|3|entity|C0010583|Cyclophosphamide|opco,phsu|||cyclophosphamide|||0|1000|891|907
SE|22||ab|3|entity|C0020456|Hyperglycemia|dsyn|||hyperglycemia|||0|1000|927|940
SE|22||ab|3|entity|C0205393|Most|qnco|||most|||0|851|948|952
SE|22||ab|3|entity|C0442799|Efficient|qlco|||efficient|||0|851|953|962
SE|22||ab|3|entity|C0178602|Dosages|qnco|||dosage|||0|851|963|969
SE|22||ab|3|entity|C0023378|Lethal Dose 50|qnco|||LD50|||0|827|984|988
SE|22||ab|3|entity|C0237820|Recovery|orgf|||recovery|||0|888|1017|1025
SE|22||ab|3|entity|C1521828|Rate|qnco|||rate|||0|888|1026|1030
SE|22||ab|3|entity|C1031740|Lethe|invt|||lethality|||0|900|1050|1059

SE|22||ab|4|text|1075|1169|(Contrary to BA 1, 250-min hyperglycemia caused no further improvement of the recovery rate.)
SE|22||ab|4|entity|C0969767|BA 1|orch,phsu|||BA 1|||0|1000|1088|1092
SE|22||ab|4|entity|C0439232|Minute of time|tmco|||min|||0|790|1098|1101
SE|22||ab|4|entity|C0020456|Hyperglycemia|dsyn|||hyperglycemia|||0|790|1102|1115
SE|22||ab|4|entity|C1517331|Further|spco|||further|||0|694|1126|1133
SE|22||ab|4|entity|C0237820|Recovery|orgf|||recovery|||0|888|1153|1161
SE|22||ab|4|entity|C1521828|Rate|qnco|||rate|||0|888|1162|1166

SE|22||ab|5|text|1169|1309|However this comparison is characterized by the fact that both substances exhibit two quite different (complementary) mechanisms of action.
SE|22||ab|5|entity|C0439861|Substance|sbst|||substances|||0|1000|1232|1242
SE|22||ab|5|entity|C0205448|Two|qnco|||two|||0|766|1251|1254
SE|22||ab|5|entity|C1547020|*Difference|qnco|||different|||0|766|1261|1270
SE|22||ab|5|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|1000|1287|1297

SE|22||ab|6|text|1309|1554|Leucocyte counts made after application of the said cancerostatics and dosages have shown a pronounced stimulation with BA 1 and with ifosfamide, the known suppression in the post-therapeutic interval usually found with standard cancerostatics.
SE|22||ab|6|entity|C0023508|White Blood Cell Count procedure|lbpr|||Leucocyte counts|||0|1000|1309|1325
SE|22||ab|6|entity|C0178602|Dosages|qnco|||dosages|||0|1000|1380|1387
SE|22||ab|6|entity|C0969767|BA 1|orch,phsu|||BA 1|||0|1000|1429|1433
SE|22||ab|6|entity|C0020823|Ifosfamide|opco,phsu|||ifosfamide|||0|1000|1443|1453
SE|22||ab|6|entity|C0205309|Known|qlco|||known|||0|888|1459|1464
SE|22||ab|6|entity|C1272706|Interval|tmco|||interval|||0|851|1501|1509
SE|22||ab|6|entity|C1442989|STANDARD|ftcn|||standard|||0|694|1529|1537

SE|22||ab|7|text|1554|1668|In combination with the cited plaque test for BA 1, blood pictures then allow conclusions on the immunity status.
SE|22||ab|7|entity|C0205195|Combined|qlco|||combination|||0|1000|1557|1568
SE|22||ab|7|entity|C0333463|Senile Plaques|acab|||plaque|||0|790|1584|1590
SE|22||ab|7|entity|C0039593|Testing|resa|||test|||0|790|1591|1595
SE|22||ab|7|entity|C0969767|BA 1|orch,phsu|||BA 1|||0|1000|1600|1604
SE|22||ab|7|entity|C0005767|Blood|tisu|||blood|||0|1000|1606|1611
SE|22||ab|7|entity|C0677637|Immune status|fndg|||immunity status|||0|964|1651|1666

SE|22||ab|8|text|1668|1899|Since IF can be taken as one of the most efficient cancerostatics--there is no other chemotherapeutic known up to now that has a more significant effect on the DS carcinosarcoma in rats -- these findings are of special importance.
SE|22||ab|8|entity|C0020823|Ifosfamide|opco,phsu|||IF|||0|1000|1674|1676
SE|22||ab|8|entity|C0205447|One|qnco|||one|||0|1000|1693|1696
SE|22||ab|8|entity|C0205393|Most|qnco|||most|||0|623|1704|1708
SE|22||ab|8|entity|C0442799|Efficient|qlco|||efficient|||0|623|1709|1718
SE|22||ab|8|entity|C0013216|Pharmacotherapy|topp|||chemotherapeutic|||0|853|1753|1769
SE|22||ab|8|entity|C0205309|Known|qlco|||known|||0|853|1770|1775
SE|22||ab|8|entity|C0205172|More|ftcn|||more|||0|851|1797|1801
SE|22||ab|8|entity|C0750502|Significant|idcn|||significant|||0|851|1802|1813
SE|22||ab|8|entity|C1280500|Effect|qlco|||effect|||0|851|1814|1820
SE|22||ab|8|entity|C0007140|Carcinosarcoma|neop|||carcinosarcoma|||0|888|1831|1845
SE|22||ab|8|entity|C0034693|Rattus norvegicus|mamm|||rats|||0|1000|1849|1853
SE|22||ab|8|entity|C0243095|Finding|ftcn|||findings|||0|1000|1863|1871
SE|22||ab|8|relation|4|4|C0020823|Ifosfamide|opco,phsu|opco|||IF|||0|1000|1674|1676|NOM|AFFECTS||1814|1820|4|1|C0007140|Carcinosarcoma|neop|neop|||carcinosarcoma|||0|888|1831|1845
SE|22||ab|8|relation|6|1|C0007140|Carcinosarcoma|neop|neop|||carcinosarcoma|||0|888|1831|1845|PREP|PROCESS_OF||1846|1848|3|1|C0034693|Rattus norvegicus|mamm|mamm|||rats|||0|1000|1849|1853

SE|22||ab|9|text|1899|2077|Finally, the total amount of leucocytes and lymphocytes as well as their time behaviour was determined from the blood picture of tumour-free rats after i.v. application of BA 1.
SE|22||ab|9|entity|C0439175|% of total|qnco|||total|||0|888|1912|1917
SE|22||ab|9|entity|C1265611|Quantity|qnco|||amount|||0|888|1918|1924
SE|22||ab|9|entity|C0023516|Leukocytes|cell|||leucocytes|||0|1000|1928|1938
SE|22||ab|9|entity|C0024264|Lymphocyte|cell|||lymphocytes|||0|1000|1943|1954
SE|22||ab|9|entity|C0040223|Time|tmco|||time|||0|888|1972|1976
SE|22||ab|9|entity|C0004927|Behavior|inbe|||behaviour|||0|888|1977|1986
SE|22||ab|9|entity|C0005767|Blood|tisu|||blood|||0|888|2011|2016
SE|22||ab|9|entity|C0441469|Picture|mnob|||picture|||0|888|2017|2024
SE|22||ab|9|entity|C0027651|Neoplasm|neop|||tumour|||0|802|2028|2034
SE|22||ab|9|entity|C0034693|Rattus norvegicus|mamm|||rats|||0|802|2040|2044
SE|22||ab|9|entity|C0969767|BA 1|orch,phsu|||BA 1|||0|1000|2071|2075

SE|22||ab|10|text|2077|2235|The thus obtained numerical values clearly show that further research work on the prophylactic use of this substance seems to be necessary and very promising.
SE|22||ab|10|entity|C1522609|Numerical value|qnco|||numerical values|||0|983|2095|2111
SE|22||ab|10|entity|C1517331|Further|spco|||further|||0|851|2130|2137
SE|22||ab|10|entity|C0035168|research|resa|||research|||0|851|2138|2146
SE|22||ab|10|entity|C0043227|Work|ocac|||work|||0|851|2147|2151
SE|22||ab|10|entity|C0679782|prophylactics use|inbe|||prophylactic use|||0|983|2159|2175
SE|22||ab|10|entity|C0439861|Substance|sbst|||substance|||0|1000|2184|2193
SE|22||ab|10|entity|C0442824|Very|qlco|||very|||0|872|2220|2224
SE|22||ab|10|entity|C1555307|promise|idcn|||promising|||0|872|2225|2234


SE|23||ti|1|text|15|80|Effect of etafenone on total and regional myocardial blood flow.
SE|23||ti|1|entity|C1280500|Effect|qlco|||Effect|||0|1000|15|21
SE|23||ti|1|entity|C0059677|etafenone|orch,phsu|||etafenone|||0|1000|25|34
SE|23||ti|1|entity|C0439175|% of total|qnco|||total|||0|1000|38|43
SE|23||ti|1|entity|C0027061|Myocardium|tisu|||myocardial|||0|916|57|67
SE|23||ti|1|entity|C0034965|Regional Blood Flow|ortf|||regional myocardial blood flow|||0|916|48|78
SE|23||ti|1|relation|0|0|C0027061|Myocardium|tisu|tisu|||myocardial|||0|916|57|67|MOD/HEAD|LOCATION_OF||57|78|0|0|C0034965|Regional Blood Flow|ortf|ortf|||regional myocardial blood flow|||0|916|48|78

SE|23||ab|1|text|86|358|The distribution of blood flow to the subendocardial, medium and subepicardial layers of the left ventricular free wall was studied in anaesthetized dogs under normoxic (A), hypoxic (B) conditions and under pharmacologically induced (etafenone) coronary vasodilation (C).
SE|23||ab|1|entity|C0520511|Distributing|idcn|||distribution|||0|1000|90|102
SE|23||ab|1|entity|C0232338|Blood flow|orgf|||blood flow|||0|1000|106|116
SE|23||ab|1|entity|C0439536|Medium|qlco|||medium|||0|861|140|146
SE|23||ab|1|entity|C0205091|Left|spco|||left|||0|824|179|183
SE|23||ab|1|entity|C0507618|Wall of ventricle|bpoc|||ventricular free wall|||0|824|184|205
SE|23||ab|1|entity|C0012984|Canis familiaris|mamm|||dogs|||0|861|235|239
SE|23||ab|1|entity|C0242184|Hypoxia|patf|||hypoxic|||0|1000|260|267
SE|23||ab|1|entity|C0348080|Condition|qlco|||conditions|||0|827|272|282
SE|23||ab|1|entity|C0059677|etafenone|orch,phsu|||etafenone|||0|1000|320|329
SE|23||ab|1|entity|C0596385|Coronary vasodilator|phsu|||coronary vasodilation|||0|950|331|352
SE|23||ab|1|relation|5|4|C0232338|Blood flow|orgf|orgf|||blood flow|||0|1000|106|116|PREP|PROCESS_OF||218|220|7|1|C0012984|Canis familiaris|mamm|mamm|||dogs|||0|861|235|239

SE|23||ab|2|text|358|450|Regional myocardial blood flow was determined by means of the particle distribution method.
SE|23||ab|2|entity|C0027061|Myocardium|tisu|||myocardial|||0|916|367|377
SE|23||ab|2|entity|C0034965|Regional Blood Flow|ortf|||Regional myocardial blood flow|||0|916|358|388
SE|23||ab|2|entity|C0597177|particle|chvs|||particle|||0|851|420|428
SE|23||ab|2|entity|C0520511|Distributing|idcn|||distribution|||0|851|429|441
SE|23||ab|2|entity|C0025663|Methods|inpr|||method|||0|851|442|448
SE|23||ab|2|relation|0|0|C0027061|Myocardium|tisu|tisu|||myocardial|||0|916|367|377|MOD/HEAD|LOCATION_OF||367|388|0|0|C0034965|Regional Blood Flow|ortf|ortf|||Regional myocardial blood flow|||0|916|358|388

SE|23||ab|3|text|450|620|In normoxia a transmural gradient of flow was observed, with the subendocardial layers receiving a significantly higher flow rate compared with the subepicardial layers.
SE|23||ab|3|entity|C0522497|Transmural|spco|||transmural|||0|888|464|474
SE|23||ab|3|entity|C0439182|% gradient|qnco|||gradient|||0|888|475|483
SE|23||ab|3|entity|C0806140|Flow|orga|||flow|||0|1000|487|491
SE|23||ab|3|entity|C1515017|Subendocardial Layer|bpoc|||subendocardial layers|||0|983|515|536
SE|23||ab|3|entity|C0205250|High|qlco|||higher|||0|764|563|569
SE|23||ab|3|entity|C0806140|Flow|orga|||flow|||0|764|570|574
SE|23||ab|3|entity|C1521828|Rate|qnco|||rate|||0|764|575|579

SE|23||ab|4|text|620|701|In hypoxia induced vasodilation this transmural gradient of flow was persistent.
SE|23||ab|4|entity|C0242184|Hypoxia|patf|||hypoxia|||0|1000|623|630
SE|23||ab|4|entity|C0042401|Vasodilation|phsf|||vasodilation|||0|1000|639|651
SE|23||ab|4|entity|C0522497|Transmural|spco|||transmural|||0|888|657|667
SE|23||ab|4|entity|C0439182|% gradient|qnco|||gradient|||0|888|668|676
SE|23||ab|4|entity|C0806140|Flow|orga|||flow|||0|1000|680|684
SE|23||ab|4|entity|C0205322|Persistent|tmco|||persistent|||0|1000|689|699

SE|23||ab|5|text|701|813|In contrast a marked redistribution of regional flow was observed under pharmacologically induced vasodilation.
SE|23||ab|5|entity|C0522501|Massive|qlco|||marked|||0|888|715|721
SE|23||ab|5|entity|C0332620|Redistribution|ftcn|||redistribution|||0|888|722|736
SE|23||ab|5|entity|C0205147|Region|spco|||regional|||0|888|740|748
SE|23||ab|5|entity|C0806140|Flow|orga|||flow|||0|888|749|753
SE|23||ab|5|entity|C0205263|Induced|ftcn|||induced|||0|790|791|798
SE|23||ab|5|entity|C0042401|Vasodilation|phsf|||vasodilation|||0|790|799|811

SE|23||ab|6|text|813|848|The transmural gradient decreased.
SE|23||ab|6|entity|C0522497|Transmural|spco|||transmural|||0|888|817|827
SE|23||ab|6|entity|C0439182|% gradient|qnco|||gradient|||0|888|828|836

SE|23||ab|7|text|848|1018|In contrast to some findings these experiments demonstrate that a considerable vasodilatory capacity exists in all layers of the myocardium and can be utilized by drugs.
SE|23||ab|7|entity|C0243095|Finding|ftcn|||findings|||0|1000|868|876
SE|23||ab|7|entity|C0681814|research study|resa|||experiments|||0|1000|883|894
SE|23||ab|7|entity|C0042401|Vasodilation|phsf|||vasodilatory|||0|754|927|939
SE|23||ab|7|entity|C1516240|Capacity|qnco|||capacity|||0|754|940|948
SE|23||ab|7|entity|C0027061|Myocardium|tisu|||myocardium|||0|1000|977|987
SE|23||ab|7|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs|||0|1000|1011|1016

SE|23||ab|8|text|1018|1243|The differences observed for the intramural distribution pattern of flow under hypoxia and drug induced vasodilation support the hypothesis that this pattern reflects corresponding gradients of regional myocardial metabolism.
SE|23||ab|8|entity|C1547020|*Difference|qnco|||differences|||0|966|1022|1033
SE|23||ab|8|entity|C0449775|Distribution pattern|spco|||distribution pattern|||0|901|1062|1082
SE|23||ab|8|entity|C0806140|Flow|orga|||flow|||0|1000|1086|1090
SE|23||ab|8|entity|C0242184|Hypoxia|patf|||hypoxia|||0|1000|1097|1104
SE|23||ab|8|entity|C0458082|Drug-induced|ftcn|||drug induced|||0|901|1109|1121
SE|23||ab|8|entity|C0042401|Vasodilation|phsf|||vasodilation|||0|901|1122|1134
SE|23||ab|8|entity|C1512571|Hypothesis|idcn|||hypothesis|||0|1000|1147|1157
SE|23||ab|8|entity|C0449774|Patterns|spco|||pattern|||0|1000|1168|1175
SE|23||ab|8|entity|C0439182|% gradient|qnco|||gradients|||0|827|1199|1208
SE|23||ab|8|entity|C0205147|Region|spco|||regional|||0|901|1212|1220
SE|23||ab|8|entity|C0428862|Myocardial metabolism|lbtr|||myocardial metabolism|||0|901|1221|1242


SE|24||ti|1|text|15|96|Influence of a new virostatic compound on the induction of enzymes in rat liver.
SE|24||ti|1|entity|C0205314|New|tmco|||new|||0|802|30|33
SE|24||ti|1|entity|C0205198|Compound|qlco|||compound|||0|802|45|53
SE|24||ti|1|entity|C0857127|Induction|topp|||induction|||0|1000|61|70
SE|24||ti|1|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|1000|74|81
SE|24||ti|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|888|85|88
SE|24||ti|1|entity|C0023884|Liver|bpoc|||liver|||0|888|89|94
SE|24||ti|1|relation|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|888|89|94|MOD/HEAD|PART_OF||85|94|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|888|85|88
SE|24||ti|1|relation|1|1|C0023884|Liver|bpoc|bpoc|||liver|||0|888|89|94|PREP|LOCATION_OF||82|84|4|1|C0014442|Enzymes|enzy,orch|orch|||enzymes|||0|1000|74|81

SE|24||ab|1|text|102|347|The virostatic compound N,N-diethyl-4-[2-(2-oxo-3-tetradecyl-1-imidazolidinyl)-ethyl]-1-piperazinecarboxamide-hydrochloride (5531) was analyzed as to its effect on the induction of tryptophan-pyrrolase and tyrosineaminotransferase in rat liver.
SE|24||ab|1|entity|C0205198|Compound|qlco|||compound|||0|773|117|125
SE|24||ab|1|entity|C1512523|hydrochloride|inch,phsu|||hydrochloride|||0|827|212|225
SE|24||ab|1|entity|C1280500|Effect|qlco|||effect|||0|1000|256|262
SE|24||ab|1|entity|C0857127|Induction|topp|||induction|||0|1000|270|279
SE|24||ab|1|entity|C0041256|Tryptophan Oxygenase|aapp,enzy|||tryptophan-pyrrolase|||0|1000|283|303
SE|24||ab|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|888|336|339
SE|24||ab|1|entity|C0023884|Liver|bpoc|||liver|||0|888|340|345
SE|24||ab|1|relation|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|888|340|345|MOD/HEAD|PART_OF||336|345|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|888|336|339
SE|24||ab|1|relation|1|1|C0023884|Liver|bpoc|bpoc|||liver|||0|888|340|345|PREP|LOCATION_OF||333|335|8|2|C0041256|Tryptophan Oxygenase|aapp,gngm,enzy|aapp|||tryptophan-pyrrolase|||0|1000|283|303

SE|24||ab|2|text|347|350|1.

SE|24||ab|3|text|350|469|The basic activity of the enzymes was not influenced by the substance either in normal or in adrenalectomized animals.
SE|24||ab|3|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|1000|376|383
SE|24||ab|3|entity|C1518422|Not|ftcn|||not|||0|1000|388|391
SE|24||ab|3|entity|C0439861|Substance|sbst|||substance|||0|861|410|419
SE|24||ab|3|entity|C0205307|Normal|qlco|||normal|||0|1000|430|436
SE|24||ab|3|entity|C0003062|Animals|anim|||animals|||0|861|460|467
SE|24||ab|3|relation|1|1|C0003062|Animals|anim|anim|||animals|||0|861|460|467|PREP|LOCATION_OF||440|442|4|3|C0014442|Enzymes|enzy,orch|orch|||enzymes|||0|1000|376|383

SE|24||ab|4|text|469|472|2.

SE|24||ab|5|text|472|608|The induction of the enzymes by cortisone increased in the presence of the compound whereas the substrate induction remained unchanged.
SE|24||ab|5|entity|C0857127|Induction|topp|||induction|||0|1000|476|485
SE|24||ab|5|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|1000|493|500
SE|24||ab|5|entity|C0010137|Cortisone|horm,phsu,strd|||cortisone|||0|1000|504|513
SE|24||ab|5|entity|C0205198|Compound|qlco|||compound|||0|1000|547|555
SE|24||ab|5|entity|C0857127|Induction|topp|||induction|||0|861|578|587
SE|24||ab|5|relation|6|2|C0010137|Cortisone|horm,phsu,strd|horm|||cortisone|||0|1000|504|513|NOM|STIMULATES||476|485|6|1|C0014442|Enzymes|enzy,orch|enzy|||enzymes|||0|1000|493|500

SE|24||ab|6|text|608|611|3.

SE|24||ab|7|text|611|764|The induction of tyrosine-aminotransferase by dexamethasonephosphate in tissue culture is inhibited if the dose of compound 5531 is higher than 5 mug/ml.
SE|24||ab|7|entity|C0857127|Induction|topp|||induction|||0|1000|615|624
SE|24||ab|7|entity|C0041487|TYROSINE AMINOTRANSFERASE|aapp,enzy|||tyrosine-aminotransferase|||0|1000|628|653
SE|24||ab|7|entity|C0040284|Tissue culture|lbpr|||tissue culture|||0|1000|683|697
SE|24||ab|7|entity|C1446466|Dose|qnco|||dose|||0|1000|718|722
SE|24||ab|7|entity|C0205198|Compound|qlco|||compound|||0|861|726|734
SE|24||ab|7|entity|C0205250|High|qlco|||higher|||0|966|743|749


SE|25||ti|1|text|15|72|Pharmacological properties of new neuroleptic compounds.
SE|25||ti|1|entity|C0205464|pharmacological|ftcn|||Pharmacological|||0|872|15|30
SE|25||ti|1|entity|C0871161|Property|qlco|||properties|||0|872|31|41
SE|25||ti|1|entity|C0205314|New|tmco|||new|||0|840|45|48
SE|25||ti|1|entity|C0040615|Antipsychotic Agents|phsu|||neuroleptic|||0|840|49|60
SE|25||ti|1|entity|C0205198|Compound|qlco|||compounds|||0|840|61|70

SE|25||ab|1|text|78|253|RMI 61 140, RMI 61 144 and RMI 61 280 are newly synthetized N-[8-R-dibenzo(b,f)oxepin-10-yl]-N'-methyl-piperazine-maleates which show interesting psychopharmacologic effects.
SE|25||ab|1|entity|C0604673|RMI 61,140|orch,phsu|||RMI 61 140|||0|1000|78|88
SE|25||ab|1|entity|C0604672|RMI 61,144|orch,phsu|||RMI 61 144|||0|1000|90|100
SE|25||ab|1|entity|C0604674|RMI 61,280|orch,phsu|||RMI 61 280|||0|1000|105|115
SE|25||ab|1|entity|C0750546|NEWLY|idcn|||newly|||0|785|120|125
SE|25||ab|1|entity|C0030007|Oxepins|orch|||oxepin|||0|637|157|163
SE|25||ab|1|entity|C0031957|piperazine|orch,phsu|||piperazine|||0|775|181|191
SE|25||ab|1|entity|C0024572|Maleates|orch|||maleates|||0|775|192|200
SE|25||ab|1|entity|C0033929|Psychopharmacology|bmod|||psychopharmacologic|||0|836|224|243
SE|25||ab|1|entity|C1280500|Effect|qlco|||effects|||0|836|244|251

SE|25||ab|2|text|253|459|This work contains the results of a study performed with these three compounds, in order to demonstrate their neuropsycholeptic activity in comparison with chloropromazine (CPZ) and chlordiazepoxide (CPD).
SE|25||ab|2|entity|C0043227|Work|ocac|||work|||0|1000|258|262
SE|25||ab|2|entity|C1274040|result|ftcn|||results|||0|966|276|283
SE|25||ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|289|294
SE|25||ab|2|entity|C0205449|Three|qnco|||three|||0|872|316|321
SE|25||ab|2|entity|C0205198|Compound|qlco|||compounds|||0|872|322|331
SE|25||ab|2|entity|C0008188|Chlordiazepoxide|orch,phsu|||chlordiazepoxide|||0|1000|435|451
SE|25||ab|2|entity|||gngm|1362|CPD|CPD|||0|1000|453|456

SE|25||ab|3|text|459|595|The inhibition of motility observed in mice shows that the compounds reduce the normal spontaneous motility as well as the muscle tone.
SE|25||ab|3|entity|C1510470|Motility|orgf|||motility|||0|1000|477|485
SE|25||ab|3|entity|C0026809|Mus|mamm|||mice|||0|1000|498|502
SE|25||ab|3|entity|C0205198|Compound|qlco|||compounds|||0|966|518|527
SE|25||ab|3|entity|C0205307|Normal|qlco|||normal|||0|851|539|545
SE|25||ab|3|entity|C0205359|Spontaneous|ftcn|||spontaneous|||0|851|546|557
SE|25||ab|3|entity|C1510470|Motility|orgf|||motility|||0|851|558|566
SE|25||ab|3|entity|C0026841|Muscle Tonus|phsf|||muscle tone|||0|1000|582|593
SE|25||ab|3|relation|2|1|C1510470|Motility|orgf|orgf|||motility|||0|1000|477|485|PREP|PROCESS_OF||495|497|4|1|C0026809|Mus|mamm|mamm|||mice|||0|1000|498|502

SE|25||ab|4|text|595|732|The central-depressant activity is evidenced by increased barbiturate-induced sleep and a remarkable eyelid ptosis can also be observed.
SE|25||ab|4|entity|C0301389|Central depressant|orch,phsu|||central-depressant|||0|901|599|617
SE|25||ab|4|entity|C0205217|Increased|qnco|||increased|||0|833|643|652
SE|25||ab|4|entity|C0004745|Barbiturates|orch,phsu|||barbiturate|||0|833|653|664
SE|25||ab|4|entity|C0205263|Induced|ftcn|||induced|||0|833|665|672
SE|25||ab|4|entity|C0037313|Sleep|orgf|||sleep|||0|833|673|678
SE|25||ab|4|entity|C1550002|Remark|idcn|||remarkable|||0|877|685|695
SE|25||ab|4|entity|C0005745|Blepharoptosis|anab|||eyelid ptosis|||0|877|696|709
SE|25||ab|4|relation|1|0|C0004745|Barbiturates|orch,phsu|orch|||barbiturate|||0|833|653|664|ADJ|AUGMENTS||665|672|1|0|C0037313|Sleep|orgf|orgf|||sleep|||0|833|673|678

SE|25||ab|5|text|732|811|Our compounds do not show any activity on electroshock just as do CPZ and CPD.
SE|25||ab|5|entity|C0205198|Compound|qlco|||compounds|||0|966|736|745
SE|25||ab|5|entity|C1518422|Not|ftcn|||not|||0|1000|749|752
SE|25||ab|5|entity|C0013870|Electroconvulsive Shock|resa|||electroshock|||0|861|774|786
SE|25||ab|5|entity|||gngm|1362|CPD|CPD|||0|1000|806|809

SE|25||ab|6|text|811|967|As to the antipsychotic outline, our compounds show strong reduction of lethality due to amphetamine in grouped mice and a strong antiapomorphine activity.
SE|25||ab|6|entity|C0040615|Antipsychotic Agents|phsu|||antipsychotic|||0|661|821|834
SE|25||ab|6|entity|C0205198|Compound|qlco|||compounds|||0|966|848|857
SE|25||ab|6|entity|C0442821|Strong|qlco|||strong|||0|694|863|869
SE|25||ab|6|entity|C1031740|Lethe|invt|||lethality|||0|900|883|892
SE|25||ab|6|entity|C0002658|Amphetamine|nsba,orch,phsu|||amphetamine|||0|1000|900|911
SE|25||ab|6|entity|C0439745|Grouped|spco|||grouped|||0|888|915|922
SE|25||ab|6|entity|C0026809|Mus|mamm|||mice|||0|888|923|927
SE|25||ab|6|entity|C0442821|Strong|qlco|||strong|||0|802|934|940
SE|25||ab|6|relation|5|1|C0002658|Amphetamine|nsba,orch,phsu|phsu|||amphetamine|||0|1000|900|911|PREP|TREATS||912|914|2|1|C0026809|Mus|mamm|mamm|||mice|||0|888|923|927

SE|25||ab|7|text|967|1081|They show also an antiaggressive effect and an inhibitory activity on avoidance behaviour much stronger than CPZ.
SE|25||ab|7|entity|C1280500|Effect|qlco|||effect|||0|861|1000|1006
SE|25||ab|7|entity|C0243077|inhibitors|chvf|||inhibitory|||0|853|1014|1024
SE|25||ab|7|entity|C0178494|Avoidance behavior|menp|||avoidance behaviour|||0|1000|1037|1056
SE|25||ab|7|entity|C0442821|Strong|qlco|||stronger|||0|966|1062|1070

SE|25||ab|8|text|1081|1209|We have also found extrapyramidal effects, as catalepsy, common to many tranquillizers of the kind of the standards used by us.
SE|25||ab|8|entity|C1280500|Effect|qlco|||effects|||0|827|1115|1122
SE|25||ab|8|entity|C0007370|Catalepsy|mobd|||catalepsy|||0|1000|1127|1136
SE|25||ab|8|entity|C0205214|Common|qnco|||common|||0|1000|1138|1144
SE|25||ab|8|entity|C0040614|Tranquilizing Agents|phsu|||tranquillizers|||0|1000|1153|1167

SE|25||ab|9|text|1209|1364|As for vegetative phenomena, the compounds show hypotensive dose related action ranging from moderate to strong, probably due to an a-receptor inhibition.
SE|25||ab|9|entity|C0205198|Compound|qlco|||compounds|||0|966|1242|1251
SE|25||ab|9|entity|C0857353|Hypotensive|patf|||hypotensive|||0|758|1257|1268
SE|25||ab|9|entity|C1446466|Dose|qnco|||dose|||0|758|1269|1273
SE|25||ab|9|entity|C1522149|Related|ftcn|||related|||0|758|1274|1281
SE|25||ab|9|entity|C1514721|Range|qnco|||ranging|||0|758|1289|1296
SE|25||ab|9|entity|C0442821|Strong|qlco|||strong|||0|888|1314|1320
SE|25||ab|9|entity|C0332148|Probable diagnosis|qlco|||probably|||0|888|1322|1330
SE|25||ab|9|entity|C1514761|Receptor Inhibition|celf|||receptor inhibition|||0|1000|1343|1362

SE|25||ab|10|text|1364|1655|Adrenolytic activity against lethal doses of adrenaline, antiserotonin and antihistaminic effects, as well as other actions (hypothermia, analgesia, etc.) confirm that RMI 61 140, RMI 61 144 and RMI 61 280 are endowed with pharmacologic properties similar and more potent than those of CPZ.
SE|25||ab|10|entity|C0242889|Adrenergic Antagonists|phsu|||Adrenolytic|||0|872|1364|1375
SE|25||ab|10|entity|C1443964|Lethal dose|qnco|||lethal doses|||0|983|1393|1405
SE|25||ab|10|entity|C0014563|Epinephrine|horm,nsba,orch,phsu|||adrenaline|||0|1000|1409|1419
SE|25||ab|10|entity|C0003360|Antihistamines|phsu|||antihistaminic|||0|855|1439|1453
SE|25||ab|10|entity|C1280500|Effect|qlco|||effects|||0|855|1454|1461
SE|25||ab|10|entity|C0020672|hypothermia, natural|sosy|||hypothermia|||0|1000|1489|1500
SE|25||ab|10|entity|C0002766|Pain management|topp|||analgesia|||0|1000|1502|1511
SE|25||ab|10|entity|C1548556|etc.|idcn|||etc|||0|1000|1513|1516
SE|25||ab|10|entity|C0604673|RMI 61,140|orch,phsu|||RMI 61 140|||0|1000|1532|1542
SE|25||ab|10|entity|C0604672|RMI 61,144|orch,phsu|||RMI 61 144|||0|1000|1544|1554
SE|25||ab|10|entity|C0604674|RMI 61,280|orch,phsu|||RMI 61 280|||0|1000|1559|1569
SE|25||ab|10|entity|C0205464|pharmacological|ftcn|||pharmacologic|||0|872|1587|1600
SE|25||ab|10|entity|C0871161|Property|qlco|||properties|||0|872|1601|1611
SE|25||ab|10|entity|C0205172|More|ftcn|||more|||0|838|1624|1628
SE|25||ab|10|entity|C0237399|Potential|qlco|||potent|||0|838|1629|1635
SE|25||ab|10|relation|4|2|C0014563|Epinephrine|horm,nsba,orch,phsu|horm|||adrenaline|||0|1000|1409|1419|NOM|INTERACTS_WITH||1454|1461|4|0|C0003360|Antihistamines|phsu|phsu|||antihistaminic|||0|855|1439|1453

SE|25||ab|11|text|1655|1784|Studies on the metabolism of brain catecholamines show that they are similar to CPZ, although with less effect on dopamine level.
SE|25||ab|11|entity|C0008972|Clinical Research|resa|||Studies|||0|966|1655|1662
SE|25||ab|11|entity|C0025519|Metabolism|orgf|||metabolism|||0|1000|1670|1680
SE|25||ab|11|entity|C0006104|Brain|bpoc|||brain|||0|888|1684|1689
SE|25||ab|11|entity|C0007412|Catecholamines|nsba,orch|||catecholamines|||0|888|1690|1704
SE|25||ab|11|entity|C1280500|Effect|qlco|||effect|||0|861|1759|1765
SE|25||ab|11|entity|C0013030|Dopamine|nsba,orch,phsu|||dopamine|||0|694|1769|1777
SE|25||ab|11|relation|0|0|C0007412|Catecholamines|nsba,orch|nsba|||catecholamines|||0|888|1690|1704|MOD/HEAD|PART_OF||1684|1704|0|0|C0006104|Brain|bpoc|bpoc|||brain|||0|888|1684|1689
SE|25||ab|11|relation|4|2|C0007412|Catecholamines|nsba,orch|nsba|||catecholamines|||0|888|1690|1704|NOM|INTERACTS_WITH||1759|1765|1|1|C0013030|Dopamine|nsba,orch,phsu|nsba|||dopamine|||0|694|1769|1777


SE|26||ti|1|text|15|137|[Studies on the action of an anticholinergic agent in combination with a tranquilizer on gastric juice secretion in man].
SE|26||ti|1|entity|C0008972|Clinical Research|resa|||Studies|||0|966|16|23
SE|26||ti|1|entity|C0242896|Anticholinergic Agents|phsu|||anticholinergic agent|||0|1000|44|65
SE|26||ti|1|entity|C0205195|Combined|qlco|||combination|||0|1000|69|80
SE|26||ti|1|entity|C0040614|Tranquilizing Agents|phsu|||tranquilizer|||0|1000|88|100
SE|26||ti|1|entity|C0017133|Gastric Juice|bdsu|||gastric juice|||0|901|104|117
SE|26||ti|1|entity|C0015283|Exocytosis|celf|||secretion|||0|901|118|127

SE|26||ab|1|text|143|539|A double-blind study with intra-individual comparisons was carried out to investigate the effects of 15 mg of (8r)-3alpha-hydroxy-8-isopropyl-1alphaH-tropanium bromide(+/-)-tropate (Sch 1000), 15 mg Sch 1000 + 10 mg oxazepam, 10 mg oxazepam and placebo with oral administration in randomized sequence on gastric juice volume, amount of acid, concentration and pH values in 12 healthy volunteers.
SE|26||ab|1|entity|C0013072|Double-Blind Method|resa|||double-blind study|||0|1000|145|163
SE|26||ab|1|entity|C0347985|During values|tmco|||intra|||0|623|169|174
SE|26||ab|1|entity|C0237401|Individual|humn|||individual|||0|623|175|185
SE|26||ab|1|entity|C0439787|Out|spco|||out|||0|1000|210|213
SE|26||ab|1|entity|C1280500|Effect|qlco|||effects|||0|966|233|240
SE|26||ab|1|entity|C0534492|2-bromopropane|orch,phsu|||isopropyl-1alphaH-tropanium bromide|||0|845|275|310
SE|26||ab|1|entity|C0022055|Sch-1000|orch,phsu|||Sch 1000|||0|1000|325|333
SE|26||ab|1|entity|C0022055|Sch-1000|orch,phsu|||Sch 1000|||0|756|342|350
SE|26||ab|1|entity|C0029997|Oxazepam|orch,phsu|||oxazepam|||0|756|359|367
SE|26||ab|1|entity|C0029997|Oxazepam|orch,phsu|||oxazepam|||0|790|375|383
SE|26||ab|1|entity|C0032042|Placebos|medd,topp|||placebo|||0|1000|388|395
SE|26||ab|1|entity|C0001563|Administration, Oral|topp|||oral administration|||0|1000|401|420
SE|26||ab|1|entity|C1514720|Randomized|ftcn|||randomized|||0|888|424|434
SE|26||ab|1|entity|C1519249|Sequence|ftcn|||sequence|||0|888|435|443
SE|26||ab|1|entity|C0017133|Gastric Juice|bdsu|||gastric juice|||0|901|447|460
SE|26||ab|1|entity|C0449468|Volume|qnco|||volume|||0|901|461|467
SE|26||ab|1|entity|C1265611|Quantity|qnco|||amount|||0|1000|469|475
SE|26||ab|1|entity|C0001128|Acids|chem|||acid|||0|1000|479|483
SE|26||ab|1|entity|C0042295|Values|qlco|||values|||0|888|506|512
SE|26||ab|1|entity|C0018684|Health|idcn|||healthy|||0|754|519|526
SE|26||ab|1|entity|C0042960|Voluntary Workers|prog|||volunteers|||0|754|527|537
SE|26||ab|1|relation|16|8|C0032042|Placebos|medd,topp|medd|||placebo|||0|1000|388|395|NOM|compared_with||186|197|16|9|C0001563|Administration, Oral|topp|topp|||oral administration|||0|1000|401|420
SE|26||ab|1|relation|17|7|C0001563|Administration, Oral|topp|topp|||oral administration|||0|1000|401|420|PREP|TREATS||513|515|1|1|C0042960|Voluntary Workers|prog,humn|humn|||volunteers|||0|754|527|537
SE|26||ab|1|relation|17|7|C0032042|Placebos|medd,topp|topp|||placebo|||0|1000|388|395|PREP|TREATS||513|515|1|1|C0042960|Voluntary Workers|prog,humn|humn|||volunteers|||0|754|527|537

SE|26||ab|2|text|539|634|The secretion parameters were measured during a 1-h basal period and a 2-h stimulation period.
SE|26||ab|2|entity|C0015283|Exocytosis|celf|||secretion|||0|888|543|552
SE|26||ab|2|entity|C0205112|Basal|spco|||basal|||0|798|591|596
SE|26||ab|2|entity|C0439531|/period|tmco|||period|||0|798|597|603
SE|26||ab|2|entity|C0439531|/period|tmco|||period|||0|861|626|632

SE|26||ab|3|text|634|702|The gastric juice was obtained in 15 min portions via stomach tube.
SE|26||ab|3|entity|C0017133|Gastric Juice|bdsu|||gastric juice|||0|1000|638|651
SE|26||ab|3|entity|C0439232|Minute of time|tmco|||min|||0|861|671|674
SE|26||ab|3|entity|C1550513|via|idcn|||via|||0|882|684|687
SE|26||ab|3|entity|C1546658|Tube, Gastric|inpr|||stomach tube|||0|882|688|700

SE|26||ab|4|text|702|773|Stimulation was effected by 1 mug/kg/h pentagastrin via drip infusion.
SE|26||ab|4|entity|C0030859|Pentagastrin|aapp,horm,phsu|||pentagastrin|||0|752|741|753
SE|26||ab|4|entity|C0013125|intravenous administration|spco|||drip infusion|||0|752|758|771

SE|26||ab|5|text|773|943|The Friedman test was used for the comparative statistical evaluation, and individual comparisons were carried out by means of the Wilcoxon test (pair-differences rank).
SE|26||ab|5|entity|C0039593|Testing|resa|||test|||0|861|786|790
SE|26||ab|5|entity|C0220917|statistical|inpr|||statistical|||0|790|820|831
SE|26||ab|5|entity|C0220825|Evaluation|ftcn|||evaluation|||0|790|832|842
SE|26||ab|5|entity|C0237401|Individual|humn|||individual|||0|694|848|858
SE|26||ab|5|entity|C0439787|Out|spco|||out|||0|1000|884|887
SE|26||ab|5|entity|C0039593|Testing|resa|||test|||0|861|913|917
SE|26||ab|5|entity|C1547020|*Difference|qnco|||differences|||0|827|924|935

SE|26||ab|6|text|943|1061|The results show that Sch 1000 and Sch 1000 + oxazepam were equal in effect on basal and stimulated secretion volume.
SE|26||ab|6|entity|C1274040|result|ftcn|||results|||0|966|947|954
SE|26||ab|6|entity|C0022055|Sch-1000|orch,phsu|||Sch 1000|||0|1000|965|973
SE|26||ab|6|entity|C0022055|Sch-1000|orch,phsu|||Sch 1000|||0|901|978|986
SE|26||ab|6|entity|C0029997|Oxazepam|orch,phsu|||oxazepam|||0|901|989|997
SE|26||ab|6|entity|C0205163|Equal|qlco|||equal|||0|1000|1003|1008
SE|26||ab|6|entity|C1280500|Effect|qlco|||effect|||0|1000|1012|1018
SE|26||ab|6|entity|C0205112|Basal|spco|||basal|||0|1000|1022|1027
SE|26||ab|6|entity|C0015283|Exocytosis|celf|||secretion|||0|790|1043|1052
SE|26||ab|6|entity|C0449468|Volume|qnco|||volume|||0|790|1053|1059

SE|26||ab|7|text|1061|1170|As compared with placebo, it was not possible to establish an effect on secretion volume for oxazepam alone.
SE|26||ab|7|entity|C0032042|Placebos|medd,topp|||placebo|||0|1000|1078|1085
SE|26||ab|7|entity|C1518422|Not|ftcn|||not|||0|888|1094|1097
SE|26||ab|7|entity|C0332149|Possible|qlco|||possible|||0|888|1098|1106
SE|26||ab|7|entity|C1280500|Effect|qlco|||effect|||0|1000|1123|1129
SE|26||ab|7|entity|C0015283|Exocytosis|celf|||secretion|||0|888|1133|1142
SE|26||ab|7|entity|C0449468|Volume|qnco|||volume|||0|888|1143|1149
SE|26||ab|7|entity|C0029997|Oxazepam|orch,phsu|||oxazepam|||0|1000|1154|1162

SE|26||ab|8|text|1170|1355|Sch 1000 and Sch 1000 + oxazepam were found to be equipotent in reducing the amount of basal acid, while oxazepam reduced this quantity only during the first 30 min of basal secretion.
SE|26||ab|8|entity|C0022055|Sch-1000|orch,phsu|||Sch 1000|||0|1000|1170|1178
SE|26||ab|8|entity|C0022055|Sch-1000|orch,phsu|||Sch 1000|||0|901|1183|1191
SE|26||ab|8|entity|C0029997|Oxazepam|orch,phsu|||oxazepam|||0|901|1194|1202
SE|26||ab|8|entity|C0392756|Reduced|qlco|||reducing|||0|966|1234|1242
SE|26||ab|8|entity|C1265611|Quantity|qnco|||amount|||0|1000|1247|1253
SE|26||ab|8|entity|C0205112|Basal|spco|||basal|||0|888|1257|1262
SE|26||ab|8|entity|C0001128|Acids|chem|||acid|||0|888|1263|1267
SE|26||ab|8|entity|C0029997|Oxazepam|orch,phsu|||oxazepam|||0|1000|1275|1283
SE|26||ab|8|entity|C1265611|Quantity|qnco|||quantity|||0|861|1297|1305
SE|26||ab|8|entity|C1279901|Firstly|qlco|||first|||0|901|1322|1327
SE|26||ab|8|entity|C0456693|/30 min|tmco|||30 min|||0|901|1328|1334
SE|26||ab|8|entity|C0205112|Basal|spco|||basal|||0|888|1338|1343
SE|26||ab|8|entity|C0015283|Exocytosis|celf|||secretion|||0|888|1344|1353

SE|26||ab|9|text|1355|1528|None of the three active preparations was capable of inhibiting the stimulated acid, although both Sch 1000 preparations produced a clear trend towards lowered mean values.
SE|26||ab|9|entity|C0205449|Three|qnco|||three|||0|840|1367|1372
SE|26||ab|9|entity|C0205177|Active|ftcn|||active|||0|840|1373|1379
SE|26||ab|9|entity|C1521827|Preparation|ftcn|||preparations|||0|840|1380|1392
SE|26||ab|9|entity|C0311403|Inhibited|qlco|||inhibiting|||0|966|1408|1418
SE|26||ab|9|entity|C0001128|Acids|chem|||acid|||0|861|1434|1438
SE|26||ab|9|entity|C0022055|Sch-1000|orch,phsu|||Sch 1000|||0|890|1454|1462
SE|26||ab|9|entity|C1521827|Preparation|ftcn|||preparations|||0|890|1463|1475
SE|26||ab|9|entity|C0522503|Translucent|qlco|||clear|||0|888|1487|1492
SE|26||ab|9|entity|C1521798|trend|tmco|||trend|||0|888|1493|1498
SE|26||ab|9|entity|C1272755|Lowered|qnco|||lowered|||0|802|1507|1514
SE|26||ab|9|entity|C0042295|Values|qlco|||values|||0|802|1520|1526

SE|26||ab|10|text|1528|1712|During the basal secretion period, all three test preparations had an inhibiting action on acid concentration, but none of them had a significant effect during the stimulation period.
SE|26||ab|10|entity|C0205112|Basal|spco|||basal|||0|851|1539|1544
SE|26||ab|10|entity|C0015283|Exocytosis|celf|||secretion|||0|851|1545|1554
SE|26||ab|10|entity|C0439531|/period|tmco|||period|||0|851|1555|1561
SE|26||ab|10|entity|C0205449|Three|qnco|||three|||0|890|1567|1572
SE|26||ab|10|entity|C1378537|Test (device)|medd|||test preparations|||0|890|1573|1590
SE|26||ab|10|entity|C0311403|Inhibited|qlco|||inhibiting|||0|661|1598|1608
SE|26||ab|10|entity|C0001128|Acids|chem|||acid|||0|694|1619|1623
SE|26||ab|10|entity|C0750502|Significant|idcn|||significant|||0|888|1662|1673
SE|26||ab|10|entity|C1280500|Effect|qlco|||effect|||0|888|1674|1680
SE|26||ab|10|entity|C0439531|/period|tmco|||period|||0|888|1704|1710

SE|26||ab|11|text|1712|1832|The pH value was savely increased only by Sch 1000 and Sch 1000 + oxazepam, and this even only during the basal period.
SE|26||ab|11|entity|C0022055|Sch-1000|orch,phsu|||Sch 1000|||0|1000|1754|1762
SE|26||ab|11|entity|C0022055|Sch-1000|orch,phsu|||Sch 1000|||0|901|1767|1775
SE|26||ab|11|entity|C0029997|Oxazepam|orch,phsu|||oxazepam|||0|901|1778|1786
SE|26||ab|11|entity|C0205112|Basal|spco|||basal|||0|888|1818|1823
SE|26||ab|11|entity|C0439531|/period|tmco|||period|||0|888|1824|1830

SE|26||ab|12|text|1832|1858|The results are discussed.
SE|26||ab|12|entity|C1274040|result|ftcn|||results|||0|966|1836|1843


SE|27||ti|1|text|15|46|Editorial: "Old lamps for new".
SE|27||ti|1|entity|C0580836|Old|tmco|||Old|||0|872|27|30
SE|27||ti|1|entity|C0392223|Lights, manufactured|medd|||lamps|||0|872|31|36
SE|27||ti|1|entity|C0205314|New|tmco|||new|||0|1000|41|44


SE|28||ti|1|text|15|52|Letter: Duration of action of AH8165.
SE|28||ti|1|entity|C0449238|Duration|tmco|||Duration|||0|1000|23|31


SE|29||ti|1|text|15|45|Lorazepam in sexual disorders.
SE|29||ti|1|entity|C0024002|Lorazepam|orch,phsu|||Lorazepam|||0|1000|15|24
SE|29||ti|1|entity|C0033953|Psychosexual Disorders|mobd|||sexual disorders|||0|1000|28|44
SE|29||ti|1|relation|1|1|C0024002|Lorazepam|orch,phsu|orch|||Lorazepam|||0|1000|15|24|PREP|TREATS||25|27|1|1|C0033953|Psychosexual Disorders|mobd|mobd|||sexual disorders|||0|1000|28|44


SE|30||ti|1|text|15|54|Lysosomal hydrolases of the epidermis.
SE|30||ti|1|entity|C0521450|Lysosomal|blor|||Lysosomal|||0|888|15|24
SE|30||ti|1|entity|C0020289|Hydrolase|aapp,enzy|||hydrolases|||0|888|25|35
SE|30||ti|1|entity|C0014520|Epidermis|tisu|||epidermis|||0|1000|43|52
SE|30||ti|1|relation|0|0|C0020289|Hydrolase|aapp,gngm,enzy|gngm|||hydrolases|||0|888|25|35|MOD/HEAD|PART_OF||15|35|0|0|C0521450|Lysosomal|blor|blor|||Lysosomal|||0|888|15|24
SE|30||ti|1|relation|1|1|C0020289|Hydrolase|aapp,gngm,enzy|aapp|||hydrolases|||0|888|25|35|PREP|PART_OF||36|38|1|1|C0014520|Epidermis|tisu|tisu|||epidermis|||0|1000|43|52

SE|30||ti|2|text|54|57|I.

SE|30||ti|3|text|57|71|Glycosidases.
SE|30||ti|3|entity|C0017976|Glycoside Hydrolases|aapp,enzy|||Glycosidases|||0|1000|57|69

SE|30||ab|1|text|77|163|Seven distinct glycosidases (EC 3.2) have been characterized in guinea-pig epidermis.
SE|30||ab|1|entity|C0205453|Seven|qnco|||Seven|||0|802|77|82
SE|30||ab|1|entity|C0017976|Glycoside Hydrolases|aapp,enzy|||glycosidases|||0|802|92|104
SE|30||ab|1|entity|C0040676|Transferase|aapp,enzy|||EC 3.2|||0|913|106|112
SE|30||ab|1|entity|C0085979|Cavia|mamm|||guinea-pig|||0|901|141|151
SE|30||ab|1|entity|C0014520|Epidermis|tisu|||epidermis|||0|901|152|161
SE|30||ab|1|relation|0|0|C0014520|Epidermis|tisu|tisu|||epidermis|||0|901|152|161|MOD/HEAD|PART_OF||141|161|0|0|C0085979|Cavia|mamm|mamm|||guinea-pig|||0|901|141|151
SE|30||ab|1|relation|1|1|C0014520|Epidermis|tisu|tisu|||epidermis|||0|901|152|161|PREP|LOCATION_OF||138|140|1|1|C0017976|Glycoside Hydrolases|aapp,gngm,enzy|aapp|||glycosidases|||0|802|92|104

SE|30||ab|2|text|163|221|Their properties indicate them to be of lysosomal origin.
SE|30||ab|2|entity|C0871161|Property|qlco|||properties|||0|966|169|179
SE|30||ab|2|entity|C0521450|Lysosomal|blor|||lysosomal|||0|888|203|212
SE|30||ab|2|entity|C0439659|Beginning|tmco|||origin|||0|888|213|219

SE|30||ab|3|text|221|474|The 'profile' of the epidermal glycosidases is significantly different from that reported for whole skin, the activities of beta-galactosidase and beta-acetylglucosaminidase being very high and those of the remaining enzymes relatively low in epidermis.
SE|30||ab|3|entity|C0221920|Epidermo-|spco|||epidermal|||0|888|242|251
SE|30||ab|3|entity|C0017976|Glycoside Hydrolases|aapp,enzy|||glycosidases|||0|888|252|264
SE|30||ab|3|entity|C1547020|*Difference|qnco|||different|||0|789|282|291
SE|30||ab|3|entity|C0444667|Whole|qnco|||whole|||0|888|315|320
SE|30||ab|3|entity|C0037267|Integumentary system|bdsy|||skin|||0|888|321|325
SE|30||ab|3|entity|C0441655|Activities|acty|||activities|||0|1000|331|341
SE|30||ab|3|entity|C0005220|beta-Galactosidase|aapp,enzy,phsu|||beta-galactosidase|||0|1000|345|363
SE|30||ab|3|entity|C0001057|Beta-N-Acetylglucosaminidase|aapp,enzy|||acetylglucosaminidase|||0|861|373|394
SE|30||ab|3|entity|C0442804|Very high|fndg|||very high|||0|1000|401|410
SE|30||ab|3|entity|C1527428|Remaining|qlco|||remaining|||0|775|428|437
SE|30||ab|3|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|775|438|445
SE|30||ab|3|entity|C0205251|low|qlco|||low|||0|775|457|460
SE|30||ab|3|entity|C0014520|Epidermis|tisu|||epidermis|||0|1000|464|473
SE|30||ab|3|relation|1|1|C0014520|Epidermis|tisu|tisu|||epidermis|||0|1000|464|473|PREP|LOCATION_OF||461|463|8|3|C0001057|Beta-N-Acetylglucosaminidase|aapp,gngm,enzy|aapp|||acetylglucosaminidase|||0|861|373|394
SE|30||ab|3|relation|1|1|C0014520|Epidermis|tisu|tisu|||epidermis|||0|1000|464|473|PREP|LOCATION_OF||461|463|8|3|C0005220|beta-Galactosidase|aapp,gngm,enzy,phsu|aapp|||beta-galactosidase|||0|1000|345|363


SE|31||ti|1|text|15|54|Lysosomal hydrolases of the epidermis.
SE|31||ti|1|entity|C0521450|Lysosomal|blor|||Lysosomal|||0|888|15|24
SE|31||ti|1|entity|C0020289|Hydrolase|aapp,enzy|||hydrolases|||0|888|25|35
SE|31||ti|1|entity|C0014520|Epidermis|tisu|||epidermis|||0|1000|43|52
SE|31||ti|1|relation|0|0|C0020289|Hydrolase|aapp,gngm,enzy|gngm|||hydrolases|||0|888|25|35|MOD/HEAD|PART_OF||15|35|0|0|C0521450|Lysosomal|blor|blor|||Lysosomal|||0|888|15|24
SE|31||ti|1|relation|1|1|C0020289|Hydrolase|aapp,gngm,enzy|aapp|||hydrolases|||0|888|25|35|PREP|PART_OF||36|38|1|1|C0014520|Epidermis|tisu|tisu|||epidermis|||0|1000|43|52

SE|31||ti|2|text|54|57|2.

SE|31||ti|3|text|57|75|Ester hydrolases.
SE|31||ti|3|entity|C0014894|ESTERASE|aapp,enzy|||Ester hydrolases|||0|983|57|73

SE|31||ab|1|text|81|170|Five distinct ester hydrolases (EC 3-1) have been characterized in guinea-pig epidermis.
SE|31||ab|1|entity|C0205451|Five|qnco|||Five|||0|813|81|85
SE|31||ab|1|entity|C0014894|ESTERASE|aapp,enzy|||ester hydrolases|||0|813|95|111
SE|31||ab|1|entity|C0085979|Cavia|mamm|||guinea-pig|||0|901|148|158
SE|31||ab|1|entity|C0014520|Epidermis|tisu|||epidermis|||0|901|159|168
SE|31||ab|1|relation|0|0|C0014520|Epidermis|tisu|tisu|||epidermis|||0|901|159|168|MOD/HEAD|PART_OF||148|168|0|0|C0085979|Cavia|mamm|mamm|||guinea-pig|||0|901|148|158
SE|31||ab|1|relation|1|1|C0014520|Epidermis|tisu|tisu|||epidermis|||0|901|159|168|PREP|LOCATION_OF||145|147|1|1|C0014894|ESTERASE|aapp,gngm,enzy|aapp|||ester hydrolases|||0|813|95|111

SE|31||ab|2|text|170|264|These are carboxylic esterase, acid phosphatase, pyrophosphatase, and arylsulphatase A and B.
SE|31||ab|2|entity|C0014894|ESTERASE|aapp,enzy|||esterase|||0|861|191|199
SE|31||ab|2|entity|C0001109|Acid Phosphatase|aapp,enzy|||acid phosphatase|||0|1000|201|217
SE|31||ab|2|entity|C0034318|pyrophosphatase|aapp,enzy|||pyrophosphatase|||0|1000|219|234
SE|31||ab|2|entity|C0003940|Arylsulfatases|aapp,enzy|||arylsulphatase|||0|1000|240|254

SE|31||ab|3|text|264|328|Their properties are consistent with those of lysosomal enzymes.
SE|31||ab|3|entity|C0871161|Property|qlco|||properties|||0|966|270|280
SE|31||ab|3|entity|C0391845|Lysosomal enzyme|aapp,enzy|||lysosomal enzymes|||0|1000|310|327


SE|32||ti|1|text|15|86|A serum haemagglutinating property dependent upon polycarboxyl groups.
SE|32||ti|1|entity|C0229671|Serum|bdsu|||serum|||0|802|17|22
SE|32||ti|1|entity|C0871161|Property|qlco|||property|||0|802|41|49
SE|32||ti|1|entity|C0441833|Groups|inpr|||groups|||0|861|78|84

SE|32||ab|1|text|92|187|A serum agglutinin reactive with red cells in the presence of polycarboxyl groups is reported.
SE|32||ab|1|entity|C0229671|Serum|bdsu|||serum|||0|888|94|99
SE|32||ab|1|entity|C0001804|Agglutinins|imft|||agglutinin|||0|888|100|110
SE|32||ab|1|entity|C0205332|Reactive|qlco|||reactive|||0|1000|111|119
SE|32||ab|1|entity|C0014792|Erythrocytes|cell|||red cells|||0|1000|125|134
SE|32||ab|1|entity|C0441833|Groups|inpr|||groups|||0|861|167|173

SE|32||ab|2|text|187|352|It is likely that this represents an additional example of the type of agglutinin previously described as agglutinating red cells in the absence of ionized calcium.
SE|32||ab|2|entity|C1524062|Additional|ftcn|||additional|||0|694|224|234
SE|32||ab|2|entity|C1547052|*Type|qnco|||type|||0|1000|250|254
SE|32||ab|2|entity|C0001804|Agglutinins|imft|||agglutinin|||0|1000|258|268
SE|32||ab|2|entity|C0014792|Erythrocytes|cell|||red cells|||0|901|307|316
SE|32||ab|2|entity|C0373561|Ionized calcium|bacs,elii|||ionized calcium|||0|1000|335|350

SE|32||ab|3|text|352|572|Experimental evidence is presented indicating that it is free polycarboxyl groups that potentiate agglutination and that any metal ion, such as calcium, capable of chelating with these groups will prove to be inhibitory.
SE|32||ab|3|entity|C1517004|Experimental|ftcn|||Experimental|||0|694|352|364
SE|32||ab|3|entity|C0001801|agglutination|moft|||agglutination|||0|1000|450|463
SE|32||ab|3|entity|C0025552|Metals|inch|||metal|||0|888|477|482
SE|32||ab|3|entity|C0022023|Ions|elii|||ion|||0|888|483|486
SE|32||ab|3|entity|C0006675|Calcium|bacs,elii|||calcium|||0|1000|496|503
SE|32||ab|3|entity|C0441833|Groups|inpr|||groups|||0|1000|537|543
SE|32||ab|3|entity|C0243077|inhibitors|chvf|||inhibitory|||0|928|561|571


SE|33||ti|1|text|15|78|Effect of human erythrocyte stromata on complement activation.
SE|33||ti|1|entity|C1280500|Effect|qlco|||Effect|||0|1000|15|21
SE|33||ti|1|entity|C0020114|Human|humn|||human|||0|840|25|30
SE|33||ti|1|entity|C0014792|Erythrocytes|cell|||erythrocyte|||0|840|31|42
SE|33||ti|1|entity|C0927195|Stroma|bpoc|||stromata|||0|840|43|51
SE|33||ti|1|entity|C0009528|Complement Activation|moft|||complement activation|||0|1000|55|76

SE|33||ab|1|text|84|249|Stroma from either normal or PNH-like red cells is capable of inhibiting, to some extent, lysis in the sucrose test and enhancing lysis in the acidified-serum test.
SE|33||ab|1|entity|C0927195|Stroma|bpoc|||Stroma|||0|1000|84|90
SE|33||ab|1|entity|C0205307|Normal|qlco|||normal|||0|861|103|109
SE|33||ab|1|entity|C0024790|Paroxysmal nocturnal hemoglobinuria|dsyn|||PNH|||0|1000|113|116
SE|33||ab|1|entity|C0014792|Erythrocytes|cell|||red cells|||0|1000|122|131
SE|33||ab|1|entity|C0311403|Inhibited|qlco|||inhibiting|||0|966|146|156
SE|33||ab|1|entity|C0439792|Extent|spco|||extent|||0|1000|166|172
SE|33||ab|1|entity|C0024348|Lysis|patf|||lysis|||0|1000|174|179
SE|33||ab|1|entity|C0038636|Sucrose|bacs,carb|||sucrose|||0|888|187|194
SE|33||ab|1|entity|C0039593|Testing|resa|||test|||0|888|195|199
SE|33||ab|1|entity|C0024348|Lysis|patf|||lysis|||0|861|214|219
SE|33||ab|1|entity|C0430257|Acidified serum lysis test, RBC|lbpr|||acidified-serum test|||0|1000|227|247

SE|33||ab|2|text|249|445|The same opposing effects are displayed by the exclusion peaks from Sephadex G-200 obtained from each stroma preparation, suggesting that the same factor could be responsible for both activities.
SE|33||ab|2|entity|C0445247|Same|qlco|||same|||0|785|253|257
SE|33||ab|2|entity|C1280500|Effect|qlco|||effects|||0|785|267|274
SE|33||ab|2|entity|C0680251|Exclusion|ftcn|||exclusion|||0|1000|296|305
SE|33||ab|2|entity|C0953905|sephadex G 200|irda,orch|||Sephadex G-200|||0|1000|317|331
SE|33||ab|2|entity|C0927195|Stroma|bpoc|||stroma|||0|888|351|357
SE|33||ab|2|entity|C1521827|Preparation|ftcn|||preparation|||0|888|358|369
SE|33||ab|2|entity|C0445247|Same|qlco|||same|||0|888|391|395
SE|33||ab|2|entity|C1521761|Factor|ftcn|||factor|||0|888|396|402
SE|33||ab|2|entity|C0441655|Activities|acty|||activities|||0|1000|433|443

SE|33||ab|3|text|445|589|Stromata and peaks also induce lysis of PNH-like cells in unacidified serum, indicating activation of complement through the alternate pathway.
SE|33||ab|3|entity|C0927195|Stroma|bpoc|||Stromata|||0|966|445|453
SE|33||ab|3|entity|C0024348|Lysis|patf|||lysis|||0|1000|476|481
SE|33||ab|3|entity|C0024790|Paroxysmal nocturnal hemoglobinuria|dsyn|||PNH|||0|1000|485|488
SE|33||ab|3|entity|C0007634|Cells|cell|||cells|||0|1000|494|499
SE|33||ab|3|entity|C0229671|Serum|bdsu|||serum|||0|861|515|520
SE|33||ab|3|entity|C0009498|Complement System Proteins|aapp,imft|||complement|||0|1000|547|557
SE|33||ab|3|entity|C1552848|alternate|idcn|||alternate|||0|888|570|579
SE|33||ab|3|entity|C0243123|biochemical pathways|ftcn|||pathway|||0|888|580|587

SE|33||ab|4|text|589|645|This is confirmed by immunoelectrophoretic observation.
SE|33||ab|4|entity|C0020997|immunoelectrophoresis|lbpr|||immunoelectrophoretic|||0|623|610|631

SE|33||ab|5|text|645|776|When serum previously activated through the alternate pathway is used in the sucrose test the amount of lysis is markedly reduced.
SE|33||ab|5|entity|C0229671|Serum|bdsu|||serum|||0|1000|650|655
SE|33||ab|5|entity|C1552848|alternate|idcn|||alternate|||0|888|689|698
SE|33||ab|5|entity|C0243123|biochemical pathways|ftcn|||pathway|||0|888|699|706
SE|33||ab|5|entity|C0038636|Sucrose|bacs,carb|||sucrose|||0|1000|722|729
SE|33||ab|5|entity|C1265611|Quantity|qnco|||amount|||0|1000|739|745
SE|33||ab|5|entity|C0024348|Lysis|patf|||lysis|||0|1000|749|754
SE|33||ab|5|entity|C0522501|Massive|qlco|||markedly|||0|1000|758|766

SE|33||ab|6|text|776|878|This would indicate that the classical pathway activation can be controlled by the alternate pathway.
SE|33||ab|6|entity|C0443177|Classical|ftcn|||classical|||0|623|805|814
SE|33||ab|6|entity|C0243123|biochemical pathways|ftcn|||pathway|||0|623|815|822
SE|33||ab|6|entity|C1552848|alternate|idcn|||alternate|||0|888|859|868
SE|33||ab|6|entity|C0243123|biochemical pathways|ftcn|||pathway|||0|888|869|876

SE|33||ab|7|text|878|996|The possible clinical significance of these factors in determining the haemolytic crisis in PNH patients is discussed.
SE|33||ab|7|entity|C0332149|Possible|qlco|||possible|||0|828|882|890
SE|33||ab|7|entity|C0205210|Clinical|qlco|||clinical|||0|828|891|899
SE|33||ab|7|entity|C0750502|Significant|idcn|||significance|||0|828|900|912
SE|33||ab|7|entity|C1521761|Factor|ftcn|||factors|||0|966|922|929
SE|33||ab|7|entity|C0302110|Hemolytic crisis|comd|||haemolytic crisis|||0|1000|949|966
SE|33||ab|7|entity|C0024790|Paroxysmal nocturnal hemoglobinuria|dsyn|||PNH|||0|888|970|973
SE|33||ab|7|entity|C0030705|Patients|podg|||patients|||0|888|974|982
SE|33||ab|7|relation|0|0|C0024790|Paroxysmal nocturnal hemoglobinuria|dsyn|dsyn|||PNH|||0|888|970|973|MOD/HEAD|PROCESS_OF||970|982|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|888|974|982
SE|33||ab|7|relation|4|1|C0302110|Hemolytic crisis|comd|comd|||haemolytic crisis|||0|1000|949|966|PREP|PROCESS_OF||967|969|1|1|C0030705|Patients|podg,humn|humn|||patients|||0|888|974|982


SE|34||ti|1|text|15|67|Determinants of intracellular pH in the erythrocyte.
SE|34||ti|1|entity|C0175996|Protoplasm|celc|||intracellular|||0|888|31|44
SE|34||ti|1|entity|C0014792|Erythrocytes|cell|||erythrocyte|||0|1000|55|66


SE|35||ti|1|text|15|122|The effect of o-salicylate upon pentose phosphate pathway activity in normal and G6PD-deficient red cells.
SE|35||ti|1|entity|C1280500|Effect|qlco|||effect|||0|1000|19|25
SE|35||ti|1|entity|C0036075|salicylate|orch,phsu|||salicylate|||0|888|31|41
SE|35||ti|1|entity|C0030892|Pentose Phosphate Pathway|moft|||pentose phosphate pathway|||0|916|47|72
SE|35||ti|1|entity|C0205307|Normal|qlco|||normal|||0|1000|85|91
SE|35||ti|1|entity|C0017757|Glucosephosphate Dehydrogenase|aapp,enzy|2539|G6PD|G6PD|||0|861|96|100
SE|35||ti|1|entity|C0011155|Deficiency|ftcn|||deficient|||0|861|101|110
SE|35||ti|1|entity|C0014792|Erythrocytes|cell|||red cells|||0|861|111|120
SE|35||ti|1|relation|4|1|C0036075|salicylate|orch,phsu|phsu|||salicylate|||0|888|31|41|NOM|AFFECTS||19|25|4|2|C0030892|Pentose Phosphate Pathway|moft|moft|||pentose phosphate pathway|||0|916|47|72

SE|35||ab|1|text|128|296|The effect of the major metabolite of aspirin, namely salicylic acid, upon the pentose phosphate pathway (PPP) of normal and G6PD-deficient red cells has been studied.
SE|35||ab|1|entity|C1280500|Effect|qlco|||effect|||0|1000|132|138
SE|35||ab|1|entity|C0205164|Major|qlco|||major|||0|872|146|151
SE|35||ab|1|entity|C0870883|Metabolites|bacs|||metabolite|||0|872|152|162
SE|35||ab|1|entity|C0004057|Aspirin|orch,phsu|||aspirin|||0|1000|166|173
SE|35||ab|1|entity|C0036079|Salicylic Acid|orch,phsu|||salicylic acid|||0|901|182|196
SE|35||ab|1|entity|C0030892|Pentose Phosphate Pathway|moft|||pentose phosphate pathway|||0|1000|207|232
SE|35||ab|1|entity|C0205307|Normal|qlco|||normal|||0|1000|242|248
SE|35||ab|1|entity|C0017757|Glucosephosphate Dehydrogenase|aapp,enzy|2539|G6PD|G6PD|||0|861|253|257
SE|35||ab|1|entity|C0011155|Deficiency|ftcn|||deficient|||0|861|258|267
SE|35||ab|1|entity|C0014792|Erythrocytes|cell|||red cells|||0|861|268|277
SE|35||ab|1|relation|0|0|C0004057|Aspirin|orch,phsu|orch|||aspirin|||0|1000|166|173|INFER|AFFECTS(SPEC)||166|196|0|0|C0030892|Pentose Phosphate Pathway|moft|moft|||pentose phosphate pathway|||0|1000|207|232
SE|35||ab|1|relation|0|0|C0004057|Aspirin|orch,phsu|orch|||aspirin|||0|1000|166|173|SPEC|ISA||166|196|0|0|C0036079|Salicylic Acid|orch,phsu|orch|||salicylic acid|||0|901|182|196
SE|35||ab|1|relation|6|3|C0036079|Salicylic Acid|orch,phsu|phsu|||salicylic acid|||0|901|182|196|NOM|AFFECTS||132|138|6|4|C0030892|Pentose Phosphate Pathway|moft|moft|||pentose phosphate pathway|||0|1000|207|232

SE|35||ab|2|text|296|382|Salicylic acid was shown to inhibit this pathway in proportion to the amount present.
SE|35||ab|2|entity|C0036079|Salicylic Acid|orch,phsu|||Salicylic acid|||0|1000|296|310
SE|35||ab|2|entity|C0243123|biochemical pathways|ftcn|||pathway|||0|1000|337|344
SE|35||ab|2|entity|C0205351|Proportional|qlco|||proportion|||0|928|348|358
SE|35||ab|2|entity|C1265611|Quantity|qnco|||amount|||0|888|366|372
SE|35||ab|2|entity|C0150312|Present|qnco|||present|||0|888|373|380

SE|35||ab|3|text|382|504|At any concentration of this substance there was greater inhibition of the PPP in G6PD-deficient than in normal red cells.
SE|35||ab|3|entity|C0439861|Substance|sbst|||substance|||0|1000|411|420
SE|35||ab|3|entity|C0443228|Largest|qnco|||greater|||0|888|431|438
SE|35||ab|3|entity|C0243123|biochemical pathways|ftcn|||PPP|||0|861|457|460
SE|35||ab|3|entity|C0017757|Glucosephosphate Dehydrogenase|aapp,enzy|2539|G6PD|G6PD|||0|888|464|468
SE|35||ab|3|entity|C0011155|Deficiency|ftcn|||deficient|||0|888|469|478
SE|35||ab|3|entity|C0205307|Normal|qlco|||normal|||0|901|487|493
SE|35||ab|3|entity|C0014792|Erythrocytes|cell|||red cells|||0|901|494|503


SE|36||ti|1|text|15|145|The effects of processing of barley-based supplements on rumen pH, rate of digestion of voluntary intake of dried grass in sheep.
SE|36||ti|1|entity|C1280500|Effect|qlco|||effects|||0|966|19|26
SE|36||ti|1|entity|C1522240|Process|phpr|||processing|||0|966|30|40
SE|36||ti|1|entity|C0004755|Hordeum|plnt|||barley|||0|606|44|50
SE|36||ti|1|entity|C0035946|Rumen|bpoc|||rumen|||0|888|72|77
SE|36||ti|1|entity|C1521828|Rate|qnco|||rate|||0|1000|82|86
SE|36||ti|1|entity|C0012238|Digestion|orgf|||digestion|||0|1000|90|99
SE|36||ti|1|entity|C0439656|Voluntary|inbe|||voluntary|||0|888|103|112
SE|36||ti|1|entity|C1512806|Intake|ftcn|||intake|||0|888|113|119
SE|36||ti|1|entity|C0018210|Poaceae|plnt|||grass|||0|861|129|134
SE|36||ti|1|entity|C0036945|Sheep|mamm|||sheep|||0|1000|138|143
SE|36||ti|1|relation|8|3|C0012238|Digestion|orgf|orgf|||digestion|||0|1000|90|99|PREP|PROCESS_OF||135|137|1|1|C0036945|Sheep|mamm|mamm|||sheep|||0|1000|138|143

SE|36||ab|1|text|151|154|1.

SE|36||ab|2|text|154|271|In one experiment the effect on rumen pH of feeding with restricted amounts of whole or pelleted barley was studied.
SE|36||ab|2|entity|C0205447|One|qnco|||one|||0|888|157|160
SE|36||ab|2|entity|C0681814|research study|resa|||experiment|||0|888|161|171
SE|36||ab|2|entity|C1280500|Effect|qlco|||effect|||0|1000|176|182
SE|36||ab|2|entity|C0035946|Rumen|bpoc|||rumen|||0|888|186|191
SE|36||ab|2|entity|C0443288|Restricted|ftcn|||restricted|||0|872|211|221
SE|36||ab|2|entity|C1265611|Quantity|qnco|||amounts|||0|872|222|229
SE|36||ab|2|entity|C0444667|Whole|qnco|||whole|||0|1000|233|238
SE|36||ab|2|entity|C0004755|Hordeum|plnt|||barley|||0|861|251|257

SE|36||ab|3|text|271|466|With whole barley there was little variation in rumen pH associated with feeding time, but with pelleted barley the pH decreased from about 7-0 before feeding to about 5-3, 2--3 h after feeding.
SE|36||ab|3|entity|C0444667|Whole|qnco|||whole|||0|888|276|281
SE|36||ab|3|entity|C0004755|Hordeum|plnt|||barley|||0|888|282|288
SE|36||ab|3|entity|C0023882|Little's Disease|dsyn|||little|||0|888|299|305
SE|36||ab|3|entity|C0205419|Variant|qlco|||variation|||0|888|306|315
SE|36||ab|3|entity|C0035946|Rumen|bpoc|||rumen|||0|888|319|324
SE|36||ab|3|entity|C0040223|Time|tmco|||time|||0|861|352|356
SE|36||ab|3|entity|C0004755|Hordeum|plnt|||barley|||0|861|376|382

SE|36||ab|4|text|466|469|2.

SE|36||ab|5|text|469|629|The rate of disappearance of dried grass during incubation in the rumens of sheep receiving either whole or pelleted barley was studied in a second experiment.
SE|36||ab|5|entity|C1521828|Rate|qnco|||rate|||0|1000|473|477
SE|36||ab|5|entity|C0018210|Poaceae|plnt|||grass|||0|861|504|509
SE|36||ab|5|entity|C0035946|Rumen|bpoc|||rumens|||0|1000|535|541
SE|36||ab|5|entity|C0036945|Sheep|mamm|||sheep|||0|1000|545|550
SE|36||ab|5|entity|C0444667|Whole|qnco|||whole|||0|861|568|573
SE|36||ab|5|entity|C0004755|Hordeum|plnt|||barley|||0|861|586|592
SE|36||ab|5|entity|C0457385|seconds|tmco|||second|||0|888|610|616
SE|36||ab|5|entity|C0681814|research study|resa|||experiment|||0|888|617|627
SE|36||ab|5|relation|5|1|C0035946|Rumen|bpoc|bpoc|||rumens|||0|1000|535|541|PREP|PART_OF||542|544|4|1|C0036945|Sheep|mamm|mamm|||sheep|||0|1000|545|550

SE|36||ab|6|text|629|848|After 24 h incubation only 423 mg/g incubated had disappeared in the rumen of sheep receiving pelleted barley while 625 mg/g incubated had disappeared when it was incubated in the rumen of sheep receiving whole barley.
SE|36||ab|6|entity|C0456696|/24h|tmco|||24 h|||0|759|635|639
SE|36||ab|6|entity|C0035946|Rumen|bpoc|||rumen|||0|1000|698|703
SE|36||ab|6|entity|C0036945|Sheep|mamm|||sheep|||0|1000|707|712
SE|36||ab|6|entity|C0004755|Hordeum|plnt|||barley|||0|861|732|738
SE|36||ab|6|entity|C0035946|Rumen|bpoc|||rumen|||0|1000|809|814
SE|36||ab|6|entity|C0036945|Sheep|mamm|||sheep|||0|1000|818|823
SE|36||ab|6|entity|C0444667|Whole|qnco|||whole|||0|888|834|839
SE|36||ab|6|entity|C0004755|Hordeum|plnt|||barley|||0|888|840|846
SE|36||ab|6|relation|2|1|C0035946|Rumen|bpoc|bpoc|||rumen|||0|1000|698|703|PREP|PART_OF||704|706|6|1|C0036945|Sheep|mamm|mamm|||sheep|||0|1000|707|712
SE|36||ab|6|relation|6|1|C0035946|Rumen|bpoc|bpoc|||rumen|||0|1000|809|814|PREP|PART_OF||815|817|2|1|C0036945|Sheep|mamm|mamm|||sheep|||0|1000|818|823

SE|36||ab|7|text|848|851|3.

SE|36||ab|8|text|851|1028|The voluntary intake of dried grass of lambs was studied in a third experiment when they received supplements of either 25 or 50 g whole or pelleted barley/kg live weight 0-75.
SE|36||ab|8|entity|C0439656|Voluntary|inbe|||voluntary|||0|888|855|864
SE|36||ab|8|entity|C1512806|Intake|ftcn|||intake|||0|888|865|871
SE|36||ab|8|entity|C0018210|Poaceae|plnt|||grass|||0|861|881|886
SE|36||ab|8|entity|C1123019|Domestic Sheep|mamm|||lambs|||0|1000|890|895
SE|36||ab|8|entity|C0205437|Third|qnco|||third|||0|888|913|918
SE|36||ab|8|entity|C0681814|research study|resa|||experiment|||0|888|919|929
SE|36||ab|8|entity|C0444667|Whole|qnco|||whole|||0|1000|982|987
SE|36||ab|8|entity|C0004755|Hordeum|plnt|||barley|||0|710|1000|1006
SE|36||ab|8|entity|C1548795|Live|qlco|||live|||0|710|1010|1014
SE|36||ab|8|entity|C0043100|Weight|qnco|||weight|||0|710|1015|1021

SE|36||ab|9|text|1028|1151|At the high level, pelleted barley reduced intake of dried grass by 534 g/kg but whole barley reduced it by only 352 g/kg.
SE|36||ab|9|entity|C0205250|High|qlco|||high|||0|791|1035|1039
SE|36||ab|9|entity|C0004755|Hordeum|plnt|||barley|||0|791|1056|1062
SE|36||ab|9|entity|C1512806|Intake|ftcn|||intake|||0|1000|1071|1077
SE|36||ab|9|entity|C0018210|Poaceae|plnt|||grass|||0|861|1087|1092
SE|36||ab|9|entity|C0444667|Whole|qnco|||whole|||0|888|1109|1114
SE|36||ab|9|entity|C0004755|Hordeum|plnt|||barley|||0|888|1115|1121

SE|36||ab|10|text|1151|1346|The digestibility of acid-detergent fibre was reduced more by pelleted barley than by whole barley but there was a tendency for a small increase in digestibility of the barley due to processing.
SE|36||ab|10|entity|C0001128|Acids|chem|||acid|||0|851|1172|1176
SE|36||ab|10|entity|C0011740|Detergents|chvf|||detergent|||0|851|1177|1186
SE|36||ab|10|entity|C0225326|Fiber|phsu|||fibre|||0|851|1187|1192
SE|36||ab|10|entity|C0205172|More|ftcn|||more|||0|1000|1205|1209
SE|36||ab|10|entity|C0004755|Hordeum|plnt|||barley|||0|861|1222|1228
SE|36||ab|10|entity|C0444667|Whole|qnco|||whole|||0|888|1237|1242
SE|36||ab|10|entity|C0004755|Hordeum|plnt|||barley|||0|888|1243|1249
SE|36||ab|10|entity|C0700321|Small|qnco|||small|||0|888|1281|1286
SE|36||ab|10|entity|C0442805|Increase|ftcn|||increase|||0|888|1287|1295
SE|36||ab|10|entity|C0004755|Hordeum|plnt|||barley|||0|1000|1320|1326
SE|36||ab|10|entity|C1522240|Process|phpr|||processing|||0|966|1334|1344

SE|36||ab|11|text|1346|1349|4.

SE|36||ab|12|text|1349|1443|The implications of these findings on supplementation of roughages with cereals are discussed.
SE|36||ab|12|entity|C0243095|Finding|ftcn|||findings|||0|1000|1375|1383
SE|36||ab|12|entity|C1515075|Supplementation|topp|||supplementation|||0|1000|1387|1402
SE|36||ab|12|entity|C0086941|Roughage|food|||roughages|||0|1000|1406|1415
SE|36||ab|12|entity|C0007757|Cereals|food|||cereals|||0|1000|1421|1428


SE|37||ti|1|text|15|123|Poly(8-aminoguanylic acid): formation of ordered self-structures and interaction with poly(cytidylic acid).
SE|37||ti|1|entity|C0747726|POLY|cnce|||Poly|||0|1000|15|19
SE|37||ti|1|entity|C0001128|Acids|chem|||acid|||0|827|36|40
SE|37||ti|1|entity|C1522492|Formation|ftcn|||formation|||0|1000|43|52
SE|37||ti|1|entity|C0036588|Self|idcn|||self|||0|773|64|68
SE|37||ti|1|entity|C0678594|Structure|spco|||structures|||0|773|69|79
SE|37||ti|1|entity|C0747726|POLY|cnce|||poly|||0|1000|101|105
SE|37||ti|1|entity|C0010729|Cytidine Monophosphate|nnon|||cytidylic acid|||0|1000|106|120

SE|37||ab|1|text|129|225|Poly(8-aminoguanylic acid) has in neutral solution a novel ordered structure of high stability.
SE|37||ab|1|entity|C0747726|POLY|cnce|||Poly|||0|1000|129|133
SE|37||ab|1|entity|C0001128|Acids|chem|||acid|||0|827|150|154
SE|37||ab|1|entity|C0037633|Solutions|sbst|||solution|||0|861|171|179
SE|37||ab|1|entity|C0679622|novel|inpr|||novel|||0|802|182|187
SE|37||ab|1|entity|C0678594|Structure|spco|||structure|||0|802|196|205
SE|37||ab|1|entity|C0205250|High|qlco|||high|||0|888|209|213
SE|37||ab|1|entity|C1317741|STABILITY|qlco|||stability|||0|888|214|223

SE|37||ab|2|text|225|353|The 8-amino group permits formation of three hydrogen bonds between two residues along the "top", or long axis, of the purines.
SE|37||ab|2|entity|C0596072|amino group|inch|||amino group|||0|901|231|242
SE|37||ab|2|entity|C1522492|Formation|ftcn|||formation|||0|1000|251|260
SE|37||ab|2|entity|C0205449|Three|qnco|||three|||0|890|264|269
SE|37||ab|2|entity|C0020276|Hydrogen Bonding|npop|||hydrogen bonds|||0|890|270|284
SE|37||ab|2|entity|C0205448|Two|qnco|||two|||0|847|293|296
SE|37||ab|2|entity|C0522487|Long axis|orga,spco|||long axis|||0|1000|326|335
SE|37||ab|2|entity|C0034140|Purines|orch|||purines|||0|1000|344|351

SE|37||ab|3|text|353|456|The usual hydrogen bonding protons and Watson-Crick pairing sites are not involved in the association.
SE|37||ab|3|entity|C0020276|Hydrogen Bonding|npop|||hydrogen bonding|||0|824|363|379
SE|37||ab|3|entity|C0033727|Protons|elii|||protons|||0|824|380|387
SE|37||ab|3|entity|C0205145|Site|spco|||sites|||0|812|413|418
SE|37||ab|3|entity|C1518422|Not|ftcn|||not|||0|1000|423|426

SE|37||ab|4|text|456|534|The bonding scheme has a twofold rotation axis and is hemiprotonated at N(7).
SE|37||ab|4|entity|C0028758|Object Attachment|menp|||bonding|||0|888|460|467
SE|37||ab|4|entity|C1519193|Scheme|inpr|||scheme|||0|888|468|474
SE|37||ab|4|entity|C0035868|Rotation|ftcn|||rotation|||0|790|489|497
SE|37||ab|4|entity|C1522496|Axis|spco|||axis|||0|790|498|502

SE|37||ab|5|text|534|697|Poly(8NH2G) is converted by alkaline titration (pK = 9.7) to a quite different ordered structure, which is the favored form over the range approximately pH 10-11.
SE|37||ab|5|entity|C0747726|POLY|cnce|||Poly|||0|1000|534|538
SE|37||ab|5|entity|C0002055|Alkalies|inch|||alkaline|||0|853|562|570
SE|37||ab|5|entity|C0162621|Titration|lbpr|||titration|||0|853|571|580
SE|37||ab|5|entity|C1547020|*Difference|qnco|||different|||0|728|603|612
SE|37||ab|5|entity|C0678594|Structure|spco|||structure|||0|728|621|630
SE|37||ab|5|entity|C0309049|FAVOR|orch,phsu,vita|||favored|||0|872|645|652
SE|37||ab|5|entity|C1522492|Formation|ftcn|||form|||0|872|653|657
SE|37||ab|5|entity|C0205136|Over|spco|||over|||0|1000|658|662
SE|37||ab|5|entity|C1514721|Range|qnco|||range|||0|736|667|672
SE|37||ab|5|entity|C0332232|Approximate|ftcn,qlco|||approximately|||0|736|673|686

SE|37||ab|6|text|697|869|The bonding scheme appears to be composed of a planar, tetrameric array of guanine residues, in which the 8-amino group does not participate in interbase hydrogen bonding.
SE|37||ab|6|entity|C0028758|Object Attachment|menp|||bonding|||0|888|701|708
SE|37||ab|6|entity|C1519193|Scheme|inpr|||scheme|||0|888|709|715
SE|37||ab|6|entity|C0039686|Tetrameres|invt|||tetrameric|||0|754|752|762
SE|37||ab|6|entity|C1510941|Array|spco|||array|||0|754|763|768
SE|37||ab|6|entity|C0018321|Guanine|bacs,nnon|||guanine|||0|847|772|779
SE|37||ab|6|entity|C0596072|amino group|inch|||amino group|||0|901|805|816
SE|37||ab|6|entity|C1518422|Not|ftcn|||not|||0|1000|822|825
SE|37||ab|6|entity|C0020276|Hydrogen Bonding|npop|||hydrogen bonding|||0|901|851|867

SE|37||ab|7|text|869|1005|Poly (8NH2G) does not interact with poly(C) in neutral solution because of the high stability of the hemiprotonated G-G self-structure.
SE|37||ab|7|entity|C0747726|POLY|cnce|||Poly|||0|1000|869|873
SE|37||ab|7|entity|C1518422|Not|ftcn|||not|||0|1000|887|890
SE|37||ab|7|entity|C0747726|POLY|cnce|||poly|||0|1000|905|909
SE|37||ab|7|entity|C0037633|Solutions|sbst|||solution|||0|861|924|932
SE|37||ab|7|entity|C0205250|High|qlco|||high|||0|888|948|952
SE|37||ab|7|entity|C1317741|STABILITY|qlco|||stability|||0|888|953|962
SE|37||ab|7|entity|C0162832|APC gene|gngm|324|APC|G-G|||0|729|985|988
SE|37||ab|7|entity|C0036588|Self|idcn|||self|||0|729|989|993
SE|37||ab|7|entity|C0678594|Structure|spco|||structure|||0|729|994|1003

SE|37||ab|8|text|1005|1111|Titration to the alkaline plateau, however, permits ready formation of a two-stranded Watson-Crick helix.
SE|37||ab|8|entity|C0162621|Titration|lbpr|||Titration|||0|1000|1005|1014
SE|37||ab|8|entity|C0002055|Alkalies|inch|||alkaline|||0|623|1022|1030
SE|37||ab|8|entity|C1522492|Formation|ftcn|||formation|||0|861|1063|1072
SE|37||ab|8|entity|C0205448|Two|qnco|||two|||0|637|1078|1081

SE|37||ab|9|text|1111|1223|In contrast to the monomer 8NH2GMP, poly(8NH2G) does not form a triple helix with poly(C) under any conditions.
SE|37||ab|9|entity|C0596973|monomer|chvs|||monomer|||0|694|1130|1137
SE|37||ab|9|entity|C0747726|POLY|cnce|||poly|||0|1000|1147|1151
SE|37||ab|9|entity|C1518422|Not|ftcn|||not|||0|1000|1164|1167
SE|37||ab|9|entity|C0994334|triple helix|spco|||triple helix|||0|1000|1175|1187
SE|37||ab|9|entity|C0747726|POLY|cnce|||poly|||0|1000|1193|1197
SE|37||ab|9|entity|C0348080|Condition|qlco|||conditions|||0|966|1211|1221

SE|37||ab|10|text|1223|1422|The properties of the ordered structures are interpreted in terms of a strong tendency of the 8-amino group to form a third interbase hydrogen bond, when this possibility is not prevented by high pH.
SE|37||ab|10|entity|C0871161|Property|qlco|||properties|||0|966|1227|1237
SE|37||ab|10|entity|C0678594|Structure|spco|||structures|||0|827|1253|1263
SE|37||ab|10|entity|C0442821|Strong|qlco|||strong|||0|694|1294|1300
SE|37||ab|10|entity|C0596072|amino group|inch|||amino group|||0|901|1319|1330
SE|37||ab|10|entity|C0205437|Third|qnco|||third|||0|824|1341|1346
SE|37||ab|10|entity|C0020276|Hydrogen Bonding|npop|||hydrogen bond|||0|824|1357|1370
SE|37||ab|10|entity|C1518422|Not|ftcn|||not|||0|1000|1397|1400
SE|37||ab|10|entity|C0205250|High|qlco|||high|||0|888|1414|1418


SE|38||ti|1|text|15|112|Effect of pH on substrate and inhibitor kinetic constants of human liver alanine aminopeptidase.
SE|38||ti|1|entity|C1280500|Effect|qlco|||Effect|||0|1000|15|21
SE|38||ti|1|entity|C0243077|inhibitors|chvf|||inhibitor|||0|829|45|54
SE|38||ti|1|entity|C0022702|Kinetics|idcn|||kinetic|||0|829|55|62
SE|38||ti|1|entity|C1547014|*Constant|qnco|||constants|||0|829|63|72
SE|38||ti|1|entity|C0020114|Human|humn|||human|||0|861|76|81
SE|38||ti|1|entity|C0023884|Liver|bpoc|||liver|||0|861|82|87
SE|38||ti|1|entity|C0054943|ALANINE AMINOPEPTIDASE|aapp,enzy,imft|||alanine aminopeptidase|||0|861|88|110
SE|38||ti|1|relation|0|0|C0054943|ALANINE AMINOPEPTIDASE|aapp,gngm,enzy,imft|aapp|||alanine aminopeptidase|||0|861|88|110|MOD/HEAD|PART_OF||82|110|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|861|82|87

SE|38||ti|2|text|112|161|Evidence for two ionizable active center groups.
SE|38||ti|2|entity|C0205448|Two|qnco|||two|||0|766|125|128
SE|38||ti|2|entity|C0205177|Active|ftcn|||active|||0|766|139|145
SE|38||ti|2|entity|C0205099|Central|spco|||center|||0|766|146|152
SE|38||ti|2|entity|C0441833|Groups|inpr|||groups|||0|766|153|159

SE|38||ab|1|text|167|449|The presence of at least two ionizable active center groups has been detected by a study of the effect of pH upon catalysis of hydrolysis of L-alanyl-beta-naphthylamide by human liver alanine aminopeptidase and upon the inhibition of hydrolysis by inhibitors and substrate analogs.
SE|38||ab|1|entity|C0205448|Two|qnco|||two|||0|734|192|195
SE|38||ab|1|entity|C0205177|Active|ftcn|||active|||0|734|206|212
SE|38||ab|1|entity|C0205099|Central|spco|||center|||0|734|213|219
SE|38||ab|1|entity|C0441833|Groups|inpr|||groups|||0|734|220|226
SE|38||ab|1|entity|C0008972|Clinical Research|resa|||study|||0|1000|250|255
SE|38||ab|1|entity|C1280500|Effect|qlco|||effect|||0|1000|263|269
SE|38||ab|1|entity|C0007382|Catalysis|npop|||catalysis|||0|1000|281|290
SE|38||ab|1|entity|C0020291|Hydrolysis|npop|||hydrolysis|||0|1000|294|304
SE|38||ab|1|entity|C0093484|2-naphthylamide|orch|||beta-naphthylamide|||0|861|317|335
SE|38||ab|1|entity|C0020114|Human|humn|||human|||0|861|339|344
SE|38||ab|1|entity|C0023884|Liver|bpoc|||liver|||0|861|345|350
SE|38||ab|1|entity|C0054943|ALANINE AMINOPEPTIDASE|aapp,enzy,imft|||alanine aminopeptidase|||0|861|351|373
SE|38||ab|1|entity|C0020291|Hydrolysis|npop|||hydrolysis|||0|1000|401|411
SE|38||ab|1|entity|C0243077|inhibitors|chvf|||inhibitors|||0|1000|415|425
SE|38||ab|1|entity|C0243071|Analog|chvs|||analogs|||0|827|440|447
SE|38||ab|1|relation|0|0|C0054943|ALANINE AMINOPEPTIDASE|aapp,gngm,enzy,imft|aapp|||alanine aminopeptidase|||0|861|351|373|MOD/HEAD|PART_OF||345|373|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|861|345|350
SE|38||ab|1|relation|9|1|C0054943|ALANINE AMINOPEPTIDASE|aapp,gngm,enzy,imft|aapp|||alanine aminopeptidase|||0|861|351|373|NOM|DISRUPTS||387|397|3|1|C0020291|Hydrolysis|npop|npop|||hydrolysis|||0|1000|401|411
SE|38||ab|1|relation|9|4|C0093484|2-naphthylamide|orch|orch|||beta-naphthylamide|||0|861|317|335|NOM|AFFECTS||263|269|9|2|C0007382|Catalysis|npop|npop|||catalysis|||0|1000|281|290

SE|38||ab|2|text|449|597|Octanoic acid, octylamine, and peptide inhibitors have been found to be competitive inhibitors and are therefore thought to bind the active center.
SE|38||ab|2|entity|C0054616|caprylic acid|lipd,phsu|||Octanoic acid|||0|1000|449|462
SE|38||ab|2|entity|C0069367|octylamine|orch|||octylamine|||0|1000|464|474
SE|38||ab|2|entity|C0030956|Peptides|aapp|||peptide|||0|888|480|487
SE|38||ab|2|entity|C0243077|inhibitors|chvf|||inhibitors|||0|888|488|498
SE|38||ab|2|entity|C0679932|competition|socb|||competitive|||0|888|521|532
SE|38||ab|2|entity|C0243077|inhibitors|chvf|||inhibitors|||0|888|533|543
SE|38||ab|2|entity|C0205177|Active|ftcn|||active|||0|888|582|588
SE|38||ab|2|entity|C0205099|Central|spco|||center|||0|888|589|595

SE|38||ab|3|text|597|807|L-Phe was previously shown to bind the active center since it was found to be a competitive inhibitor of the hydrolysis of tripeptide substrates (Garner, C. W., and Behal, F. J. (1975), Biochemistry 14, 3208).
SE|38||ab|3|entity|C0031453|Phenylalanine|aapp,bacs,phsu|||Phe|||0|861|599|602
SE|38||ab|3|entity|C0205177|Active|ftcn|||active|||0|888|636|642
SE|38||ab|3|entity|C0205099|Central|spco|||center|||0|888|643|649
SE|38||ab|3|entity|C0679932|competition|socb|||competitive|||0|872|677|688
SE|38||ab|3|entity|C0243077|inhibitors|chvf|||inhibitor|||0|872|689|698
SE|38||ab|3|entity|C0020291|Hydrolysis|npop|||hydrolysis|||0|1000|706|716
SE|38||ab|3|entity|C0005477|Biochemistry|ocdi|||Biochemistry|||0|861|783|795
SE|38||ab|3|relation|2|2|C0031453|Phenylalanine|aapp,gngm,bacs,phsu|aapp|||Phe|||0|861|599|602|NOM|DISRUPTS||689|698|6|1|C0020291|Hydrolysis|npop|npop|||hydrolysis|||0|1000|706|716

SE|38||ab|4|text|807|825|A plot of pKm vs.
SE|38||ab|4|entity|||gngm|5315|PKM|pKm|||0|1000|817|820

SE|38||ab|5|text|825|1010|pH for the substrate L-Ala-beta-naphthylamide showed that binding decreased below pH 5.9 and above 7.5, the points at which the theoretical curve undergoes an integral change in slope.
SE|38||ab|5|entity|C0702172|Alar|hops,orch|||Ala|||0|763|848|851
SE|38||ab|5|entity|C0093484|2-naphthylamide|orch|||beta-naphthylamide|||0|763|852|870
SE|38||ab|5|entity|C0542339|Inferior|spco|||below|||0|750|901|906
SE|38||ab|5|entity|C0205134|Curved|spco|||curve|||0|789|965|970
SE|38||ab|5|entity|C0443238|Integral|qnco|||integral|||0|888|984|992
SE|38||ab|5|entity|C0807955|SLOPE|fndg|||slope|||0|1000|1003|1008

SE|38||ab|6|text|1010|1137|These points are interpreted as the pKa either of substrate ionizable groups or binding-dependent enzyme active center groups.
SE|38||ab|6|entity|C0010531|Cyclic AMP-Dependent Protein Kinases|aapp,enzy|||pKa|||0|861|1046|1049
SE|38||ab|6|entity|C0441833|Groups|inpr|||groups|||0|827|1080|1086
SE|38||ab|6|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|769|1108|1114
SE|38||ab|6|entity|C0205177|Active|ftcn|||active|||0|769|1115|1121
SE|38||ab|6|entity|C0205099|Central|spco|||center|||0|769|1122|1128
SE|38||ab|6|entity|C0441833|Groups|inpr|||groups|||0|769|1129|1135

SE|38||ab|7|text|1137|1162|Similar plots of pKm vs.
SE|38||ab|7|entity|||gngm|5315|PKM|pKm|||0|1000|1154|1157

SE|38||ab|8|text|1162|1220|pH for L-alanyl-p-nitroanilide (as substrate) and pKi vs.

SE|38||ab|9|text|1220|1362|pH for L-Leu-L-Leu-L-Leu and D-Leu-L-Tyr (as inhibitors) gave pairs fo pKa values of 5.8 and 7.4, 6.0 and 7.5, and 5.7 and 7.5, respectively.
SE|38||ab|9|entity|C0064815|leucyl-leucyl-leucine|aapp|||Leu-L-Leu-L-Leu|||0|879|1229|1244
SE|38||ab|9|entity|C0214061|leucyltyrosine|aapp|7299|TYR|Leu-L-Tyr|||0|890|1251|1260
SE|38||ab|9|entity|C0243077|inhibitors|chvf|||inhibitors|||0|1000|1265|1275
SE|38||ab|9|entity|C0010531|Cyclic AMP-Dependent Protein Kinases|aapp,enzy|||pKa|||0|851|1291|1294
SE|38||ab|9|entity|C0042295|Values|qlco|||values|||0|851|1295|1301

SE|38||ab|10|text|1362|1530|All the above substrates (and D-Leu-L-Tyr) have pKa values near 7.5; therefore, the binding-dependent group with a pKa value near 7.5 is possibly this substrate group.
SE|38||ab|10|entity|C1282910|Upper|spco|||above|||0|694|1370|1375
SE|38||ab|10|entity|C0214061|leucyltyrosine|aapp|7299|TYR|Leu-L-Tyr|||0|890|1394|1403
SE|38||ab|10|entity|C0010531|Cyclic AMP-Dependent Protein Kinases|aapp,enzy|||pKa|||0|888|1410|1413
SE|38||ab|10|entity|C0042295|Values|qlco|||values|||0|888|1414|1420
SE|38||ab|10|entity|C0441833|Groups|inpr|||group|||0|790|1464|1469
SE|38||ab|10|entity|C0010531|Cyclic AMP-Dependent Protein Kinases|aapp,enzy|||pKa|||0|694|1477|1480
SE|38||ab|10|entity|C0332149|Possible|qlco|||possibly|||0|1000|1499|1507
SE|38||ab|10|entity|C0441833|Groups|inpr|||group|||0|861|1523|1528

SE|38||ab|11|text|1530|1555|Similar plots of pKi vs.

SE|38||ab|12|text|1555|1701|pH for the inhibitors L-Phe, L-Met, L-Leu, octylamine, and octanoic acid had only one bending point at 7.7, 7.6, 7.4, 6.3, and 5.9, respectively.
SE|38||ab|12|entity|C0243077|inhibitors|chvf|||inhibitors|||0|840|1566|1576
SE|38||ab|12|entity|C0031453|Phenylalanine|aapp,bacs,phsu|||Phe|||0|840|1579|1582
SE|38||ab|12|entity|C0023401|Leucine|aapp,bacs,phsu|||Leu|||0|763|1593|1596
SE|38||ab|12|entity|C0069367|octylamine|orch|||octylamine|||0|1000|1598|1608
SE|38||ab|12|entity|C0054616|caprylic acid|lipd,phsu|||octanoic acid|||0|1000|1614|1627
SE|38||ab|12|entity|C0205447|One|qnco|||one|||0|861|1637|1640
SE|38||ab|12|entity|C0470355|7+7|qnco|||7.7|||0|1000|1658|1661

SE|38||ab|13|text|1701|1802|Amino acid inhibitors, octylamine, and octanoic acid have no groups with pKa values between 5 and 9.
SE|38||ab|13|entity|C0596075|aminoacid inhibitor|phsu|||Amino acid inhibitors|||0|983|1701|1722
SE|38||ab|13|entity|C0069367|octylamine|orch|||octylamine|||0|1000|1724|1734
SE|38||ab|13|entity|C0054616|caprylic acid|lipd,phsu|||octanoic acid|||0|1000|1740|1753
SE|38||ab|13|entity|C0441833|Groups|inpr|||groups|||0|1000|1762|1768
SE|38||ab|13|entity|C0010531|Cyclic AMP-Dependent Protein Kinases|aapp,enzy|||pKa|||0|888|1774|1777
SE|38||ab|13|entity|C0042295|Values|qlco|||values|||0|888|1778|1784

SE|38||ab|14|text|1802|2059|These data indicate that there are two active center ionizable groups with pKa values of approximately 6.0 and 7.5 which are involved in substrate binding or inhibitory amino acid binding but not in catalysis since Vmax was constant at all pH values tested.
SE|38||ab|14|entity|C1511726|Data|idcn|||data|||0|1000|1808|1812
SE|38||ab|14|entity|C0205448|Two|qnco|||two|||0|766|1837|1840
SE|38||ab|14|entity|C0205177|Active|ftcn|||active|||0|766|1841|1847
SE|38||ab|14|entity|C0205099|Central|spco|||center|||0|766|1848|1854
SE|38||ab|14|entity|C0441833|Groups|inpr|||groups|||0|766|1865|1871
SE|38||ab|14|entity|C0010531|Cyclic AMP-Dependent Protein Kinases|aapp,enzy|||pKa|||0|888|1877|1880
SE|38||ab|14|entity|C0042295|Values|qlco|||values|||0|888|1881|1887
SE|38||ab|14|entity|C0332232|Approximate|ftcn,qlco|||approximately|||0|827|1891|1904
SE|38||ab|14|entity|C0243077|inhibitors|chvf|||inhibitory|||0|892|1960|1970
SE|38||ab|14|entity|C1148572|amino acid binding|moft|||amino acid binding|||0|892|1971|1989
SE|38||ab|14|entity|C1518422|Not|ftcn|||not|||0|1000|1994|1997
SE|38||ab|14|entity|C0007382|Catalysis|npop|||catalysis|||0|1000|2001|2010
SE|38||ab|14|entity|C1547014|*Constant|qnco|||constant|||0|1000|2026|2034
SE|38||ab|14|entity|C0042295|Values|qlco|||values|||0|888|2045|2051


SE|39||ti|1|text|15|99|Formation of transient complexes in the glutamate dehydrogenase catalyzed reaction.
SE|39||ti|1|entity|C1522492|Formation|ftcn|||Formation|||0|1000|15|24
SE|39||ti|1|entity|C0040704|Transient Population Group|popg|||transient|||0|888|28|37
SE|39||ti|1|entity|C0439855|Complex|qlco|||complexes|||0|888|38|47
SE|39||ti|1|entity|C0017786|Glutamate Dehydrogenase|aapp,enzy|||glutamate dehydrogenase|||0|1000|55|78
SE|39||ti|1|entity|C0443286|Reaction|ftcn|||reaction|||0|1000|89|97

SE|39||ab|1|text|105|231|The reaction of glutamate dehydrogenase and glutamate (gl) with NAD+ and NADP+ has been studied with stopped-flow techniques.
SE|39||ab|1|entity|C0443286|Reaction|ftcn|||reaction|||0|1000|109|117
SE|39||ab|1|entity|C0017786|Glutamate Dehydrogenase|aapp,enzy|||glutamate dehydrogenase|||0|1000|121|144
SE|39||ab|1|entity|C0017789|Glutamates|aapp|||glutamate|||0|1000|149|158
SE|39||ab|1|entity|C0027270|Nicotinamide adenine dinucleotide (NAD)|bacs,nnon|||NAD|||0|1000|169|172
SE|39||ab|1|entity|C0027303|NADP|bacs,nnon|||NADP|||0|1000|178|182
SE|39||ab|1|entity|C0597528|stop flow technique|diap|||stopped-flow techniques|||0|977|206|229

SE|39||ab|2|text|231|300|The enzyme was in all experiments present in excess of the coenzyme.
SE|39||ab|2|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|235|241
SE|39||ab|2|entity|C0681814|research study|resa|||experiments|||0|1000|253|264
SE|39||ab|2|entity|C0442802|Excessive|qlco|||excess|||0|928|276|282
SE|39||ab|2|entity|C0009235|Coenzymes|bacs,orch|||coenzyme|||0|1000|290|298
SE|39||ab|2|relation|0|0|C0009235|Coenzymes|bacs,orch|bacs|||coenzyme|||0|1000|290|298|SPEC|ISA||235|298|0|0|C0014442|Enzymes|enzy,orch|enzy|||enzyme|||0|1000|235|241

SE|39||ab|3|text|300|446|The results indicate that the ternary complex (E-NAD(P)H-kg) is present as an intermediate in the formation of the stable complex (E-NAD(P)H-gl).
SE|39||ab|3|entity|C1274040|result|ftcn|||results|||0|966|304|311
SE|39||ab|3|entity|C0325881|Terns|bird|||ternary|||0|853|330|337
SE|39||ab|3|entity|C0439855|Complex|qlco|||complex|||0|853|338|345
SE|39||ab|3|entity|C0027270|Nicotinamide adenine dinucleotide (NAD)|bacs,nnon|||E-NAD|||0|861|347|352
SE|39||ab|3|entity|C0150312|Present|qnco|||present|||0|1000|364|371
SE|39||ab|3|entity|C0205103|Intermediate|spco|||intermediate|||0|1000|378|390
SE|39||ab|3|entity|C1522492|Formation|ftcn|||formation|||0|1000|398|407
SE|39||ab|3|entity|C0439855|Complex|qlco|||complex|||0|861|422|429
SE|39||ab|3|entity|C0027270|Nicotinamide adenine dinucleotide (NAD)|bacs,nnon|||E-NAD|||0|861|431|436
SE|39||ab|3|entity|C0017789|Glutamates|aapp|||gl|||0|851|441|443

SE|39||ab|4|text|446|520|The identification of the complexes is based on their absorption spectra.
SE|39||ab|4|entity|C0439855|Complex|qlco|||complexes|||0|1000|472|481

SE|39||ab|5|text|520|750|The binding of the coenzyme to (E-gl) is the rate-limiting step in the formation of (E-NAD(P)H-kg) while the dissociation of alpha-ketoglutarate (kg) from this complex is the rate-limiting step in the formation of (E-NAD(P)H-gl).
SE|39||ab|5|entity|C0009235|Coenzymes|bacs,orch|||coenzyme|||0|1000|539|547
SE|39||ab|5|entity|C0017789|Glutamates|aapp|||gl|||0|861|554|556
SE|39||ab|5|entity|C1521828|Rate|qnco|||rate|||0|840|565|569
SE|39||ab|5|entity|C0439801|Limited|ftcn|||limiting|||0|840|570|578
SE|39||ab|5|entity|C1261552|Step|ftcn|||step|||0|840|579|583
SE|39||ab|5|entity|C1522492|Formation|ftcn|||formation|||0|1000|591|600
SE|39||ab|5|entity|C0027270|Nicotinamide adenine dinucleotide (NAD)|bacs,nnon|||E-NAD|||0|861|605|610
SE|39||ab|5|entity|C0086168|Dissociation|mobd|||dissociation|||0|1000|629|641
SE|39||ab|5|entity|C1291208|2-Oxoglutarate|orch,phsu|||alpha-ketoglutarate|||0|1000|645|664
SE|39||ab|5|entity|C0439855|Complex|qlco|||complex|||0|1000|680|687
SE|39||ab|5|entity|C1521828|Rate|qnco|||rate|||0|840|695|699
SE|39||ab|5|entity|C0439801|Limited|ftcn|||limiting|||0|840|700|708
SE|39||ab|5|entity|C1261552|Step|ftcn|||step|||0|840|709|713
SE|39||ab|5|entity|C1522492|Formation|ftcn|||formation|||0|1000|721|730
SE|39||ab|5|entity|C0027270|Nicotinamide adenine dinucleotide (NAD)|bacs,nnon|||E-NAD|||0|861|735|740
SE|39||ab|5|entity|C0017789|Glutamates|aapp|||gl|||0|851|745|747

SE|39||ab|6|text|750|855|The Km for glutamate was 20-25 mM in the first reaction and 3 mM in the formation of the stable complex.
SE|39||ab|6|entity|C0017789|Glutamates|aapp|||glutamate|||0|1000|761|770
SE|39||ab|6|entity|C1279901|Firstly|qlco|||first|||0|888|791|796
SE|39||ab|6|entity|C0443286|Reaction|ftcn|||reaction|||0|888|797|805
SE|39||ab|6|entity|C1522492|Formation|ftcn|||formation|||0|1000|822|831
SE|39||ab|6|entity|C0439855|Complex|qlco|||complex|||0|861|846|853

SE|39||ab|7|text|855|903|The Km values were independent of the coenzyme.
SE|39||ab|7|entity|C0042295|Values|qlco|||values|||0|888|862|868
SE|39||ab|7|entity|C0009235|Coenzymes|bacs,orch|||coenzyme|||0|1000|893|901

SE|39||ab|8|text|903|986|The reaction rates with NAD+ were approximately 50% greater than those with NADP+.
SE|39||ab|8|entity|C0678608|reaction rate|tmco|||reaction rates|||0|983|907|921
SE|39||ab|8|entity|C0027270|Nicotinamide adenine dinucleotide (NAD)|bacs,nnon|||NAD|||0|1000|927|930
SE|39||ab|8|entity|C0332232|Approximate|ftcn,qlco|||approximately|||0|802|937|950
SE|39||ab|8|entity|C0443228|Largest|qnco|||greater|||0|802|955|962
SE|39||ab|8|entity|C0027303|NADP|bacs,nnon|||NADP|||0|1000|979|983

SE|39||ab|9|text|986|1131|Furthermore, high glutamate concentration inhibited the formation of (E-NADH-kg) while no substrate inhibition was found with NADP+ as coenzyme.
SE|39||ab|9|entity|C0205250|High|qlco|||high|||0|623|999|1003
SE|39||ab|9|entity|C0017789|Glutamates|aapp|||glutamate|||0|623|1004|1013
SE|39||ab|9|entity|C1522492|Formation|ftcn|||formation|||0|1000|1042|1051
SE|39||ab|9|entity|C0027289|NADH|bacs,nnon,phsu|||E-NADH|||0|660|1056|1062
SE|39||ab|9|entity|C0027303|NADP|bacs,nnon|||NADP|||0|1000|1112|1116
SE|39||ab|9|entity|C0009235|Coenzymes|bacs,orch|||coenzyme|||0|1000|1121|1129

SE|39||ab|10|text|1131|1200|ADP enhanced while GTP reduced the rate of (E-NAD(P)H-gl) formation.
SE|39||ab|10|entity|||gngm|23038|WDTC1|ADP|||0|1000|1131|1134
SE|39||ab|10|entity|C0018353|Guanosine Triphosphate|bacs,nnon|||GTP|||0|1000|1150|1153
SE|39||ab|10|entity|C1521828|Rate|qnco|||rate|||0|1000|1166|1170
SE|39||ab|10|entity|C0027270|Nicotinamide adenine dinucleotide (NAD)|bacs,nnon|||E-NAD|||0|861|1175|1180
SE|39||ab|10|entity|C0017789|Glutamates|aapp|||gl|||0|851|1185|1187
SE|39||ab|10|entity|C1522492|Formation|ftcn|||formation|||0|1000|1189|1198

SE|39||ab|11|text|1200|1351|The rate of formation of (E-NAD(P)H-kg) was inhibited by ADP, while it increased at high glutamate concentration when small amounts of GTP were added.
SE|39||ab|11|entity|C1521828|Rate|qnco|||rate|||0|1000|1204|1208
SE|39||ab|11|entity|C1522492|Formation|ftcn|||formation|||0|1000|1212|1221
SE|39||ab|11|entity|C0027270|Nicotinamide adenine dinucleotide (NAD)|bacs,nnon|||E-NAD|||0|861|1226|1231
SE|39||ab|11|entity|||gngm|23038|WDTC1|ADP|||0|1000|1257|1260
SE|39||ab|11|entity|C0205250|High|qlco|||high|||0|623|1284|1288
SE|39||ab|11|entity|C0017789|Glutamates|aapp|||glutamate|||0|623|1289|1298
SE|39||ab|11|entity|C0700321|Small|qnco|||small|||0|872|1318|1323
SE|39||ab|11|entity|C1265611|Quantity|qnco|||amounts|||0|872|1324|1331
SE|39||ab|11|entity|C0018353|Guanosine Triphosphate|bacs,nnon|||GTP|||0|1000|1335|1338
SE|39||ab|11|relation|4|1|||gngm,aapp|gngm|23038|WDTC1|ADP|||0|1000|1257|1260|VERB|INHIBITS||1244|1253|4|2|C0027270|Nicotinamide adenine dinucleotide (NAD)|bacs,nnon|bacs|||E-NAD|||0|861|1226|1231

SE|39||ab|12|text|1351|1548|The results show that the higher activity found with NAD+ compared to NADP+ under steady-state assay conditions do not necessarily involve binding of NAD+ to the ADP activating site of the enzyme.
SE|39||ab|12|entity|C1274040|result|ftcn|||results|||0|966|1355|1362
SE|39||ab|12|entity|C0205250|High|qlco|||higher|||0|872|1377|1383
SE|39||ab|12|entity|C0027270|Nicotinamide adenine dinucleotide (NAD)|bacs,nnon|||NAD|||0|1000|1404|1407
SE|39||ab|12|entity|C0027303|NADP|bacs,nnon|||NADP|||0|1000|1421|1425
SE|39||ab|12|entity|C0678587|steady state|npop|||steady-state|||0|850|1433|1445
SE|39||ab|12|entity|C1510438|Assay|lbpr|||assay|||0|850|1446|1451
SE|39||ab|12|entity|C0348080|Condition|qlco|||conditions|||0|850|1452|1462
SE|39||ab|12|entity|C1518422|Not|ftcn|||not|||0|1000|1466|1469
SE|39||ab|12|entity|C0027270|Nicotinamide adenine dinucleotide (NAD)|bacs,nnon|||NAD|||0|1000|1501|1504
SE|39||ab|12|entity|||gngm|23038|WDTC1|ADP|||0|773|1513|1516
SE|39||ab|12|entity|C1515877|Activate|ftcn|||activating|||0|773|1517|1527
SE|39||ab|12|entity|C0205145|Site|spco|||site|||0|773|1528|1532
SE|39||ab|12|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|1540|1546
SE|39||ab|12|relation|3|1|C0027270|Nicotinamide adenine dinucleotide (NAD)|bacs,nnon|bacs|||NAD|||0|1000|1404|1407|VERB|compared_with||1409|1417|5|1|C0027303|NADP|bacs,nnon|bacs|||NADP|||0|1000|1421|1425
SE|39||ab|12|relation|5|2|C0027303|NADP|bacs,nnon|bacs|||NADP|||0|1000|1421|1425|VERB|INTERACTS_WITH||1490|1497|3|1|C0027270|Nicotinamide adenine dinucleotide (NAD)|bacs,nnon|bacs|||NAD|||0|1000|1501|1504

SE|39||ab|13|text|1548|1838|Moreover, the substrate inhibition found at high glutamate concentration under steady-state assay condition is not due to the formation of (E-NAD(P)H-gl) as this complex is formed with Km of 3 mM glutamate, and the substrate inhibition is only significant at 20-30 times this concentration.
SE|39||ab|13|entity|C0205250|High|qlco|||high|||0|623|1592|1596
SE|39||ab|13|entity|C0017789|Glutamates|aapp|||glutamate|||0|623|1597|1606
SE|39||ab|13|entity|C0678587|steady state|npop|||steady-state|||0|861|1627|1639
SE|39||ab|13|entity|C1510438|Assay|lbpr|||assay|||0|861|1640|1645
SE|39||ab|13|entity|C0348080|Condition|qlco|||condition|||0|861|1646|1655
SE|39||ab|13|entity|C1518422|Not|ftcn|||not|||0|1000|1659|1662
SE|39||ab|13|entity|C1522492|Formation|ftcn|||formation|||0|1000|1674|1683
SE|39||ab|13|entity|C0027270|Nicotinamide adenine dinucleotide (NAD)|bacs,nnon|||E-NAD|||0|861|1688|1693
SE|39||ab|13|entity|C0017789|Glutamates|aapp|||gl|||0|851|1698|1700
SE|39||ab|13|entity|C0439855|Complex|qlco|||complex|||0|1000|1710|1717
SE|39||ab|13|entity|C0017789|Glutamates|aapp|||glutamate|||0|851|1744|1753
SE|39||ab|13|entity|C0750502|Significant|idcn|||significant|||0|861|1792|1803
SE|39||ab|13|entity|C0040223|Time|tmco|||times|||0|793|1813|1818


SE|40||ti|1|text|15|97|Human brain and placental choline acetyltransferase: purification and properties.
SE|40||ti|1|entity|C0020114|Human|humn|||Human|||0|888|15|20
SE|40||ti|1|entity|C0006104|Brain|bpoc|||brain|||0|888|21|26
SE|40||ti|1|entity|C0230956|Infraclass Eutheria|mamm|||placental|||0|901|31|40
SE|40||ti|1|entity|C0008407|Choline O-Acetyltransferase|aapp,enzy|||choline acetyltransferase|||0|901|41|66
SE|40||ti|1|entity|C0243114|purification|lbpr,resa|||purification|||0|1000|68|80
SE|40||ti|1|entity|C0871161|Property|qlco|||properties|||0|966|85|95
SE|40||ti|1|relation|0|0|C0006104|Brain|bpoc|bpoc|||brain|||0|888|21|26|MOD/HEAD|PART_OF||15|26|0|0|C0020114|Human|grup,humn|humn|||Human|||0|888|15|20
SE|40||ti|1|relation|0|0|C0008407|Choline O-Acetyltransferase|aapp,gngm,enzy|aapp|||choline acetyltransferase|||0|901|41|66|MOD/HEAD|PART_OF||31|66|0|0|C0230956|Infraclass Eutheria|mamm|mamm|||placental|||0|901|31|40

SE|40||ab|1|text|103|292|Choline acetyltransferase (EC 2.3.1.6) catalyzes the biosynthesis of acetylcholine according to the following chemical equation: acetyl-CoA + choline in equilibrium to acetylcholine + CoA.
SE|40||ab|1|entity|C0008407|Choline O-Acetyltransferase|aapp,enzy|||Choline acetyltransferase|||0|1000|103|128
SE|40||ab|1|entity|C0040676|Transferase|aapp,enzy|||EC 2|||0|840|130|134
SE|40||ab|1|entity|C0005572|bioformation|ftcn|||biosynthesis|||0|1000|156|168
SE|40||ab|1|entity|C0001041|Acetylcholine|nsba,orch,phsu|||acetylcholine|||0|1000|172|185
SE|40||ab|1|entity|C0332282|Following|tmco|||following|||0|851|203|212
SE|40||ab|1|entity|C0220806|Chemicals|chem|||chemical|||0|851|213|221
SE|40||ab|1|entity|C0552449|Equation|cnce|||equation|||0|851|222|230
SE|40||ab|1|entity|C0001026|Acetyl Coenzyme A|bacs,lipd,nnon|||acetyl-CoA|||0|901|232|242
SE|40||ab|1|entity|C0008405|Choline|bacs,orch,phsu|||choline|||0|901|245|252
SE|40||ab|1|entity|C0014653|Equilibrium|orgf|||equilibrium|||0|1000|256|267
SE|40||ab|1|entity|C0001041|Acetylcholine|nsba,orch,phsu|||acetylcholine|||0|694|271|284
SE|40||ab|1|relation|1|1|C0008407|Choline O-Acetyltransferase|aapp,gngm,enzy|aapp|||Choline acetyltransferase|||0|1000|103|128|VERB|INTERACTS_WITH||142|151|6|2|C0001041|Acetylcholine|nsba,orch,phsu|nsba|||acetylcholine|||0|1000|172|185

SE|40||ab|2|text|292|442|In addition to nervous tissue, primate placenta is the only other animal source which contains appreciable acetylcholine and its biosynthetic enzyme.
SE|40||ab|2|entity|C0027757|Nerve Tissue|tisu|||nervous tissue|||0|1000|307|321
SE|40||ab|2|entity|C0033147|Primates|mamm|||primate|||0|888|323|330
SE|40||ab|2|entity|C0032043|Placenta|emst|||placenta|||0|888|331|339
SE|40||ab|2|entity|C1510898|Animal Sources|qlco|||animal source|||0|983|358|371
SE|40||ab|2|entity|C0001041|Acetylcholine|nsba,orch,phsu|||acetylcholine|||0|861|399|412
SE|40||ab|2|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|861|434|440
SE|40||ab|2|relation|0|0|C0032043|Placenta|emst|emst|||placenta|||0|888|331|339|MOD/HEAD|PART_OF||323|339|0|0|C0033147|Primates|mamm|mamm|||primate|||0|888|323|330
SE|40||ab|2|relation|2|1|C0001041|Acetylcholine|nsba,orch,phsu|nsba|||acetylcholine|||0|861|399|412|VERB|PART_OF||378|386|4|2|C0032043|Placenta|emst|emst|||placenta|||0|888|331|339

SE|40||ab|3|text|442|632|Human brain caudate nucleus and human placental choline acetyltransferase were purified to electrophoretic homogeneity using ion-exchange and blue dextran-Sepharose affinity chromatography.
SE|40||ab|3|entity|C0020114|Human|humn|||Human|||0|861|442|447
SE|40||ab|3|entity|C0006104|Brain|bpoc|||brain|||0|861|448|453
SE|40||ab|3|entity|C1269580|Entire caudate nucleus|bpoc|||caudate nucleus|||0|861|454|469
SE|40||ab|3|entity|C0020114|Human|humn|||human|||0|861|474|479
SE|40||ab|3|entity|C0230956|Infraclass Eutheria|mamm|||placental|||0|861|480|489
SE|40||ab|3|entity|C0008407|Choline O-Acetyltransferase|aapp,enzy|||choline acetyltransferase|||0|861|490|515
SE|40||ab|3|entity|C0013855|Electrophoresis|lbpr|||electrophoretic|||0|623|533|548
SE|40||ab|3|entity|C0022013|Ion Exchange|npop|||ion-exchange|||0|1000|567|579
SE|40||ab|3|entity|C0053856|blue dextran-sepharose|irda,orch|||blue dextran-Sepharose|||0|893|584|606
SE|40||ab|3|entity|C0008551|Chromatography, Affinity|lbpr|||affinity chromatography|||0|893|607|630
SE|40||ab|3|relation|0|0|C0008407|Choline O-Acetyltransferase|aapp,gngm,enzy|aapp|||choline acetyltransferase|||0|861|490|515|MOD/HEAD|PART_OF||480|515|0|0|C0230956|Infraclass Eutheria|mamm|mamm|||placental|||0|861|480|489
SE|40||ab|3|relation|0|0|C0008551|Chromatography, Affinity|lbpr|lbpr|||affinity chromatography|||0|893|607|630|MOD/HEAD|USES||584|630|0|0|C0053856|blue dextran-sepharose|irda,orch|irda|||blue dextran-Sepharose|||0|893|584|606
SE|40||ab|3|relation|0|0|C1269580|Entire caudate nucleus|bpoc|bpoc|||caudate nucleus|||0|861|454|469|MOD/HEAD|PART_OF||448|469|0|0|C0006104|Brain|bpoc|bpoc|||brain|||0|861|448|453

SE|40||ab|4|text|632|775|The molecular weights determined by Sephadex G-150 gel filtration and sodium dodecyl sulfate gel electrophoresis are 67000 plus or minus 3000.
SE|40||ab|4|entity|C0026385|Molecular Weight|qnco|||molecular weights|||0|1000|636|653
SE|40||ab|4|entity|C1120000|sephadex G 150|irda,orch|||Sephadex G-150|||0|893|668|682
SE|40||ab|4|entity|C0008559|Chromatography, Gel|lbpr|||gel filtration|||0|893|683|697
SE|40||ab|4|entity|C0037506|Sodium Dodecyl Sulfate|bodm,lipd,phsu|||sodium dodecyl sulfate|||0|893|702|724
SE|40||ab|4|entity|C0596607|Gel Electrophoresis|lbpr|||gel electrophoresis|||0|893|725|744
SE|40||ab|4|entity|C0332288|Without|qlco|||minus|||0|861|763|768
SE|40||ab|4|relation|0|0|C0596607|Gel Electrophoresis|lbpr|lbpr|||gel electrophoresis|||0|893|725|744|MOD/HEAD|USES||702|744|0|0|C0037506|Sodium Dodecyl Sulfate|bodm,lipd,phsu|phsu|||sodium dodecyl sulfate|||0|893|702|724
SE|40||ab|4|relation|2|1|C0008559|Chromatography, Gel|lbpr|lbpr|||gel filtration|||0|893|683|697|VERB|MEASURES||654|664|1|1|C0026385|Molecular Weight|qnco|qnco|||molecular weights|||0|1000|636|653
SE|40||ab|4|relation|2|1|C0596607|Gel Electrophoresis|lbpr|lbpr|||gel electrophoresis|||0|893|725|744|VERB|MEASURES||654|664|1|1|C0026385|Molecular Weight|qnco|qnco|||molecular weights|||0|1000|636|653

SE|40||ab|5|text|775|873|N-Ethylmaleimide, p-chloromercuribenzoate, and dithiobis(2-nitrobenzoic acid) inhibit the enzyme.
SE|40||ab|5|entity|C0015101|Ethylmaleimide|irda,orch|||N-Ethylmaleimide|||0|1000|775|791
SE|40||ab|5|entity|C0008247|Chloromercuribenzoates|irda,orch|||chloromercuribenzoate|||0|872|795|816
SE|40||ab|5|entity|C0260053|Nitrobenzoic acid|orch|||nitrobenzoic acid|||0|901|834|851
SE|40||ab|5|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|865|871
SE|40||ab|5|relation|4|3|C0008247|Chloromercuribenzoates|irda,orch|orch|||chloromercuribenzoate|||0|872|795|816|VERB|INHIBITS||853|860|1|1|C0014442|Enzymes|enzy,orch|enzy|||enzyme|||0|1000|865|871

SE|40||ab|6|text|873|949|Dithiothreitol reverses the inhibition produced by the latter two reagents.
SE|40||ab|6|entity|C0012789|Dithiothreitol|carb,phsu|||Dithiothreitol|||0|1000|873|887
SE|40||ab|6|entity|C0205448|Two|qnco|||two|||0|790|935|938
SE|40||ab|6|entity|C0034760|Reagents|irda|||reagents|||0|790|939|947

SE|40||ab|7|text|949|1040|The pKa of the group associated with N-ethylmaleimide inhibition is 8.6 plus or minus 0.3.
SE|40||ab|7|entity|C0010531|Cyclic AMP-Dependent Protein Kinases|aapp,enzy|||pKa|||0|1000|953|956
SE|40||ab|7|entity|C0441833|Groups|inpr|||group|||0|1000|964|969
SE|40||ab|7|entity|C0015101|Ethylmaleimide|irda,orch|||N-ethylmaleimide|||0|901|986|1002
SE|40||ab|7|entity|C0332288|Without|qlco|||minus|||0|827|1029|1034
SE|40||ab|7|relation|2|2|C0010531|Cyclic AMP-Dependent Protein Kinases|aapp,gngm,enzy|aapp|||pKa|||0|1000|953|956|NOM|INHIBITS||1003|1013|2|0|C0015101|Ethylmaleimide|irda,orch|orch|||N-ethylmaleimide|||0|901|986|1002

SE|40||ab|8|text|1040|1121|A chemically competent acetyl-thioenzyme is isolable by Sephadex gel filtration.
SE|40||ab|8|entity|C0231188|Competent|ftcn|||competent|||0|645|1053|1062
SE|40||ab|8|entity|C0074343|sephadex|irda,orch|||Sephadex|||0|901|1096|1104
SE|40||ab|8|entity|C0008559|Chromatography, Gel|lbpr|||gel filtration|||0|901|1105|1119
SE|40||ab|8|relation|0|0|C0008559|Chromatography, Gel|lbpr|lbpr|||gel filtration|||0|901|1105|1119|MOD/HEAD|USES||1096|1119|0|0|C0074343|sephadex|irda,orch|irda|||Sephadex|||0|901|1096|1104

SE|40||ab|9|text|1121|1221|The enzymes from the brain and placenta are thus far physically and biochemically indistinguishable.
SE|40||ab|9|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|1000|1125|1132
SE|40||ab|9|entity|C0006104|Brain|bpoc|||brain|||0|1000|1142|1147
SE|40||ab|9|entity|C0032043|Placenta|emst|||placenta|||0|1000|1152|1160
SE|40||ab|9|entity|C1517331|Further|spco|||far|||0|793|1170|1173
SE|40||ab|9|relation|3|1|C0006104|Brain|bpoc|bpoc|||brain|||0|1000|1142|1147|PREP|LOCATION_OF||1133|1137|1|1|C0014442|Enzymes|enzy,orch|orch|||enzymes|||0|1000|1125|1132
SE|40||ab|9|relation|3|1|C0032043|Placenta|emst|emst|||placenta|||0|1000|1152|1160|PREP|LOCATION_OF||1133|1137|1|1|C0014442|Enzymes|enzy,orch|orch|||enzymes|||0|1000|1125|1132


SE|41||ti|1|text|15|108|Stabilization of the globular structure of ferricytochrome c by chloride in acidic solvents.
SE|41||ti|1|entity|C1293130|Stabilization|topp|||Stabilization|||0|1000|15|28
SE|41||ti|1|entity|C0332501|Spherical shape|spco|||globular|||0|888|36|44
SE|41||ti|1|entity|C0678594|Structure|spco|||structure|||0|888|45|54
SE|41||ti|1|entity|C0010749|CYTOCHROME C|aapp,enzy|||ferricytochrome c|||0|1000|58|75
SE|41||ti|1|entity|C0008203|Chlorides|inch|||chloride|||0|1000|79|87
SE|41||ti|1|entity|C0001128|Acids|chem|||acidic|||0|853|91|97
SE|41||ti|1|entity|C0037638|Solvents|irda|||solvents|||0|853|98|106

SE|41||ab|1|text|114|294|Increasing concentrations of chloride were found to increase the resolution between two visible absorbance spectral transitions associated with acidification of ferricytochrome c.
SE|41||ab|1|entity|C0442808|Increasing|ftcn|||Increasing|||0|888|114|124
SE|41||ab|1|entity|C0008203|Chlorides|inch|||chloride|||0|1000|143|151
SE|41||ab|1|entity|C1514893|Resolution|ftcn|||resolution|||0|1000|179|189
SE|41||ab|1|entity|C0205448|Two|qnco|||two|||0|569|198|201
SE|41||ab|1|entity|C0205379|Visible|qlco|||visible|||0|569|202|209
SE|41||ab|1|entity|C1268822|Optical density function|clna|||absorbance|||0|569|210|220
SE|41||ab|1|entity|C1522821|acidification|celf|||acidification|||0|1000|258|271
SE|41||ab|1|entity|C0010749|CYTOCHROME C|aapp,enzy|||ferricytochrome c|||0|1000|275|292

SE|41||ab|2|text|294|569|Analysis of a variety of spectral and viscosity measurements indicates that protonation of a single group having an apparent pK of 2.1 +/- 0.2 and an intrinsic pK of about 5.3 displaces the methionine ligand without significantly perturbing the native globular conformation.
SE|41||ab|2|entity|C0936012|Analysis|resa|||Analysis|||0|1000|294|302
SE|41||ab|2|entity|C0201798|Viscosity measurement|lbpr|||viscosity measurements|||0|983|332|354
SE|41||ab|2|entity|C0178812|protonation|phpr|||protonation|||0|1000|370|381
SE|41||ab|2|entity|C0037179|Unmarried person|popg|||single|||0|888|387|393
SE|41||ab|2|entity|C0441833|Groups|inpr|||group|||0|888|394|399
SE|41||ab|2|entity|C0750489|APPARENT|idcn|||apparent|||0|872|410|418
SE|41||ab|2|entity|C0205102|Intrinsic|spco|||intrinsic|||0|872|444|453
SE|41||ab|2|entity|C0025646|Methionine|aapp,bacs,phsu|||methionine|||0|888|484|494
SE|41||ab|2|entity|C0023688|Ligands|chem|||ligand|||0|888|495|501
SE|41||ab|2|entity|C0302891|Native|ftcn|||native|||0|623|539|545
SE|41||ab|2|entity|C0332501|Spherical shape|spco|||globular|||0|623|546|554

SE|41||ab|3|text|569|755|Analysis of methylated ferricytochrome c suggests that protonation of a carboxylate ion, most likely a heme propionate residue, is responsible for displacement of the methionine ligand.
SE|41||ab|3|entity|C0936012|Analysis|resa|||Analysis|||0|1000|569|577
SE|41||ab|3|entity|C0746574|METHYLATE|phsu|||methylated|||0|877|581|591
SE|41||ab|3|entity|C0010749|CYTOCHROME C|aapp,enzy|||ferricytochrome c|||0|877|592|609
SE|41||ab|3|entity|C0178812|protonation|phpr|||protonation|||0|1000|624|635
SE|41||ab|3|entity|C0178528|carboxylate|orch|||carboxylate|||0|888|641|652
SE|41||ab|3|entity|C0022023|Ions|elii|||ion|||0|888|653|656
SE|41||ab|3|entity|C0750501|MOST LIKELY|idcn|||most likely|||0|1000|658|669
SE|41||ab|3|entity|C0018966|Heme|bacs,orch|||heme|||0|828|672|676
SE|41||ab|3|entity|C0033474|Propionates|orch|||propionate|||0|828|677|687
SE|41||ab|3|entity|C0025646|Methionine|aapp,bacs,phsu|||methionine|||0|888|736|746
SE|41||ab|3|entity|C0023688|Ligands|chem|||ligand|||0|888|747|753

SE|41||ab|4|text|755|935|Addition of a proton to a second group having an apparent pK of 1.2 +/- 0.1 displaces the histidine ligand and unfolds the protein from a globular conformation into a random coil.
SE|41||ab|4|entity|C0442796|Additive|qlco|||Addition|||0|928|755|763
SE|41||ab|4|entity|C0033727|Protons|elii|||proton|||0|1000|769|775
SE|41||ab|4|entity|C0680398|secondary group|popg|||second group|||0|964|781|793
SE|41||ab|4|entity|C0750489|APPARENT|idcn|||apparent|||0|872|804|812
SE|41||ab|4|entity|C0019602|Histidine|aapp,bacs,phsu|||histidine|||0|888|845|854
SE|41||ab|4|entity|C0023688|Ligands|chem|||ligand|||0|888|855|861
SE|41||ab|4|entity|C0033684|Proteins|aapp,bacs|||protein|||0|1000|878|885
SE|41||ab|4|entity|C0332501|Spherical shape|spco|||globular|||0|694|893|901
SE|41||ab|4|entity|C0439605|Random|qlco|||random|||0|872|922|928
SE|41||ab|4|entity|C0444764|Coils|spco|||coil|||0|872|929|933

SE|41||ab|5|text|935|1042|It is most likely that the second protonation occurs on the imidazole ring of the histidine ligand itself.
SE|41||ab|5|entity|C0750501|MOST LIKELY|idcn|||most likely|||0|1000|941|952
SE|41||ab|5|entity|C0457385|seconds|tmco|||second|||0|888|962|968
SE|41||ab|5|entity|C0178812|protonation|phpr|||protonation|||0|888|969|980
SE|41||ab|5|entity|C0020923|Imidazole|orch,phsu|||imidazole|||0|694|995|1004
SE|41||ab|5|entity|C0019602|Histidine|aapp,bacs,phsu|||histidine|||0|888|1017|1026
SE|41||ab|5|entity|C0023688|Ligands|chem|||ligand|||0|888|1027|1033

SE|41||ab|6|text|1042|1156|Chloride is proposed to perturb these transitions by ligation in the fifth coordination position of the heme ion.
SE|41||ab|6|entity|C0008203|Chlorides|inch|||Chloride|||0|1000|1042|1050
SE|41||ab|6|entity|C0023690|Ligation|topp|||ligation|||0|1000|1095|1103
SE|41||ab|6|entity|C0205439|Fifth|qnco|||fifth|||0|802|1111|1116
SE|41||ab|6|entity|C0733755|Positioning Attribute|spco|||position|||0|802|1130|1138
SE|41||ab|6|entity|C0018966|Heme|bacs,orch|||heme|||0|888|1146|1150
SE|41||ab|6|entity|C0022023|Ions|elii|||ion|||0|888|1151|1154

SE|41||ab|7|text|1156|1251|Such ligation stabilizes a globular conformation of ferricytochrome c at pH 0.0 and 25 degrees.
SE|41||ab|7|entity|C0023690|Ligation|topp|||ligation|||0|1000|1161|1169
SE|41||ab|7|entity|C0332501|Spherical shape|spco|||globular|||0|694|1183|1191
SE|41||ab|7|entity|C0010749|CYTOCHROME C|aapp,enzy|||ferricytochrome c|||0|1000|1208|1225


SE|42||ti|1|text|15|137|A competitive labeling method for the determination of the chemical properties of solitary functional groups in proteins.
SE|42||ti|1|entity|C0679932|competition|socb|||competitive|||0|802|17|28
SE|42||ti|1|entity|C0025663|Methods|inpr|||method|||0|802|38|44
SE|42||ti|1|entity|C0680730|Adjudication|gora|||determination|||0|1000|53|66
SE|42||ti|1|entity|C0243178|chemical properties|npop|||chemical properties|||0|1000|74|93
SE|42||ti|1|entity|C0205171|Singular|qnco|||solitary|||0|890|97|105
SE|42||ti|1|entity|C0598132|functional group|chvf|||functional groups|||0|890|106|123
SE|42||ti|1|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|1000|127|135

SE|42||ab|1|text|143|260|The properties of the functional groups in a protein can be used as built-in-probes of the structure of the protein.
SE|42||ab|1|entity|C0871161|Property|qlco|||properties|||0|966|147|157
SE|42||ab|1|entity|C0598132|functional group|chvf|||functional groups|||0|983|165|182
SE|42||ab|1|entity|C0033684|Proteins|aapp,bacs|||protein|||0|1000|188|195
SE|42||ab|1|entity|C0182400|Probes|medd|||probes|||0|827|220|226
SE|42||ab|1|entity|C0678594|Structure|spco|||structure|||0|1000|234|243
SE|42||ab|1|entity|C0033684|Proteins|aapp,bacs|||protein|||0|1000|251|258

SE|42||ab|2|text|260|415|We have developed a general procedure whereby the ionization constant and chemical reactivity of solitary functional groups in proteins may be determined.
SE|42||ab|2|entity|C0205246|Generalized|spco|||general|||0|790|280|287
SE|42||ab|2|entity|C0184661|Procedures|hlca|||procedure|||0|790|288|297
SE|42||ab|2|entity|C0596802|ionization constant|qnco|||ionization constant|||0|1000|310|329
SE|42||ab|2|entity|C0678596|chemical reactivity|npop|||chemical reactivity|||0|1000|334|353
SE|42||ab|2|entity|C0205171|Singular|qnco|||solitary|||0|890|357|365
SE|42||ab|2|entity|C0598132|functional group|chvf|||functional groups|||0|890|366|383
SE|42||ab|2|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|1000|387|395

SE|42||ab|3|text|415|554|The method may be applied to the side chain of histidine, tyrosine, lysine, and cysteine, as well as to the amino terminus of the protein.
SE|42||ab|3|entity|C0025663|Methods|inpr|||method|||0|1000|419|425
SE|42||ab|3|entity|C0441987|Side|spco|||side|||0|861|448|452
SE|42||ab|3|entity|C0019602|Histidine|aapp,bacs,phsu|||histidine|||0|1000|462|471
SE|42||ab|3|entity|C0041485|Tyrosine|aapp,bacs,phsu|||tyrosine|||0|1000|473|481
SE|42||ab|3|entity|C0024337|Lysine|aapp,bacs,phsu|||lysine|||0|1000|483|489
SE|42||ab|3|entity|C0010654|Cysteine|aapp,bacs|||cysteine|||0|1000|495|503
SE|42||ab|3|entity|C0033684|Proteins|aapp,bacs|||protein|||0|1000|545|552

SE|42||ab|4|text|554|740|The method, which is an extension of the competitive labeling technique using [3H]- and [14C]1-fluoro-2,4-dinitrobenzene (N2ph-F) in a double-labeling procedure, is rapid and sensitive.
SE|42||ab|4|entity|C0025663|Methods|inpr|||method|||0|1000|558|564
SE|42||ab|4|entity|C0231448|Extension|ftcn|||extension|||0|1000|578|587
SE|42||ab|4|entity|C0679932|competition|socb|||competitive|||0|802|595|606
SE|42||ab|4|entity|C0449851|Techniques|ftcn|||technique|||0|802|616|625
SE|42||ab|4|entity|C0012459|Dinitrobenzenes|orch|||dinitrobenzene|||0|861|660|674
SE|42||ab|4|entity|C0205173|Duplicate|ftcn|||double|||0|802|689|695
SE|42||ab|4|entity|C0184661|Procedures|hlca|||procedure|||0|802|705|714
SE|42||ab|4|entity|C0439831|Rapid|qlco|||rapid|||0|1000|719|724
SE|42||ab|4|entity|C0332324|Sensitive|ftcn|||sensitive|||0|1000|729|738

SE|42||ab|5|text|740|916|Advantage is taken of the fact that after acid hydrolysis of a dinitrophenylated protein, a derivative is obtained which must be derived from a unique position in the protein.
SE|42||ab|5|entity|C0001128|Acids|chem|||acid|||0|888|782|786
SE|42||ab|5|entity|C0020291|Hydrolysis|npop|||hydrolysis|||0|888|787|797
SE|42||ab|5|entity|C0033684|Proteins|aapp,bacs|||protein|||0|861|821|828
SE|42||ab|5|entity|C1527240|Derivative|ftcn|||derivative|||0|1000|832|842
SE|42||ab|5|entity|C0733755|Positioning Attribute|spco|||position|||0|861|891|899
SE|42||ab|5|entity|C0033684|Proteins|aapp,bacs|||protein|||0|1000|907|914

SE|42||ab|6|text|916|1110|The method has been applied to the solitary histidine residue of lysozyme, alpha-lytic protease, and Streptomyces griseus (S.G.) trypsin, as well as to the amino terminus of the latter protein.
SE|42||ab|6|entity|C0025663|Methods|inpr|||method|||0|1000|920|926
SE|42||ab|6|entity|C0205171|Singular|qnco|||solitary|||0|828|951|959
SE|42||ab|6|entity|C0019602|Histidine|aapp,bacs,phsu|||histidine|||0|828|960|969
SE|42||ab|6|entity|C0026794|Muramidase|aapp,enzy,phsu|||lysozyme|||0|1000|981|989
SE|42||ab|6|entity|C0067084|myxobacter alpha-lytic proteinase|aapp,enzy|||alpha-lytic protease|||0|1000|991|1011
SE|42||ab|6|entity|C0038423|Streptomyces griseus|bact|||Streptomyces griseus|||0|1000|1017|1037
SE|42||ab|6|entity|C0565930|per second|qnco|||S.G.|||0|802|1039|1043
SE|42||ab|6|entity|C0041236|TRYPSIN|aapp,enzy,phsu|||trypsin|||0|802|1045|1052
SE|42||ab|6|entity|C0033684|Proteins|aapp,bacs|||protein|||0|861|1101|1108

SE|42||ab|7|text|1110|1623|The following parameters were obtained for reaction with N2ph-F at 20 degrees C in 0.1 N KCl: the histidine of hen egg-white lysozyme, pKa of 6.4 and second-order velocity constant of 0.188 M-1 min-1; the histidine of alpha-lytic protease, pKa of 6.5 and second-order velocity constant of 0.0235 M-1 min-1; the histidine of S.G. trypsin, pKa of 6.5 and second-order velocity constant of 0.0328 M-1 min-1; the valyl amino terminus of S.G. trypsin, pKa of 8.1 and second-order velocity constant of 0.403 M-1 min-1.
SE|42||ab|7|entity|C0332282|Following|tmco|||following|||0|888|1114|1123
SE|42||ab|7|entity|C0443286|Reaction|ftcn|||reaction|||0|1000|1153|1161
SE|42||ab|7|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|1180|1189
SE|42||ab|7|entity|C0019602|Histidine|aapp,bacs,phsu|||histidine|||0|1000|1208|1217
SE|42||ab|7|entity|C0007457|Caucasoid Race|popg|||white|||0|916|1229|1234
SE|42||ab|7|entity|C0964782|hen egg lysozyme|aapp,enzy|||hen egg-white lysozyme|||0|916|1221|1243
SE|42||ab|7|entity|C0010531|Cyclic AMP-Dependent Protein Kinases|aapp,enzy|||pKa|||0|1000|1245|1248
SE|42||ab|7|entity|C0442748|6/4|fndg|||6.4|||0|1000|1252|1255
SE|42||ab|7|entity|C0457385|seconds|tmco|||second|||0|775|1260|1266
SE|42||ab|7|entity|C0439830|Velocity|ftcn|||velocity|||0|775|1273|1281
SE|42||ab|7|entity|C1547014|*Constant|qnco|||constant|||0|775|1282|1290
SE|42||ab|7|entity|C0441923|M+|inpr|||M-1|||0|728|1300|1303
SE|42||ab|7|entity|C0439232|Minute of time|tmco|||min|||0|728|1304|1307
SE|42||ab|7|entity|C0019602|Histidine|aapp,bacs,phsu|||histidine|||0|1000|1315|1324
SE|42||ab|7|entity|C0067084|myxobacter alpha-lytic proteinase|aapp,enzy|||alpha-lytic protease|||0|1000|1328|1348
SE|42||ab|7|entity|C0010531|Cyclic AMP-Dependent Protein Kinases|aapp,enzy|||pKa|||0|1000|1350|1353
SE|42||ab|7|entity|C0442749|6/5|fndg|||6.5|||0|1000|1357|1360
SE|42||ab|7|entity|C0457385|seconds|tmco|||second|||0|775|1365|1371
SE|42||ab|7|entity|C0439830|Velocity|ftcn|||velocity|||0|775|1378|1386
SE|42||ab|7|entity|C1547014|*Constant|qnco|||constant|||0|775|1387|1395
SE|42||ab|7|entity|C0441923|M+|inpr|||M-1|||0|728|1406|1409
SE|42||ab|7|entity|C0439232|Minute of time|tmco|||min|||0|728|1410|1413
SE|42||ab|7|entity|C0019602|Histidine|aapp,bacs,phsu|||histidine|||0|1000|1421|1430
SE|42||ab|7|entity|C0041236|TRYPSIN|aapp,enzy,phsu|||trypsin|||0|802|1439|1446
SE|42||ab|7|entity|C0010531|Cyclic AMP-Dependent Protein Kinases|aapp,enzy|||pKa|||0|1000|1448|1451
SE|42||ab|7|entity|C0442749|6/5|fndg|||6.5|||0|1000|1455|1458
SE|42||ab|7|entity|C0457385|seconds|tmco|||second|||0|775|1463|1469
SE|42||ab|7|entity|C0439830|Velocity|ftcn|||velocity|||0|775|1476|1484
SE|42||ab|7|entity|C1547014|*Constant|qnco|||constant|||0|775|1485|1493
SE|42||ab|7|entity|C0441923|M+|inpr|||M-1|||0|728|1504|1507
SE|42||ab|7|entity|C0439232|Minute of time|tmco|||min|||0|728|1508|1511
SE|42||ab|7|entity|C0041236|TRYPSIN|aapp,enzy,phsu|||trypsin|||0|802|1548|1555
SE|42||ab|7|entity|C0010531|Cyclic AMP-Dependent Protein Kinases|aapp,enzy|||pKa|||0|1000|1557|1560
SE|42||ab|7|entity|C0457385|seconds|tmco|||second|||0|775|1572|1578
SE|42||ab|7|entity|C0439830|Velocity|ftcn|||velocity|||0|775|1585|1593
SE|42||ab|7|entity|C1547014|*Constant|qnco|||constant|||0|775|1594|1602
SE|42||ab|7|entity|C0441923|M+|inpr|||M-1|||0|728|1612|1615
SE|42||ab|7|entity|C0439232|Minute of time|tmco|||min|||0|728|1616|1619
SE|42||ab|7|relation|0|0|C0964782|hen egg lysozyme|aapp,gngm,enzy|aapp|||hen egg-white lysozyme|||0|916|1221|1243|MOD/HEAD|PART_OF||1229|1243|0|0|C0007457|Caucasoid Race|popg,humn|humn|||white|||0|916|1229|1234
SE|42||ab|7|relation|6|1|C0019602|Histidine|aapp,gngm,bacs,phsu|bacs|||histidine|||0|1000|1208|1217|PREP|PART_OF||1218|1220|15|1|C0964782|hen egg lysozyme|aapp,gngm,enzy|aapp|||hen egg-white lysozyme|||0|916|1221|1243
SE|42||ab|7|relation|10|1|C0019602|Histidine|aapp,gngm,bacs,phsu|bacs|||histidine|||0|1000|1315|1324|PREP|PART_OF||1325|1327|11|1|C0067084|myxobacter alpha-lytic proteinase|aapp,gngm,enzy|aapp|||alpha-lytic protease|||0|1000|1328|1348
SE|42||ab|7|relation|14|1|C0019602|Histidine|aapp,gngm,bacs,phsu|bacs|||histidine|||0|1000|1421|1430|PREP|PART_OF||1431|1433|7|1|C0041236|TRYPSIN|aapp,gngm,enzy,phsu|aapp|||trypsin|||0|802|1439|1446

SE|42||ab|8|text|1623|1895|In addition, the results obtained provide clues as to the microenvironments of these functional groups, and indicate that the proteins studied undergo pH-dependent conformational changes which affect the microenvironment, and hence the chemical reactivity of these groups.
SE|42||ab|8|entity|C1274040|result|ftcn|||results|||0|966|1640|1647
SE|42||ab|8|entity|C0598132|functional group|chvf|||functional groups|||0|983|1708|1725
SE|42||ab|8|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|1000|1749|1757
SE|42||ab|8|entity|C0301641|Macromolecular alteration|moft|||conformational changes|||0|852|1787|1809
SE|42||ab|8|entity|C0678596|chemical reactivity|npop|||chemical reactivity|||0|1000|1859|1878
SE|42||ab|8|entity|C0441833|Groups|inpr|||groups|||0|1000|1888|1894
SE|42||ab|8|relation|6|1|C0033684|Proteins|aapp,gngm,bacs|aapp|||proteins|||0|1000|1749|1757|ADJ|STIMULATES||1777|1786|6|0|C0301641|Macromolecular alteration|moft|moft|||conformational changes|||0|852|1787|1809


SE|43||ti|1|text|15|86|Modification of arginine and lysine in proteins with 2,4-pentanedione.
SE|43||ti|1|entity|C1522413|Modification|ftcn|||Modification|||0|1000|15|27
SE|43||ti|1|entity|C0003765|Arginine|aapp,bacs,phsu|||arginine|||0|1000|31|39
SE|43||ti|1|entity|C0024337|Lysine|aapp,bacs,phsu|||lysine|||0|1000|44|50
SE|43||ti|1|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|1000|54|62
SE|43||ti|1|entity|C0576735|Pentanedione|orch|||pentanedione|||0|861|72|84
SE|43||ti|1|relation|3|1|C0003765|Arginine|aapp,gngm,bacs,phsu|aapp|||arginine|||0|1000|31|39|PREP|COEXISTS_WITH||51|53|2|1|C0033684|Proteins|aapp,gngm,bacs|gngm|||proteins|||0|1000|54|62
SE|43||ti|1|relation|3|1|C0024337|Lysine|aapp,gngm,bacs,phsu|aapp|||lysine|||0|1000|44|50|PREP|COEXISTS_WITH||51|53|2|1|C0033684|Proteins|aapp,gngm,bacs|gngm|||proteins|||0|1000|54|62
SE|43||ti|1|relation|4|4|C0576735|Pentanedione|orch|orch|||pentanedione|||0|861|72|84|NOM|INTERACTS_WITH||15|27|4|1|C0003765|Arginine|aapp,gngm,bacs,phsu|aapp|||arginine|||0|1000|31|39
SE|43||ti|1|relation|4|4|C0576735|Pentanedione|orch|orch|||pentanedione|||0|861|72|84|NOM|INTERACTS_WITH||15|27|4|1|C0024337|Lysine|aapp,gngm,bacs,phsu|aapp|||lysine|||0|1000|44|50

SE|43||ab|1|text|92|196|Primary amines react with 2,4-pentanedione at pH 6-9 to form enamines, N-alkyl-4-amino-3-penten-2-ones.
SE|43||ab|1|entity|C0002508|Amines|orch|||amines|||0|888|100|106
SE|43||ab|1|entity|C0576735|Pentanedione|orch|||pentanedione|||0|861|122|134
SE|43||ab|1|entity|C1177206|ALKYL|phsu|||alkyl|||0|738|165|170
SE|43||ab|1|entity|C0205447|One|qnco|||ones|||0|738|190|194

SE|43||ab|2|text|196|300|The latter compounds readily regenerate the primary amine at low pH or on treatment with hydroxylamine.
SE|43||ab|2|entity|C0205198|Compound|qlco|||compounds|||0|827|207|216
SE|43||ab|2|entity|C0002508|Amines|orch|||amine|||0|888|248|253
SE|43||ab|2|entity|C0728725|Hydrogen ion increase|fndg|||low pH|||0|1000|257|263
SE|43||ab|2|entity|C0020362|Hydroxylamine|inch|||hydroxylamine|||0|1000|285|298

SE|43||ab|3|text|300|538|Guanidine and substituted guanidines react with 2,4-pentanedione to form N-substituted 2-amino-4,6-dimethylpyrimidines at a rate which is lower by at least a factor of 20 than the rate of reaction of 2,4-pentanedione with primary amines.
SE|43||ab|3|entity|C0018320|Guanidines|orch|||Guanidine|||0|1000|300|309
SE|43||ab|3|entity|C0018320|Guanidines|orch|||guanidines|||0|861|326|336
SE|43||ab|3|entity|C0576735|Pentanedione|orch|||pentanedione|||0|861|352|364
SE|43||ab|3|entity|C1521828|Rate|qnco|||rate|||0|1000|424|428
SE|43||ab|3|entity|C0441994|Lower|ftcn|||lower|||0|1000|438|443
SE|43||ab|3|entity|C1521761|Factor|ftcn|||factor|||0|1000|458|464
SE|43||ab|3|entity|C1521828|Rate|qnco|||rate|||0|1000|480|484
SE|43||ab|3|entity|C0443286|Reaction|ftcn|||reaction|||0|1000|488|496
SE|43||ab|3|entity|C0576735|Pentanedione|orch|||pentanedione|||0|861|504|516
SE|43||ab|3|entity|C0002508|Amines|orch|||amines|||0|888|530|536

SE|43||ab|4|text|538|655|Selective modification of lysine and arginine side chains in proteins can readily be achieved with 2,4-pentanedione.
SE|43||ab|4|entity|C1522413|Modification|ftcn|||modification|||0|861|548|560
SE|43||ab|4|entity|C0024337|Lysine|aapp,bacs,phsu|||lysine|||0|1000|564|570
SE|43||ab|4|entity|C0003765|Arginine|aapp,bacs,phsu|||arginine|||0|790|575|583
SE|43||ab|4|entity|C0441987|Side|spco|||side|||0|790|584|588
SE|43||ab|4|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|1000|599|607
SE|43||ab|4|entity|C0576735|Pentanedione|orch|||pentanedione|||0|861|641|653
SE|43||ab|4|relation|3|2|C0003765|Arginine|aapp,gngm,bacs,phsu|aapp|||arginine|||0|790|575|583|PREP|COEXISTS_WITH||596|598|2|1|C0033684|Proteins|aapp,gngm,bacs|gngm|||proteins|||0|1000|599|607
SE|43||ab|4|relation|3|2|C0024337|Lysine|aapp,gngm,bacs,phsu|aapp|||lysine|||0|1000|564|570|PREP|COEXISTS_WITH||596|598|2|1|C0033684|Proteins|aapp,gngm,bacs|gngm|||proteins|||0|1000|599|607

SE|43||ab|5|text|655|746|Modification of lysine is favored by reaction at pH 7 or for short reaction times at pH 9.
SE|43||ab|5|entity|C1522413|Modification|ftcn|||Modification|||0|1000|655|667
SE|43||ab|5|entity|C0024337|Lysine|aapp,bacs,phsu|||lysine|||0|1000|671|677
SE|43||ab|5|entity|C0443286|Reaction|ftcn|||reaction|||0|1000|692|700
SE|43||ab|5|entity|C0034746|Reaction Time|tmco|||reaction times|||0|890|722|736

SE|43||ab|6|text|746|908|Selective modification of arginine is achieved by reaction with 2,4-pentanedione for long times at pH 9, followed by treatment of the protein with hydroxylamine.
SE|43||ab|6|entity|C1522413|Modification|ftcn|||modification|||0|861|756|768
SE|43||ab|6|entity|C0003765|Arginine|aapp,bacs,phsu|||arginine|||0|1000|772|780
SE|43||ab|6|entity|C0443286|Reaction|ftcn|||reaction|||0|1000|796|804
SE|43||ab|6|entity|C0576735|Pentanedione|orch|||pentanedione|||0|861|814|826
SE|43||ab|6|entity|C0205166|Long|qlco|||long|||0|872|831|835
SE|43||ab|6|entity|C0040223|Time|tmco|||times|||0|872|836|841
SE|43||ab|6|entity|C0033684|Proteins|aapp,bacs|||protein|||0|1000|880|887
SE|43||ab|6|entity|C0020362|Hydroxylamine|inch|||hydroxylamine|||0|1000|893|906

SE|43||ab|7|text|908|1018|The extent of modification of lysine and arginine side chains can readily be measured spectrophotometrically.
SE|43||ab|7|entity|C0439792|Extent|spco|||extent|||0|1000|912|918
SE|43||ab|7|entity|C1522413|Modification|ftcn|||modification|||0|1000|922|934
SE|43||ab|7|entity|C0024337|Lysine|aapp,bacs,phsu|||lysine|||0|1000|938|944
SE|43||ab|7|entity|C0003765|Arginine|aapp,bacs,phsu|||arginine|||0|790|949|957
SE|43||ab|7|entity|C0441987|Side|spco|||side|||0|790|958|962

SE|43||ab|8|text|1018|1165|Modification of lysozyme with 2,4-pentanedione at pH 7 results in modification of 3.8 lysine residues and less than 0.4 arginine residue in 24 hr.
SE|43||ab|8|entity|C1522413|Modification|ftcn|||Modification|||0|1000|1018|1030
SE|43||ab|8|entity|C0026794|Muramidase|aapp,enzy,phsu|||lysozyme|||0|1000|1034|1042
SE|43||ab|8|entity|C0576735|Pentanedione|orch|||pentanedione|||0|861|1052|1064
SE|43||ab|8|entity|C1274040|result|ftcn|||results|||0|785|1073|1080
SE|43||ab|8|entity|C1522413|Modification|ftcn|||modification|||0|1000|1084|1096
SE|43||ab|8|entity|C0024337|Lysine|aapp,bacs,phsu|||lysine|||0|747|1104|1110
SE|43||ab|8|entity|C0003765|Arginine|aapp,bacs,phsu|||arginine|||0|714|1138|1146
SE|43||ab|8|relation|7|2|C0576735|Pentanedione|orch|orch|||pentanedione|||0|861|1052|1064|NOM|INTERACTS_WITH||1018|1030|7|1|C0026794|Muramidase|aapp,gngm,enzy,phsu|aapp|||lysozyme|||0|1000|1034|1042

SE|43||ab|9|text|1165|1302|Modification of lysozyme with 2,4-pentanedione at pH 9 results in modification of 4 lysine residues and 4.5 arginine residues in 100 hr.
SE|43||ab|9|entity|C1522413|Modification|ftcn|||Modification|||0|1000|1165|1177
SE|43||ab|9|entity|C0026794|Muramidase|aapp,enzy,phsu|||lysozyme|||0|1000|1181|1189
SE|43||ab|9|entity|C0576735|Pentanedione|orch|||pentanedione|||0|861|1199|1211
SE|43||ab|9|entity|C1274040|result|ftcn|||results|||0|785|1220|1227
SE|43||ab|9|entity|C1522413|Modification|ftcn|||modification|||0|1000|1231|1243
SE|43||ab|9|entity|C0024337|Lysine|aapp,bacs,phsu|||lysine|||0|748|1249|1255
SE|43||ab|9|entity|C0450367|4/5|qnco|||4.5|||0|840|1269|1272
SE|43||ab|9|entity|C0003765|Arginine|aapp,bacs,phsu|||arginine|||0|840|1273|1281
SE|43||ab|9|relation|7|2|C0576735|Pentanedione|orch|orch|||pentanedione|||0|861|1199|1211|NOM|INTERACTS_WITH||1165|1177|7|1|C0026794|Muramidase|aapp,gngm,enzy,phsu|aapp|||lysozyme|||0|1000|1181|1189

SE|43||ab|10|text|1302|1453|Treatment of this modified protein with hydroxylamine regenerated the modified lysine residues but caused no change in the modified arginine residues.
SE|43||ab|10|entity|C0205349|Altered|ftcn|||modified|||0|888|1320|1328
SE|43||ab|10|entity|C0033684|Proteins|aapp,bacs|||protein|||0|888|1329|1336
SE|43||ab|10|entity|C0020362|Hydroxylamine|inch|||hydroxylamine|||0|1000|1342|1355
SE|43||ab|10|entity|C0205349|Altered|ftcn|||modified|||0|824|1372|1380
SE|43||ab|10|entity|C0024337|Lysine|aapp,bacs,phsu|||lysine|||0|824|1381|1387
SE|43||ab|10|entity|C0205349|Altered|ftcn|||modified|||0|824|1425|1433
SE|43||ab|10|entity|C0003765|Arginine|aapp,bacs,phsu|||arginine|||0|824|1434|1442

SE|43||ab|11|text|1453|1537|One arginine residue seems to be essential for the catalytic activity of the enzyme.
SE|43||ab|11|entity|C0205447|One|qnco|||One|||0|828|1453|1456
SE|43||ab|11|entity|C0003765|Arginine|aapp,bacs,phsu|||arginine|||0|828|1457|1465
SE|43||ab|11|entity|C0205224|Essential|qlco|||essential|||0|1000|1486|1495
SE|43||ab|11|entity|C0243102|enzyme activity|moft|||catalytic activity|||0|1000|1504|1522
SE|43||ab|11|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|1530|1536


SE|44||ti|1|text|15|70|The origin of the alkaline inactivation of pepsinogen.
SE|44||ti|1|entity|C0439659|Beginning|tmco|||origin|||0|1000|19|25
SE|44||ti|1|entity|C0002055|Alkalies|inch|||alkaline|||0|853|33|41
SE|44||ti|1|entity|C0544461|Inactivation|comd|||inactivation|||0|853|42|54
SE|44||ti|1|entity|C0030913|Pepsinogens|aapp,bacs|||pepsinogen|||0|1000|58|68
SE|44||ti|1|relation|1|0|C0002055|Alkalies|inch|inch|||alkaline|||0|853|33|41|NOM|INHIBITS||42|54|1|1|C0030913|Pepsinogens|aapp,gngm,bacs|gngm|||pepsinogen|||0|1000|58|68

SE|44||ab|1|text|76|185|Above pH 8.5, pepsinogen is converted into a form which cannot be activated to pepsin on exposure to low pH.
SE|44||ab|1|entity|C1282910|Upper|spco|||Above|||0|750|76|81
SE|44||ab|1|entity|C0030913|Pepsinogens|aapp,bacs|||pepsinogen|||0|1000|90|100
SE|44||ab|1|entity|C1522492|Formation|ftcn|||form|||0|1000|121|125
SE|44||ab|1|entity|C0728725|Hydrogen ion increase|fndg|||low pH|||0|1000|177|183

SE|44||ab|2|text|185|285|Intermediate exposure to neutral pH, however, returns the protein to a form which can be activated.
SE|44||ab|2|entity|C0205103|Intermediate|spco|||Intermediate|||0|694|185|197
SE|44||ab|2|entity|C0033684|Proteins|aapp,bacs|||protein|||0|1000|243|250
SE|44||ab|2|entity|C1522492|Formation|ftcn|||form|||0|1000|256|260

SE|44||ab|3|text|285|414|Evidence is presented for a reversible, small conformational change in the molecule, distinct from the unfolding of the protein.
SE|44||ab|3|entity|C0205343|Reversible|ftcn|||reversible|||0|861|313|323
SE|44||ab|3|entity|C0700321|Small|qnco|||small|||0|861|325|330
SE|44||ab|3|entity|C0301641|Macromolecular alteration|moft|||conformational change|||0|861|331|352
SE|44||ab|3|entity|C0567416|Molecule|sbst|||molecule|||0|1000|360|368
SE|44||ab|3|entity|C0033684|Proteins|aapp,bacs|||protein|||0|1000|405|412

SE|44||ab|4|text|414|559|At the same time, the molecule is converted to a form of limited solubility, which is precipitated at low pH, where activation is normally seen.
SE|44||ab|4|entity|C0567416|Molecule|sbst|||molecule|||0|1000|436|444
SE|44||ab|4|entity|C1522492|Formation|ftcn|||form|||0|1000|463|467
SE|44||ab|4|entity|C0439801|Limited|ftcn|||limited|||0|888|471|478
SE|44||ab|4|entity|C0037628|Solubility|qnco|||solubility|||0|888|479|489
SE|44||ab|4|entity|C0728725|Hydrogen ion increase|fndg|||low pH|||0|1000|516|522

SE|44||ab|5|text|559|650|The results are interpreted in terms of the peculiar structure of the pepsinogen molecule.
SE|44||ab|5|entity|C1274040|result|ftcn|||results|||0|966|563|570
SE|44||ab|5|entity|C0678594|Structure|spco|||structure|||0|861|612|621
SE|44||ab|5|entity|C0030913|Pepsinogens|aapp,bacs|||pepsinogen|||0|888|629|639
SE|44||ab|5|entity|C0567416|Molecule|sbst|||molecule|||0|888|640|648

SE|44||ab|6|text|650|863|Titration of the basic NH2-terminal region produced an open form, which can return to the native form at neutral pH, but which is maintained at low pH by neutralization of carboxylate groups in the pepsin portion.
SE|44||ab|6|entity|C0162621|Titration|lbpr|||Titration|||0|1000|650|659
SE|44||ab|6|entity|C0025033|Mechlorethamine|hops,orch,phsu|||NH2|||0|815|673|676
SE|44||ab|6|entity|C0205147|Region|spco|||region|||0|815|686|692
SE|44||ab|6|entity|C0175566|Open|spco|||open|||0|888|705|709
SE|44||ab|6|entity|C1522492|Formation|ftcn|||form|||0|888|710|714
SE|44||ab|6|entity|C0302891|Native|ftcn|||native|||0|888|740|746
SE|44||ab|6|entity|C1522492|Formation|ftcn|||form|||0|888|747|751
SE|44||ab|6|entity|C0728725|Hydrogen ion increase|fndg|||low pH|||0|1000|794|800
SE|44||ab|6|entity|C1446680|Neutralization|lbpr|||neutralization|||0|1000|804|818
SE|44||ab|6|entity|C0178528|carboxylate|orch|||carboxylate|||0|888|822|833
SE|44||ab|6|entity|C0441833|Groups|inpr|||groups|||0|888|834|840
SE|44||ab|6|relation|3|1|C1446680|Neutralization|lbpr|lbpr|||neutralization|||0|1000|804|818|PREP|METHOD_OF||801|803|6|6|C0162621|Titration|lbpr|lbpr|||Titration|||0|1000|650|659


SE|45||ti|1|text|15|96|Bovine liver dihydrofolate reductase: purification and properties of the enzyme.
SE|45||ti|1|entity|C0007452|Cattle|mamm|||Bovine|||0|861|15|21
SE|45||ti|1|entity|C0023884|Liver|bpoc|||liver|||0|861|22|27
SE|45||ti|1|entity|C0039667|Dihydrofolate Reductase|aapp,enzy|1719|DHFR|dihydrofolate reductase|||0|861|28|51
SE|45||ti|1|entity|C0243114|purification|lbpr,resa|||purification|||0|1000|53|65
SE|45||ti|1|entity|C0871161|Property|qlco|||properties|||0|966|70|80
SE|45||ti|1|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|88|94
SE|45||ti|1|relation|0|0|C0039667|Dihydrofolate Reductase|aapp,gngm,enzy|aapp|1719|DHFR|dihydrofolate reductase|||0|861|28|51|MOD/HEAD|PART_OF||22|51|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|861|22|27

SE|45||ab|1|text|102|231|A purification procedure is reported for obtaining bovine liver dihydrofolate reductase in high yield and amounts of 100-200 mg.
SE|45||ab|1|entity|C0243114|purification|lbpr,resa|||purification|||0|888|104|116
SE|45||ab|1|entity|C0184661|Procedures|hlca|||procedure|||0|888|117|126
SE|45||ab|1|entity|C1301820|Obtained|ftcn|||obtaining|||0|831|143|152
SE|45||ab|1|entity|C0007452|Cattle|mamm|||bovine|||0|831|153|159
SE|45||ab|1|entity|C0023884|Liver|bpoc|||liver|||0|831|160|165
SE|45||ab|1|entity|C0039667|Dihydrofolate Reductase|aapp,enzy|1719|DHFR|dihydrofolate reductase|||0|831|166|189
SE|45||ab|1|entity|C0205250|High|qlco|||high|||0|694|193|197
SE|45||ab|1|relation|0|0|C0039667|Dihydrofolate Reductase|aapp,gngm,enzy|aapp|1719|DHFR|dihydrofolate reductase|||0|831|166|189|MOD/HEAD|PART_OF||160|189|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|831|160|165

SE|45||ab|2|text|231|341|A key step in the procedure is the use of an affinity gel prepared by coupling pteroyl-L-lysine to Sepharose.
SE|45||ab|2|entity|C1554080|Key|idcn|||key|||0|888|233|236
SE|45||ab|2|entity|C1261552|Step|ftcn|||step|||0|888|237|241
SE|45||ab|2|entity|C0184661|Procedures|hlca|||procedure|||0|1000|249|258
SE|45||ab|2|entity|C0017243|Gel|bodm|||gel|||0|888|285|288
SE|45||ab|2|entity|C0010222|Couples|famg|||coupling|||0|753|301|309
SE|45||ab|2|entity|C0024337|Lysine|aapp,bacs,phsu|||lysine|||0|753|320|326
SE|45||ab|2|entity|C0036681|Sepharose|bodm,carb|||Sepharose|||0|1000|330|339

SE|45||ab|3|text|341|543|The purified reductase has a specific activity of about 100 units/mg and is homogeneous as judged by analytical ultracentrifugation, polyacrylamide gel electrophoresis, and titration with methotrexate.
SE|45||ab|3|entity|C0030016|Oxidoreductase|aapp,enzy|||reductase|||0|861|354|363
SE|45||ab|3|entity|C0439148|Unit|qnco|||units|||0|750|401|406
SE|45||ab|3|entity|C0596085|analytical ultracentrifugation|lbpr|||analytical ultracentrifugation|||0|1000|442|472
SE|45||ab|3|entity|C0013862|Electrophoresis, Polyacrylamide Gel|lbpr|||polyacrylamide gel electrophoresis|||0|1000|474|508
SE|45||ab|3|entity|C0162621|Titration|lbpr|||titration|||0|1000|514|523
SE|45||ab|3|entity|C0025677|Methotrexate|orch,phsu|||methotrexate|||0|1000|529|541
SE|45||ab|3|relation|7|1|C0013862|Electrophoresis, Polyacrylamide Gel|lbpr|lbpr|||polyacrylamide gel electrophoresis|||0|1000|474|508|PREP|USES||524|528|1|1|C0025677|Methotrexate|orch,phsu|phsu|||methotrexate|||0|1000|529|541
SE|45||ab|3|relation|7|1|C0162621|Titration|lbpr|lbpr|||titration|||0|1000|514|523|PREP|USES||524|528|1|1|C0025677|Methotrexate|orch,phsu|phsu|||methotrexate|||0|1000|529|541
SE|45||ab|3|relation|7|1|C0596085|analytical ultracentrifugation|lbpr|lbpr|||analytical ultracentrifugation|||0|1000|442|472|PREP|USES||524|528|1|1|C0025677|Methotrexate|orch,phsu|phsu|||methotrexate|||0|1000|529|541

SE|45||ab|4|text|543|630|The products of the first step of Edman degradation indicated a minimum purity of 79%.
SE|45||ab|4|entity|C1514468|product|qnco|||products|||0|966|547|555
SE|45||ab|4|entity|C1279901|Firstly|qlco|||first|||0|888|563|568
SE|45||ab|4|entity|C1261552|Step|ftcn|||step|||0|888|569|573
SE|45||ab|4|entity|C0243125|degradation|ftcn|||degradation|||0|861|583|594
SE|45||ab|4|entity|C1524031|Minimum|qlco|||minimum|||0|694|607|614

SE|45||ab|5|text|630|771|The reductase has a molecular weight of about 21500 on the basis of amino acid composition and 22100 +/- 300 from equilibrium sedimentation.
SE|45||ab|5|entity|C0030016|Oxidoreductase|aapp,enzy|||reductase|||0|1000|634|643
SE|45||ab|5|entity|C0026385|Molecular Weight|qnco|||molecular weight|||0|1000|650|666
SE|45||ab|5|entity|C1527178|Basis|ftcn|||basis|||0|1000|689|694
SE|45||ab|5|entity|C0002520|Amino Acids|aapp,bacs,phsu|||amino acid|||0|888|698|708
SE|45||ab|5|entity|C0486616|Composition|clna|||composition|||0|888|709|720
SE|45||ab|5|entity|C0014653|Equilibrium|orgf|||equilibrium|||0|888|744|755
SE|45||ab|5|entity|C0597428|Sedimentation procedure|lbpr|||sedimentation|||0|888|756|769

SE|45||ab|6|text|771|858|It is not inhibited by antiserum to the Streptococcus faecium reductase (isoenzyme 2).
SE|45||ab|6|entity|C1518422|Not|ftcn|||not|||0|1000|777|780
SE|45||ab|6|entity|C0020960|Immune Sera|aapp,imft,phsu|||antiserum|||0|1000|794|803
SE|45||ab|6|entity|C0085495|Enterococcus faecium|bact|||Streptococcus faecium|||0|901|811|832
SE|45||ab|6|entity|C0030016|Oxidoreductase|aapp,enzy|||reductase|||0|901|833|842
SE|45||ab|6|entity|C0022173|Isoenzymes|aapp,enzy|||isoenzyme|||0|861|844|853
SE|45||ab|6|relation|0|0|C0030016|Oxidoreductase|aapp,gngm,enzy|aapp|||reductase|||0|901|833|842|MOD/HEAD|PART_OF||811|842|0|0|C0085495|Enterococcus faecium|bact|bact|||Streptococcus faecium|||0|901|811|832

SE|45||ab|7|text|858|1048|Unlike the reductase of many other vertebrate tissues, the bovine enzyme is inhibited by mercurials rather than activated and it has a single pH optimum at both low and high ionic strength.
SE|45||ab|7|entity|C0030016|Oxidoreductase|aapp,enzy|||reductase|||0|1000|869|878
SE|45||ab|7|entity|C0042567|Vertebrates|vtbt|||vertebrate|||0|888|893|903
SE|45||ab|7|entity|C0040300|Body tissue|tisu|||tissues|||0|888|904|911
SE|45||ab|7|entity|C0007452|Cattle|mamm|||bovine|||0|888|917|923
SE|45||ab|7|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|888|924|930
SE|45||ab|7|entity|C0459768|Mercurial|phsu|||mercurials|||0|966|947|957
SE|45||ab|7|entity|C1515877|Activate|ftcn|||activated|||0|966|970|979
SE|45||ab|7|entity|C0037179|Unmarried person|popg|||single|||0|623|993|999
SE|45||ab|7|entity|C0205251|low|qlco|||low|||0|1000|1019|1022
SE|45||ab|7|entity|C0205250|High|qlco|||high|||0|901|1027|1031
SE|45||ab|7|entity|C0086486|Ionic Strength|lbtr|||ionic strength|||0|901|1032|1046
SE|45||ab|7|relation|0|0|C0040300|Body tissue|tisu|tisu|||tissues|||0|888|904|911|MOD/HEAD|PART_OF||893|911|0|0|C0042567|Vertebrates|vtbt|vtbt|||vertebrate|||0|888|893|903
SE|45||ab|7|relation|5|1|C0459768|Mercurial|phsu|phsu|||mercurials|||0|966|947|957|VERB|INHIBITS||934|943|3|3|C0030016|Oxidoreductase|aapp,gngm,enzy|gngm|||reductase|||0|1000|869|878

SE|45||ab|8|text|1048|1156|However, the position of the pH optimum is shifted and the activity increased by increasing ionic strength.
SE|45||ab|8|entity|C0733755|Positioning Attribute|spco|||position|||0|1000|1061|1069
SE|45||ab|8|entity|C0442808|Increasing|ftcn|||increasing|||0|901|1129|1139
SE|45||ab|8|entity|C0086486|Ionic Strength|lbtr|||ionic strength|||0|901|1140|1154

SE|45||ab|9|text|1156|1260|Automatic Edman degradation has been used to determine 34 of the amino-terminal 37 amino acid residues.
SE|45||ab|9|entity|C0205554|Automated|ftcn|||Automatic|||0|802|1156|1165
SE|45||ab|9|entity|C0243125|degradation|ftcn|||degradation|||0|802|1172|1183
SE|45||ab|9|entity|C0002520|Amino Acids|aapp,bacs,phsu|||amino acid|||0|753|1239|1249

SE|45||ab|10|text|1260|1399|Considerable homology exists between this region and the corresponding regions of the reductase from S. faecium and from Escherichia coli.
SE|45||ab|10|entity|C1334043|Homologous Gene|gngm|||homology|||0|761|1273|1281
SE|45||ab|10|entity|C0205147|Region|spco|||region|||0|1000|1302|1308
SE|45||ab|10|entity|C0205147|Region|spco|||regions|||0|827|1331|1338
SE|45||ab|10|entity|C0030016|Oxidoreductase|aapp,enzy|||reductase|||0|1000|1346|1355
SE|45||ab|10|entity|C0014834|Escherichia coli|bact|||Escherichia coli|||0|1000|1381|1397

SE|45||ab|11|text|1399|1509|This strengthens the idea that this region contributes to the structure of the binding site for dihydrofolate.
SE|45||ab|11|entity|C0205147|Region|spco|||region|||0|1000|1435|1441
SE|45||ab|11|entity|C0678594|Structure|spco|||structure|||0|1000|1461|1470
SE|45||ab|11|entity|C0005456|Binding Sites|rcpt|||binding site|||0|1000|1478|1490
SE|45||ab|11|entity|C0058075|dihydrofolate|bacs,orch,phsu|||dihydrofolate|||0|1000|1495|1508


SE|46||ti|1|text|15|88|Purification and properties of Escherichia coli dihydrofolate reductase.
SE|46||ti|1|entity|C0243114|purification|lbpr,resa|||Purification|||0|1000|15|27
SE|46||ti|1|entity|C0871161|Property|qlco|||properties|||0|966|32|42
SE|46||ti|1|entity|C0014834|Escherichia coli|bact|||Escherichia coli|||0|888|46|62
SE|46||ti|1|entity|C0039667|Dihydrofolate Reductase|aapp,enzy|1719|DHFR|dihydrofolate reductase|||0|888|63|86
SE|46||ti|1|relation|0|0|C0039667|Dihydrofolate Reductase|aapp,gngm,enzy|aapp|1719|DHFR|dihydrofolate reductase|||0|888|63|86|MOD/HEAD|PART_OF||46|86|0|0|C0014834|Escherichia coli|bact|bact|||Escherichia coli|||0|888|46|62

SE|46||ab|1|text|94|311|Dihydrofolate reductase has been purified 40-fold to apparent homogeneity from a trimethoprim-resistant strain of Escherichia coli (RT 500) using a procedure that includes methotrexate affinity column chromatography.
SE|46||ab|1|entity|C0039667|Dihydrofolate Reductase|aapp,enzy|1719|DHFR|Dihydrofolate reductase|||0|1000|94|117
SE|46||ab|1|entity|C0332462|Fold|spco|||fold|||0|888|139|143
SE|46||ab|1|entity|C0750489|APPARENT|idcn|||apparent|||0|694|147|155
SE|46||ab|1|entity|C0041042|Trimethoprim Resistance|orga|||trimethoprim-resistant|||0|877|175|197
SE|46||ab|1|entity|C0456178|Microbiology subtype strains|inpr|||strain|||0|877|198|204
SE|46||ab|1|entity|C0014834|Escherichia coli|bact|||Escherichia coli|||0|1000|208|224
SE|46||ab|1|entity|C0184661|Procedures|hlca|||procedure|||0|1000|242|251
SE|46||ab|1|entity|C0025677|Methotrexate|orch,phsu|||methotrexate|||0|861|266|278
SE|46||ab|1|entity|C1185738|Column|bpoc|||column|||0|861|288|294
SE|46||ab|1|entity|C0008551|Chromatography, Affinity|lbpr|||affinity column chromatography|||0|861|279|309

SE|46||ab|2|text|311|525|Determinations of the molecular weight of the enzyme based on its amino acid composition, sedimentation velocity, and sodium dodecyl sulfate gel electrophoresis gave values of 17680, 17470 and 18300, respectively.
SE|46||ab|2|entity|C0680730|Adjudication|gora|||Determinations|||0|966|311|325
SE|46||ab|2|entity|C0026385|Molecular Weight|qnco|||molecular weight|||0|1000|333|349
SE|46||ab|2|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|357|363
SE|46||ab|2|entity|C0002520|Amino Acids|aapp,bacs,phsu|||amino acid|||0|888|377|387
SE|46||ab|2|entity|C0486616|Composition|clna|||composition|||0|888|388|399
SE|46||ab|2|entity|C0597430|sedimentation velocity|qnco|||sedimentation velocity|||0|1000|401|423
SE|46||ab|2|entity|C0037506|Sodium Dodecyl Sulfate|bodm,lipd,phsu|||sodium dodecyl sulfate|||0|893|429|451
SE|46||ab|2|entity|C0596607|Gel Electrophoresis|lbpr|||gel electrophoresis|||0|893|452|471
SE|46||ab|2|entity|C0042295|Values|qlco|||values|||0|1000|477|483
SE|46||ab|2|relation|0|0|C0596607|Gel Electrophoresis|lbpr|lbpr|||gel electrophoresis|||0|893|452|471|MOD/HEAD|USES||429|471|0|0|C0037506|Sodium Dodecyl Sulfate|bodm,lipd,phsu|phsu|||sodium dodecyl sulfate|||0|893|429|451

SE|46||ab|3|text|525|784|An aggregated form of the enzyme with a low specific activity can be separated from the monomer by gel filtration; treatment of the aggregate with mercaptoethanol or dithiothreitol results in an increase in enzymic activity and a regeneration of the monomer.
SE|46||ab|3|entity|C0332621|Aggregation|ftcn|||aggregated|||0|888|528|538
SE|46||ab|3|entity|C1522492|Formation|ftcn|||form|||0|888|539|543
SE|46||ab|3|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|551|557
SE|46||ab|3|entity|C0205251|low|qlco|||low|||0|802|565|568
SE|46||ab|3|entity|C0596973|monomer|chvs|||monomer|||0|1000|613|620
SE|46||ab|3|entity|C0008559|Chromatography, Gel|lbpr|||gel filtration|||0|1000|624|638
SE|46||ab|3|entity|C0205418|Aggregate|qlco|||aggregate|||0|1000|657|666
SE|46||ab|3|entity|C0025402|2-Mercaptoethanol|orch|||mercaptoethanol|||0|1000|672|687
SE|46||ab|3|entity|C0012789|Dithiothreitol|carb,phsu|||dithiothreitol|||0|1000|691|705
SE|46||ab|3|entity|C0442805|Increase|ftcn|||increase|||0|1000|720|728
SE|46||ab|3|entity|C0596973|monomer|chvs|||monomer|||0|1000|775|782

SE|46||ab|4|text|784|888|Also, multiple molecular forms of the monomer have been detected by polyacrylamide gel electrophoresis.
SE|46||ab|4|entity|C0439064|Numerous|qnco|||multiple|||0|851|790|798
SE|46||ab|4|entity|C1521991|Molecular|qlco|||molecular|||0|851|799|808
SE|46||ab|4|entity|C0596973|monomer|chvs|||monomer|||0|1000|822|829
SE|46||ab|4|entity|C0013862|Electrophoresis, Polyacrylamide Gel|lbpr|||polyacrylamide gel electrophoresis|||0|1000|852|886

SE|46||ab|5|text|888|988|The unresolved enzyme exhibits two pH optima (pH 4.5 and pH 7.0) with dihydrofolate as a substrate.
SE|46||ab|5|entity|C0443342|Unresolved|qlco|||unresolved|||0|888|892|902
SE|46||ab|5|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|888|903|909
SE|46||ab|5|entity|C0205448|Two|qnco|||two|||0|623|919|922
SE|46||ab|5|entity|C0058075|dihydrofolate|bacs,orch,phsu|||dihydrofolate|||0|1000|958|971

SE|46||ab|6|text|988|1065|Highest activities are observed in buffers containing large organic cations.
SE|46||ab|6|entity|C1522410|Highest|qlco|||Highest|||0|888|988|995
SE|46||ab|6|entity|C0441655|Activities|acty|||activities|||0|888|996|1006
SE|46||ab|6|entity|C0006353|Buffers|bacs,irda|||buffers|||0|1000|1023|1030
SE|46||ab|6|entity|C0549177|Large|qnco|||large|||0|851|1042|1047
SE|46||ab|6|entity|C0747055|ORGANIC|qlco|||organic|||0|851|1048|1055
SE|46||ab|6|entity|C0007447|Cations|chvs|||cations|||0|851|1056|1063

SE|46||ab|7|text|1065|1193|In 100 mM imidazolium chloride (pH 7), the specific activity is 47 mumol of dihydrofolate reduced per min per mg at 30 degrees.
SE|46||ab|7|entity|C0008203|Chlorides|inch|||chloride|||0|763|1087|1095
SE|46||ab|7|entity|C0058075|dihydrofolate|bacs,orch,phsu|||dihydrofolate|||0|1000|1141|1154
SE|46||ab|7|entity|C0439232|Minute of time|tmco|||min|||0|1000|1167|1170

SE|46||ab|8|text|1193|1267|Folic acid also serves as a substrate with a single pH optimum of pH 4.5.
SE|46||ab|8|entity|C0016410|Folic Acid|orch,phsu,vita|||Folic acid|||0|1000|1193|1203
SE|46||ab|8|entity|C0037179|Unmarried person|popg|||single|||0|623|1238|1244

SE|46||ab|9|text|1267|1388|At this pH the Km for folate is 16 muM, and the Vmax is 1/1000 of the rate observed with dihydrofolate as the substrate.
SE|46||ab|9|entity|C0178638|Folate|orch,vita|||folate|||0|1000|1289|1295
SE|46||ab|9|entity|C1009574|Chrysanthemum x morifolium|plnt|||muM|||0|861|1302|1305
SE|46||ab|9|entity|C1521828|Rate|qnco|||rate|||0|1000|1337|1341
SE|46||ab|9|entity|C0058075|dihydrofolate|bacs,orch,phsu|||dihydrofolate|||0|1000|1356|1369

SE|46||ab|10|text|1388|1564|Monovalent cations (Na+, K+, Rb+, and Cs+) inhibit dihydrofolate reductase; at a given ionic strength the degree of inhibition is a function of the ionic radius of the cation.
SE|46||ab|10|entity|C0007449|Cations, Monovalent|chvs|||Monovalent cations|||0|1000|1388|1406
SE|46||ab|10|entity|C0039667|Dihydrofolate Reductase|aapp,enzy|1719|DHFR|dihydrofolate reductase|||0|1000|1439|1462
SE|46||ab|10|entity|C1442162|GIVEN|cnce|||given|||0|901|1469|1474
SE|46||ab|10|entity|C0086486|Ionic Strength|lbtr|||ionic strength|||0|901|1475|1489
SE|46||ab|10|entity|C0031843|physiological aspects|phsf|||function|||0|1000|1520|1528
SE|46||ab|10|entity|C0022023|Ions|elii|||ionic|||0|853|1536|1541
SE|46||ab|10|entity|C1279083|Entire radius|bpoc|||radius|||0|853|1542|1548
SE|46||ab|10|entity|C0007447|Cations|chvs|||cation|||0|1000|1556|1562

SE|46||ab|11|text|1564|1669|Divalent cations are more potent inhibitors; the I50 of BaCl2 is 250 muM, as compared to 125 mM for KCl.
SE|46||ab|11|entity|C0007448|Cations, Divalent|chvs|||Divalent cations|||0|1000|1564|1580
SE|46||ab|11|entity|C0205172|More|ftcn|||more|||0|818|1585|1589
SE|46||ab|11|entity|C0237399|Potential|qlco|||potent|||0|818|1590|1596
SE|46||ab|11|entity|C0243077|inhibitors|chvf|||inhibitors|||0|818|1597|1607
SE|46||ab|11|entity|C0052972|barium chloride|hops,inch|||BaCl2|||0|1000|1620|1625
SE|46||ab|11|entity|C1009574|Chrysanthemum x morifolium|plnt|||muM|||0|861|1633|1636

SE|46||ab|12|text|1669|1716|Anions neither inhibit nor activate the enzyme.
SE|46||ab|12|entity|C0003075|Anions|elii|||Anions|||0|1000|1669|1675
SE|46||ab|12|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|1709|1715
SE|46||ab|12|relation|1|1|C0003075|Anions|elii|elii|||Anions|||0|1000|1669|1675|VERB|STIMULATES|negation|1696|1704|1|1|C0014442|Enzymes|enzy,orch|enzy|||enzyme|||0|1000|1709|1715


SE|47||ti|1|text|15|163|The influence of pH on the interaction of inhibitors with triosephosphate isomerase and determination of the pKa of the active-site carboxyl group.
SE|47||ti|1|entity|C0243077|inhibitors|chvf|||inhibitors|||0|1000|57|67
SE|47||ti|1|entity|C0041078|Triose-Phosphate Isomerase|aapp,enzy|||triosephosphate isomerase|||0|1000|73|98
SE|47||ti|1|entity|C0680730|Adjudication|gora|||determination|||0|1000|103|116
SE|47||ti|1|entity|C0010531|Cyclic AMP-Dependent Protein Kinases|aapp,enzy|||pKa|||0|1000|124|127
SE|47||ti|1|entity|C0205681|Active Site|ftcn,spco|||active-site|||0|888|135|146
SE|47||ti|1|entity|C0596260|carboxyl group|inch|||carboxyl group|||0|888|147|161
SE|47||ti|1|relation|5|2|C0041078|Triose-Phosphate Isomerase|aapp,gngm,enzy|enzy|||triosephosphate isomerase|||0|1000|73|98|NOM|INTERACTS_WITH||42|53|5|1|C0243077|inhibitors|chvf|chvf|||inhibitors|||0|1000|57|67

SE|47||ab|1|text|169|594|Ionization effects on the binding of the potential transition state analogues 2-phosphoglycolate and 2-phosphoglycolohydroxamate appear to be attributable to the changing state of ionization of the ligands themselves, therefore it is unnecessary to postulate the additional involvement of an ionizing residue at the active site of triosephosphate isomerase to explain the influence of changing pH on Ki in the neutral range.
SE|47||ab|1|entity|C0596801|ionization|phpr|||Ionization|||0|872|169|179
SE|47||ab|1|entity|C1280500|Effect|qlco|||effects|||0|872|180|187
SE|47||ab|1|entity|C0237399|Potential|qlco|||potential|||0|732|210|219
SE|47||ab|1|entity|C1442792|State|ftcn|||state|||0|732|231|236
SE|47||ab|1|entity|C0243071|Analog|chvs|||analogues|||0|732|237|246
SE|47||ab|1|entity|C0070868|phosphoglycolate|orch|||phosphoglycolate|||0|732|249|265
SE|47||ab|1|entity|C0070870|phosphoglycolohydroxamate|orch,phsu|||phosphoglycolohydroxamate|||0|861|272|297
SE|47||ab|1|entity|C0392747|Changing|ftcn|||changing|||0|888|331|339
SE|47||ab|1|entity|C1442792|State|ftcn|||state|||0|888|340|345
SE|47||ab|1|entity|C0596801|ionization|phpr|||ionization|||0|1000|349|359
SE|47||ab|1|entity|C0023688|Ligands|chem|||ligands|||0|1000|367|374
SE|47||ab|1|entity|C1524062|Additional|ftcn|||additional|||0|694|432|442
SE|47||ab|1|entity|C0205681|Active Site|ftcn,spco|||active site|||0|1000|485|496
SE|47||ab|1|entity|C0041078|Triose-Phosphate Isomerase|aapp,enzy|||triosephosphate isomerase|||0|1000|500|525
SE|47||ab|1|entity|C0392747|Changing|ftcn|||changing|||0|888|554|562
SE|47||ab|1|entity|C1514721|Range|qnco|||range|||0|861|587|592

SE|47||ab|2|text|594|705|The binding of the competitive inhibitor inorganic sulfate is insensitive to changing pH in the neutral range.
SE|47||ab|2|entity|C0679932|competition|socb|||competitive|||0|852|613|624
SE|47||ab|2|entity|C0243077|inhibitors|chvf|||inhibitor|||0|852|625|634
SE|47||ab|2|entity|C0038720|Sulfates, Inorganic|inch|||inorganic sulfate|||0|852|635|652
SE|47||ab|2|entity|C0237677|Insensitivity|menp|||insensitive|||0|928|656|667
SE|47||ab|2|entity|C0392747|Changing|ftcn|||changing|||0|888|671|679
SE|47||ab|2|entity|C1514721|Range|qnco|||range|||0|861|698|703

SE|47||ab|3|text|705|899|3-Chloroacetol sulfate, synthesized as an active-site-specific reagent for triosephosphate isomerase, is used to provide an indication of the pKa of the essential carboxyl group of this enzyme.
SE|47||ab|3|entity|C0038720|Sulfates, Inorganic|inch|||sulfate|||0|802|720|727
SE|47||ab|3|entity|C0205681|Active Site|ftcn,spco|||active-site|||0|824|747|758
SE|47||ab|3|entity|C0034760|Reagents|irda|||reagent|||0|824|768|775
SE|47||ab|3|entity|C0041078|Triose-Phosphate Isomerase|aapp,enzy|||triosephosphate isomerase|||0|1000|780|805
SE|47||ab|3|entity|C0392360|Reason for|idcn|||indication|||0|1000|829|839
SE|47||ab|3|entity|C0010531|Cyclic AMP-Dependent Protein Kinases|aapp,enzy|||pKa|||0|1000|847|850
SE|47||ab|3|entity|C0205224|Essential|qlco|||essential|||0|901|858|867
SE|47||ab|3|entity|C0596260|carboxyl group|inch|||carboxyl group|||0|901|868|882
SE|47||ab|3|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|891|897
SE|47||ab|3|relation|1|1|C0038720|Sulfates, Inorganic|inch|inch|||sulfate|||0|802|720|727|VERB|INTERACTS_WITH||729|740|6|1|C0034760|Reagents|irda|irda|||reagent|||0|824|768|775

SE|47||ab|4|text|899|1245|Previously described active-site-specific reagents for the isomerase were phosphate esters, and their changing state of ionization (accompanied by possible changes in their affinity for the active site) may have complicated earlier attempts to determine the pKa of the essential carboxyl group from the pH dependence of the rate of inactivation.
SE|47||ab|4|entity|C0205681|Active Site|ftcn,spco|||active-site|||0|824|920|931
SE|47||ab|4|entity|C0034760|Reagents|irda|||reagents|||0|824|941|949
SE|47||ab|4|entity|C0022202|Isomerase|aapp,enzy|||isomerase|||0|1000|958|967
SE|47||ab|4|entity|C0599126|phosphate ester|opco|||phosphate esters|||0|983|973|989
SE|47||ab|4|entity|C0392747|Changing|ftcn|||changing|||0|888|1001|1009
SE|47||ab|4|entity|C1442792|State|ftcn|||state|||0|888|1010|1015
SE|47||ab|4|entity|C0596801|ionization|phpr|||ionization|||0|1000|1019|1029
SE|47||ab|4|entity|C0332149|Possible|qlco|||possible|||0|872|1046|1054
SE|47||ab|4|entity|C0205681|Active Site|ftcn,spco|||active site|||0|1000|1089|1100
SE|47||ab|4|entity|C1279919|Early|tmco|||earlier|||0|966|1123|1130
SE|47||ab|4|entity|C0010531|Cyclic AMP-Dependent Protein Kinases|aapp,enzy|||pKa|||0|1000|1157|1160
SE|47||ab|4|entity|C0205224|Essential|qlco|||essential|||0|901|1168|1177
SE|47||ab|4|entity|C0596260|carboxyl group|inch|||carboxyl group|||0|901|1178|1192
SE|47||ab|4|entity|C0439857|Dependence|mobd|||dependence|||0|888|1205|1215
SE|47||ab|4|entity|C1521828|Rate|qnco|||rate|||0|1000|1223|1227
SE|47||ab|4|entity|C0544461|Inactivation|comd|||inactivation|||0|1000|1231|1243

SE|47||ab|5|text|1245|1370|Being a strong monoprotic acid, chloroacetol sulfate is better suited to the determination of the pKa of the carboxyl group.
SE|47||ab|5|entity|C0302921|Strong acid|inch|||strong monoprotic acid|||0|913|1253|1275
SE|47||ab|5|entity|C0038720|Sulfates, Inorganic|inch|||sulfate|||0|861|1290|1297
SE|47||ab|5|entity|C0332272|Better|qlco|||better|||0|1000|1301|1307
SE|47||ab|5|entity|C0680730|Adjudication|gora|||determination|||0|1000|1322|1335
SE|47||ab|5|entity|C0010531|Cyclic AMP-Dependent Protein Kinases|aapp,enzy|||pKa|||0|1000|1343|1346
SE|47||ab|5|entity|C0596260|carboxyl group|inch|||carboxyl group|||0|1000|1354|1368

SE|47||ab|6|text|1370|1559|Chloroacetol sulfate inactivates triosephosphate isomerase by the selective esterification of the same carboxyl group as that which is esterified by the phosphate esters described earlier.
SE|47||ab|6|entity|C0038720|Sulfates, Inorganic|inch|||sulfate|||0|861|1383|1390
SE|47||ab|6|entity|C0041078|Triose-Phosphate Isomerase|aapp,enzy|||triosephosphate isomerase|||0|1000|1403|1428
SE|47||ab|6|entity|C0014895|Esterification|npop|||esterification|||0|861|1446|1460
SE|47||ab|6|entity|C0445247|Same|qlco|||same|||0|901|1468|1472
SE|47||ab|6|entity|C0596260|carboxyl group|inch|||carboxyl group|||0|901|1473|1487
SE|47||ab|6|entity|C0599126|phosphate ester|opco|||phosphate esters|||0|983|1523|1539
SE|47||ab|6|entity|C1279919|Early|tmco|||earlier|||0|966|1550|1557
SE|47||ab|6|relation|1|1|C0038720|Sulfates, Inorganic|inch|inch|||sulfate|||0|861|1383|1390|VERB|INHIBITS||1391|1402|4|1|C0041078|Triose-Phosphate Isomerase|aapp,gngm,enzy|gngm|||triosephosphate isomerase|||0|1000|1403|1428

SE|47||ab|7|text|1559|1725|From the pH dependence of the rate of inactivation of yeast triosephosphate isomerase, the apparent pKa of the active-site carboxyl group is estimated as 3.9 +/- 0.1.
SE|47||ab|7|entity|C0439857|Dependence|mobd|||dependence|||0|888|1571|1581
SE|47||ab|7|entity|C1521828|Rate|qnco|||rate|||0|1000|1589|1593
SE|47||ab|7|entity|C0544461|Inactivation|comd|||inactivation|||0|1000|1597|1609
SE|47||ab|7|entity|C0036025|Saccharomyces cerevisiae|fngs|||yeast|||0|901|1613|1618
SE|47||ab|7|entity|C0041078|Triose-Phosphate Isomerase|aapp,enzy|||triosephosphate isomerase|||0|901|1619|1644
SE|47||ab|7|entity|C0750489|APPARENT|idcn|||apparent|||0|888|1650|1658
SE|47||ab|7|entity|C0010531|Cyclic AMP-Dependent Protein Kinases|aapp,enzy|||pKa|||0|888|1659|1662
SE|47||ab|7|entity|C0205681|Active Site|ftcn,spco|||active-site|||0|888|1670|1681
SE|47||ab|7|entity|C0596260|carboxyl group|inch|||carboxyl group|||0|888|1682|1696
SE|47||ab|7|relation|0|0|C0041078|Triose-Phosphate Isomerase|aapp,gngm,enzy|aapp|||triosephosphate isomerase|||0|901|1619|1644|MOD/HEAD|PART_OF||1613|1644|0|0|C0036025|Saccharomyces cerevisiae|fngs|fngs|||yeast|||0|901|1613|1618
SE|47||ab|7|relation|5|4|C0010531|Cyclic AMP-Dependent Protein Kinases|aapp,gngm,enzy|aapp|||pKa|||0|888|1659|1662|NOM|INTERACTS_WITH||1571|1581|5|5|C0596260|carboxyl group|inch|inch|||carboxyl group|||0|888|1682|1696


SE|48||ti|1|text|15|102|Monoanion inhibition and 35Cl nuclear magnetic resonance studies of renal dipeptidase.
SE|48||ti|1|entity|C0024485|Magnetic Resonance Imaging|diap|||nuclear magnetic resonance|||0|923|45|71
SE|48||ti|1|entity|C0207803|membrane dipeptidase|aapp,enzy|||renal dipeptidase|||0|1000|83|100

SE|48||ab|1|text|108|291|Kinetic analyses of monoanion inhibition and 15Cl nuclear magnetic resonance at 5.88 MHz were employed to study monoanion interactions with the zinc metalloenzyme, renal dipeptidase.
SE|48||ab|1|entity|C0022702|Kinetics|idcn|||Kinetic|||0|872|108|115
SE|48||ab|1|entity|C0936012|Analysis|resa|||analyses|||0|872|116|124
SE|48||ab|1|entity|C0024485|Magnetic Resonance Imaging|diap|||nuclear magnetic resonance|||0|923|158|184
SE|48||ab|1|entity|C0556962|MHz|qnco|||MHz|||0|802|193|196
SE|48||ab|1|entity|C0043481|Zinc|bacs,elii,phsu|||zinc|||0|888|252|256
SE|48||ab|1|entity|C0596918|metalloenzyme|aapp,enzy|||metalloenzyme|||0|888|257|270
SE|48||ab|1|entity|C0207803|membrane dipeptidase|aapp,enzy|||renal dipeptidase|||0|1000|272|289

SE|48||ab|2|text|291|586|The enzyme-catalyzed hydrolysis of glycyldehydrophenylalanine exhibited competitive inhibition when the reaction rate was determined in the presence of the monovalent anions fluoride, chloride, bromide, iodide, azide, nitrate, or thiocyanate or upon the addition of the divalent anion, sulfate.
SE|48||ab|2|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|840|295|301
SE|48||ab|2|entity|C0007382|Catalysis|npop|||catalyzed|||0|840|302|311
SE|48||ab|2|entity|C0020291|Hydrolysis|npop|||hydrolysis|||0|840|312|322
SE|48||ab|2|entity|C0301626|Competitive inhibition|phsf|||competitive inhibition|||0|1000|363|385
SE|48||ab|2|entity|C0678608|reaction rate|tmco|||reaction rate|||0|1000|395|408
SE|48||ab|2|entity|C0003075|Anions|elii|||anions|||0|790|458|464
SE|48||ab|2|entity|C0016327|Fluorides|inch,phsu|||fluoride|||0|790|465|473
SE|48||ab|2|entity|C0008203|Chlorides|inch|||chloride|||0|1000|475|483
SE|48||ab|2|entity|C0006222|Bromides|inch|||bromide|||0|1000|485|492
SE|48||ab|2|entity|C0021966|Iodides|inch|||iodide|||0|1000|494|500
SE|48||ab|2|entity|C0004492|Azides|chvs|||azide|||0|1000|502|507
SE|48||ab|2|entity|C0699857|Nitrate|inch|||nitrate|||0|1000|509|516
SE|48||ab|2|entity|C0039887|Thiocyanates|orch|||thiocyanate|||0|1000|521|532
SE|48||ab|2|entity|C0442796|Additive|qlco|||addition|||0|928|545|553
SE|48||ab|2|entity|C0003075|Anions|elii|||anion|||0|861|570|575
SE|48||ab|2|entity|C0038720|Sulfates, Inorganic|inch|||sulfate|||0|1000|577|584
SE|48||ab|2|relation|0|0|C0016327|Fluorides|inch,phsu|inch|||fluoride|||0|790|465|473|MOD/HEAD|ISA||458|473|0|0|C0003075|Anions|elii|elii|||anions|||0|790|458|464
SE|48||ab|2|relation|10|10|C0038720|Sulfates, Inorganic|inch|inch|||sulfate|||0|1000|577|584|NOM|COEXISTS_WITH||431|439|10|1|C0006222|Bromides|inch|inch|||bromide|||0|1000|485|492
SE|48||ab|2|relation|10|10|C0038720|Sulfates, Inorganic|inch|inch|||sulfate|||0|1000|577|584|NOM|COEXISTS_WITH||431|439|10|1|C0008203|Chlorides|inch|inch|||chloride|||0|1000|475|483
SE|48||ab|2|relation|10|10|C0038720|Sulfates, Inorganic|inch|inch|||sulfate|||0|1000|577|584|NOM|COEXISTS_WITH||431|439|10|1|C0016327|Fluorides|inch,phsu|inch|||fluoride|||0|790|465|473
SE|48||ab|2|relation|10|10|C0038720|Sulfates, Inorganic|inch|inch|||sulfate|||0|1000|577|584|NOM|COEXISTS_WITH||431|439|10|1|C0021966|Iodides|inch|inch|||iodide|||0|1000|494|500
SE|48||ab|2|relation|10|10|C0038720|Sulfates, Inorganic|inch|inch|||sulfate|||0|1000|577|584|NOM|COEXISTS_WITH||431|439|10|1|C0039887|Thiocyanates|orch|orch|||thiocyanate|||0|1000|521|532
SE|48||ab|2|relation|10|10|C0038720|Sulfates, Inorganic|inch|inch|||sulfate|||0|1000|577|584|NOM|COEXISTS_WITH||431|439|10|1|C0699857|Nitrate|inch|inch|||nitrate|||0|1000|509|516

SE|48||ab|3|text|586|639|Competitive inhibition was produced by these anions.
SE|48||ab|3|entity|C0301626|Competitive inhibition|phsf|||Competitive inhibition|||0|1000|586|608
SE|48||ab|3|entity|C0003075|Anions|elii|||anions|||0|1000|631|637

SE|48||ab|4|text|639|768|One anion was bound per enzyme molecule, and except in the case of fluoride all of the anions appeared to bind at the same site.
SE|48||ab|4|entity|C0205447|One|qnco|||One|||0|888|639|642
SE|48||ab|4|entity|C0003075|Anions|elii|||anion|||0|888|643|648
SE|48||ab|4|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|888|663|669
SE|48||ab|4|entity|C0567416|Molecule|sbst|||molecule|||0|888|670|678
SE|48||ab|4|entity|C0016327|Fluorides|inch,phsu|||fluoride|||0|1000|706|714
SE|48||ab|4|entity|C0003075|Anions|elii|||anions|||0|1000|726|732
SE|48||ab|4|entity|C0445247|Same|qlco|||same|||0|888|757|761
SE|48||ab|4|entity|C0205145|Site|spco|||site|||0|888|762|766

SE|48||ab|5|text|768|941|Cyanide ion produced a much more effective inhibition of renal dipeptidase than the other monoanions, and it was shown that two cyanide ions were bound per enzyme molecule.
SE|48||ab|5|entity|C0010505|Cyanides|inch|||Cyanide|||0|888|768|775
SE|48||ab|5|entity|C0022023|Ions|elii|||ion|||0|888|776|779
SE|48||ab|5|entity|C0205172|More|ftcn|||more|||0|851|796|800
SE|48||ab|5|entity|C0207803|membrane dipeptidase|aapp,enzy|||renal dipeptidase|||0|1000|825|842
SE|48||ab|5|entity|C0205448|Two|qnco|||two|||0|851|892|895
SE|48||ab|5|entity|C0010505|Cyanides|inch|||cyanide|||0|851|896|903
SE|48||ab|5|entity|C0022023|Ions|elii|||ions|||0|851|904|908
SE|48||ab|5|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|888|924|930
SE|48||ab|5|entity|C0567416|Molecule|sbst|||molecule|||0|888|931|939
SE|48||ab|5|relation|0|0|C0010505|Cyanides|inch|inch|||Cyanide|||0|888|768|775|MOD/HEAD|ISA||768|779|0|0|C0022023|Ions|elii|elii|||ion|||0|888|776|779
SE|48||ab|5|relation|0|0|C0010505|Cyanides|inch|inch|||cyanide|||0|851|896|903|INFER|INHIBITS(SPEC)||896|908|0|0|C0207803|membrane dipeptidase|aapp,gngm,enzy|gngm|||renal dipeptidase|||0|1000|825|842
SE|48||ab|5|relation|0|0|C0010505|Cyanides|inch|inch|||cyanide|||0|851|896|903|MOD/HEAD|ISA||896|908|0|0|C0022023|Ions|elii|elii|||ions|||0|851|904|908
SE|48||ab|5|relation|4|3|C0022023|Ions|elii|elii|||ions|||0|851|904|908|NOM|INHIBITS||811|821|4|1|C0207803|membrane dipeptidase|aapp,gngm,enzy|gngm|||renal dipeptidase|||0|1000|825|842

SE|48||ab|6|text|941|1090|An investigation of the effect of pH upon monoanion inhibition suggested that the anion inhibitors bind to the group with a pK of approximately 7.8.
SE|48||ab|6|entity|C1280500|Effect|qlco|||effect|||0|1000|965|971
SE|48||ab|6|entity|C0003075|Anions|elii|||anion|||0|888|1023|1028
SE|48||ab|6|entity|C0243077|inhibitors|chvf|||inhibitors|||0|888|1029|1039
SE|48||ab|6|entity|C0441833|Groups|inpr|||group|||0|1000|1052|1057
SE|48||ab|6|entity|C0332232|Approximate|ftcn,qlco|||approximately|||0|827|1071|1084

SE|48||ab|7|text|1090|1193|Complete dissociation of this group (approximately pH 8.4) eliminates the inhibitory effect of anions.
SE|48||ab|7|entity|C0205197|Complete|qlco|||Complete|||0|888|1090|1098
SE|48||ab|7|entity|C0086168|Dissociation|mobd|||dissociation|||0|888|1099|1111
SE|48||ab|7|entity|C0441833|Groups|inpr|||group|||0|1000|1120|1125
SE|48||ab|7|entity|C0332232|Approximate|ftcn,qlco|||approximately|||0|861|1127|1140
SE|48||ab|7|entity|C0470358|8+4|qnco|||8.4|||0|861|1144|1147
SE|48||ab|7|entity|C0243077|inhibitors|chvf|||inhibitory|||0|853|1164|1174
SE|48||ab|7|entity|C1280500|Effect|qlco|||effect|||0|853|1175|1181
SE|48||ab|7|entity|C0003075|Anions|elii|||anions|||0|1000|1185|1191

SE|48||ab|8|text|1193|1366|The 35Cl line broadening produced by renal dipeptidase in 0.5 M NaCl solutions was 100 times more effective than that produced by equivalent concentrations of aquozinc(II).
SE|48||ab|8|entity|C0205132|Linear|spco|||line|||0|861|1202|1206
SE|48||ab|8|entity|C0207803|membrane dipeptidase|aapp,enzy|||renal dipeptidase|||0|1000|1230|1247
SE|48||ab|8|entity|C0444499|0/5|qnco|||0.5|||0|840|1251|1254
SE|48||ab|8|entity|C0037494|Sodium Chloride|bacs,inch,phsu|||NaCl|||0|840|1257|1261
SE|48||ab|8|entity|C0037633|Solutions|sbst|||solutions|||0|840|1262|1271
SE|48||ab|8|entity|C0040223|Time|tmco|||times|||0|827|1280|1285
SE|48||ab|8|entity|C0205172|More|ftcn|||more|||0|888|1286|1290
SE|48||ab|8|entity|C0439185|Eq|qnco|||equivalent|||0|888|1323|1333

SE|48||ab|9|text|1366|1504|The line broadening was dependent upon the concentration of the metalloenzyme and independent of the frequency of the exciting radiation.
SE|48||ab|9|entity|C0205132|Linear|spco|||line|||0|861|1370|1374
SE|48||ab|9|entity|C0596918|metalloenzyme|aapp,enzy|||metalloenzyme|||0|1000|1430|1443
SE|48||ab|9|entity|C0439603|Frequencies (time pattern)|tmco|||frequency|||0|1000|1467|1476
SE|48||ab|9|entity|C0034519|Electromagnetic Energy|npop|||radiation|||0|861|1493|1502

SE|48||ab|10|text|1504|1661|When zinc ion was removed from the metalloenzyme by dialysis or when chloride was titrated from the metalloenzyme by cyanide, line broadening was decreased.
SE|48||ab|10|entity|C0043481|Zinc|bacs,elii,phsu|||zinc|||0|888|1509|1513
SE|48||ab|10|entity|C0022023|Ions|elii|||ion|||0|888|1514|1517
SE|48||ab|10|entity|C0596918|metalloenzyme|aapp,enzy|||metalloenzyme|||0|1000|1539|1552
SE|48||ab|10|entity|C0011946|Dialysis procedure|topp|||dialysis|||0|1000|1556|1564
SE|48||ab|10|entity|C0008203|Chlorides|inch|||chloride|||0|1000|1573|1581
SE|48||ab|10|entity|C0596918|metalloenzyme|aapp,enzy|||metalloenzyme|||0|1000|1604|1617
SE|48||ab|10|entity|C0010505|Cyanides|inch|||cyanide|||0|1000|1621|1628
SE|48||ab|10|entity|C0205132|Linear|spco|||line|||0|861|1630|1634

SE|48||ab|11|text|1661|1868|Treatment of renal dipeptidase with saturating concentrations of the competitive inhibitor, guanosine triphosphate, in the presence of 0.5 M NaCl also produced a significant decrease in the 35Cl line width.
SE|48||ab|11|entity|C0207803|membrane dipeptidase|aapp,enzy|||renal dipeptidase|||0|1000|1674|1691
SE|48||ab|11|entity|C0522534|Saturated|qnco|||saturating|||0|872|1697|1707
SE|48||ab|11|entity|C0679932|competition|socb|||competitive|||0|872|1730|1741
SE|48||ab|11|entity|C0243077|inhibitors|chvf|||inhibitor|||0|872|1742|1751
SE|48||ab|11|entity|C0018353|Guanosine Triphosphate|bacs,nnon|||guanosine triphosphate|||0|1000|1753|1775
SE|48||ab|11|entity|C0444499|0/5|qnco|||0.5|||0|861|1796|1799
SE|48||ab|11|entity|C0037494|Sodium Chloride|bacs,inch,phsu|||NaCl|||0|861|1802|1806
SE|48||ab|11|entity|C0750502|Significant|idcn|||significant|||0|888|1823|1834
SE|48||ab|11|entity|C0547047|Decrease|qnco|||decrease|||0|888|1835|1843
SE|48||ab|11|entity|C0205132|Linear|spco|||line|||0|790|1856|1860
SE|48||ab|11|entity|C0487742|Width|qnco|||width|||0|790|1861|1866
SE|48||ab|11|relation|5|1|C0018353|Guanosine Triphosphate|bacs,nnon|bacs|||guanosine triphosphate|||0|1000|1753|1775|NOM|COEXISTS_WITH||1784|1792|3|1|C0037494|Sodium Chloride|bacs,inch,phsu|bacs|||NaCl|||0|861|1802|1806

SE|48||ab|12|text|1868|1995|The 35Cl line broadening produced by renal dipeptidase was shown to decrease with increasing pH through the range pH 5.8-10.8.
SE|48||ab|12|entity|C0205132|Linear|spco|||line|||0|861|1877|1881
SE|48||ab|12|entity|C0207803|membrane dipeptidase|aapp,enzy|||renal dipeptidase|||0|1000|1905|1922
SE|48||ab|12|entity|C0442808|Increasing|ftcn|||increasing|||0|888|1950|1960
SE|48||ab|12|entity|C1514721|Range|qnco|||range|||0|716|1976|1981

SE|48||ab|13|text|1995|2130|This line-width variation with pH appeared to result from the titration of a site on the metalloprotein with an approximate pK of 7.4.
SE|48||ab|13|entity|C0205132|Linear|spco|||line|||0|851|2000|2004
SE|48||ab|13|entity|C0487742|Width|qnco|||width|||0|851|2005|2010
SE|48||ab|13|entity|C0205419|Variant|qlco|||variation|||0|851|2011|2020
SE|48||ab|13|entity|C0162621|Titration|lbpr|||titration|||0|1000|2057|2066
SE|48||ab|13|entity|C0205145|Site|spco|||site|||0|1000|2072|2076
SE|48||ab|13|entity|C0025544|Metalloproteins|aapp,bacs|||metalloprotein|||0|1000|2084|2098
SE|48||ab|13|entity|C0332232|Approximate|ftcn,qlco|||approximate|||0|872|2107|2118

SE|48||ab|14|text|2130|2362|Temperature studies of 35Cl line broadening by the metalloenzyme in the presence of chloride and cyanide inhibitors suggest that the fast exchange process pertains and that the dominant relaxation mechanism is quadrupolar in nature.
SE|48||ab|14|entity|C0039476|Temperature|qnco|||Temperature|||0|1000|2130|2141
SE|48||ab|14|entity|C0205132|Linear|spco|||line|||0|861|2158|2162
SE|48||ab|14|entity|C0596918|metalloenzyme|aapp,enzy|||metalloenzyme|||0|1000|2181|2194
SE|48||ab|14|entity|C0008203|Chlorides|inch|||chloride|||0|1000|2214|2222
SE|48||ab|14|entity|C0010505|Cyanides|inch|||cyanide|||0|888|2227|2234
SE|48||ab|14|entity|C0243077|inhibitors|chvf|||inhibitors|||0|888|2235|2245
SE|48||ab|14|entity|C0456962|Fast|qlco|||fast|||0|851|2263|2267
SE|48||ab|14|entity|C0678640|exchange|socb|||exchange|||0|851|2268|2276
SE|48||ab|14|entity|C1522240|Process|phpr|||process|||0|851|2277|2284
SE|48||ab|14|entity|C1527180|Dominant|ftcn|||dominant|||0|851|2307|2315
SE|48||ab|14|entity|C0035028|Relaxation|dora,topp|||relaxation|||0|851|2316|2326
SE|48||ab|14|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|851|2327|2336
SE|48||ab|14|entity|C0349590|Nature|idcn|||nature|||0|1000|2355|2361
SE|48||ab|14|relation|4|1|C0596918|metalloenzyme|aapp,gngm,enzy|aapp|||metalloenzyme|||0|1000|2181|2194|NOM|COEXISTS_WITH||2202|2210|6|1|C0008203|Chlorides|inch|inch|||chloride|||0|1000|2214|2222


SE|49||ti|1|text|15|126|The interaction of bovine erythrocyte superoxide dismutase with hydrogen peroxide: inactivation of the enzyme.
SE|49||ti|1|entity|C0007452|Cattle|mamm|||bovine|||0|861|34|40
SE|49||ti|1|entity|C0014792|Erythrocytes|cell|||erythrocyte|||0|861|41|52
SE|49||ti|1|entity|C0038838|Superoxide Dismutase|aapp,enzy,phsu|||superoxide dismutase|||0|861|53|73
SE|49||ti|1|entity|C0020281|Hydrogen Peroxide|inch,irda,phsu|||hydrogen peroxide|||0|1000|79|96
SE|49||ti|1|entity|C0544461|Inactivation|comd|||inactivation|||0|1000|98|110
SE|49||ti|1|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|118|124
SE|49||ti|1|relation|0|0|C0038838|Superoxide Dismutase|aapp,gngm,enzy,phsu|aapp|||superoxide dismutase|||0|861|53|73|MOD/HEAD|PART_OF||41|73|0|0|C0014792|Erythrocytes|cell|cell|||erythrocyte|||0|861|41|52
SE|49||ti|1|relation|4|2|C0020281|Hydrogen Peroxide|inch,irda,phsu|inch|||hydrogen peroxide|||0|1000|79|96|NOM|INTERACTS_WITH||19|30|4|1|C0038838|Superoxide Dismutase|aapp,gngm,enzy,phsu|aapp|||superoxide dismutase|||0|861|53|73

SE|49||ab|1|text|132|234|Bovine erythrocyte superoxide dismutase was slowly and irreversibly inactivated by hydrogen peroxide.
SE|49||ab|1|entity|C0007452|Cattle|mamm|||Bovine|||0|861|132|138
SE|49||ab|1|entity|C0014792|Erythrocytes|cell|||erythrocyte|||0|861|139|150
SE|49||ab|1|entity|C0038838|Superoxide Dismutase|aapp,enzy,phsu|||superoxide dismutase|||0|861|151|171
SE|49||ab|1|entity|C0020281|Hydrogen Peroxide|inch,irda,phsu|||hydrogen peroxide|||0|1000|215|232
SE|49||ab|1|relation|0|0|C0038838|Superoxide Dismutase|aapp,gngm,enzy,phsu|aapp|||superoxide dismutase|||0|861|151|171|MOD/HEAD|PART_OF||139|171|0|0|C0014792|Erythrocytes|cell|cell|||erythrocyte|||0|861|139|150
SE|49||ab|1|relation|1|1|C0020281|Hydrogen Peroxide|inch,irda,phsu|inch|||hydrogen peroxide|||0|1000|215|232|VERB|INHIBITS||200|211|1|1|C0038838|Superoxide Dismutase|aapp,gngm,enzy,phsu|gngm|||superoxide dismutase|||0|861|151|171

SE|49||ab|2|text|234|419|The rate of this inactivation was directly dependent upon the concentrations of both H2O2 and of enzyme, and its second-order rate constant at pH 10.0 and 25 degrees was 6.7 M-1 sec-1.
SE|49||ab|2|entity|C1521828|Rate|qnco|||rate|||0|1000|238|242
SE|49||ab|2|entity|C0544461|Inactivation|comd|||inactivation|||0|1000|251|263
SE|49||ab|2|entity|C0020281|Hydrogen Peroxide|inch,irda,phsu|||H2O2|||0|1000|319|323
SE|49||ab|2|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|331|337
SE|49||ab|2|entity|C0457385|seconds|tmco|||second|||0|775|347|353
SE|49||ab|2|entity|C1521828|Rate|qnco|||rate|||0|775|360|364
SE|49||ab|2|entity|C1547014|*Constant|qnco|||constant|||0|775|365|373
SE|49||ab|2|entity|||gngm|1128,100507027|CHRM1,MRLN|M-1|||0|766|408|411
SE|49||ab|2|entity|C0457385|seconds|tmco|||sec|||0|766|412|415

SE|49||ab|3|text|419|659|Inactivation was preceded by a bleaching due to rapid reduction of Cu2+ on the enzyme, and following this there was a gradual reappearance of a new absorption in the visible region, which was coincident with the loss of catalytic activity.
SE|49||ab|3|entity|C0544461|Inactivation|comd|||Inactivation|||0|1000|419|431
SE|49||ab|3|entity|C0303749|Bleach|inch|||bleaching|||0|966|450|459
SE|49||ab|3|entity|C0439831|Rapid|qlco|||rapid|||0|694|467|472
SE|49||ab|3|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|498|504
SE|49||ab|3|entity|C0439833|Gradual|qlco|||gradual|||0|694|537|544
SE|49||ab|3|entity|C0205314|New|tmco|||new|||0|694|563|566
SE|49||ab|3|entity|C0205379|Visible|qlco|||visible|||0|888|585|592
SE|49||ab|3|entity|C0205147|Region|spco|||region|||0|888|593|599
SE|49||ab|3|entity|C1517945|Loss|qnco|||loss|||0|1000|631|635
SE|49||ab|3|entity|C0243102|enzyme activity|moft|||catalytic activity|||0|1000|639|657

SE|49||ab|4|text|659|775|Inactivation of the enzyme was pH-dependent and indicated an essential ionization whose pKa was approximately 10.2.
SE|49||ab|4|entity|C0544461|Inactivation|comd|||Inactivation|||0|1000|659|671
SE|49||ab|4|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|679|685
SE|49||ab|4|entity|C0205224|Essential|qlco|||essential|||0|888|720|729
SE|49||ab|4|entity|C0596801|ionization|phpr|||ionization|||0|888|730|740
SE|49||ab|4|entity|C0010531|Cyclic AMP-Dependent Protein Kinases|aapp,enzy|||pKa|||0|1000|747|750
SE|49||ab|4|entity|C0332232|Approximate|ftcn,qlco|||approximately|||0|827|755|768
SE|49||ab|4|relation|5|5|C0010531|Cyclic AMP-Dependent Protein Kinases|aapp,gngm,enzy|aapp|||pKa|||0|1000|747|750|NOM|INHIBITS||659|671|5|1|C0014442|Enzymes|enzy,orch|enzy|||enzyme|||0|1000|679|685

SE|49||ab|5|text|775|907|Replacement of H2O by D2O raised this pKa but did not diminish the catalytic activity of superoxide dismutase, measured at pH 10.0.
SE|49||ab|5|entity|C0035139|Surgical Replantation|topp|||Replacement|||0|1000|775|786
SE|49||ab|5|entity|C0010531|Cyclic AMP-Dependent Protein Kinases|aapp,enzy|||pKa|||0|1000|813|816
SE|49||ab|5|entity|C1518422|Not|ftcn|||not|||0|1000|825|828
SE|49||ab|5|entity|C0243102|enzyme activity|moft|||catalytic activity|||0|1000|842|860
SE|49||ab|5|entity|C0038838|Superoxide Dismutase|aapp,enzy,phsu|||superoxide dismutase|||0|1000|864|884
SE|49||ab|5|relation|4|1|C0010531|Cyclic AMP-Dependent Protein Kinases|aapp,gngm,enzy|aapp|||pKa|||0|1000|813|816|VERB|DISRUPTS|negation|829|837|2|1|C0243102|enzyme activity|moft|moft|||catalytic activity|||0|1000|842|860

SE|49||ab|6|text|907|1024|Several compounds, including xanthine, urate, formate, and azide, protected the enzyme against inactivation by H2O2.
SE|49||ab|6|entity|C0443302|Several|qnco|||Several|||0|872|907|914
SE|49||ab|6|entity|C0205198|Compound|qlco|||compounds|||0|872|915|924
SE|49||ab|6|entity|C0043314|xanthine|bacs,nnon|||xanthine|||0|1000|936|944
SE|49||ab|6|entity|C0935936|Urate|bacs,orch|||urate|||0|1000|946|951
SE|49||ab|6|entity|C0016572|Formates|orch|||formate|||0|1000|953|960
SE|49||ab|6|entity|C0004492|Azides|chvs|||azide|||0|1000|966|971
SE|49||ab|6|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|987|993
SE|49||ab|6|entity|C0544461|Inactivation|comd|||inactivation|||0|1000|1002|1014
SE|49||ab|6|entity|C0020281|Hydrogen Peroxide|inch,irda,phsu|||H2O2|||0|1000|1018|1022

SE|49||ab|7|text|1024|1097|Alcohols and benzoate, which scavenge hydroxyl radical, did not protect.
SE|49||ab|7|entity|C0001975|Alcohols|orch,phsu|||Alcohols|||0|1000|1024|1032
SE|49||ab|7|entity|C0005058|Benzoates|orch|||benzoate|||0|1000|1037|1045
SE|49||ab|7|entity|C0063146|Hydroxyl Radical|inch|||hydroxyl radical|||0|1000|1062|1078
SE|49||ab|7|entity|C1518422|Not|ftcn|||not|||0|1000|1084|1087
SE|49||ab|7|relation|2|1|C0001975|Alcohols|orch,phsu|orch|||Alcohols|||0|1000|1024|1032|VERB|INHIBITS||1053|1061|1|1|C0063146|Hydroxyl Radical|inch|inch|||hydroxyl radical|||0|1000|1062|1078
SE|49||ab|7|relation|2|1|C0005058|Benzoates|orch|orch|||benzoate|||0|1000|1037|1045|VERB|INHIBITS||1053|1061|1|1|C0063146|Hydroxyl Radical|inch|inch|||hydroxyl radical|||0|1000|1062|1078

SE|49||ab|8|text|1097|1176|Compounds with special affinity for singlet oxygen were similarly ineffective.
SE|49||ab|8|entity|C0205198|Compound|qlco|||Compounds|||0|966|1097|1106
SE|49||ab|8|entity|C0074565|Singlet Oxygen|bacs,elii|||singlet oxygen|||0|1000|1133|1147

SE|49||ab|9|text|1176|1340|The data were interpreted in terms of the reduction of the enzyme-bound Cu2+ to Cu+, by H2O2, followed by a Fenton's type reaction of the Cu+ with additional H2O2.
SE|49||ab|9|entity|C1511726|Data|idcn|||data|||0|1000|1180|1184
SE|49||ab|9|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|660|1235|1241
SE|49||ab|9|entity|C0020281|Hydrogen Peroxide|inch,irda,phsu|||H2O2|||0|1000|1264|1268
SE|49||ab|9|entity|C1547052|*Type|qnco|||type|||0|790|1293|1297
SE|49||ab|9|entity|C0443286|Reaction|ftcn|||reaction|||0|790|1298|1306
SE|49||ab|9|entity|C1524062|Additional|ftcn|||additional|||0|888|1323|1333
SE|49||ab|9|entity|C0020281|Hydrogen Peroxide|inch,irda,phsu|||H2O2|||0|888|1334|1338

SE|49||ab|10|text|1340|1496|This would generate Cu2+-OH- or its ionized equivalent, Cu2+-O--, which could then oxidatively attack an adjacent histidine and thus inactivate the enzyme.
SE|49||ab|10|entity|C0439185|Eq|qnco|||equivalent|||0|861|1384|1394
SE|49||ab|10|entity|C0205117|Adjacent|spco|||adjacent|||0|888|1445|1453
SE|49||ab|10|entity|C0019602|Histidine|aapp,bacs,phsu|||histidine|||0|888|1454|1463
SE|49||ab|10|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|1488|1494
SE|49||ab|10|relation|4|1|C0019602|Histidine|aapp,gngm,bacs,phsu|aapp|||histidine|||0|888|1454|1463|VERB|INHIBITS||1473|1483|1|1|C0014442|Enzymes|enzy,orch|enzy|||enzyme|||0|1000|1488|1494

SE|49||ab|11|text|1496|1631|Compounds which protected the enzyme could have done so by reacting with the bound oxidant, in competition with the adjacent histidine.
SE|49||ab|11|entity|C0205198|Compound|qlco|||Compounds|||0|966|1496|1505
SE|49||ab|11|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|1526|1532
SE|49||ab|11|entity|C0085403|Oxidants|chvf|||oxidant|||0|861|1579|1586
SE|49||ab|11|entity|C0679932|competition|socb|||competition|||0|1000|1591|1602
SE|49||ab|11|entity|C0205117|Adjacent|spco|||adjacent|||0|888|1612|1620
SE|49||ab|11|entity|C0019602|Histidine|aapp,bacs,phsu|||histidine|||0|888|1621|1630


SE|50||ti|1|text|15|126|Circular dichroism and fluorescence studies of homogeneous antibodies to type III pneumococcal polysaccharide.
SE|50||ti|1|entity|C0008813|Circular Dichroism|lbpr,npop|||Circular dichroism|||0|1000|15|33
SE|50||ti|1|entity|C0016315|Fluorescence|npop|||fluorescence|||0|1000|38|50
SE|50||ti|1|entity|C0003241|Antibodies|aapp,imft|||antibodies|||0|861|74|84
SE|50||ti|1|entity|C0071310|pneumococcal polysaccharide, type III|carb|||type III pneumococcal polysaccharide|||0|1000|88|124

SE|50||ab|1|text|132|319|The near-ultraviolet circular dichroism (CD) of three homogeneous anti-type III pneumococcal antibodies in the absence and the presence of the specific hexasaccharide ligand was studied.
SE|50||ab|1|entity|C0475806|1/3 meter|fndg|||near|||0|861|136|140
SE|50||ab|1|entity|C1532472|Ultra-violet|qlco|||ultraviolet|||0|861|141|152
SE|50||ab|1|entity|C0008813|Circular Dichroism|lbpr,npop|||circular dichroism|||0|861|153|171
SE|50||ab|1|entity|C0205449|Three|qnco|||three|||0|787|180|185
SE|50||ab|1|entity|C0441731|Type 3|clas|||type III|||0|787|203|211
SE|50||ab|1|entity|C0038410|Streptococcus pneumoniae|bact|||pneumococcal|||0|787|212|224
SE|50||ab|1|entity|C0003242|Antibodies, Anti-Idiotypic|aapp,imft|||anti-type III pneumococcal antibodies|||0|787|198|235
SE|50||ab|1|entity|C0023688|Ligands|chem|||ligand|||0|827|299|305

SE|50||ab|2|text|319|517|In addition recombinations and hybridizations of H and L chains derived from two of these antibodies were carried out and the CD spectra of bound and free reconstituted IgG molecules were measured.
SE|50||ab|2|entity|C0034865|Recombination, Genetic|genf|||recombinations|||0|853|331|345
SE|50||ab|2|entity|C0020202|Crossbreeding|genf|||hybridizations|||0|966|350|364
SE|50||ab|2|entity|C0205448|Two|qnco|||two|||0|1000|396|399
SE|50||ab|2|entity|C0003241|Antibodies|aapp,imft|||antibodies|||0|1000|409|419
SE|50||ab|2|entity|C0439787|Out|spco|||out|||0|1000|433|436
SE|50||ab|2|entity|C0008813|Circular Dichroism|lbpr,npop|||CD|||0|734|445|447
SE|50||ab|2|entity|C0567416|Molecule|sbst|||molecules|||0|779|492|501

SE|50||ab|3|text|517|681|The results indicate that the CD spectra of the native antibodies in the 260-310-nm range are very similar in shape and sign and exhibit a positive band at 285 nm.
SE|50||ab|3|entity|C1274040|result|ftcn|||results|||0|966|521|528
SE|50||ab|3|entity|C0008813|Circular Dichroism|lbpr,npop|||CD|||0|734|547|549
SE|50||ab|3|entity|C0302891|Native|ftcn|||native|||0|888|565|571
SE|50||ab|3|entity|C0003241|Antibodies|aapp,imft|||antibodies|||0|888|572|582
SE|50||ab|3|entity|C1514721|Range|qnco|||range|||0|812|601|606
SE|50||ab|3|entity|C0442824|Very|qlco|||very|||0|853|611|615
SE|50||ab|3|entity|C0332479|Shapes|spco|||shape|||0|1000|627|632
SE|50||ab|3|entity|C0311392|Physical findings|sosy|||sign|||0|1000|637|641
SE|50||ab|3|entity|C1446409|Positive|qlco|||positive|||0|888|656|664
SE|50||ab|3|entity|C0175723|Bands|medd|||band|||0|888|665|669

SE|50||ab|4|text|681|910|The homologous reconstituted antibody molecules exhibited CD spectra very similar in shape and sign to those of the native antibody molecules although recombinant molecules are no longer stabilized by interchain disulfide bonds.
SE|50||ab|4|entity|C1334043|Homologous Gene|gngm|||homologous|||0|740|685|695
SE|50||ab|4|entity|C0003241|Antibodies|aapp,imft|||antibody|||0|740|710|718
SE|50||ab|4|entity|C0567416|Molecule|sbst|||molecules|||0|740|719|728
SE|50||ab|4|entity|C0008813|Circular Dichroism|lbpr,npop|||CD|||0|734|739|741
SE|50||ab|4|entity|C0442824|Very|qlco|||very|||0|853|750|754
SE|50||ab|4|entity|C0332479|Shapes|spco|||shape|||0|1000|766|771
SE|50||ab|4|entity|C0311392|Physical findings|sosy|||sign|||0|1000|776|780
SE|50||ab|4|entity|C0302891|Native|ftcn|||native|||0|840|797|803
SE|50||ab|4|entity|C0003241|Antibodies|aapp,imft|||antibody|||0|840|804|812
SE|50||ab|4|entity|C0567416|Molecule|sbst|||molecules|||0|840|813|822
SE|50||ab|4|entity|C0567416|Molecule|sbst|||molecules|||0|855|844|853
SE|50||ab|4|entity|C0205166|Long|qlco|||longer|||0|966|861|867
SE|50||ab|4|entity|C0596454|disulfide bond|npop|||disulfide bonds|||0|884|893|908

SE|50||ab|5|text|910|1133|Upon addition of the hexasaccharide ligand, a significant decrease in amplitude of the CD spectra (18-21%) occurred in all three native antibodies and their Fab fragments as well as in the homologous recombinant molecules.
SE|50||ab|5|entity|C0442796|Additive|qlco|||addition|||0|928|915|923
SE|50||ab|5|entity|C0023688|Ligands|chem|||ligand|||0|861|946|952
SE|50||ab|5|entity|C0750502|Significant|idcn|||significant|||0|888|956|967
SE|50||ab|5|entity|C0547047|Decrease|qnco|||decrease|||0|888|968|976
SE|50||ab|5|entity|C0008813|Circular Dichroism|lbpr,npop|||CD|||0|734|997|999
SE|50||ab|5|entity|C0205449|Three|qnco|||three|||0|851|1033|1038
SE|50||ab|5|entity|C0302891|Native|ftcn|||native|||0|851|1039|1045
SE|50||ab|5|entity|C0003241|Antibodies|aapp,imft|||antibodies|||0|851|1046|1056
SE|50||ab|5|entity|C0021031|Fab Immunoglobulins|aapp,imft|2187|FANCB|Fab fragments|||0|983|1067|1080
SE|50||ab|5|entity|C1334043|Homologous Gene|gngm|||homologous|||0|805|1099|1109
SE|50||ab|5|entity|C0567416|Molecule|sbst|||molecules|||0|805|1122|1131

SE|50||ab|6|text|1133|1248|No CD spectral changes could be detected upon interaction of the hapten ligand with the heterologous recombinants.
SE|50||ab|6|entity|C0008813|Circular Dichroism|lbpr,npop|||CD|||0|808|1136|1138
SE|50||ab|6|entity|C0018593|Haptens|imft|||hapten|||0|888|1198|1204
SE|50||ab|6|entity|C0023688|Ligands|chem|||ligand|||0|888|1205|1211
SE|50||ab|6|entity|C0439860|Heterologous|qlco|||heterologous|||0|888|1221|1233

SE|50||ab|7|text|1248|1387|All homogeneous antibodies studied exhibited fluorescence quenching upon oligosaccharide binding and a blue shift of the emission maximum.
SE|50||ab|7|entity|C0003241|Antibodies|aapp,imft|||antibodies|||0|861|1264|1274
SE|50||ab|7|entity|C0015272|Exhibits|mnob|||exhibited|||0|606|1283|1292
SE|50||ab|7|entity|C0016315|Fluorescence|npop|||fluorescence|||0|606|1293|1305
SE|50||ab|7|entity|C0028959|Oligosaccharides|carb|||oligosaccharide|||0|694|1321|1336
SE|50||ab|7|entity|C0233929|Emission|orgf|||emission|||0|888|1369|1377
SE|50||ab|7|entity|C0806909|Maximum|fndg|||maximum|||0|888|1378|1385
SE|50||ab|7|relation|2|2|C0003241|Antibodies|aapp,gngm,imft|aapp|||antibodies|||0|861|1264|1274|NOM|INTERACTS_WITH||1337|1344|2|0|C0028959|Oligosaccharides|carb|carb|||oligosaccharide|||0|694|1321|1336

SE|50||ab|8|text|1387|1488|This property allowed the determination of the binding constant of one selected antibody to be made.
SE|50||ab|8|entity|C0871161|Property|qlco|||property|||0|1000|1392|1400
SE|50||ab|8|entity|C0680730|Adjudication|gora|||determination|||0|1000|1413|1426
SE|50||ab|8|entity|C1547014|*Constant|qnco|||constant|||0|861|1442|1450
SE|50||ab|8|entity|C0205447|One|qnco|||one|||0|840|1454|1457
SE|50||ab|8|entity|C0003241|Antibodies|aapp,imft|||antibody|||0|840|1467|1475

SE|50||ab|9|text|1488|1658|Taken together, CD and fluorescence spectroscopic data suggest that oligosaccharide ligands induced detectable conformational changes in the Fab fragment of the antibody.
SE|50||ab|9|entity|C0008813|Circular Dichroism|lbpr,npop|||CD|||0|1000|1504|1506
SE|50||ab|9|entity|C0242506|Fluorescence Spectroscopy|lbpr|||fluorescence spectroscopic|||0|877|1511|1537
SE|50||ab|9|entity|C1511726|Data|idcn|||data|||0|877|1538|1542
SE|50||ab|9|entity|C0028959|Oligosaccharides|carb|||oligosaccharide|||0|888|1556|1571
SE|50||ab|9|entity|C0023688|Ligands|chem|||ligands|||0|888|1572|1579
SE|50||ab|9|entity|C0301641|Macromolecular alteration|moft|||conformational changes|||0|884|1599|1621
SE|50||ab|9|entity|C0021031|Fab Immunoglobulins|aapp,imft|2187|FANCB|Fab fragment|||0|1000|1629|1641
SE|50||ab|9|entity|C0003241|Antibodies|aapp,imft|||antibody|||0|1000|1649|1657
SE|50||ab|9|relation|3|1|C0028959|Oligosaccharides|carb|carb|||oligosaccharide|||0|888|1556|1571|VERB|AUGMENTS||1580|1587|3|1|C0301641|Macromolecular alteration|moft|moft|||conformational changes|||0|884|1599|1621


SE|51||ti|1|text|15|139|Conformational changes induced in a homogeneous anti-type III pneumococcal antibody by oligosaccharides of increasing size.
SE|51||ti|1|entity|C0301641|Macromolecular alteration|moft|||Conformational changes|||0|983|15|37
SE|51||ti|1|entity|C0441731|Type 3|clas|||type III|||0|798|68|76
SE|51||ti|1|entity|C0038410|Streptococcus pneumoniae|bact|||pneumococcal|||0|798|77|89
SE|51||ti|1|entity|C0003242|Antibodies, Anti-Idiotypic|aapp,imft|||anti-type III pneumococcal antibody|||0|798|63|98
SE|51||ti|1|entity|C0028959|Oligosaccharides|carb|||oligosaccharides|||0|1000|102|118
SE|51||ti|1|entity|C0442808|Increasing|ftcn|||increasing|||0|888|122|132
SE|51||ti|1|entity|C0456389|size|spco|||size|||0|888|133|137

SE|51||ab|1|text|145|351|The circular polarization of luminescence (CPL) emitted by tryptophan residues was used as a sensitive probe for measuring ligand-induced structural changes in a homogeneous type III pneumococcal antibody.
SE|51||ab|1|entity|C1282913|Circular|spco|||circular|||0|740|149|157
SE|51||ab|1|entity|C0946292|POLARIZATION|orga|||polarization|||0|740|158|170
SE|51||ab|1|entity|C1450275|luminescence|npop|||luminescence|||0|740|174|186
SE|51||ab|1|entity|C0041249|Tryptophan|aapp,bacs,phsu|||tryptophan|||0|847|204|214
SE|51||ab|1|entity|C0332324|Sensitive|ftcn|||sensitive|||0|888|238|247
SE|51||ab|1|entity|C0182400|Probes|medd|||probe|||0|888|248|253
SE|51||ab|1|entity|C0079809|Measures|qnco|||measuring|||0|750|258|267
SE|51||ab|1|entity|C0023688|Ligands|chem|||ligand|||0|750|268|274
SE|51||ab|1|entity|C0205263|Induced|ftcn|||induced|||0|750|275|282
SE|51||ab|1|entity|C0441731|Type 3|clas|||type III|||0|798|319|327
SE|51||ab|1|entity|C0038410|Streptococcus pneumoniae|bact|||pneumococcal|||0|798|328|340
SE|51||ab|1|entity|C0003241|Antibodies|aapp,imft|||antibody|||0|798|341|349
SE|51||ab|1|relation|0|0|C0003241|Antibodies|aapp,gngm,imft|aapp|||antibody|||0|798|341|349|MOD/HEAD|PART_OF||328|349|0|0|C0038410|Streptococcus pneumoniae|bact|bact|||pneumococcal|||0|798|328|340

SE|51||ab|2|text|351|483|A series of oligosaccharide ligands of increasing size derived from type III polysaccharide by partial acid hydrolysis was assayed.
SE|51||ab|2|entity|C0028959|Oligosaccharides|carb|||oligosaccharide|||0|888|363|378
SE|51||ab|2|entity|C0023688|Ligands|chem|||ligands|||0|888|379|386
SE|51||ab|2|entity|C0442808|Increasing|ftcn|||increasing|||0|888|390|400
SE|51||ab|2|entity|C0456389|size|spco|||size|||0|888|401|405
SE|51||ab|2|entity|C0441731|Type 3|clas|||type III|||0|901|419|427
SE|51||ab|2|entity|C0032594|Polysaccharides|carb,phsu|||polysaccharide|||0|901|428|442
SE|51||ab|2|entity|C0728938|Partial|qnco|||partial|||0|851|446|453
SE|51||ab|2|entity|C0001128|Acids|chem|||acid|||0|851|454|458
SE|51||ab|2|entity|C0020291|Hydrolysis|npop|||hydrolysis|||0|851|459|469
SE|51||ab|2|relation|2|1|C0032594|Polysaccharides|carb,phsu|carb|||polysaccharide|||0|901|428|442|VERB|CONVERTS_TO||406|413|3|2|C0028959|Oligosaccharides|carb|carb|||oligosaccharide|||0|888|363|378

SE|51||ab|3|text|483|799|Ligand-induced changes in the circular polarization of fluorescence of the antibody were observed for all antigens tested, including tetra-, hexa-, and octasaccharides and a 16-residue oligomer, the largest changes being recorded upon interaction with the intact soluble type III pneumococcal (SIII) polysaccharide.
SE|51||ab|3|entity|C0023688|Ligands|chem|||Ligand|||0|840|483|489
SE|51||ab|3|entity|C0205263|Induced|ftcn|||induced|||0|840|490|497
SE|51||ab|3|entity|C1282913|Circular|spco|||circular|||0|888|513|521
SE|51||ab|3|entity|C0946292|POLARIZATION|orga|||polarization|||0|888|522|534
SE|51||ab|3|entity|C0016315|Fluorescence|npop|||fluorescence|||0|1000|538|550
SE|51||ab|3|entity|C0003241|Antibodies|aapp,imft|||antibody|||0|1000|558|566
SE|51||ab|3|entity|C0003320|Antigens|bacs,imft|||antigens|||0|1000|589|597
SE|51||ab|3|entity|||gngm|3073|HEXA|hexa|||0|1000|624|628
SE|51||ab|3|entity|C0443228|Largest|qnco|||largest|||0|872|682|689
SE|51||ab|3|entity|C0205266|Intact|qlco|||intact|||0|824|739|745
SE|51||ab|3|entity|C0441731|Type 3|clas|||type III|||0|824|754|762
SE|51||ab|3|entity|C0038410|Streptococcus pneumoniae|bact|||pneumococcal|||0|1000|763|775
SE|51||ab|3|entity|||gngm|6921,6923,6924|ELOC,ELOB,ELOA|SIII|||0|1000|777|781
SE|51||ab|3|entity|C0032594|Polysaccharides|carb,phsu|||polysaccharide|||0|1000|783|797

SE|51||ab|4|text|799|956|When Fab' or F(ab')2 fragments were used instead of the antibody IgG for binding of SIII polysaccharide, the extent of conformational changes was decreased.
SE|51||ab|4|entity|||gngm|2187|FANCB|Fab|||0|1000|804|807
SE|51||ab|4|entity|C0050347|AB 2|orch,phsu|||ab')2|||0|824|814|819
SE|51||ab|4|entity|C0486805|FRAGMENTS|bdsu|||fragments|||0|824|820|829
SE|51||ab|4|entity|C0003241|Antibodies|aapp,imft|||antibody|||0|694|855|863
SE|51||ab|4|entity|||gngm|6921,6923,6924|ELOC,ELOB,ELOA|SIII|||0|861|883|887
SE|51||ab|4|entity|C0032594|Polysaccharides|carb,phsu|||polysaccharide|||0|861|888|902
SE|51||ab|4|entity|C0439792|Extent|spco|||extent|||0|1000|908|914
SE|51||ab|4|entity|C0301641|Macromolecular alteration|moft|||conformational changes|||0|983|918|940
SE|51||ab|4|relation|3|3|||gngm,aapp|gngm|2187|FANCB|Fab|||0|1000|804|807|NOM|INTERACTS_WITH||872|879|3|1|C0032594|Polysaccharides|carb,phsu|carb|||polysaccharide|||0|861|888|902

SE|51||ab|5|text|956|1102|This suggests interactions between Fab and Fc portions in the IgG molecule and subsequent conformational changes in Fc part upon antigen binding.
SE|51||ab|5|entity|||gngm|2187|FANCB|Fab|||0|1000|991|994
SE|51||ab|5|entity|C0567416|Molecule|sbst|||molecule|||0|861|1022|1030
SE|51||ab|5|entity|C0750530|SUBSEQUENT|idcn|||subsequent|||0|890|1035|1045
SE|51||ab|5|entity|C0301641|Macromolecular alteration|moft|||conformational changes|||0|890|1046|1068
SE|51||ab|5|entity|C0449719|Part|spco|||part|||0|888|1075|1079
SE|51||ab|5|entity|C1148575|antigen binding|moft|||antigen binding|||0|1000|1085|1100

SE|51||ab|6|text|1102|1389|Reduction of interchain disulfide bonds abolished the additional spectral changes attributed to the Fc part but not the changes observed in the Fab part, thus suggesting that the presence of the interchain disulfide bond in the hinge region is required for maximal CPL changes to occur.
SE|51||ab|6|entity|C0596454|disulfide bond|npop|||disulfide bonds|||0|884|1126|1141
SE|51||ab|6|entity|C1524062|Additional|ftcn|||additional|||0|785|1156|1166
SE|51||ab|6|entity|C0449719|Part|spco|||part|||0|888|1205|1209
SE|51||ab|6|entity|C1518422|Not|ftcn|||not|||0|1000|1214|1217
SE|51||ab|6|entity|||gngm|2187|FANCB|Fab|||0|861|1246|1249
SE|51||ab|6|entity|C0449719|Part|spco|||part|||0|861|1250|1254
SE|51||ab|6|entity|C0596454|disulfide bond|npop|||disulfide bond|||0|901|1308|1322
SE|51||ab|6|entity|C0457406|Hinge|medd|||hinge|||0|888|1330|1335
SE|51||ab|6|entity|C0205147|Region|spco|||region|||0|888|1336|1342
SE|51||ab|6|entity|C0205289|Maximal|qlco|||maximal|||0|734|1359|1366
SE|51||ab|6|entity|C1282913|Circular|spco|||CPL|||0|734|1367|1370
SE|51||ab|6|entity|C0946292|POLARIZATION|orga|||CPL|||0|734|1367|1370
SE|51||ab|6|entity|C1450275|luminescence|npop|||CPL|||0|734|1367|1370

SE|51||ab|7|text|1389|1592|Small monovalent ligands, i.e., the tetra-, hexa-, and octasaccharides, were capable of inducing CPL changes in the Fab part of the antibody molecule as well as CPL changes attributed to the Fc portion.
SE|51||ab|7|entity|C0700321|Small|qnco|||Small|||0|802|1389|1394
SE|51||ab|7|entity|C0023688|Ligands|chem|||ligands|||0|802|1406|1413
SE|51||ab|7|entity|||gngm|3073|HEXA|hexa|||0|1000|1433|1437
SE|51||ab|7|entity|C0205263|Induced|ftcn|||inducing|||0|726|1477|1485
SE|51||ab|7|entity|C1282913|Circular|spco|||CPL|||0|726|1486|1489
SE|51||ab|7|entity|C0946292|POLARIZATION|orga|||CPL|||0|726|1486|1489
SE|51||ab|7|entity|C1450275|luminescence|npop|||CPL|||0|726|1486|1489
SE|51||ab|7|entity|||gngm|2187|FANCB|Fab|||0|861|1505|1508
SE|51||ab|7|entity|C0449719|Part|spco|||part|||0|861|1509|1513
SE|51||ab|7|entity|C0003241|Antibodies|aapp,imft|||antibody|||0|888|1521|1529
SE|51||ab|7|entity|C0567416|Molecule|sbst|||molecule|||0|888|1530|1538
SE|51||ab|7|entity|C1282913|Circular|spco|||CPL|||0|749|1550|1553
SE|51||ab|7|entity|C0946292|POLARIZATION|orga|||CPL|||0|749|1550|1553
SE|51||ab|7|entity|C1450275|luminescence|npop|||CPL|||0|749|1550|1553

SE|51||ab|8|text|1592|1842|A multivalent ligand containing about 16 sugar residues appears to be the minimal antigenic size required for triggering conformational changes attributed to the Fc part, similar to those seen in the interaction with the whole polysaccharide antigen.
SE|51||ab|8|entity|C0023688|Ligands|chem|||ligand|||0|861|1606|1612
SE|51||ab|8|entity|C0242209|Sugars|carb,phsu|||sugar|||0|748|1633|1638
SE|51||ab|8|entity|C0547040|Minimal|qlco|||minimal|||0|828|1666|1673
SE|51||ab|8|entity|C0003320|Antigens|bacs,imft|||antigenic|||0|828|1674|1683
SE|51||ab|8|entity|C0456389|size|spco|||size|||0|828|1684|1688
SE|51||ab|8|entity|C1444748|Triggered by|qlco|||triggering|||0|879|1702|1712
SE|51||ab|8|entity|C0301641|Macromolecular alteration|moft|||conformational changes|||0|879|1713|1735
SE|51||ab|8|entity|C0449719|Part|spco|||part|||0|888|1757|1761
SE|51||ab|8|entity|C0444667|Whole|qnco|||whole|||0|851|1813|1818
SE|51||ab|8|entity|C0032594|Polysaccharides|carb,phsu|||polysaccharide|||0|851|1819|1833
SE|51||ab|8|entity|C0003320|Antigens|bacs,imft|||antigen|||0|851|1834|1841


SE|52||ti|1|text|15|95|Evidence of the involvement of a 50S ribosomal protein in several active sites.
SE|52||ti|1|entity|C0035552|Ribosomal Proteins|aapp,bacs|||ribosomal protein|||0|901|52|69
SE|52||ti|1|entity|C0443302|Several|qnco|||several|||0|901|73|80
SE|52||ti|1|entity|C0205681|Active Site|ftcn,spco|||active sites|||0|901|81|93

SE|52||ab|1|text|101|279|The functional role of the Bacillus stearothermophilus 50S ribosomal protein B-L3 (probably homologous to the Escherichia coli protein L2) was examined by chemical modification.
SE|52||ab|1|entity|C0205245|Functional|ftcn|||functional|||0|888|105|115
SE|52||ab|1|entity|C0035820|Role|socb|||role|||0|888|116|120
SE|52||ab|1|entity|C0004594|Bacillus stearothermophilus|bact|||Bacillus stearothermophilus|||0|790|128|155
SE|52||ab|1|entity|C0073294|ribosomal protein L3|aapp|||ribosomal protein B-L3|||0|790|160|182
SE|52||ab|1|entity|C0332148|Probable diagnosis|qlco|||probably|||0|853|184|192
SE|52||ab|1|entity|C1334043|Homologous Gene|gngm|||homologous|||0|853|193|203
SE|52||ab|1|entity|C0950080|Escherichia coli Proteins|aapp|||Escherichia coli protein|||0|740|211|235
SE|52||ab|1|entity|C0220806|Chemicals|chem|||chemical|||0|888|256|264
SE|52||ab|1|entity|C1522413|Modification|ftcn|||modification|||0|888|265|277
SE|52||ab|1|relation|4|3|C0073294|ribosomal protein L3|aapp,gngm|aapp|||ribosomal protein B-L3|||0|790|160|182|NOM|INTERACTS_WITH||265|277|4|0|C0220806|Chemicals|chem|chem|||chemical|||0|888|256|264

SE|52||ab|2|text|279|483|The complex [B-L3-23S RNA] was photooxidized in the presence of rose bengal and the modified protein incorporated by reconstitution into 50S ribosomal subunits containing all other unmodified components.
SE|52||ab|2|entity|C0439855|Complex|qlco|||complex|||0|1000|283|290
SE|52||ab|2|entity|C1552137|23s|bpoc|||L3-23S|||0|750|294|300
SE|52||ab|2|entity|C0035668|RNA|bacs,nnon|||RNA|||0|750|301|304
SE|52||ab|2|entity|C0035857|Rose Bengal|irda,orch|||rose bengal|||0|1000|343|354
SE|52||ab|2|entity|C0205349|Altered|ftcn|||modified|||0|888|363|371
SE|52||ab|2|entity|C0033684|Proteins|aapp,bacs|||protein|||0|888|372|379
SE|52||ab|2|entity|C1166816|cytosolic large ribosomal subunit (sensu Bacteria)|celc|||50S ribosomal subunits|||0|988|416|438
SE|52||ab|2|entity|C1524073|Component, LOINC Axis 1|clas|||components|||0|827|471|481
SE|52||ab|2|relation|0|0|C0035668|RNA|bacs,nnon|bacs|||RNA|||0|750|301|304|MOD/HEAD|PART_OF||294|304|0|0|C1552137|23s|bpoc|bpoc|||L3-23S|||0|750|294|300

SE|52||ab|3|text|483|765|Particles containing photooxidized B-L3 are defective in several functional assays, including (1) poly(U)-directed poly(Phe) synthesis, (2) peptidyltransferase activity, (3) ability to associate with a [30S-poly(U)-Phe-tRNA] complex, and (4) binding of elongation factor G and GTP.
SE|52||ab|3|entity|C0597177|particle|chvs|||Particles|||0|966|483|492
SE|52||ab|3|entity|C0332452|Defective|ftcn|||defective|||0|1000|527|536
SE|52||ab|3|entity|C0443302|Several|qnco|||several|||0|840|540|547
SE|52||ab|3|entity|C0205245|Functional|ftcn|||functional|||0|840|548|558
SE|52||ab|3|entity|C1510438|Assay|lbpr|||assays|||0|840|559|565
SE|52||ab|3|entity|C0747726|POLY|cnce|||poly|||0|1000|581|585
SE|52||ab|3|entity|C0747726|POLY|cnce|||poly|||0|861|598|602
SE|52||ab|3|entity|C0031453|Phenylalanine|aapp,bacs,phsu|||Phe|||0|1000|603|606
SE|52||ab|3|entity|C0869032|Synthesis|phpr|||synthesis|||0|1000|608|617
SE|52||ab|3|entity|C1151915|peptidyltransferase activity|moft|||peptidyltransferase activity|||0|1000|623|651
SE|52||ab|3|entity|C0085732|Ability|orga|||ability|||0|1000|657|664
SE|52||ab|3|entity|C1552144|30s|bpoc|||30S|||0|888|686|689
SE|52||ab|3|entity|C0747726|POLY|cnce|||poly|||0|888|690|694
SE|52||ab|3|entity|C0077362|tRNA, phenylalanine-|aapp,nnon|4553|TRNA|Phe-tRNA|||0|1000|698|706
SE|52||ab|3|entity|C0439855|Complex|qlco|||complex|||0|1000|708|715
SE|52||ab|3|entity|C0086206|Elongation Factor|aapp,bacs|||elongation factor|||0|884|736|753
SE|52||ab|3|entity|C0018353|Guanosine Triphosphate|bacs,nnon|||GTP|||0|1000|760|763

SE|52||ab|4|text|765|1099|The rates of loss of the partial functional activities during photooxidation of B-L3 indicate that at least two independent inactivating events are occurring, a faster one, involving oxidation of one or more histidine residues, affecting peptidyltransferase and subunit association activities and a slower one affecting EF-G binding.
SE|52||ab|4|entity|C1521828|Rate|qnco|||rates|||0|966|769|774
SE|52||ab|4|entity|C1517945|Loss|qnco|||loss|||0|1000|778|782
SE|52||ab|4|entity|C0728938|Partial|qnco|||partial|||0|851|790|797
SE|52||ab|4|entity|C0205245|Functional|ftcn|||functional|||0|851|798|808
SE|52||ab|4|entity|C0441655|Activities|acty|||activities|||0|851|809|819
SE|52||ab|4|entity|C0205448|Two|qnco|||two|||0|740|873|876
SE|52||ab|4|entity|C0441471|Events|evnt|||events|||0|740|902|908
SE|52||ab|4|entity|C0456962|Fast|qlco|||faster|||0|872|926|932
SE|52||ab|4|entity|C0205447|One|qnco|||one|||0|872|933|936
SE|52||ab|4|entity|C0030011|Oxidation|phpr|||oxidation|||0|1000|948|957
SE|52||ab|4|entity|C0205447|One|qnco|||one|||0|1000|961|964
SE|52||ab|4|entity|C0205172|More|ftcn|||more|||0|824|968|972
SE|52||ab|4|entity|C0019602|Histidine|aapp,bacs,phsu|||histidine|||0|824|973|982
SE|52||ab|4|entity|C0030962|Peptidyltransferase|aapp,enzy|||peptidyltransferase|||0|1000|1003|1022
SE|52||ab|4|entity|C0441655|Activities|acty|||activities|||0|827|1047|1057
SE|52||ab|4|entity|C0439834|Slow|qlco|||slower|||0|614|1064|1070
SE|52||ab|4|entity|C0205447|One|qnco|||one|||0|614|1071|1074
SE|52||ab|4|entity|C0059038|Peptide Elongation Factor G|aapp,enzy|||EF-G|||0|614|1085|1089

SE|52||ab|5|text|1099|1291|Therefore the protein B-L3 has one or more histidine residues which are essential for peptidyltransferase and subunit association, and another residue which is essential for EF-G-GTP binding.
SE|52||ab|5|entity|C0377800|protein B|aapp,rcpt|||protein B|||0|734|1113|1122
SE|52||ab|5|entity|C0205447|One|qnco|||one|||0|1000|1130|1133
SE|52||ab|5|entity|C0205172|More|ftcn|||more|||0|824|1137|1141
SE|52||ab|5|entity|C0019602|Histidine|aapp,bacs,phsu|||histidine|||0|824|1142|1151
SE|52||ab|5|entity|C0205224|Essential|qlco|||essential|||0|1000|1171|1180
SE|52||ab|5|entity|C0030962|Peptidyltransferase|aapp,enzy|||peptidyltransferase|||0|1000|1185|1204
SE|52||ab|5|entity|C0205224|Essential|qlco|||essential|||0|1000|1259|1268
SE|52||ab|5|entity|C0059038|Peptide Elongation Factor G|aapp,enzy|||EF-G|||0|888|1273|1277
SE|52||ab|5|entity|C1149035|GTP Binding|moft|||GTP binding|||0|888|1278|1289

SE|52||ab|6|text|1291|1447|B-L3 may be the ribosomal peptidyltransferase protein, or a part of the active site, and may contribute functional groups to the other active sites as well.
SE|52||ab|6|entity|C0030962|Peptidyltransferase|aapp,enzy|||peptidyltransferase|||0|901|1317|1336
SE|52||ab|6|entity|C0035552|Ribosomal Proteins|aapp,bacs|||ribosomal peptidyltransferase protein|||0|901|1307|1344
SE|52||ab|6|entity|C0449719|Part|spco|||part|||0|1000|1351|1355
SE|52||ab|6|entity|C0205681|Active Site|ftcn,spco|||active site|||0|1000|1363|1374
SE|52||ab|6|entity|C0598132|functional group|chvf|||functional groups|||0|983|1395|1412
SE|52||ab|6|entity|C0205681|Active Site|ftcn,spco|||active sites|||0|1000|1426|1438
SE|52||ab|6|entity|C0205170|Good|qlco|||well|||0|1000|1442|1446
SE|52||ab|6|relation|0|0|C0030962|Peptidyltransferase|aapp,gngm,enzy|aapp|||peptidyltransferase|||0|901|1317|1336|MOD/HEAD|ISA||1317|1344|0|0|C0035552|Ribosomal Proteins|aapp,gngm,bacs|aapp|||ribosomal peptidyltransferase protein|||0|901|1307|1344
SE|52||ab|6|relation|0|0|C0035552|Ribosomal Proteins|aapp,gngm,bacs|bacs|||ribosomal peptidyltransferase protein|||0|901|1307|1344|MOD/HEAD|PART_OF||1317|1344|0|0|C0030962|Peptidyltransferase|aapp,gngm,enzy|aapp|||peptidyltransferase|||0|901|1317|1336


SE|53||ti|1|text|15|77|The interaction of phospholipase A2 with micellar interfaces.
SE|53||ti|1|entity|C0031667|Phospholipase A2|aapp,enzy|||phospholipase A2|||0|1000|34|50
SE|53||ti|1|entity|C0025938|Micelles|sbst|||micellar|||0|623|56|64

SE|53||ti|2|text|77|112|The role of the N-terminal region.
SE|53||ti|2|entity|C0035820|Role|socb|||role|||0|1000|81|85
SE|53||ti|2|entity|C0205147|Region|spco|||region|||0|840|104|110

SE|53||ab|1|text|118|527|The localization of the previously postulated interface recognition site (IRS) in porcine pancreatic phospholipase A2, required for a specific interaction between the enzyme and organized lipid-water interfaces, was investigated by ultraviolet difference spectroscopy, by measurements of the intrinsic fluorescence of the unique Trp residue, and by protection experiments against specific tryptic hydrolysis.
SE|53||ab|1|entity|C0475264|localization|ftcn|||localization|||0|1000|122|134
SE|53||ab|1|entity|C0205145|Site|spco|||site|||0|804|186|190
SE|53||ab|1|entity|C0039005|Family suidae|mamm|||porcine|||0|861|200|207
SE|53||ab|1|entity|C0030274|Pancreas|bpoc|||pancreatic|||0|861|208|218
SE|53||ab|1|entity|C0031667|Phospholipase A2|aapp,enzy|||phospholipase A2|||0|861|219|235
SE|53||ab|1|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|285|291
SE|53||ab|1|entity|C1300196|Organized|qlco|||organized|||0|608|296|305
SE|53||ab|1|entity|C0023779|Lipids|lipd|||lipid|||0|608|306|311
SE|53||ab|1|entity|C0020311|Hydrotherapy|topp|||water|||0|608|312|317
SE|53||ab|1|entity|C1547020|*Difference|qnco|||difference|||0|901|362|372
SE|53||ab|1|entity|C0260250|ultraviolet spectroscopy|lbpr|||ultraviolet difference spectroscopy|||0|901|350|385
SE|53||ab|1|entity|C0242485|Measurement|ftcn|||measurements|||0|1000|390|402
SE|53||ab|1|entity|C0205102|Intrinsic|spco|||intrinsic|||0|888|410|419
SE|53||ab|1|entity|C0016315|Fluorescence|npop|||fluorescence|||0|888|420|432
SE|53||ab|1|entity|C0041249|Tryptophan|aapp,bacs,phsu|7306|TYRP1|Trp|||0|754|447|450
SE|53||ab|1|entity|C0681814|research study|resa|||experiments|||0|888|478|489
SE|53||ab|1|entity|C0041236|TRYPSIN|aapp,enzy,phsu|||tryptic|||0|754|507|514
SE|53||ab|1|entity|C0020291|Hydrolysis|npop|||hydrolysis|||0|754|515|525
SE|53||ab|1|relation|0|0|C0031667|Phospholipase A2|aapp,gngm,enzy|aapp|||phospholipase A2|||0|861|219|235|MOD/HEAD|PART_OF||208|235|0|0|C0030274|Pancreas|bpoc|bpoc|||pancreatic|||0|861|208|218
SE|53||ab|1|relation|3|1|C0031667|Phospholipase A2|aapp,gngm,enzy|aapp|||phospholipase A2|||0|861|219|235|NOM|INTERACTS_WITH||261|272|8|1|C0014442|Enzymes|enzy,orch|enzy|||enzyme|||0|1000|285|291

SE|53||ab|2|text|527|800|Using the enzymically nondegradable substrate analogues: CnH(2n+1)(0-)OOCH2CH2N+(CH3)3-(H,OH), it is shown that the rather hydrophobic N-terminal sequence of the enzyme, viz., Ala-Leu-Trp-Gln-Phe-Arg, is directly involved in the interaction with the lipid-water interface.
SE|53||ab|2|entity|C0243071|Analog|chvs|||analogues|||0|779|573|582
SE|53||ab|2|entity|C1519249|Sequence|ftcn|||sequence|||0|725|673|681
SE|53||ab|2|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|689|695
SE|53||ab|2|entity|C0023401|Leucine|aapp,bacs,phsu|||Leu|||0|839|707|710
SE|53||ab|2|entity|C0041249|Tryptophan|aapp,bacs,phsu|7306|TYRP1|Trp|||0|839|711|714
SE|53||ab|2|entity|C0051080|alanylglutamine|aapp,phsu|||Ala-Leu-Trp-Gln|||0|839|703|718
SE|53||ab|2|entity|C0208326|phenylalanylarginine|aapp|27,473|ABL2,RERE|Phe-Arg|||0|839|719|726
SE|53||ab|2|entity|C0023779|Lipids|lipd|||lipid|||0|623|777|782
SE|53||ab|2|entity|C0020311|Hydrotherapy|topp|||water|||0|623|783|788

SE|53||ab|3|text|800|888|Besides hydrophobic probably also polar interactions contribute to the binding process.
SE|53||ab|3|entity|C0332148|Probable diagnosis|qlco|||probably|||0|785|820|828
SE|53||ab|3|entity|C0813983|polar|qnco|||polar|||0|785|834|839
SE|53||ab|3|entity|C0678607|Hydrophobic Interactions|moft|||hydrophobic probably also polar interactions|||0|785|808|852
SE|53||ab|3|entity|C1522240|Process|phpr|||process|||0|861|879|886

SE|53||ab|4|text|888|1147|At neutral or acidic pH the presence of a salt bridge between the N-terminal alpha-NH3+ group and a negatively charged side chain stablizes the interface recognition site and allows the enzyme to penetrate micellar surfaces, even in the absence of metal ion.
SE|53||ab|4|entity|C0001128|Acids|chem|||acidic|||0|853|902|908
SE|53||ab|4|entity|C0036140|Salts|chvs|||salt|||0|694|930|934
SE|53||ab|4|entity|C0439095|Alpha|inpr|||alpha|||0|758|965|970
SE|53||ab|4|entity|C0441833|Groups|inpr|||group|||0|758|976|981
SE|53||ab|4|entity|C0007961|charge amounts|qnco|||charged|||0|545|999|1006
SE|53||ab|4|entity|C0441987|Side|spco|||side|||0|545|1007|1011
SE|53||ab|4|entity|C0205145|Site|spco|||site|||0|827|1054|1058
SE|53||ab|4|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|1074|1080
SE|53||ab|4|entity|C0025938|Micelles|sbst|||micellar|||0|836|1094|1102
SE|53||ab|4|entity|C0205148|Surface|spco|||surfaces|||0|836|1103|1111
SE|53||ab|4|entity|C0025552|Metals|inch|||metal|||0|888|1136|1141
SE|53||ab|4|entity|C0022023|Ions|elii|||ion|||0|888|1142|1145

SE|53||ab|5|text|1147|1256|At alkaline pH, interaction of the enzyme with micellar interfaces requires the presence of Ca2+ (Ba2+) ions.
SE|53||ab|5|entity|C0002055|Alkalies|inch|||alkaline|||0|853|1150|1158
SE|53||ab|5|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|1182|1188
SE|53||ab|5|entity|C0025938|Micelles|sbst|||micellar|||0|623|1194|1202
SE|53||ab|5|entity|||gngm|760|CA2|Ca2|||0|1000|1239|1242
SE|53||ab|5|entity|C0022023|Ions|elii|||ions|||0|1000|1251|1255


SE|54||ti|1|text|15|98|Phospholipase A2 as a probe of phospholipid distribution in erythrocyte membranes.
SE|54||ti|1|entity|C0031667|Phospholipase A2|aapp,enzy|||Phospholipase A2|||0|1000|15|31
SE|54||ti|1|entity|C0182400|Probes|medd|||probe|||0|1000|37|42
SE|54||ti|1|entity|C0031676|Phospholipids|bacs,lipd|||phospholipid|||0|888|46|58
SE|54||ti|1|entity|C0520511|Distributing|idcn|||distribution|||0|888|59|71
SE|54||ti|1|entity|C0014780|Erythrocyte Membrane|celc|||erythrocyte membranes|||0|1000|75|96
SE|54||ti|1|relation|1|1|C0014780|Erythrocyte Membrane|celc|celc|||erythrocyte membranes|||0|1000|75|96|PREP|LOCATION_OF||72|74|3|3|C0031667|Phospholipase A2|aapp,gngm,enzy|aapp|||Phospholipase A2|||0|1000|15|31

SE|54||ti|2|text|98|160|Factors influencing the apparent specificity of the reaction.
SE|54||ti|2|entity|C1521761|Factor|ftcn|||Factors|||0|966|98|105
SE|54||ti|2|entity|C0750489|APPARENT|idcn|||apparent|||0|888|122|130
SE|54||ti|2|entity|C0037791|Specificity|qnco|||specificity|||0|888|131|142
SE|54||ti|2|entity|C0443286|Reaction|ftcn|||reaction|||0|1000|150|158

SE|54||ab|1|text|166|267|The action of snake venom phospholipases A2 in intact human erythrocytes was investigated in detail.
SE|54||ab|1|entity|C0037380|Snake Venoms|bacs,hops|||snake venom|||0|877|180|191
SE|54||ab|1|entity|C0031667|Phospholipase A2|aapp,enzy|||phospholipases A2|||0|877|192|209
SE|54||ab|1|entity|C0205266|Intact|qlco|||intact|||0|851|213|219
SE|54||ab|1|entity|C0020114|Human|humn|||human|||0|851|220|225
SE|54||ab|1|entity|C0014792|Erythrocytes|cell|||erythrocytes|||0|851|226|238
SE|54||ab|1|relation|0|0|C0014792|Erythrocytes|cell|cell|||erythrocytes|||0|851|226|238|MOD/HEAD|PART_OF||220|238|0|0|C0020114|Human|grup,humn|humn|||human|||0|851|220|225
SE|54||ab|1|relation|3|1|C0031667|Phospholipase A2|aapp,gngm,enzy|aapp|||phospholipases A2|||0|877|192|209|NOM|AFFECTS||170|176|3|2|C0014792|Erythrocytes|cell|cell|||erythrocytes|||0|851|226|238

SE|54||ab|2|text|267|450|The basis phospholipase from Agkistrodon halys blomhifii was found to induce both hydrolysis of membrane phospholipids and total cell hemolysis under certain experimental conditions.
SE|54||ab|2|entity|C1527178|Basis|ftcn|||basis|||0|888|271|276
SE|54||ab|2|entity|C0031671|Phospholipase|aapp,enzy|||phospholipase|||0|888|277|290
SE|54||ab|2|entity|C0327518|Agkistrodon halys|rept|||Agkistrodon halys|||0|734|296|313
SE|54||ab|2|entity|C0020291|Hydrolysis|npop|||hydrolysis|||0|1000|349|359
SE|54||ab|2|entity|C0596901|Membrane|celc|||membrane|||0|888|363|371
SE|54||ab|2|entity|C0031676|Phospholipids|bacs,lipd|||phospholipids|||0|888|372|385
SE|54||ab|2|entity|C0439175|% of total|qnco|||total|||0|851|390|395
SE|54||ab|2|entity|C0007634|Cells|cell|||cell|||0|851|396|400
SE|54||ab|2|entity|C0019054|hemolysis|celf|||hemolysis|||0|851|401|410
SE|54||ab|2|entity|C1517004|Experimental|ftcn|||experimental|||0|840|425|437
SE|54||ab|2|entity|C0348080|Condition|qlco|||conditions|||0|840|438|448
SE|54||ab|2|relation|0|0|C0007634|Cells|cell|cell|||cell|||0|851|396|400|MOD/HEAD|LOCATION_OF||396|410|0|0|C0019054|hemolysis|celf|celf|||hemolysis|||0|851|401|410
SE|54||ab|2|relation|0|0|C0031676|Phospholipids|bacs,lipd|bacs|||phospholipids|||0|888|372|385|MOD/HEAD|PART_OF||363|385|0|0|C0596901|Membrane|celc|celc|||membrane|||0|888|363|371
SE|54||ab|2|relation|2|2|C0031671|Phospholipase|aapp,gngm,enzy|aapp|||phospholipase|||0|888|277|290|VERB|AUGMENTS||337|343|4|1|C0020291|Hydrolysis|npop|npop|||hydrolysis|||0|1000|349|359

SE|54||ab|3|text|450|834|The hydrolytic action of the basic enzyme was found to consist of two sequential events: (a) hydrolysis of 70% of the total cell ph osphatidylcholine without any evident hemolysis; and (b) complete hydrolysis of the remaining phosphatidylcholine, followed closely by extensive phosphatidylethanolamine hydrolysis and finally with onset of hemolysis, attack on the phosphatidylserine.
SE|54||ab|3|entity|C0020291|Hydrolysis|npop|||hydrolytic|||0|623|454|464
SE|54||ab|3|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|853|485|491
SE|54||ab|3|entity|C0205448|Two|qnco|||two|||0|851|516|519
SE|54||ab|3|entity|C1548958|Sequential|idcn|||sequential|||0|851|520|530
SE|54||ab|3|entity|C0441471|Events|evnt|||events|||0|851|531|537
SE|54||ab|3|entity|C0020291|Hydrolysis|npop|||hydrolysis|||0|1000|543|553
SE|54||ab|3|entity|C0439175|% of total|qnco|||total|||0|608|568|573
SE|54||ab|3|entity|C0007634|Cells|cell|||cell|||0|608|574|578
SE|54||ab|3|entity|C0019054|hemolysis|celf|||hemolysis|||0|861|620|629
SE|54||ab|3|entity|C0020291|Hydrolysis|npop|||hydrolysis|||0|1000|648|658
SE|54||ab|3|entity|C1527428|Remaining|qlco|||remaining|||0|888|666|675
SE|54||ab|3|entity|C0031617|Lecithin|bacs,lipd,phsu|||phosphatidylcholine|||0|888|676|695
SE|54||ab|3|entity|C0205231|Extensive|qlco|||extensive|||0|851|717|726
SE|54||ab|3|entity|C0031618|Phosphatidylethanolamines|bacs,lipd,phsu|||phosphatidylethanolamine|||0|851|727|751
SE|54||ab|3|entity|C0020291|Hydrolysis|npop|||hydrolysis|||0|851|752|762
SE|54||ab|3|entity|C0332162|Onset|qlco|||onset|||0|1000|780|785
SE|54||ab|3|entity|C0019054|hemolysis|celf|||hemolysis|||0|1000|789|798
SE|54||ab|3|entity|C0277793|Onset of illness|fndg|||attack|||0|1000|800|806
SE|54||ab|3|entity|C0031623|Phosphatidylserines|lipd|||phosphatidylserine|||0|1000|814|832

SE|54||ab|4|text|834|884|At pH 7.4 and 10 mM Ca2+ only stage (a) occurred.
SE|54||ab|4|entity|||gngm|760|CA2|Ca2|||0|660|854|857

SE|54||ab|5|text|884|1042|However, a slight elevation of the pH of incubation to pH 8.0 and/or inclusion of 40 mM Ca2+ in the reaction mixture caused both events (a) and (b) to occur.
SE|54||ab|5|entity|C0547040|Minimal|qlco|||slight|||0|888|895|901
SE|54||ab|5|entity|C0439775|Elevation procedure|topp|||elevation|||0|888|902|911
SE|54||ab|5|entity|C1512693|Inclusion|qlco|||inclusion|||0|1000|953|962
SE|54||ab|5|entity|||gngm|760|CA2|Ca2|||0|623|972|975
SE|54||ab|5|entity|C0443286|Reaction|ftcn|||reaction|||0|888|984|992
SE|54||ab|5|entity|C0439962|Mixture|sbst|||mixture|||0|888|993|1000
SE|54||ab|5|entity|C0441471|Events|evnt|||events|||0|1000|1013|1019

SE|54||ab|6|text|1042|1143|The addition of glucose limited the action of the enzyme to stage (a) under any reaction conditions.
SE|54||ab|6|entity|C0442796|Additive|qlco|||addition|||0|928|1046|1054
SE|54||ab|6|entity|C0017725|Glucose|bacs,carb,phsu|||glucose|||0|1000|1058|1065
SE|54||ab|6|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|1092|1098
SE|54||ab|6|entity|C0443286|Reaction|ftcn|||reaction|||0|872|1122|1130
SE|54||ab|6|entity|C0348080|Condition|qlco|||conditions|||0|872|1131|1141

SE|54||ab|7|text|1143|1277|An investigation showed that enzymically induced hemolysis occurred under conditions where the intracellular ATP levels were lowered.
SE|54||ab|7|entity|C0205263|Induced|ftcn|||induced|||0|790|1184|1191
SE|54||ab|7|entity|C0019054|hemolysis|celf|||hemolysis|||0|790|1192|1201
SE|54||ab|7|entity|C0348080|Condition|qlco|||conditions|||0|827|1217|1227
SE|54||ab|7|entity|C0175996|Protoplasm|celc|||intracellular|||0|851|1238|1251
SE|54||ab|7|entity|C1366628|ATP8A2 gene|gngm|51761|ATP8A2|ATP|||0|851|1252|1255
SE|54||ab|7|entity|C0441889|Levels|inpr|||levels|||0|851|1256|1262
SE|54||ab|7|relation|0|0|C1366628|ATP8A2 gene|gngm,aapp|gngm|51761|ATP8A2|ATP|||0|851|1252|1255|MOD/HEAD|PART_OF||1238|1255|0|0|C0175996|Protoplasm|celc|celc|||intracellular|||0|851|1238|1251

SE|54||ab|8|text|1277|1404|Data are presented which suggest that stage (b) is mediated by in influx of Ca2+ into the cell when the levels of ATP are low.
SE|54||ab|8|entity|C1511726|Data|idcn|||Data|||0|1000|1277|1281
SE|54||ab|8|entity|C1306673|Stage|qlco|||stage|||0|1000|1315|1320
SE|54||ab|8|entity|||gngm|9531|BAG3|b) is|||0|1000|1322|1327
SE|54||ab|8|entity|||gngm|760|CA2|Ca2|||0|1000|1353|1356
SE|54||ab|8|entity|C0007634|Cells|cell|||cell|||0|1000|1367|1371
SE|54||ab|8|entity|C0441889|Levels|inpr|||levels|||0|1000|1381|1387
SE|54||ab|8|entity|C1366628|ATP8A2 gene|gngm|51761|ATP8A2|ATP|||0|1000|1391|1394
SE|54||ab|8|entity|C0205251|low|qlco|||low|||0|1000|1399|1402
SE|54||ab|8|relation|5|1|||gngm,aapp|aapp|760|CA2|Ca2|||0|1000|1353|1356|PREP|ADMINISTERED_TO||1358|1362|4|1|C0007634|Cells|cell|cell|||cell|||0|1000|1367|1371

SE|54||ab|9|text|1404|1556|Interestingly the phosphllipase from Naja naja venom (Pakistan) yielded results similar to those observed with the basic enzyme from Agkistrodon venom.
SE|54||ab|9|entity|C0009165|Cobra Venoms|aapp,bacs,hops|||Naja naja venom|||0|913|1441|1456
SE|54||ab|9|entity|C0030211|Pakistan|geoa|||Pakistan|||0|1000|1458|1466
SE|54||ab|9|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|853|1525|1531
SE|54||ab|9|entity|C0050974|Agkistrodon venoms|bacs,hops|||Agkistrodon venom|||0|983|1537|1554

SE|54||ab|10|text|1556|1743|However, the enzyme from Crotalus adamanteus and the acidic enzyme also present in the Agkistrodon venom produced only slight hydrolysis or hemolysis under any of the conditions studied.
SE|54||ab|10|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|1569|1575
SE|54||ab|10|entity|C0327533|Crotalus adamanteus|rept|||Crotalus adamanteus|||0|1000|1581|1600
SE|54||ab|10|entity|C0001128|Acids|chem|||acidic|||0|853|1609|1615
SE|54||ab|10|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|853|1616|1622
SE|54||ab|10|entity|C0050974|Agkistrodon venoms|bacs,hops|||Agkistrodon venom|||0|983|1643|1660
SE|54||ab|10|entity|C0547040|Minimal|qlco|||slight|||0|790|1675|1681
SE|54||ab|10|entity|C0020291|Hydrolysis|npop|||hydrolysis|||0|790|1682|1692
SE|54||ab|10|entity|C0019054|hemolysis|celf|||hemolysis|||0|1000|1696|1705
SE|54||ab|10|entity|C0348080|Condition|qlco|||conditions|||0|966|1723|1733
SE|54||ab|10|relation|3|3|C0014442|Enzymes|enzy,orch|enzy|||enzyme|||0|1000|1569|1575|PREP|COEXISTS_WITH||1636|1638|4|1|C0050974|Agkistrodon venoms|bacs,hops|bacs|||Agkistrodon venom|||0|983|1643|1660

SE|54||ab|11|text|1743|1895|Other species of erythrocytes, e.g., guinea pig, monkey, pig, and rat, were tested but only those from guinea pig behaved similarly to the human cells.
SE|54||ab|11|entity|C1548151|Species|idcn|||species|||0|1000|1749|1756
SE|54||ab|11|entity|C0014792|Erythrocytes|cell|||erythrocytes|||0|1000|1760|1772
SE|54||ab|11|entity|C0085979|Cavia|mamm|||guinea pig|||0|1000|1780|1790
SE|54||ab|11|entity|C0026447|Monkeys|mamm|||monkey|||0|1000|1792|1798
SE|54||ab|11|entity|C0039005|Family suidae|mamm|||pig|||0|1000|1800|1803
SE|54||ab|11|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|1000|1809|1812
SE|54||ab|11|entity|C0085979|Cavia|mamm|||guinea pig|||0|1000|1846|1856
SE|54||ab|11|entity|C0427861|Human cells|lbtr|||human cells|||0|1000|1882|1893

SE|54||ab|12|text|1895|1978|Pig, monkey, and rat erythrocytes underwent very limited hydrolysis and hemolysis.
SE|54||ab|12|entity|C0039005|Family suidae|mamm|||Pig|||0|1000|1895|1898
SE|54||ab|12|entity|C0026447|Monkeys|mamm|||monkey|||0|1000|1900|1906
SE|54||ab|12|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|888|1912|1915
SE|54||ab|12|entity|C0014792|Erythrocytes|cell|||erythrocytes|||0|888|1916|1928
SE|54||ab|12|entity|C0442824|Very|qlco|||very|||0|851|1939|1943
SE|54||ab|12|entity|C0439801|Limited|ftcn|||limited|||0|851|1944|1951
SE|54||ab|12|entity|C0020291|Hydrolysis|npop|||hydrolysis|||0|851|1952|1962
SE|54||ab|12|entity|C0019054|hemolysis|celf|||hemolysis|||0|1000|1967|1976
SE|54||ab|12|relation|0|0|C0014792|Erythrocytes|cell|cell|||erythrocytes|||0|888|1916|1928|MOD/HEAD|PART_OF||1912|1928|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|888|1912|1915

SE|54||ab|13|text|1978|2129|It is evident that the use of these phospholipases to probe the localization of phospholipds in erythrocyte membranes must be approached with caution.
SE|54||ab|13|entity|C0031671|Phospholipase|aapp,enzy|||phospholipases|||0|1000|2014|2028
SE|54||ab|13|entity|C0475264|localization|ftcn|||localization|||0|1000|2042|2054
SE|54||ab|13|entity|C0014780|Erythrocyte Membrane|celc|||erythrocyte membranes|||0|1000|2074|2095
SE|54||ab|13|relation|2|1|C0014780|Erythrocyte Membrane|celc|celc|||erythrocyte membranes|||0|1000|2074|2095|PREP|LOCATION_OF||2071|2073|5|3|C0031671|Phospholipase|aapp,gngm,enzy|aapp|||phospholipases|||0|1000|2014|2028

SE|54||ab|14|text|2129|2174|Certain facets of this problem are discussed.
SE|54||ab|14|entity|C0222679|Structure of articular surface of bone|blor|||facets|||0|872|2137|2143


SE|55||ti|1|text|15|87|Subunit interactions in yeast glyceraldehyde-3-phosphate dehydrogenase.
SE|55||ti|1|entity|C0036025|Saccharomyces cerevisiae|fngs|||yeast|||0|928|39|44
SE|55||ti|1|entity|C0017857|Glyceraldehyde-3-Phosphate Dehydrogenases|aapp,enzy|||glyceraldehyde-3-phosphate dehydrogenase|||0|928|45|85

SE|55||ab|1|text|93|240|The spontaneous inactivation of yeast glyceraldehyde-3-phosphate dehydrogenase was found to fit a simple two-state model at pH 8.5 and 25 degrees.
SE|55||ab|1|entity|C0205359|Spontaneous|ftcn|||spontaneous|||0|888|97|108
SE|55||ab|1|entity|C0544461|Inactivation|comd|||inactivation|||0|888|109|121
SE|55||ab|1|entity|C0036025|Saccharomyces cerevisiae|fngs|||yeast|||0|928|125|130
SE|55||ab|1|entity|C0017857|Glyceraldehyde-3-Phosphate Dehydrogenases|aapp,enzy|||glyceraldehyde-3-phosphate dehydrogenase|||0|928|131|171
SE|55||ab|1|entity|C0205352|Simple|qlco|||simple|||0|833|191|197
SE|55||ab|1|entity|C0205448|Two|qnco|||two|||0|833|198|201
SE|55||ab|1|entity|C1442792|State|ftcn|||state|||0|833|202|207
SE|55||ab|1|entity|C0026336|Study models|inpr,resd|||model|||0|833|208|213

SE|55||ab|2|text|240|371|The first step is a relatively rapid dissociation of the tetramer to dimers with the equilibrium largely in favor of the tetramer.
SE|55||ab|2|entity|C1279901|Firstly|qlco|||first|||0|888|244|249
SE|55||ab|2|entity|C1261552|Step|ftcn|||step|||0|888|250|254
SE|55||ab|2|entity|C0439831|Rapid|qlco|||rapid|||0|790|271|276
SE|55||ab|2|entity|C0086168|Dissociation|mobd|||dissociation|||0|790|277|289
SE|55||ab|2|entity|C0039686|Tetrameres|invt|||tetramer|||0|966|297|305
SE|55||ab|2|entity|C0596448|dimer|chvs|||dimers|||0|966|309|315
SE|55||ab|2|entity|C0014653|Equilibrium|orgf|||equilibrium|||0|861|325|336
SE|55||ab|2|entity|C0039686|Tetrameres|invt|||tetramer|||0|966|361|369

SE|55||ab|3|text|371|430|In the absence of NAD+ the dimer inactivates irreversibly.
SE|55||ab|3|entity|C0027270|Nicotinamide adenine dinucleotide (NAD)|bacs,nnon|||NAD|||0|1000|389|392
SE|55||ab|3|entity|C0596448|dimer|chvs|||dimer|||0|1000|398|403

SE|55||ab|4|text|430|565|The apoenzyme is quite stable with a half-life for complete activity loss proportional to the square root of the enzyme concentration.
SE|55||ab|4|entity|C0003589|Apoenzymes|aapp,enzy|||apoenzyme|||0|1000|434|443
SE|55||ab|4|entity|C0018517|Half-Life|tmco|||half-life|||0|1000|467|476
SE|55||ab|4|entity|C0205197|Complete|qlco|||complete|||0|851|481|489
SE|55||ab|4|entity|C1517945|Loss|qnco|||loss|||0|851|499|503
SE|55||ab|4|entity|C0205351|Proportional|qlco|||proportional|||0|1000|504|516
SE|55||ab|4|entity|C0242726|Plant Roots|plnt|||root|||0|861|531|535
SE|55||ab|4|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|694|543|549

SE|55||ab|5|text|565|866|Perturbances of the protein structure (by pH, ionic strength, and specific salts), which have no effect on the tetrameric state of the molecule, result in an alteration of the cooperativity of NAD+ binding, the reactivity of the active-site sulfhydryl group, and the catalytic activity of the enzyme.
SE|55||ab|5|entity|C1510464|Protein Structure|aapp|||protein structure|||0|1000|585|602
SE|55||ab|5|entity|C0086486|Ionic Strength|lbtr|||ionic strength|||0|1000|611|625
SE|55||ab|5|entity|C0036140|Salts|chvs|||salts|||0|861|640|645
SE|55||ab|5|entity|C1280500|Effect|qlco|||effect|||0|1000|662|668
SE|55||ab|5|entity|C0039686|Tetrameres|invt|||tetrameric|||0|853|676|686
SE|55||ab|5|entity|C1442792|State|ftcn|||state|||0|853|687|692
SE|55||ab|5|entity|C0567416|Molecule|sbst|||molecule|||0|1000|700|708
SE|55||ab|5|entity|C1274040|result|ftcn|||result|||0|1000|710|716
SE|55||ab|5|entity|C1515926|Alteration|idcn|||alteration|||0|1000|723|733
SE|55||ab|5|entity|C0679729|cooperative|orgt|||cooperativity|||0|928|741|754
SE|55||ab|5|entity|C0027270|Nicotinamide adenine dinucleotide (NAD)|bacs,nnon|||NAD|||0|694|758|761
SE|55||ab|5|entity|C0205332|Reactive|qlco|||reactivity|||0|928|776|786
SE|55||ab|5|entity|C0205681|Active Site|ftcn,spco|||active-site|||0|888|794|805
SE|55||ab|5|entity|C0038734|Sulfhydryl Compounds|orch|||sulfhydryl group|||0|888|806|822
SE|55||ab|5|entity|C0243102|enzyme activity|moft|||catalytic activity|||0|1000|832|850
SE|55||ab|5|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|858|864
SE|55||ab|5|relation|11|10|C1510464|Protein Structure|aapp,gngm|aapp|||protein structure|||0|1000|585|602|NOM|INTERACTS_WITH||763|770|11|0|C0027270|Nicotinamide adenine dinucleotide (NAD)|bacs,nnon|bacs|||NAD|||0|694|758|761

SE|55||ab|6|text|866|1041|Covalent modification of two of the four active-site sulfhydryl groups has profound effects on the enzymic activity which are mediated by changes in the subunit interactions.
SE|55||ab|6|entity|C0678601|covalence|npop|||Covalent|||0|853|866|874
SE|55||ab|6|entity|C1522413|Modification|ftcn|||modification|||0|853|875|887
SE|55||ab|6|entity|C0205448|Two|qnco|||two|||0|1000|891|894
SE|55||ab|6|entity|C0205450|Four|qnco|||four|||0|849|902|906
SE|55||ab|6|entity|C0205681|Active Site|ftcn,spco|||active-site|||0|849|907|918
SE|55||ab|6|entity|C0038734|Sulfhydryl Compounds|orch|||sulfhydryl groups|||0|849|919|936
SE|55||ab|6|entity|C0439808|Profound|qlco|||profound|||0|872|941|949
SE|55||ab|6|entity|C1280500|Effect|qlco|||effects|||0|872|950|957

SE|55||ab|7|text|1041|1181|Sedimentation analysis and hybridization studies indicate that the interaction between subunits remains strong after covalent modification.
SE|55||ab|7|entity|C0597428|Sedimentation procedure|lbpr|||Sedimentation|||0|888|1041|1054
SE|55||ab|7|entity|C0936012|Analysis|resa|||analysis|||0|888|1055|1063
SE|55||ab|7|entity|C0020202|Crossbreeding|genf|||hybridization|||0|872|1068|1081
SE|55||ab|7|entity|C0008972|Clinical Research|resa|||studies|||0|872|1082|1089
SE|55||ab|7|entity|C0442821|Strong|qlco|||strong|||0|1000|1145|1151
SE|55||ab|7|entity|C0678601|covalence|npop|||covalent|||0|853|1158|1166
SE|55||ab|7|entity|C1522413|Modification|ftcn|||modification|||0|853|1167|1179

SE|55||ab|8|text|1181|1271|Under normal physiological and equilibrium dialysis conditions the protein is a tetramer.
SE|55||ab|8|entity|C0205307|Normal|qlco|||normal|||0|888|1187|1193
SE|55||ab|8|entity|C0205463|Physiological|ftcn|||physiological|||0|888|1194|1207
SE|55||ab|8|entity|C1553177|Equilibrium dialysis|lbpr|||equilibrium dialysis|||0|1000|1212|1232
SE|55||ab|8|entity|C0033684|Proteins|aapp,bacs|||protein|||0|1000|1248|1255
SE|55||ab|8|entity|C0039686|Tetrameres|invt|||tetramer|||0|966|1261|1269

SE|55||ab|9|text|1271|1393|Equilibrium dialysis studies of NAD+ binding to the enzyme at pH 8.5 and 25 degrees reveal a mixed cooperativity pattern.
SE|55||ab|9|entity|C1553177|Equilibrium dialysis|lbpr|||Equilibrium dialysis|||0|1000|1271|1291
SE|55||ab|9|entity|C0027270|Nicotinamide adenine dinucleotide (NAD)|bacs,nnon|||NAD|||0|694|1303|1306
SE|55||ab|9|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|1323|1329
SE|55||ab|9|entity|C0205430|Mixed|ftcn|||mixed|||0|828|1364|1369
SE|55||ab|9|entity|C0679729|cooperative|orgt|||cooperativity|||0|828|1370|1383
SE|55||ab|9|entity|C0449774|Patterns|spco|||pattern|||0|828|1384|1391
SE|55||ab|9|relation|1|0|C0027270|Nicotinamide adenine dinucleotide (NAD)|bacs,nnon|bacs|||NAD|||0|694|1303|1306|NOM|INTERACTS_WITH||1308|1315|3|1|C0014442|Enzymes|enzy,orch|enzy|||enzyme|||0|1000|1323|1329

SE|55||ab|10|text|1393|1609|A model consistent with these observations and the observed half-of-the-sites reactivity is that of ligand induced sequential conformational changes which are transferred across strongly interacting subunit domains.
SE|55||ab|10|entity|C0026336|Study models|inpr,resd|||model|||0|1000|1395|1400
SE|55||ab|10|entity|C0205145|Site|spco|||sites|||0|853|1465|1470
SE|55||ab|10|entity|C0205332|Reactive|qlco|||reactivity|||0|853|1471|1481
SE|55||ab|10|entity|C0023688|Ligands|chem|||ligand|||0|1000|1493|1499
SE|55||ab|10|entity|C1548958|Sequential|idcn|||sequential|||0|890|1508|1518
SE|55||ab|10|entity|C0301641|Macromolecular alteration|moft|||conformational changes|||0|890|1519|1541
SE|55||ab|10|relation|6|1|C0023688|Ligands|chem|chem|||ligand|||0|1000|1493|1499|VERB|AUGMENTS||1500|1507|2|1|C0301641|Macromolecular alteration|moft|moft|||conformational changes|||0|890|1519|1541

SE|55||ab|11|text|1609|1745|Methods for distinguishing negatively cooperative binding patterns from mixtures of denatured enzyme and multiple species are discussed.
SE|55||ab|11|entity|C0025663|Methods|inpr|||Methods|||0|1000|1609|1616
SE|55||ab|11|entity|C0679729|cooperative|orgt|||cooperative|||0|742|1647|1658
SE|55||ab|11|entity|C0449774|Patterns|spco|||patterns|||0|742|1667|1675
SE|55||ab|11|entity|C0439962|Mixture|sbst|||mixtures|||0|966|1681|1689
SE|55||ab|11|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|861|1703|1709
SE|55||ab|11|entity|C0439064|Numerous|qnco|||multiple|||0|888|1714|1722
SE|55||ab|11|entity|C1548151|Species|idcn|||species|||0|888|1723|1730


SE|56||ti|1|text|15|109|Kinetic light scattering studies on the dissociation of hemoglobin from Lumbricus terrestris.
SE|56||ti|1|entity|C0022702|Kinetics|idcn|||Kinetic|||0|852|15|22
SE|56||ti|1|entity|C0596837|LIGHT SCATTERING|phpr|||light scattering|||0|852|23|39
SE|56||ti|1|entity|C0008972|Clinical Research|resa|||studies|||0|852|40|47
SE|56||ti|1|entity|C0086168|Dissociation|mobd|||dissociation|||0|1000|55|67
SE|56||ti|1|entity|C0019046|Hemoglobin|aapp,bacs|||hemoglobin|||0|1000|71|81
SE|56||ti|1|entity|C0524678|Lumbricus terrestris|invt|||Lumbricus terrestris|||0|1000|87|107

SE|56||ab|1|text|115|300|The kinetics of the pH-induced dissociation of the 3 X 10(6) mol wt hemoglobin from Lumbricus terrestris (the earthworm) have been studied in a light-scattering stopped-flow apparatus.
SE|56||ab|1|entity|C0022702|Kinetics|idcn|||kinetics|||0|1000|119|127
SE|56||ab|1|entity|C0205263|Induced|ftcn|||induced|||0|851|138|145
SE|56||ab|1|entity|C0086168|Dissociation|mobd|||dissociation|||0|851|146|158
SE|56||ab|1|entity|C0027960|Nevus|neop|||mol|||0|851|176|179
SE|56||ab|1|entity|C0019046|Hemoglobin|aapp,bacs|||hemoglobin|||0|851|183|193
SE|56||ab|1|entity|C0524678|Lumbricus terrestris|invt|||Lumbricus terrestris|||0|1000|199|219
SE|56||ab|1|entity|C0086194|Pheretima sieboldi|invt|||earthworm|||0|1000|225|234
SE|56||ab|1|entity|C0596837|LIGHT SCATTERING|phpr|||light-scattering|||0|1000|259|275
SE|56||ab|1|entity|C0806140|Flow|orga|||flow|||0|888|284|288
SE|56||ab|1|entity|C0243111|apparatus|mnob|||apparatus|||0|888|289|298

SE|56||ab|2|text|300|383|The ligand dependent dissociation data were fit well by a simple sequential model.
SE|56||ab|2|entity|C0023688|Ligands|chem|||ligand|||0|833|304|310
SE|56||ab|2|entity|C0086168|Dissociation|mobd|||dissociation|||0|833|321|333
SE|56||ab|2|entity|C1511726|Data|idcn|||data|||0|833|334|338
SE|56||ab|2|entity|C0205170|Good|qlco|||well|||0|1000|348|352
SE|56||ab|2|entity|C0205352|Simple|qlco|||simple|||0|851|358|364
SE|56||ab|2|entity|C1548958|Sequential|idcn|||sequential|||0|851|365|375
SE|56||ab|2|entity|C0026336|Study models|inpr,resd|||model|||0|851|376|381

SE|56||ab|3|text|383|471|The data for CO and oxyhemoglobin are consistent with Hb12 leads to 2Hb6 leads to 12Hb.
SE|56||ab|3|entity|C1511726|Data|idcn|||data|||0|1000|387|391
SE|56||ab|3|entity|C0030069|Oxyhemoglobin|aapp,bacs|||oxyhemoglobin|||0|1000|403|416

SE|56||ab|4|text|471|586|Methemoglobin at pH 7 appears to be hexameric and the dissociation is consistent with the model: Hb6 leads to 6Hb.
SE|56||ab|4|entity|C0025635|Methemoglobin|aapp,bacs|||Methemoglobin|||0|1000|471|484
SE|56||ab|4|entity|C0086168|Dissociation|mobd|||dissociation|||0|1000|525|537
SE|56||ab|4|entity|C0026336|Study models|inpr,resd|||model|||0|1000|561|566
SE|56||ab|4|entity|||gngm|956,3892|ENTPD3,KRT86|Hb6|||0|1000|568|571

SE|56||ab|5|text|586|805|In a sequential decay scheme for which light-scattering changes are monitored, the relative amounts of rapid and slow phase are determined by the rate constants as well as the molecular weights of intermediate species.
SE|56||ab|5|entity|C1548958|Sequential|idcn|||sequential|||0|851|591|601
SE|56||ab|5|entity|C1265875|Disintegration|acab|||decay|||0|851|602|607
SE|56||ab|5|entity|C1519193|Scheme|inpr|||scheme|||0|851|608|614
SE|56||ab|5|entity|C0596837|LIGHT SCATTERING|phpr|||light-scattering|||0|890|625|641
SE|56||ab|5|entity|C0205345|Relative|qlco|||relative|||0|872|669|677
SE|56||ab|5|entity|C1265611|Quantity|qnco|||amounts|||0|872|678|685
SE|56||ab|5|entity|C0439831|Rapid|qlco|||rapid|||0|1000|689|694
SE|56||ab|5|entity|C0439834|Slow|qlco|||slow|||0|888|699|703
SE|56||ab|5|entity|C0205390|Phase|tmco|||phase|||0|888|704|709
SE|56||ab|5|entity|C1521828|Rate|qnco|||rate|||0|872|732|736
SE|56||ab|5|entity|C1547014|*Constant|qnco|||constants|||0|872|737|746
SE|56||ab|5|entity|C0026385|Molecular Weight|qnco|||molecular weights|||0|1000|762|779
SE|56||ab|5|entity|C0205103|Intermediate|spco|||intermediate|||0|888|783|795
SE|56||ab|5|entity|C1548151|Species|idcn|||species|||0|888|796|803

SE|56||ab|6|text|805|979|Assignment of the hexameric intermediate is supported by an investigation of the sensitivity of the theoretical kinetic curves to the molecular weights of the intermediates.
SE|56||ab|6|entity|C1516050|Assignment|ftcn|||Assignment|||0|1000|805|815
SE|56||ab|6|entity|C0205103|Intermediate|spco|||intermediate|||0|861|833|845
SE|56||ab|6|entity|C0022702|Kinetics|idcn|||kinetic|||0|748|917|924
SE|56||ab|6|entity|C0205134|Curved|spco|||curves|||0|748|925|931
SE|56||ab|6|entity|C0026385|Molecular Weight|qnco|||molecular weights|||0|1000|939|956
SE|56||ab|6|entity|C0205103|Intermediate|spco|||intermediates|||0|966|964|977

SE|56||ab|7|text|979|1294|This assignment is further supported by the following: (1) the same model will fit the data for oxy- and CO-hemoglobin at all three temperatures (a 24-29-fold variation in rate constants), (2) evidence from electron microscopy shows hexameric forms, and (3) methemoglobin is apparently stable as a hexamer at pH 7.
SE|56||ab|7|entity|C1516050|Assignment|ftcn|||assignment|||0|1000|984|994
SE|56||ab|7|entity|C1517331|Further|spco|||further|||0|1000|998|1005
SE|56||ab|7|entity|C0332282|Following|tmco|||following|||0|1000|1023|1032
SE|56||ab|7|entity|C0445247|Same|qlco|||same|||0|888|1042|1046
SE|56||ab|7|entity|C0026336|Study models|inpr,resd|||model|||0|888|1047|1052
SE|56||ab|7|entity|C1511726|Data|idcn|||data|||0|1000|1066|1070
SE|56||ab|7|entity|C0019046|Hemoglobin|aapp,bacs|||hemoglobin|||0|861|1087|1097
SE|56||ab|7|entity|C0205449|Three|qnco|||three|||0|888|1105|1110
SE|56||ab|7|entity|C0039476|Temperature|qnco|||temperatures|||0|888|1111|1123
SE|56||ab|7|entity|C0332462|Fold|spco|||fold|||0|750|1133|1137
SE|56||ab|7|entity|C0205419|Variant|qlco|||variation|||0|750|1138|1147
SE|56||ab|7|entity|C1521828|Rate|qnco|||rate|||0|872|1151|1155
SE|56||ab|7|entity|C1547014|*Constant|qnco|||constants|||0|872|1156|1165
SE|56||ab|7|entity|C0026019|Electron Microscopy|lbpr|||electron microscopy|||0|1000|1186|1205
SE|56||ab|7|entity|C0025635|Methemoglobin|aapp,bacs|||methemoglobin|||0|1000|1237|1250
SE|56||ab|7|entity|C0750541|APPARENTLY|idcn|||apparently|||0|694|1254|1264

SE|56||ab|8|text|1294|1382|When CO replaces O2 as the ligand, the dissociation rate increases by a factor of four.
SE|56||ab|8|entity|C0023688|Ligands|chem|||ligand|||0|1000|1321|1327
SE|56||ab|8|entity|C0086168|Dissociation|mobd|||dissociation|||0|888|1333|1345
SE|56||ab|8|entity|C1521828|Rate|qnco|||rate|||0|888|1346|1350
SE|56||ab|8|entity|C1521761|Factor|ftcn|||factor|||0|1000|1366|1372
SE|56||ab|8|entity|C0205450|Four|qnco|||four|||0|1000|1376|1380

SE|56||ab|9|text|1382|1664|The met is about 20 times faster than the initial oxyhemoglobin dissociation rate, but perhaps more relevant for comparing dissociation of the hexamer, the met rate was respectively 100 times and 500 times faster than that for the assumed hexameric forms of CO- and oxy-hemoglobin.
SE|56||ab|9|entity|C0040223|Time|tmco|||times|||0|793|1402|1407
SE|56||ab|9|entity|C0456962|Fast|qlco|||faster|||0|966|1408|1414
SE|56||ab|9|entity|C0205265|Initially|tmco|||initial|||0|833|1424|1431
SE|56||ab|9|entity|C0030069|Oxyhemoglobin|aapp,bacs|||oxyhemoglobin|||0|833|1432|1445
SE|56||ab|9|entity|C0086168|Dissociation|mobd|||dissociation|||0|833|1446|1458
SE|56||ab|9|entity|C1521828|Rate|qnco|||rate|||0|833|1459|1463
SE|56||ab|9|entity|C0086168|Dissociation|mobd|||dissociation|||0|861|1505|1517
SE|56||ab|9|entity|C1521828|Rate|qnco|||rate|||0|888|1542|1546
SE|56||ab|9|entity|C0040223|Time|tmco|||times|||0|793|1568|1573
SE|56||ab|9|entity|C0040223|Time|tmco|||times|||0|827|1582|1587
SE|56||ab|9|entity|C0456962|Fast|qlco|||faster|||0|966|1588|1594
SE|56||ab|9|entity|C0030069|Oxyhemoglobin|aapp,bacs|||oxy-hemoglobin|||0|1000|1648|1662

SE|56||ab|10|text|1664|1843|The activation energies for the dodecamer to hexamer dissociation and for the dissociation of the hexamer to smaller forms were about 30 kcal/mol for oxy-, CO-, and methemoglobin.
SE|56||ab|10|entity|C0424589|Vitality|fndg|||energies|||0|827|1679|1687
SE|56||ab|10|entity|C0086168|Dissociation|mobd|||dissociation|||0|861|1717|1729
SE|56||ab|10|entity|C0086168|Dissociation|mobd|||dissociation|||0|1000|1742|1754
SE|56||ab|10|entity|C0547044|Smaller|qlco|||smaller|||0|888|1773|1780
SE|56||ab|10|entity|C0439259|Calories|qnco|||kcal|||0|750|1801|1805
SE|56||ab|10|entity|C0027960|Nevus|neop|||mol|||0|750|1806|1809
SE|56||ab|10|entity|C0025635|Methemoglobin|aapp,bacs|||methemoglobin|||0|1000|1829|1842


SE|57||ti|1|text|15|140|The reversible reduction of horse metmyoglobin by the iron(II) complex of trans-1,2-diaminocyclohexane-N,N,N,n-tetraacetate.
SE|57||ti|1|entity|C0205343|Reversible|ftcn|||reversible|||0|694|19|29
SE|57||ti|1|entity|C0019944|Equus caballus|mamm|||horse|||0|888|43|48
SE|57||ti|1|entity|C0025852|Metmyoglobin|aapp,bacs|||metmyoglobin|||0|888|49|61
SE|57||ti|1|entity|C0302583|Iron|bacs,elii,phsu|||iron|||0|1000|69|73
SE|57||ti|1|entity|C0439855|Complex|qlco|||complex|||0|1000|78|85
SE|57||ti|1|relation|0|0|C0025852|Metmyoglobin|aapp,gngm,bacs|aapp|||metmyoglobin|||0|888|49|61|MOD/HEAD|PART_OF||43|61|0|0|C0019944|Equus caballus|mamm|mamm|||horse|||0|888|43|48

SE|57||ab|1|text|146|288|The reduction of metmyoglobin by the iron(II) complex of trans-1,2-diaminocyclohexane-N,N,N'N'-tetraacetate (FeCDTA2-) has been investigated.
SE|57||ab|1|entity|C0025852|Metmyoglobin|aapp,bacs|||metmyoglobin|||0|1000|163|175
SE|57||ab|1|entity|C0302583|Iron|bacs,elii,phsu|||iron|||0|1000|183|187
SE|57||ab|1|entity|C0439855|Complex|qlco|||complex|||0|1000|192|199

SE|57||ab|2|text|288|412|The equilibrium constant, measured spectrophotometrically, is 0.21 with a resulting reduction potential of 0.050 V for Mb0.
SE|57||ab|2|entity|C0678590|equilibrium constant|npop|||equilibrium constant|||0|1000|292|312
SE|57||ab|2|entity|C1274040|result|ftcn|||resulting|||0|785|362|371
SE|57||ab|2|entity|C0237399|Potential|qlco|||potential|||0|785|382|391

SE|57||ab|3|text|412|521|The rate constant for the reduction is 28 M-1 sec-1 with a deltaH ++ of 13 kcal M-1 and deltaS ++ of -11 eu.
SE|57||ab|3|entity|C1521828|Rate|qnco|||rate|||0|888|416|420
SE|57||ab|3|entity|C1547014|*Constant|qnco|||constant|||0|888|421|429
SE|57||ab|3|entity|C0441923|M+|inpr|||M-1|||0|725|454|457
SE|57||ab|3|entity|C0457385|seconds|tmco|||sec|||0|725|458|461
SE|57||ab|3|entity|C0439259|Calories|qnco|||kcal|||0|750|487|491
SE|57||ab|3|entity|C0441923|M+|inpr|||M-1|||0|750|492|495

SE|57||ab|4|text|521|665|Both CN- and OH- inhibit the reduction because of the relatively low reactivity of cyanometmyoglobin (Mb+CN-) and ionized metmyglobin (Mb+OH-).
SE|57||ab|4|entity|C0205251|low|qlco|||low|||0|754|586|589
SE|57||ab|4|entity|C0205332|Reactive|qlco|||reactivity|||0|754|590|600
SE|57||ab|4|entity|C0056664|cyanometmyoglobin|aapp|||cyanometmyoglobin|||0|1000|604|621

SE|57||ab|5|text|665|800|The rate constant for the reduction of Mb+CN- by FeCDTA2- is 4.0 X 10(-2) M-1 sec-1 and that for reduction of Mb+OH- is 4.8 M-1 sec-1.
SE|57||ab|5|entity|C1521828|Rate|qnco|||rate|||0|888|669|673
SE|57||ab|5|entity|C1547014|*Constant|qnco|||constant|||0|888|674|682
SE|57||ab|5|entity|C0441923|M+|inpr|||M-1|||0|747|739|742
SE|57||ab|5|entity|C0457385|seconds|tmco|||sec|||0|747|743|746
SE|57||ab|5|entity|||gngm|1128,100507027|CHRM1,MRLN|M-1|||0|766|789|792
SE|57||ab|5|entity|C0457385|seconds|tmco|||sec|||0|766|793|796

SE|57||ab|6|text|800|890|The nitric oxide complex of metmyoglobin is reduced with a rate constant of 10 M-1 sec-1.
SE|57||ab|6|entity|C0028128|Nitric Oxide|bacs,inch|||nitric oxide|||0|901|804|816
SE|57||ab|6|entity|C0439855|Complex|qlco|||complex|||0|901|817|824
SE|57||ab|6|entity|C0025852|Metmyoglobin|aapp,bacs|||metmyoglobin|||0|1000|828|840
SE|57||ab|6|entity|C1521828|Rate|qnco|||rate|||0|888|859|863
SE|57||ab|6|entity|C1547014|*Constant|qnco|||constant|||0|888|864|872
SE|57||ab|6|entity|C0441923|M+|inpr|||M-1|||0|725|879|882
SE|57||ab|6|entity|C0457385|seconds|tmco|||sec|||0|725|883|886

SE|57||ab|7|text|890|957|The kinetics of oxidation of oxymyoglobin by FeCDTA- were studied.
SE|57||ab|7|entity|C0022702|Kinetics|idcn|||kinetics|||0|1000|894|902
SE|57||ab|7|entity|C0030011|Oxidation|phpr|||oxidation|||0|1000|906|915
SE|57||ab|7|entity|C0069830|oxymyoglobin|aapp|||oxymyoglobin|||0|1000|919|931

SE|57||ab|8|text|957|1059|The data are consistent with a mechanism where oxidation takes place entirely through the deoxy form.
SE|57||ab|8|entity|C1511726|Data|idcn|||data|||0|1000|961|965
SE|57||ab|8|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|802|988|997
SE|57||ab|8|entity|C0030011|Oxidation|phpr|||oxidation|||0|802|1004|1013
SE|57||ab|8|entity|C1522492|Formation|ftcn|||form|||0|861|1053|1057

SE|57||ab|9|text|1059|1221|A rate constant of 1.45 X 10(2) M-1 sec-1 was calculated for the oxidation of deoxymyoglobin by FeCDTA-, in equilibrium constant and rate constant for reduction.
SE|57||ab|9|entity|C1521828|Rate|qnco|||rate|||0|888|1061|1065
SE|57||ab|9|entity|C1547014|*Constant|qnco|||constant|||0|888|1066|1074
SE|57||ab|9|entity|C0441923|M+|inpr|||M-1|||0|747|1091|1094
SE|57||ab|9|entity|C0457385|seconds|tmco|||sec|||0|747|1095|1098
SE|57||ab|9|entity|C0030011|Oxidation|phpr|||oxidation|||0|1000|1124|1133
SE|57||ab|9|entity|C0057444|deoxymyoglobin|aapp|||deoxymyoglobin|||0|1000|1137|1151
SE|57||ab|9|entity|C0678590|equilibrium constant|npop|||equilibrium constant|||0|1000|1167|1187
SE|57||ab|9|entity|C1521828|Rate|qnco|||rate|||0|888|1192|1196
SE|57||ab|9|entity|C1547014|*Constant|qnco|||constant|||0|888|1197|1205

SE|57||ab|10|text|1221|1303|The above data are discussed in terms of a simple outer-sphere reduction reaction.
SE|57||ab|10|entity|C1282910|Upper|spco|||above|||0|888|1225|1230
SE|57||ab|10|entity|C1511726|Data|idcn|||data|||0|888|1231|1235
SE|57||ab|10|entity|C0205352|Simple|qlco|||simple|||0|766|1264|1270
SE|57||ab|10|entity|C0205101|Extrinsic|spco|||outer|||0|766|1271|1276
SE|57||ab|10|entity|C0946401|SPHERE|orga|||sphere|||0|766|1277|1283
SE|57||ab|10|entity|C0443286|Reaction|ftcn|||reaction|||0|766|1294|1302


SE|58||ti|1|text|15|85|Constitution and properties of axonal membranes of crustacean nerves.
SE|58||ti|1|entity|C0009807|Constitutions|rnlw|||Constitution|||0|1000|15|27
SE|58||ti|1|entity|C0871161|Property|qlco|||properties|||0|966|32|42
SE|58||ti|1|entity|C0004461|Axon|celc|||axonal|||0|853|46|52
SE|58||ti|1|entity|C0025255|Tissue membrane|tisu|||membranes|||0|853|53|62
SE|58||ti|1|entity|C0010395|Crustacea|invt|||crustacean|||0|888|66|76
SE|58||ti|1|entity|C0027740|Nerve|tisu|||nerves|||0|888|77|83
SE|58||ti|1|relation|3|1|C0025255|Tissue membrane|tisu|tisu|||membranes|||0|853|53|62|PREP|PART_OF||63|65|1|1|C0027740|Nerve|tisu|tisu|||nerves|||0|888|77|83

SE|58||ab|1|text|91|249|The purification of axonal membranes of crustaceans was followed by measuring enrichment in [3H]tetrodotoxin binding capacity and in Na+, K+-ATPase activity.
SE|58||ab|1|entity|C0243114|purification|lbpr,resa|||purification|||0|1000|95|107
SE|58||ab|1|entity|C0004461|Axon|celc|||axonal|||0|853|111|117
SE|58||ab|1|entity|C0025255|Tissue membrane|tisu|||membranes|||0|853|118|127
SE|58||ab|1|entity|C0010395|Crustacea|invt|||crustaceans|||0|1000|131|142
SE|58||ab|1|entity|C0079809|Measures|qnco|||measuring|||0|661|159|168
SE|58||ab|1|entity|C0039705|Tetrodotoxin|bacs,hops,orch|||tetrodotoxin|||0|901|187|199
SE|58||ab|1|entity|C0439155|Binding capacity|qnco|||binding capacity|||0|901|200|216
SE|58||ab|1|entity|C0064194|K ATPase|aapp,enzy|||K+-ATPase|||0|901|229|238
SE|58||ab|1|relation|7|1|C0025255|Tissue membrane|tisu|tisu|||membranes|||0|853|118|127|PREP|LOCATION_OF||108|110|1|1|C0243114|purification|lbpr,resa|lbpr|||purification|||0|1000|95|107

SE|58||ab|2|text|249|401|A characteristic of these membranes is their high content of lipids and their low content of protein as compared to other types of plasmatic membranes.
SE|58||ab|2|entity|C1521970|Characteristics|grpa|||characteristic|||0|966|251|265
SE|58||ab|2|entity|C0025255|Tissue membrane|tisu|||membranes|||0|1000|275|284
SE|58||ab|2|entity|C0205250|High|qlco|||high|||0|694|294|298
SE|58||ab|2|entity|C0023779|Lipids|lipd|||lipids|||0|1000|310|316
SE|58||ab|2|entity|C0205251|low|qlco|||low|||0|694|327|330
SE|58||ab|2|entity|C0033684|Proteins|aapp,bacs|||protein|||0|1000|342|349
SE|58||ab|2|entity|C0332307|Type - attribute|qlco|||types|||0|1000|371|376
SE|58||ab|2|entity|C0007603|Cell membrane|celc|||plasmatic membranes|||0|964|380|399

SE|58||ab|3|text|401|500|The axonal membrane contains myosin-like, actin-like, tropomyosin-like, and tubulin-like proteins.
SE|58||ab|3|entity|C0004461|Axon|celc|||axonal|||0|853|405|411
SE|58||ab|3|entity|C0596901|Membrane|celc|||membrane|||0|853|412|420
SE|58||ab|3|entity|C0001271|Actins|aapp,bacs|||actin|||0|1000|443|448
SE|58||ab|3|entity|C0041197|Tropomyosin|aapp,bacs|||tropomyosin|||0|1000|455|466
SE|58||ab|3|entity|C0041348|Tubulin|aapp,bacs|||tubulin|||0|1000|477|484
SE|58||ab|3|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|1000|490|498
SE|58||ab|3|relation|0|0|C0596901|Membrane|celc|celc|||membrane|||0|853|412|420|MOD/HEAD|PART_OF||405|420|0|0|C0004461|Axon|celc|celc|||axonal|||0|853|405|411

SE|58||ab|4|text|500|558|It also contains Na+, K+-ATPase and acetylcholinesterase.
SE|58||ab|4|entity|C0064194|K ATPase|aapp,enzy|||K+-ATPase|||0|1000|522|531
SE|58||ab|4|entity|C0001044|Acetylcholinesterase|aapp,enzy|||acetylcholinesterase|||0|1000|536|556

SE|58||ab|5|text|558|661|The molecular weights of these two enzymes after solubilization are 280,000 and 270,000, respectively.
SE|58||ab|5|entity|C0026385|Molecular Weight|qnco|||molecular weights|||0|1000|562|579
SE|58||ab|5|entity|C0205448|Two|qnco|||two|||0|888|589|592
SE|58||ab|5|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|888|593|600

SE|58||ab|6|text|661|768|The molecular weights of the catalytic subunits are 96,000 for ATPase and 71,000 for acetylcholinesterase.
SE|58||ab|6|entity|C0026385|Molecular Weight|qnco|||molecular weights|||0|1000|665|682
SE|58||ab|6|entity|C0600499|Catalytic Domain|amas|||catalytic subunits|||0|1000|690|708
SE|58||ab|6|entity|C0001473|ATP phosphohydrolase|aapp,enzy|||ATPase|||0|1000|724|730
SE|58||ab|6|entity|C0001044|Acetylcholinesterase|aapp,enzy|||acetylcholinesterase|||0|1000|746|766

SE|58||ab|7|text|768|943|We confirmed the presence of a nicotine binding component in the axonal membrane of the lobster but we have been unable to find [3H]nicotine binding to crab axonal membranes.
SE|58||ab|7|entity|C0028040|Nicotine|hops,orch,phsu|||nicotine|||0|802|799|807
SE|58||ab|7|entity|C1524073|Component, LOINC Axis 1|clas|||component|||0|802|816|825
SE|58||ab|7|entity|C0004461|Axon|celc|||axonal|||0|853|833|839
SE|58||ab|7|entity|C0596901|Membrane|celc|||membrane|||0|853|840|848
SE|58||ab|7|entity|C1140675|Lobster|invt|||lobster|||0|1000|856|863
SE|58||ab|7|entity|C0028040|Nicotine|hops,orch,phsu|||nicotine|||0|694|900|908
SE|58||ab|7|entity|C0004461|Axon|celc|||axonal|||0|853|925|931
SE|58||ab|7|entity|C0025255|Tissue membrane|tisu|||membranes|||0|853|932|941
SE|58||ab|7|relation|0|0|C0596901|Membrane|celc|celc|||membrane|||0|853|840|848|MOD/HEAD|PART_OF||833|848|0|0|C0004461|Axon|celc|celc|||axonal|||0|853|833|839

SE|58||ab|8|text|943|1029|The binding to axonal membranes og of the sodium channel, has been studied in detail.
SE|58||ab|8|entity|C0004461|Axon|celc|||axonal|||0|587|958|964
SE|58||ab|8|entity|C0025255|Tissue membrane|tisu|||membranes|||0|587|965|974
SE|58||ab|8|entity|C0037492|Sodium Channel|aapp,bacs|||sodium channel|||0|1000|985|999

SE|58||ab|9|text|1029|1144|The dissociation constant for the binding of [3H]tetrodotoxin to the axonal membrane receptor is 2.9 nM at pH 7.4.
SE|58||ab|9|entity|C0086168|Dissociation|mobd|||dissociation|||0|888|1033|1045
SE|58||ab|9|entity|C1547014|*Constant|qnco|||constant|||0|888|1046|1054
SE|58||ab|9|entity|C0039705|Tetrodotoxin|bacs,hops,orch|||tetrodotoxin|||0|1000|1078|1090
SE|58||ab|9|entity|C0004461|Axon|celc|||axonal|||0|877|1098|1104
SE|58||ab|9|entity|C0230664|Membrane receptor|rcpt|||membrane receptor|||0|877|1105|1122
SE|58||ab|9|relation|0|0|C0230664|Membrane receptor|rcpt|rcpt|||membrane receptor|||0|877|1105|1122|MOD/HEAD|PART_OF||1098|1122|0|0|C0004461|Axon|celc|celc|||axonal|||0|877|1098|1104

SE|58||ab|10|text|1144|1418|The concentration of the tetrodotoxin receptor in crustacean membranes is about 10 pmol/mg of membrane protein, 7 times less than the acetylcholinesterase, 30 times less than the Na+, K+-ATPase, and 30 times less than the nicotine binding component in the lobster membrane.
SE|58||ab|10|entity|C0076350|tetrodotoxin-binding protein|aapp|||tetrodotoxin receptor|||0|1000|1169|1190
SE|58||ab|10|entity|C0010395|Crustacea|invt|||crustacean|||0|888|1194|1204
SE|58||ab|10|entity|C0025255|Tissue membrane|tisu|||membranes|||0|888|1205|1214
SE|58||ab|10|entity|C0439192|pmol|qnco|||pmol|||0|750|1227|1231
SE|58||ab|10|entity|C0025252|Membrane Proteins|aapp,bacs|||membrane protein|||0|1000|1238|1254
SE|58||ab|10|entity|C0040223|Time|tmco|||times|||0|793|1258|1263
SE|58||ab|10|entity|C0001044|Acetylcholinesterase|aapp,enzy|||acetylcholinesterase|||0|1000|1278|1298
SE|58||ab|10|entity|C0040223|Time|tmco|||times|||0|793|1303|1308
SE|58||ab|10|entity|C0064194|K ATPase|aapp,enzy|||K+-ATPase|||0|1000|1328|1337
SE|58||ab|10|entity|C0040223|Time|tmco|||times|||0|793|1346|1351
SE|58||ab|10|entity|C0028040|Nicotine|hops,orch,phsu|||nicotine|||0|802|1366|1374
SE|58||ab|10|entity|C1524073|Component, LOINC Axis 1|clas|||component|||0|802|1383|1392
SE|58||ab|10|entity|C1140675|Lobster|invt|||lobster|||0|888|1400|1407
SE|58||ab|10|entity|C0596901|Membrane|celc|||membrane|||0|888|1408|1416
SE|58||ab|10|relation|0|0|C0076350|tetrodotoxin-binding protein|aapp,gngm|aapp|||tetrodotoxin receptor|||0|1000|1169|1190|SPEC|ISA||1169|1254|0|0|C0025252|Membrane Proteins|aapp,gngm,bacs|aapp|||membrane protein|||0|1000|1238|1254
SE|58||ab|10|relation|1|1|C0596901|Membrane|celc|celc|||membrane|||0|888|1408|1416|PREP|LOCATION_OF||1393|1395|12|3|C0064194|K ATPase|aapp,gngm,enzy|aapp|||K+-ATPase|||0|1000|1328|1337
SE|58||ab|10|relation|11|1|C0025255|Tissue membrane|tisu|tisu|||membranes|||0|888|1205|1214|PREP|LOCATION_OF||1191|1193|2|1|C0076350|tetrodotoxin-binding protein|aapp,gngm|aapp|||tetrodotoxin receptor|||0|1000|1169|1190

SE|58||ab|11|text|1418|1588|A reasonable estimate indicates that approximately only one peptide chain in 1000 constitutes the tetrodotoxin binding part of the sodium channel in the axonal membrane.
SE|58||ab|11|entity|C0392360|Reason for|idcn|||reasonable|||0|623|1420|1430
SE|58||ab|11|entity|C0332232|Approximate|ftcn,qlco|||approximately|||0|574|1455|1468
SE|58||ab|11|entity|C0205447|One|qnco|||one|||0|574|1474|1477
SE|58||ab|11|entity|C0030956|Peptides|aapp|||peptide|||0|574|1478|1485
SE|58||ab|11|entity|C0039705|Tetrodotoxin|bacs,hops,orch|||tetrodotoxin|||0|802|1516|1528
SE|58||ab|11|entity|C0449719|Part|spco|||part|||0|802|1537|1541
SE|58||ab|11|entity|C0037492|Sodium Channel|aapp,bacs|||sodium channel|||0|1000|1549|1563
SE|58||ab|11|entity|C0004461|Axon|celc|||axonal|||0|853|1571|1577
SE|58||ab|11|entity|C0596901|Membrane|celc|||membrane|||0|853|1578|1586
SE|58||ab|11|relation|0|0|C0596901|Membrane|celc|celc|||membrane|||0|853|1578|1586|MOD/HEAD|PART_OF||1571|1586|0|0|C0004461|Axon|celc|celc|||axonal|||0|853|1571|1577
SE|58||ab|11|relation|1|1|C0596901|Membrane|celc|celc|||membrane|||0|853|1578|1586|PREP|LOCATION_OF||1564|1566|4|1|C0037492|Sodium Channel|aapp,gngm,bacs|aapp|||sodium channel|||0|1000|1549|1563

SE|58||ab|12|text|1588|1715|Veratridine, which acts selectively on the resting sodium permeability, binds to the phospholipid part of the axonal membrane.
SE|58||ab|12|entity|C0042525|Veratridine|bacs,orch,phsu|||Veratridine|||0|1000|1588|1599
SE|58||ab|12|entity|C0035253|Rest|dora|||resting|||0|851|1631|1638
SE|58||ab|12|entity|C0037473|Sodium|bacs,elii|||sodium|||0|851|1639|1645
SE|58||ab|12|entity|C0031164|Permeability|npop|||permeability|||0|851|1646|1658
SE|58||ab|12|entity|C0031676|Phospholipids|bacs,lipd|||phospholipid|||0|888|1673|1685
SE|58||ab|12|entity|C0449719|Part|spco|||part|||0|888|1686|1690
SE|58||ab|12|entity|C0004461|Axon|celc|||axonal|||0|853|1698|1704
SE|58||ab|12|entity|C0596901|Membrane|celc|||membrane|||0|853|1705|1713
SE|58||ab|12|relation|0|0|C0596901|Membrane|celc|celc|||membrane|||0|853|1705|1713|MOD/HEAD|PART_OF||1698|1713|0|0|C0004461|Axon|celc|celc|||axonal|||0|853|1698|1704
SE|58||ab|12|relation|2|0|C0031676|Phospholipids|bacs,lipd|bacs|||phospholipid|||0|888|1673|1685|NOM|PART_OF||1686|1690|1|1|C0596901|Membrane|celc|celc|||membrane|||0|853|1705|1713

SE|58||ab|13|text|1715|1795|[3H]Veratridine binding to membranes parallels the electrophysiological effect.
SE|58||ab|13|entity|C0042525|Veratridine|bacs,orch,phsu|||Veratridine|||0|694|1719|1730
SE|58||ab|13|entity|C0025255|Tissue membrane|tisu|||membranes|||0|1000|1742|1751
SE|58||ab|13|entity|C1280500|Effect|qlco|||effect|||0|861|1787|1793

SE|58||ab|14|text|1795|1855|Veratridine and tetrodotoxin have different receptor sites.
SE|58||ab|14|entity|C0042525|Veratridine|bacs,orch,phsu|||Veratridine|||0|1000|1795|1806
SE|58||ab|14|entity|C0039705|Tetrodotoxin|bacs,hops,orch|||tetrodotoxin|||0|1000|1811|1823
SE|58||ab|14|entity|C1547020|*Difference|qnco|||different|||0|877|1829|1838
SE|58||ab|14|entity|C0005456|Binding Sites|rcpt|||receptor sites|||0|877|1839|1853

SE|58||ab|15|text|1855|2049|Although tetrodotoxin can repolarize the excitable membrane of a giant axon depolarized by veratridine, veratridine does not affect the binding of [3H]tetrodotoxin to purified axonal membranes.
SE|58||ab|15|entity|C0039705|Tetrodotoxin|bacs,hops,orch|||tetrodotoxin|||0|1000|1864|1876
SE|58||ab|15|entity|C0857393|Excitable|sosy|||excitable|||0|888|1896|1905
SE|58||ab|15|entity|C0596901|Membrane|celc|||membrane|||0|888|1906|1914
SE|58||ab|15|entity|C1325529|giant axon|celc|||giant axon|||0|1000|1920|1930
SE|58||ab|15|entity|C0042525|Veratridine|bacs,orch,phsu|||veratridine|||0|1000|1946|1957
SE|58||ab|15|entity|C0042525|Veratridine|bacs,orch,phsu|||veratridine|||0|1000|1959|1970
SE|58||ab|15|entity|C1518422|Not|ftcn|||not|||0|1000|1976|1979
SE|58||ab|15|entity|C0039705|Tetrodotoxin|bacs,hops,orch|||tetrodotoxin|||0|1000|2006|2018
SE|58||ab|15|entity|C0004461|Axon|celc|||axonal|||0|754|2031|2037
SE|58||ab|15|entity|C0025255|Tissue membrane|tisu|||membranes|||0|754|2038|2047
SE|58||ab|15|relation|2|1|C0596901|Membrane|celc|celc|||membrane|||0|888|1906|1914|PREP|PART_OF||1915|1917|7|1|C1325529|giant axon|celc|celc|||giant axon|||0|1000|1920|1930
SE|58||ab|15|relation|6|1|C0042525|Veratridine|bacs,orch,phsu|bacs|||veratridine|||0|1000|1946|1957|VERB|AFFECTS||1931|1942|3|1|C1325529|giant axon|celc|celc|||giant axon|||0|1000|1920|1930

SE|58||ab|16|text|2049|2141|Similarly, tetrodotoxin does not affect the binding of [3H]veratridine to axonal membranes.
SE|58||ab|16|entity|C0039705|Tetrodotoxin|bacs,hops,orch|||tetrodotoxin|||0|1000|2060|2072
SE|58||ab|16|entity|C1518422|Not|ftcn|||not|||0|1000|2078|2081
SE|58||ab|16|entity|C0042525|Veratridine|bacs,orch,phsu|||veratridine|||0|1000|2108|2119
SE|58||ab|16|entity|C0004461|Axon|celc|||axonal|||0|853|2123|2129
SE|58||ab|16|entity|C0025255|Tissue membrane|tisu|||membranes|||0|853|2130|2139

SE|58||ab|17|text|2141|2328|Scorpion neurotoxin I, a presynaptic toxin which affects both the Na+ and the K+ channels, does not interfere with the binding of [3H]tetrodotoxin or [3H]veratridine to axonal membranes.
SE|58||ab|17|entity|C0036451|Scorpions|invt|||Scorpion|||0|888|2141|2149
SE|58||ab|17|entity|C0027934|Neurotoxins|hops|||neurotoxin|||0|888|2150|2160
SE|58||ab|17|entity|C0040549|Toxin|bacs,hops|||toxin|||0|861|2178|2183
SE|58||ab|17|entity|C0439799|Channel|spco|||channels|||0|872|2222|2230
SE|58||ab|17|entity|C1518422|Not|ftcn|||not|||0|1000|2237|2240
SE|58||ab|17|entity|C0039705|Tetrodotoxin|bacs,hops,orch|||tetrodotoxin|||0|1000|2275|2287
SE|58||ab|17|entity|C0042525|Veratridine|bacs,orch,phsu|||veratridine|||0|1000|2295|2306
SE|58||ab|17|entity|C0004461|Axon|celc|||axonal|||0|853|2310|2316
SE|58||ab|17|entity|C0025255|Tissue membrane|tisu|||membranes|||0|853|2317|2326

SE|58||ab|18|text|2328|2518|Tetrodotoxin, veratridine, and scorpion neurotoxin I, which have in common the perturbation of the normal functioning of the sodium channel, act upon three different types of receptor sites.
SE|58||ab|18|entity|C0039705|Tetrodotoxin|bacs,hops,orch|||Tetrodotoxin|||0|1000|2328|2340
SE|58||ab|18|entity|C0042525|Veratridine|bacs,orch,phsu|||veratridine|||0|1000|2342|2353
SE|58||ab|18|entity|C0036451|Scorpions|invt|||scorpion|||0|888|2359|2367
SE|58||ab|18|entity|C0027934|Neurotoxins|hops|||neurotoxin|||0|888|2368|2378
SE|58||ab|18|entity|C0205214|Common|qnco|||common|||0|1000|2396|2402
SE|58||ab|18|entity|C0205307|Normal|qlco|||normal|||0|872|2427|2433
SE|58||ab|18|entity|C0031843|physiological aspects|phsf|||functioning|||0|872|2434|2445
SE|58||ab|18|entity|C0037492|Sodium Channel|aapp,bacs|||sodium channel|||0|1000|2453|2467
SE|58||ab|18|entity|C0205449|Three|qnco|||three|||0|828|2478|2483
SE|58||ab|18|entity|C1547020|*Difference|qnco|||different|||0|828|2484|2493
SE|58||ab|18|entity|C0332307|Type - attribute|qlco|||types|||0|828|2494|2499
SE|58||ab|18|entity|C0005456|Binding Sites|rcpt|||receptor sites|||0|1000|2503|2517


SE|59||ti|1|text|15|48|Regulation of nitrogen fixation.
SE|59||ti|1|entity|C0851285|Regulation|gora|||Regulation|||0|1000|15|25
SE|59||ti|1|entity|C0028161|Nitrogen Fixation|orgf|||nitrogen fixation|||0|1000|29|46

SE|59||ti|2|text|48|106|Nitrogenase-derepressed mutants of Klebsiella pneumoniae.
SE|59||ti|2|entity|C0028174|Nitrogenase|aapp,enzy|||Nitrogenase|||0|785|48|59
SE|59||ti|2|entity|C0596988|Mutant|comd|||mutants|||0|785|72|79
SE|59||ti|2|entity|C0001699|Klebsiella pneumonia bacterium|bact|||Klebsiella pneumoniae|||0|1000|83|104

SE|59||ab|1|text|112|115|1.

SE|59||ab|2|text|115|230|A new procedure is described for selecting nitrogenase-derepressed mutants based on the method of Brenchley et al.
SE|59||ab|2|entity|C0205314|New|tmco|||new|||0|888|117|120
SE|59||ab|2|entity|C0184661|Procedures|hlca|||procedure|||0|888|121|130
SE|59||ab|2|entity|C1519229|Selenium and Vitamin E Efficacy Trial|resa|||selecting|||0|753|148|157
SE|59||ab|2|entity|C0028174|Nitrogenase|aapp,enzy|||nitrogenase|||0|753|158|169
SE|59||ab|2|entity|C0596988|Mutant|comd|||mutants|||0|753|182|189
SE|59||ab|2|entity|C0025663|Methods|inpr|||method|||0|1000|203|209

SE|59||ab|3|text|230|392|(Brenchley, J.E., Prival, M.J. and Magasanik, B. (1973) J. Biol. Chem. 248, 6122-6128) for isolating histidase-constitutive mutants of a non-N2-fixing bacterium.
SE|59||ab|3|entity|C0007996|Science of Chemistry|ocdi|||Chem|||0|812|295|299
SE|59||ab|3|entity|C0205409|Isolated|ftcn|||isolating|||0|816|321|330
SE|59||ab|3|entity|C0019601|Histidine Ammonia-Lyase|aapp,enzy|||histidase|||0|816|331|340
SE|59||ab|3|entity|C0596988|Mutant|comd|||mutants|||0|816|354|361
SE|59||ab|3|entity|C0016184|Fixatives|irda|||fixing|||0|733|374|380
SE|59||ab|3|entity|C0004611|Bacteria|bact|||bacterium|||0|733|381|390

SE|59||ab|4|text|392|395|2.

SE|59||ab|5|text|395|539|Nitrogenase levels of the new mutants in the presence of NH4+ were as high as 100% of the nitrogenase activity detected in the absence of NH4+.
SE|59||ab|5|entity|C0028174|Nitrogenase|aapp,enzy|||Nitrogenase|||0|888|395|406
SE|59||ab|5|entity|C0441889|Levels|inpr|||levels|||0|888|407|413
SE|59||ab|5|entity|C0205314|New|tmco|||new|||0|872|421|424
SE|59||ab|5|entity|C0596988|Mutant|comd|||mutants|||0|872|425|432
SE|59||ab|5|entity|C0205250|High|qlco|||high|||0|1000|465|469
SE|59||ab|5|entity|C1151337|nitrogenase activity|moft|||nitrogenase activity|||0|1000|485|505

SE|59||ab|6|text|539|542|3.

SE|59||ab|7|text|542|667|Biochemical characterization of these nitrogen fixation (nif) derepressed mutants reveals that they fall into three classes.
SE|59||ab|7|entity|C0205474|Biochemical|ftcn|||Biochemical|||0|694|542|553
SE|59||ab|7|entity|C0028161|Nitrogen Fixation|orgf|||nitrogen fixation|||0|1000|580|597
SE|59||ab|7|entity|C0596988|Mutant|comd|||mutants|||0|966|616|623
SE|59||ab|7|entity|C0205449|Three|qnco|||three|||0|888|652|657
SE|59||ab|7|entity|C0456387|Class|inpr|||classes|||0|888|658|665

SE|59||ab|8|text|667|831|Three mutants (strains SK-24, 28 and 29), requiring glutamate for growth, synthesize nitrogenase and glutamine synthetase constitutively (in the presence of NH4+).
SE|59||ab|8|entity|C0205449|Three|qnco|||Three|||0|872|667|672
SE|59||ab|8|entity|C0596988|Mutant|comd|||mutants|||0|872|673|680
SE|59||ab|8|entity|C0017789|Glutamates|aapp|||glutamate|||0|1000|719|728
SE|59||ab|8|entity|C0018270|Growth|orgf|||growth|||0|1000|733|739
SE|59||ab|8|entity|C0028174|Nitrogenase|aapp,enzy|||nitrogenase|||0|1000|752|763
SE|59||ab|8|entity|C0017801|Glutamate-Ammonia Ligase|aapp,enzy|||glutamine synthetase|||0|901|768|788
SE|59||ab|8|relation|3|1|C0018270|Growth|orgf|orgf|||growth|||0|1000|733|739|VERB|PRODUCES||741|751|4|1|C0017801|Glutamate-Ammonia Ligase|aapp,gngm,enzy|aapp|||glutamine synthetase|||0|901|768|788
SE|59||ab|8|relation|3|1|C0018270|Growth|orgf|orgf|||growth|||0|1000|733|739|VERB|PRODUCES||741|751|4|1|C0028174|Nitrogenase|aapp,gngm,enzy|enzy|||nitrogenase|||0|1000|752|763

SE|59||ab|9|text|831|1063|A second class of mutants (strains SK-27 and 37) requiring glutamine for growth produces derepressed levels of nitrogenase activity and synthesized catalytically inactive glutamine synthetase protein, as determined immunologically.
SE|59||ab|9|entity|C0457385|seconds|tmco|||second|||0|888|833|839
SE|59||ab|9|entity|C0008902|Classification|clas|||class|||0|888|840|845
SE|59||ab|9|entity|C0596988|Mutant|comd|||mutants|||0|966|849|856
SE|59||ab|9|entity|C1514872|Required|ftcn|||requiring|||0|872|880|889
SE|59||ab|9|entity|C0017797|Glutamine|aapp,bacs|||glutamine|||0|872|890|899
SE|59||ab|9|entity|C0018270|Growth|orgf|||growth|||0|1000|904|910
SE|59||ab|9|entity|C0441889|Levels|inpr|||levels|||0|861|932|938
SE|59||ab|9|entity|C1151337|nitrogenase activity|moft|||nitrogenase activity|||0|1000|942|962
SE|59||ab|9|entity|C0205254|Sedentary|fndg|||inactive|||0|798|993|1001
SE|59||ab|9|entity|C0017801|Glutamate-Ammonia Ligase|aapp,enzy|||glutamine synthetase|||0|798|1002|1022
SE|59||ab|9|entity|C0033684|Proteins|aapp,bacs|||protein|||0|798|1023|1030
SE|59||ab|9|relation|6|3|C0018270|Growth|orgf|orgf|||growth|||0|1000|904|910|VERB|PRODUCES||967|978|1|1|C0017801|Glutamate-Ammonia Ligase|aapp,gngm,enzy|enzy|||glutamine synthetase|||0|798|1002|1022

SE|59||ab|10|text|1063|1294|A third class of glutamine-requiring, nitrogenase-derepressed mutants (strain SK-25 and 26) synthesizes neither a catalytically active glutamine synthetase enzyme nor an immunologically cross-reactive glutamine synthetase protein.
SE|59||ab|10|entity|C0205437|Third|qnco|||third|||0|888|1065|1070
SE|59||ab|10|entity|C0008902|Classification|clas|||class|||0|888|1071|1076
SE|59||ab|10|entity|C0017797|Glutamine|aapp,bacs|||glutamine|||0|872|1080|1089
SE|59||ab|10|entity|C1514872|Required|ftcn|||requiring|||0|872|1090|1099
SE|59||ab|10|entity|C0028174|Nitrogenase|aapp,enzy|||nitrogenase|||0|785|1101|1112
SE|59||ab|10|entity|C0596988|Mutant|comd|||mutants|||0|785|1125|1132
SE|59||ab|10|entity|C0456178|Microbiology subtype strains|inpr|||strain|||0|827|1134|1140
SE|59||ab|10|entity|C0205177|Active|ftcn|||active|||0|798|1191|1197
SE|59||ab|10|entity|C0017801|Glutamate-Ammonia Ligase|aapp,enzy|||glutamine synthetase|||0|798|1198|1218
SE|59||ab|10|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|798|1219|1225
SE|59||ab|10|entity|C0205332|Reactive|qlco|||reactive|||0|762|1255|1263
SE|59||ab|10|entity|C0017801|Glutamate-Ammonia Ligase|aapp,enzy|||glutamine synthetase|||0|762|1264|1284
SE|59||ab|10|entity|C0033684|Proteins|aapp,bacs|||protein|||0|762|1285|1292

SE|59||ab|11|text|1294|1297|4.

SE|59||ab|12|text|1297|1487|F-prime complementation analysis reveals that the mutant strains SK-25, 26, 27, 37 map in a segment of the Klebsiella chromosome corresponding to the region coding for glutamine synthetase.
SE|59||ab|12|entity|C0936012|Analysis|resa|||analysis|||0|812|1321|1329
SE|59||ab|12|entity|C0596988|Mutant|comd|||mutant|||0|1000|1347|1353
SE|59||ab|12|entity|C0024779|Maps|inpr,mnob|||map|||0|861|1380|1383
SE|59||ab|12|entity|C0441635|Anatomical segmentation|spco|||segment|||0|1000|1389|1396
SE|59||ab|12|entity|C0022727|Klebsiella|bact|||Klebsiella|||0|888|1404|1414
SE|59||ab|12|entity|C0008633|Chromosomes|celc|||chromosome|||0|888|1415|1425
SE|59||ab|12|entity|C0205147|Region|spco|||region|||0|888|1447|1453
SE|59||ab|12|entity|C0009219|Coding|ocac|||coding|||0|888|1454|1460
SE|59||ab|12|entity|C0017801|Glutamate-Ammonia Ligase|aapp,enzy|||glutamine synthetase|||0|1000|1465|1485

SE|59||ab|13|text|1487|1664|Since the mutant strains SK-27 and SK-37 produce inactive glutamine synthetase protein, it is concluded that these mutations map within the glutamine synthetase structural gene.
SE|59||ab|13|entity|C0596988|Mutant|comd|||mutant|||0|1000|1497|1503
SE|59||ab|13|entity|C0205254|Sedentary|fndg|||inactive|||0|861|1536|1544
SE|59||ab|13|entity|C0017801|Glutamate-Ammonia Ligase|aapp,enzy|||glutamine synthetase|||0|861|1545|1565
SE|59||ab|13|entity|C0033684|Proteins|aapp,bacs|||protein|||0|861|1566|1573
SE|59||ab|13|entity|C0026882|Mutation|genf|||mutations|||0|1000|1602|1611
SE|59||ab|13|entity|C0017801|Glutamate-Ammonia Ligase|aapp,enzy|||glutamine synthetase|||0|888|1627|1647
SE|59||ab|13|entity|C0017366|Structural gene|gngm|||structural gene|||0|888|1648|1663
SE|59||ab|13|relation|1|1|C0017366|Structural gene|gngm,aapp|gngm|||structural gene|||0|888|1648|1663|PREP|LOCATION_OF||1616|1622|3|1|C0026882|Mutation|genf|genf|||mutations|||0|1000|1602|1611
SE|59||ab|13|relation|1|1|C0596988|Mutant|comd|comd|||mutant|||0|1000|1497|1503|VERB|PRODUCES||1528|1535|3|1|C0017801|Glutamate-Ammonia Ligase|aapp,gngm,enzy|enzy|||glutamine synthetase|||0|861|1545|1565


SE|60||ti|1|text|15|83|The reaction between the superoxide anion radical and cytochrome c.
SE|60||ti|1|entity|C0443286|Reaction|ftcn|||reaction|||0|1000|19|27
SE|60||ti|1|entity|C0003075|Anions|elii|||anion|||0|901|51|56
SE|60||ti|1|entity|C0038836|Superoxides|elii|||superoxide anion radical|||0|901|40|64
SE|60||ti|1|entity|C0010749|CYTOCHROME C|aapp,enzy|||cytochrome c|||0|1000|69|81
SE|60||ti|1|relation|0|0|C0038836|Superoxides|elii|elii|||superoxide anion radical|||0|901|40|64|MOD/HEAD|ISA||51|64|0|0|C0003075|Anions|elii|elii|||anion|||0|901|51|56

SE|60||ab|1|text|89|92|1.

SE|60||ab|2|text|92|184|The superoxide anion radical (O2-) reacts with ferricytochrome c to form ferrocytochrome c.
SE|60||ab|2|entity|C0003075|Anions|elii|||anion|||0|901|107|112
SE|60||ab|2|entity|C0038836|Superoxides|elii|||superoxide anion radical|||0|901|96|120
SE|60||ab|2|entity|C0010749|CYTOCHROME C|aapp,enzy|||ferricytochrome c|||0|1000|139|156
SE|60||ab|2|entity|C0010749|CYTOCHROME C|aapp,enzy|||ferrocytochrome c|||0|1000|165|182
SE|60||ab|2|relation|0|0|C0038836|Superoxides|elii|elii|||superoxide anion radical|||0|901|96|120|MOD/HEAD|ISA||107|120|0|0|C0003075|Anions|elii|elii|||anion|||0|901|107|112

SE|60||ab|3|text|184|226|No intermediate complexes are observable.
SE|60||ab|3|entity|C0205103|Intermediate|spco|||intermediate|||0|888|187|199
SE|60||ab|3|entity|C0439855|Complex|qlco|||complexes|||0|888|200|209

SE|60||ab|4|text|226|291|No reaction could be detected between O2- and ferrocytochrome c.
SE|60||ab|4|entity|C0443286|Reaction|ftcn|||reaction|||0|1000|229|237
SE|60||ab|4|entity|C0010749|CYTOCHROME C|aapp,enzy|||ferrocytochrome c|||0|1000|272|289

SE|60||ab|5|text|291|294|2.

SE|60||ab|6|text|294|380|At 20 degrees C the rate constant for the reaction at pH 4.7 to 6.7 is 1.4-10(6) M-1.
SE|60||ab|6|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|300|309
SE|60||ab|6|entity|C1521828|Rate|qnco|||rate|||0|888|314|318
SE|60||ab|6|entity|C1547014|*Constant|qnco|||constant|||0|888|319|327
SE|60||ab|6|entity|C0443286|Reaction|ftcn|||reaction|||0|1000|336|344
SE|60||ab|6|entity|C0441923|M+|inpr|||M-1|||0|861|375|378

SE|60||ab|7|text|380|457|S -1 and as the pH increases above 6.7 the rate constant steadily decreases.
SE|60||ab|7|entity|C1521828|Rate|qnco|||rate|||0|764|423|427
SE|60||ab|7|entity|C1547014|*Constant|qnco|||constant|||0|764|428|436
SE|60||ab|7|entity|C0547047|Decrease|qnco|||decreases|||0|764|446|455

SE|60||ab|8|text|457|535|The dependence on pH is the same for tuna heart and horse heart cytochrome c.
SE|60||ab|8|entity|C0439857|Dependence|mobd|||dependence|||0|1000|461|471
SE|60||ab|8|entity|C0445247|Same|qlco|||same|||0|1000|485|489
SE|60||ab|8|entity|C0018787|Heart|bpoc|||heart|||0|861|499|504
SE|60||ab|8|entity|C0019944|Equus caballus|mamm|||horse|||0|861|509|514
SE|60||ab|8|entity|C0018787|Heart|bpoc|||heart|||0|861|515|520
SE|60||ab|8|entity|C0010749|CYTOCHROME C|aapp,enzy|||cytochrome c|||0|861|521|533
SE|60||ab|8|relation|0|0|C0010749|CYTOCHROME C|aapp,gngm,enzy|aapp|||cytochrome c|||0|861|521|533|MOD/HEAD|PART_OF||515|533|0|0|C0018787|Heart|bpoc|bpoc|||heart|||0|861|515|520

SE|60||ab|9|text|535|651|No reaction could be demonstrated between O2- and the form of cytochrome c which exists above pH approximately 9.2.
SE|60||ab|9|entity|C0443286|Reaction|ftcn|||reaction|||0|1000|538|546
SE|60||ab|9|entity|C1522492|Formation|ftcn|||form|||0|1000|589|593
SE|60||ab|9|entity|C0010749|CYTOCHROME C|aapp,enzy|||cytochrome c|||0|1000|597|609
SE|60||ab|9|entity|C0332232|Approximate|ftcn,qlco|||approximately|||0|750|632|645

SE|60||ab|10|text|651|932|The dependence of the rate constant on pH can be explained if cytochrome c has pKs of 7.45 and 9.2, and O2- reacts with the form present below pH 7.45 with k = 1.4-10(6) M-1 - S-1, the form above pH 7.45 with k = 3.0- 10(5) M-1 - S-1, and the form present above pH 9.2 with k = 0.
SE|60||ab|10|entity|C0439857|Dependence|mobd|||dependence|||0|1000|655|665
SE|60||ab|10|entity|C1521828|Rate|qnco|||rate|||0|888|673|677
SE|60||ab|10|entity|C1547014|*Constant|qnco|||constant|||0|888|678|686
SE|60||ab|10|entity|C0010749|CYTOCHROME C|aapp,enzy|||cytochrome c|||0|1000|713|725
SE|60||ab|10|entity|C0100762|A-RAF Protein Kinase|aapp,enzy|||pKs|||0|1000|730|733
SE|60||ab|10|entity|C1522492|Formation|ftcn|||form|||0|719|775|779
SE|60||ab|10|entity|C0150312|Present|qnco|||present|||0|719|780|787
SE|60||ab|10|entity|C0441923|M+|inpr|||M-1|||0|645|821|824
SE|60||ab|10|entity|C1522492|Formation|ftcn|||form|||0|1000|836|840
SE|60||ab|10|entity|C0441923|M+|inpr|||M-1|||0|645|875|878
SE|60||ab|10|entity|C1522492|Formation|ftcn|||form|||0|888|894|898
SE|60||ab|10|entity|C0150312|Present|qnco|||present|||0|888|899|906

SE|60||ab|11|text|932|935|3.

SE|60||ab|12|text|935|1079|The reaction has an activation energy of 20 kJ mol-1 and an enthalpy of activation at 25 degrees C of 18 kJ mol-1 both above and below pH 7.45.
SE|60||ab|12|entity|C0443286|Reaction|ftcn|||reaction|||0|1000|939|947
SE|60||ab|12|entity|C0424589|Vitality|fndg|||energy|||0|861|966|972
SE|60||ab|12|entity|C0027960|Nevus|neop|||mol|||0|750|982|985
SE|60||ab|12|entity|C0599530|enthalpy|qnco|||enthalpy|||0|1000|995|1003
SE|60||ab|12|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|1024|1033
SE|60||ab|12|entity|C0027960|Nevus|neop|||mol|||0|750|1043|1046
SE|60||ab|12|entity|C1282910|Upper|spco|||above|||0|1000|1054|1059
SE|60||ab|12|entity|C0542339|Inferior|spco|||below|||0|750|1064|1069

SE|60||ab|13|text|1079|1272|It is suggested that O2- may reduce cytochrome c through a track composed of aromatic amino acids, and that little protein rearrangement is required for the formation of the activated complex.
SE|60||ab|13|entity|C0010749|CYTOCHROME C|aapp,enzy|||cytochrome c|||0|1000|1115|1127
SE|60||ab|13|entity|C0040594|Track|mnob|||track|||0|1000|1138|1143
SE|60||ab|13|entity|C0301713|Amino Acids, Aromatic|aapp|||aromatic amino acids|||0|1000|1156|1176
SE|60||ab|13|entity|C0023882|Little's Disease|dsyn|||little|||0|623|1187|1193
SE|60||ab|13|entity|C0033684|Proteins|aapp,bacs|||protein|||0|623|1194|1201
SE|60||ab|13|entity|C1522492|Formation|ftcn|||formation|||0|1000|1236|1245
SE|60||ab|13|entity|C1515877|Activate|ftcn|||activated|||0|872|1253|1262
SE|60||ab|13|entity|C0439855|Complex|qlco|||complex|||0|872|1263|1270

SE|60||ab|14|text|1272|1275|4.

SE|60||ab|15|text|1275|1471|No reduction of ferricytochrome c by HO2 radicals could be demonstrated at pH 1.2-6.2 but at pH 5.3, HO2 radicals oxidize ferrocytochrome c with a rate constant of about 5-10(5)-5-10(6) M-1 - S-1.
SE|60||ab|15|entity|C0010749|CYTOCHROME C|aapp,enzy|||ferricytochrome c|||0|1000|1291|1308
SE|60||ab|15|entity|||gngm|3163|HMOX2|HO2|||0|1000|1312|1315
SE|60||ab|15|entity|C0601906|PH.3|phsu|||pH 5.3|||0|913|1368|1374
SE|60||ab|15|entity|||gngm|3163|HMOX2|HO2|||0|1000|1376|1379
SE|60||ab|15|entity|C0010749|CYTOCHROME C|aapp,enzy|||ferrocytochrome c|||0|1000|1397|1414
SE|60||ab|15|entity|C1521828|Rate|qnco|||rate|||0|888|1422|1426
SE|60||ab|15|entity|C1547014|*Constant|qnco|||constant|||0|888|1427|1435
SE|60||ab|15|entity|C0439084|>5|qnco|||5-10|||0|861|1453|1457
SE|60||ab|15|entity|C0441923|M+|inpr|||M-1|||0|645|1461|1464


SE|61||ti|1|text|15|173|Identification of the 120 mus phase in the decay of delayed fluorescence in spinach chloroplasts and subchloroplast particles as the intrinsic back reaction.
SE|61||ti|1|entity|C0026809|Mus|mamm|||mus|||0|790|41|44
SE|61||ti|1|entity|C0205390|Phase|tmco|||phase|||0|790|45|50
SE|61||ti|1|entity|C1265875|Disintegration|acab|||decay|||0|1000|58|63
SE|61||ti|1|entity|C0205421|Deferred|tmco|||delayed|||0|888|67|74
SE|61||ti|1|entity|C0016315|Fluorescence|npop|||fluorescence|||0|888|75|87
SE|61||ti|1|entity|C0008266|Chloroplasts|celc|||chloroplasts|||0|861|99|111
SE|61||ti|1|entity|C0597177|particle|chvs|||particles|||0|827|131|140
SE|61||ti|1|entity|C0205102|Intrinsic|spco|||intrinsic|||0|851|148|157
SE|61||ti|1|entity|C0004600|Back|blor|||back|||0|851|158|162
SE|61||ti|1|entity|C0443286|Reaction|ftcn|||reaction|||0|851|163|171
SE|61||ti|1|relation|3|1|C0008266|Chloroplasts|celc|celc|||chloroplasts|||0|861|99|111|PREP|LOCATION_OF||88|90|4|1|C0016315|Fluorescence|npop|npop|||fluorescence|||0|888|75|87

SE|61||ti|2|text|173|246|The dependence of the level of this phase on the thylakoids internal pH.
SE|61||ti|2|entity|C0439857|Dependence|mobd|||dependence|||0|1000|177|187
SE|61||ti|2|entity|C0205390|Phase|tmco|||phase|||0|1000|209|214
SE|61||ti|2|entity|C0751961|Thylakoids|celc|||thylakoids|||0|851|222|232
SE|61||ti|2|entity|C0205102|Intrinsic|spco|||internal|||0|851|233|241

SE|61||ab|1|text|252|489|After a 500 mus laser flash a 120 mus phase in the decay of delayed fluorescence is visible under a variety of circumstances in spinach chloroplasts and subchloroplast particles enriched in Photosystem II prepared by means of digitonin.
SE|61||ab|1|entity|C0026809|Mus|mamm|||mus|||0|790|264|267
SE|61||ab|1|entity|C0023089|Lasers|mnob|||laser|||0|790|268|273
SE|61||ab|1|entity|C0026809|Mus|mamm|||mus|||0|790|286|289
SE|61||ab|1|entity|C0205390|Phase|tmco|||phase|||0|790|290|295
SE|61||ab|1|entity|C1265875|Disintegration|acab|||decay|||0|1000|303|308
SE|61||ab|1|entity|C0205421|Deferred|tmco|||delayed|||0|888|312|319
SE|61||ab|1|entity|C0016315|Fluorescence|npop|||fluorescence|||0|888|320|332
SE|61||ab|1|entity|C0205379|Visible|qlco|||visible|||0|1000|336|343
SE|61||ab|1|entity|C0008266|Chloroplasts|celc|||chloroplasts|||0|861|388|400
SE|61||ab|1|entity|C0597177|particle|chvs|||particles|||0|827|420|429
SE|61||ab|1|entity|C0599132|Photosystem II|celc|||Photosystem II|||0|1000|442|456
SE|61||ab|1|entity|C0012256|Digitonin|carb,irda|||digitonin|||0|1000|478|487
SE|61||ab|1|relation|4|1|C0008266|Chloroplasts|celc|celc|||chloroplasts|||0|861|388|400|PREP|LOCATION_OF||377|379|7|4|C0016315|Fluorescence|npop|npop|||fluorescence|||0|888|320|332

SE|61||ab|2|text|489|604|The level of this phase is high in the case of inhibition of oxygen evolution at the donor side of Photosystem II.
SE|61||ab|2|entity|C0205390|Phase|tmco|||phase|||0|1000|507|512
SE|61||ab|2|entity|C0205250|High|qlco|||high|||0|1000|516|520
SE|61||ab|2|entity|C0030054|Oxygen|elii,phsu|||oxygen|||0|888|550|556
SE|61||ab|2|entity|C0015219|Evolution|genf|||evolution|||0|888|557|566
SE|61||ab|2|entity|C0441987|Side|spco|||side|||0|861|580|584
SE|61||ab|2|entity|C0599132|Photosystem II|celc|||Photosystem II|||0|1000|588|602

SE|61||ab|3|text|604|669|Comparison with the results of Babcock and Sauer (1975) Biochim.
SE|61||ab|3|entity|C1274040|result|ftcn|||results|||0|966|624|631

SE|61||ab|4|text|669|679|Bio-phys.
SE|61||ab|4|entity|C0205460|biological|ftcn|||Bio|||0|888|669|672
SE|61||ab|4|entity|C0205485|Physical|ftcn|||phys|||0|888|673|677

SE|61||ab|5|text|679|888|Acta 376, 329-344, indicates that their EPR signal IIf which they suppose to be due to Z+, the oxidized first secondary donor of Photosystem II, is well correlated with a large amplitude of our 120 mus phase.
SE|61||ab|5|entity|||gngm|2069|EREG|EPR|||0|1000|719|722
SE|61||ab|5|entity|C1279901|Firstly|qlco|||first|||0|583|783|788
SE|61||ab|5|entity|C1522484|metastatic qualifier|qnco|||secondary|||0|583|789|798
SE|61||ab|5|entity|C0599132|Photosystem II|celc|||Photosystem II|||0|1000|808|822
SE|61||ab|5|entity|C0205170|Good|qlco|||well|||0|1000|827|831
SE|61||ab|5|entity|C0549177|Large|qnco|||large|||0|694|850|855
SE|61||ab|5|entity|C0026809|Mus|mamm|||mus|||0|790|877|880
SE|61||ab|5|entity|C0205390|Phase|tmco|||phase|||0|790|881|886

SE|61||ab|6|text|888|1057|We explain our 120 mus phase by the intrinsic back reaction of the excited reaction center in the presence of Z+, as predicted by Van Gorkom and Donze (1973) Photochem.
SE|61||ab|6|entity|C0026809|Mus|mamm|||mus|||0|790|907|910
SE|61||ab|6|entity|C0205390|Phase|tmco|||phase|||0|790|911|916
SE|61||ab|6|entity|C0205102|Intrinsic|spco|||intrinsic|||0|851|924|933
SE|61||ab|6|entity|C0004600|Back|blor|||back|||0|851|934|938
SE|61||ab|6|entity|C0443286|Reaction|ftcn|||reaction|||0|851|939|947
SE|61||ab|6|entity|C0443286|Reaction|ftcn|||reaction|||0|790|963|971
SE|61||ab|6|entity|C0205099|Central|spco|||center|||0|790|972|978
SE|61||ab|6|entity|C0557775|Van|mnob|||Van|||0|694|1018|1021

SE|61||ab|7|text|1057|1068|Photobiol.

SE|61||ab|8|text|1068|1081|17, 333-342.

SE|61||ab|9|text|1081|1154|The redox state of Z+ is dependent on the internal pH of the thylakoids.
SE|61||ab|9|entity|C0030012|Oxidation-Reduction|npop|||redox state|||0|1000|1085|1096
SE|61||ab|9|entity|C0205102|Intrinsic|spco|||internal|||0|888|1123|1131
SE|61||ab|9|entity|C0751961|Thylakoids|celc|||thylakoids|||0|1000|1142|1152

SE|61||ab|10|text|1154|1254|The results on the effect of pH in the mus region are compared with those obtained in the ms region.
SE|61||ab|10|entity|C1274040|result|ftcn|||results|||0|966|1158|1165
SE|61||ab|10|entity|C1280500|Effect|qlco|||effect|||0|1000|1173|1179
SE|61||ab|10|entity|C0026809|Mus|mamm|||mus|||0|888|1193|1196
SE|61||ab|10|entity|C0205147|Region|spco|||region|||0|888|1197|1203
SE|61||ab|10|entity|C0205147|Region|spco|||region|||0|861|1247|1253


SE|62||ti|1|text|15|114|Light-induced changes of absorbance and electron spin resonance in small photosystem II particles.
SE|62||ti|1|entity|C0023693|Light|npop|||Light|||0|840|15|20
SE|62||ti|1|entity|C0205263|Induced|ftcn|||induced|||0|840|21|28
SE|62||ti|1|entity|C1268822|Optical density function|clna|||absorbance|||0|1000|40|50
SE|62||ti|1|entity|C0013852|Electrons|qnco|||electron|||0|840|55|63
SE|62||ti|1|entity|C0858625|Spinning|sosy|||spin|||0|840|64|68
SE|62||ti|1|entity|C0459800|Vibration - physical agent|npop|||resonance|||0|840|69|78
SE|62||ti|1|entity|C0700321|Small|qnco|||small|||0|850|82|87
SE|62||ti|1|entity|C0599132|Photosystem II|celc|||photosystem II|||0|850|88|102
SE|62||ti|1|entity|C0597177|particle|chvs|||particles|||0|850|103|112

SE|62||ab|1|text|120|234|Photosystem II reaction center components have been studied in small system II particles prepared with digitonin.
SE|62||ab|1|entity|C0080021|Photosystem II Reaction Center|aapp,bacs|||Photosystem II reaction center|||0|917|120|150
SE|62||ab|1|entity|C1524073|Component, LOINC Axis 1|clas|||components|||0|917|151|161
SE|62||ab|1|entity|C0700321|Small|qnco|||small|||0|764|183|188
SE|62||ab|1|entity|C0449913|System|ftcn|||system|||0|764|189|195
SE|62||ab|1|entity|C0597177|particle|chvs|||particles|||0|764|199|208
SE|62||ab|1|entity|C0012256|Digitonin|carb,irda|||digitonin|||0|1000|223|232

SE|62||ab|2|text|234|469|Upon illumination the reduction of the primary acceptor was indicated by absorbance changes due to the reduction of a plastoquinone to the semiquinone anion and by a small blue shifts of absorption bands near 545 nm (C550) and 685 nm.
SE|62||ab|2|entity|C0023693|Light|npop|||illumination|||0|1000|239|251
SE|62||ab|2|entity|C0000901|Acceptors|popg|||acceptor|||0|872|281|289
SE|62||ab|2|entity|C1268822|Optical density function|clna|||absorbance|||0|1000|307|317
SE|62||ab|2|entity|C0032169|Plastoquinone|bacs,orch|||plastoquinone|||0|1000|352|365
SE|62||ab|2|entity|C0074316|semiquinone radicals|orch|||semiquinone anion|||0|1000|373|390
SE|62||ab|2|entity|C0700321|Small|qnco|||small|||0|660|400|405
SE|62||ab|2|entity|C0175723|Bands|medd|||bands|||0|861|432|437

SE|62||ab|3|text|469|557|The semiquinone to chlorophyll ratio was between 1/20 and 1/70 in various preparations.
SE|62||ab|3|entity|C0597433|semiquinone|orch|||semiquinone|||0|1000|473|484
SE|62||ab|3|entity|C0008260|Chlorophyll|bacs,orch|||chlorophyll|||0|888|488|499
SE|62||ab|3|entity|C0456603|Ratio|inpr|||ratio|||0|888|500|505
SE|62||ab|3|entity|C1521827|Preparation|ftcn|||preparations|||0|827|543|555

SE|62||ab|4|text|557|852|The terminal electron donor in this reaction did not cause large absorbance changes but its oxidized form was revealed by a hitherto unknown electron spin resonance (ESR) signal, which had some properties of the well-known signal II but a linewidth and g-value much nearer to those of signal I.
SE|62||ab|4|entity|C0599915|electron donor|chvf|||electron donor|||0|901|570|584
SE|62||ab|4|entity|C0443286|Reaction|ftcn|||reaction|||0|1000|593|601
SE|62||ab|4|entity|C1518422|Not|ftcn|||not|||0|1000|606|609
SE|62||ab|4|entity|C0549177|Large|qnco|||large|||0|840|616|621
SE|62||ab|4|entity|C1268822|Optical density function|clna|||absorbance|||0|840|622|632
SE|62||ab|4|entity|C1522492|Formation|ftcn|||form|||0|861|658|662
SE|62||ab|4|entity|C0439673|Unknown|idcn|||unknown|||0|559|690|697
SE|62||ab|4|entity|C0013852|Electrons|qnco|||electron|||0|559|698|706
SE|62||ab|4|entity|C0858625|Spinning|sosy|||spin|||0|559|707|711
SE|62||ab|4|entity|C0459800|Vibration - physical agent|npop|||resonance|||0|559|712|721
SE|62||ab|4|entity|C0871161|Property|qlco|||properties|||0|966|751|761
SE|62||ab|4|entity|C0205170|Good|qlco|||well|||0|583|769|773
SE|62||ab|4|entity|C0205309|Known|qlco|||known|||0|583|774|779
SE|62||ab|4|entity|C0205107|Proximal|spco|||nearer|||0|966|823|829

SE|62||ab|5|text|852|1005|Upon darkening absorbance and ESR changes decayed together in a cyclic or back reaction which was stimulated by 3-(3,4 dichlorophenyl)-1,1-dimethylurea.
SE|62||ab|5|entity|C1268822|Optical density function|clna|||absorbance|||0|861|867|877
SE|62||ab|5|entity|C0013852|Electrons|qnco|||ESR|||0|816|882|885
SE|62||ab|5|entity|C0858625|Spinning|sosy|||ESR|||0|816|882|885
SE|62||ab|5|entity|C0459800|Vibration - physical agent|npop|||ESR|||0|816|882|885
SE|62||ab|5|entity|C0439596|Cyclical|tmco|||cyclic|||0|1000|916|922
SE|62||ab|5|entity|C0004600|Back|blor|||back|||0|888|926|930
SE|62||ab|5|entity|C0443286|Reaction|ftcn|||reaction|||0|888|931|939

SE|62||ab|6|text|1005|1062|The donor could be oxidized by ferricyanide in the dark.
SE|62||ab|6|entity|C0015864|Ferricyanides|inch|||ferricyanide|||0|1000|1036|1048

SE|62||ab|7|text|1062|1296|Illumination in the presence of ferricyanide induced absorbance and ESR changes, rapidly reversed upon darkening, which may be ascribed to the oxidation of a chlorophyll a dimer, possibly the primary electron donor of photosystem II.
SE|62||ab|7|entity|C0023693|Light|npop|||Illumination|||0|1000|1062|1074
SE|62||ab|7|entity|C0015864|Ferricyanides|inch|||ferricyanide|||0|851|1094|1106
SE|62||ab|7|entity|C0205263|Induced|ftcn|||induced|||0|851|1107|1114
SE|62||ab|7|entity|C1268822|Optical density function|clna|||absorbance|||0|851|1115|1125
SE|62||ab|7|entity|C0013852|Electrons|qnco|||ESR|||0|816|1130|1133
SE|62||ab|7|entity|C0858625|Spinning|sosy|||ESR|||0|816|1130|1133
SE|62||ab|7|entity|C0459800|Vibration - physical agent|npop|||ESR|||0|816|1130|1133
SE|62||ab|7|entity|C0030011|Oxidation|phpr|||oxidation|||0|1000|1205|1214
SE|62||ab|7|entity|C0008260|Chlorophyll|bacs,orch|||chlorophyll|||0|1000|1220|1231
SE|62||ab|7|entity|C0596448|dimer|chvs|||dimer|||0|1000|1234|1239
SE|62||ab|7|entity|C0332149|Possible|qlco|||possibly|||0|1000|1241|1249
SE|62||ab|7|entity|C0599915|electron donor|chvf|||electron donor|||0|901|1262|1276
SE|62||ab|7|entity|C0599132|Photosystem II|celc|||photosystem II|||0|1000|1280|1294
SE|62||ab|7|relation|4|2|C0596448|dimer|chvs|chvs|||dimer|||0|1000|1234|1239|NOM|INTERACTS_WITH||1205|1214|4|1|C0008260|Chlorophyll|bacs,orch|bacs|||chlorophyll|||0|1000|1220|1231

SE|62||ab|8|text|1296|1438|In addition an ESR signal with 15 to 20 gauss linewidth and a slower dark decay was observed, which may have been caused by a secondary donor.
SE|62||ab|8|entity|C0013852|Electrons|qnco|||ESR|||0|597|1311|1314
SE|62||ab|8|entity|C0858625|Spinning|sosy|||ESR|||0|597|1311|1314
SE|62||ab|8|entity|C0459800|Vibration - physical agent|npop|||ESR|||0|597|1311|1314
SE|62||ab|8|entity|C1551088|Gauss|qnco|||gauss|||0|660|1336|1341
SE|62||ab|8|entity|C0439834|Slow|qlco|||slower|||0|785|1358|1364
SE|62||ab|8|entity|C1265875|Disintegration|acab|||decay|||0|785|1370|1375
SE|62||ab|8|entity|C1522484|metastatic qualifier|qnco|||secondary|||0|694|1422|1431


SE|63||ti|1|text|15|91|Enzymic reactions of fatty acid hydroperoxides in extracts of potato tuber.
SE|63||ti|1|entity|C0443286|Reaction|ftcn|||reactions|||0|827|23|32
SE|63||ti|1|entity|C0015684|Fatty Acids|bacs,lipd|||fatty acid|||0|884|36|46
SE|63||ti|1|entity|C0020281|Hydrogen Peroxide|inch,irda,phsu|||hydroperoxides|||0|884|47|61
SE|63||ti|1|entity|C1555707|extract|idcn|||extracts|||0|966|65|73
SE|63||ti|1|entity|C0032846|Potato|food|||potato|||0|888|77|83
SE|63||ti|1|entity|C0319634|Tuber|fngs|||tuber|||0|888|84|89

SE|63||ti|2|text|91|95|II.

SE|63||ti|3|text|95|237|Conversion of 9- and 13-hydroperoxy-octadecadienoic acids to monohydroxydienoic acid, epoxyhydroxy- and trihydroxymonoenoic acid derivatives.
SE|63||ti|3|entity|C0439836|Conversions|spco|||Conversion|||0|966|95|105
SE|63||ti|3|entity|C0069315|octadecadienoic acid|lipd|||octadecadienoic acids|||0|844|131|152
SE|63||ti|3|entity|C0001128|Acids|chem|||acid|||0|861|175|179
SE|63||ti|3|entity|C0001128|Acids|chem|||acid|||0|790|219|223
SE|63||ti|3|entity|C0243072|derivatives|chvs|||derivatives|||0|790|224|235

SE|63||ab|1|text|243|246|1.

SE|63||ab|2|text|246|440|Crude extracts and partially purified enzyme preparations from potato tubers catalyse, at pH 5-7, the conversion of linoleic acid hydroperoxides to a range of oxygenated fatty acid derivatives.
SE|63||ab|2|entity|C1258023|Complex Extracts|chem|||Crude extracts|||0|1000|246|260
SE|63||ab|2|entity|C0360722|Enzyme agent|aapp,enzy,phsu|||enzyme preparations|||0|861|284|303
SE|63||ab|2|entity|C0032846|Potato|food|||potato|||0|888|309|315
SE|63||ab|2|entity|C0319634|Tuber|fngs|||tubers|||0|888|316|322
SE|63||ab|2|entity|C0439836|Conversions|spco|||conversion|||0|966|348|358
SE|63||ab|2|entity|C0065015|linoleic acid hydroperoxide|lipd|||linoleic acid hydroperoxides|||0|983|362|390
SE|63||ab|2|entity|C1514721|Range|qnco|||range|||0|1000|396|401
SE|63||ab|2|entity|C0015684|Fatty Acids|bacs,lipd|||fatty acid|||0|824|416|426
SE|63||ab|2|entity|C0243072|derivatives|chvs|||derivatives|||0|824|427|438
SE|63||ab|2|relation|3|2|C0360722|Enzyme agent|aapp,gngm,enzy,phsu|aapp|||enzyme preparations|||0|861|284|303|NOM|INTERACTS_WITH||348|358|3|1|C0065015|linoleic acid hydroperoxide|lipd|lipd|||linoleic acid hydroperoxides|||0|983|362|390
SE|63||ab|2|relation|3|2|C1258023|Complex Extracts|chem|chem|||Crude extracts|||0|1000|246|260|NOM|INTERACTS_WITH||348|358|3|1|C0065015|linoleic acid hydroperoxide|lipd|lipd|||linoleic acid hydroperoxides|||0|983|362|390
SE|63||ab|2|relation|5|1|C0319634|Tuber|fngs|fngs|||tubers|||0|888|316|322|PREP|LOCATION_OF||304|308|2|1|C0360722|Enzyme agent|aapp,gngm,enzy,phsu|aapp|||enzyme preparations|||0|861|284|303

SE|63||ab|3|text|440|443|2.

SE|63||ab|4|text|443|545|9-D- and 13-L-hydroperoxide isomers are converted at similar rates to equivalent (isomeric) products.
SE|63||ab|4|entity|C0020281|Hydrogen Peroxide|inch,irda,phsu|||hydroperoxide|||0|733|457|470
SE|63||ab|4|entity|C0022203|Isomerism|npop|||isomers|||0|733|471|478
SE|63||ab|4|entity|C1521828|Rate|qnco|||rates|||0|836|504|509
SE|63||ab|4|entity|C0439185|Eq|qnco|||equivalent|||0|1000|513|523
SE|63||ab|4|entity|C0022203|Isomerism|npop|||isomeric|||0|928|525|533
SE|63||ab|4|entity|C1514468|product|qnco|||products|||0|966|535|543

SE|63||ab|5|text|545|548|3.

SE|63||ab|6|text|548|782|The major products from the 13-hydroperoxide isomer were identified as the corresponding monohydroxydienoic acid derivative, threo-11-hydroxy-trans12,13-epoxy-octadec-cis9-enoic acid and 9,12,13-trihydroxy-octadec-trans10-enoic acid.
SE|63||ab|6|entity|C0205164|Major|qlco|||major|||0|872|552|557
SE|63||ab|6|entity|C1514468|product|qnco|||products|||0|872|558|566
SE|63||ab|6|entity|C0020281|Hydrogen Peroxide|inch,irda,phsu|||hydroperoxide|||0|790|579|592
SE|63||ab|6|entity|C0022203|Isomerism|npop|||isomer|||0|790|593|599
SE|63||ab|6|entity|C0001128|Acids|chem|||acid|||0|750|656|660
SE|63||ab|6|entity|C1527240|Derivative|ftcn|||derivative|||0|750|661|671
SE|63||ab|6|entity|C0001128|Acids|chem|||acid|||0|799|726|730
SE|63||ab|6|entity|C0001128|Acids|chem|||acid|||0|799|776|780

SE|63||ab|7|text|782|958|The corresponding products from the 9-hydroperoxide were the monohydroxydienoic acid, 9,10-epoxy-11-hydroxy-octadec-12-enoic acid and 9,10,13-trihydroxy-octadec-11-enoic acid.
SE|63||ab|7|entity|C1514468|product|qnco|||products|||0|827|800|808
SE|63||ab|7|entity|C0020281|Hydrogen Peroxide|inch,irda,phsu|||hydroperoxide|||0|861|820|833
SE|63||ab|7|entity|C0001128|Acids|chem|||acid|||0|861|862|866
SE|63||ab|7|entity|C0020317|Hydroxy Acids|orch|||hydroxy-octadec-12-enoic acid|||0|834|882|911
SE|63||ab|7|entity|C0001128|Acids|chem|||acid|||0|799|952|956

SE|63||ab|8|text|958|961|4.

SE|63||ab|9|text|961|1077|No separation of activities forming the different products was achieved by partial purification of enzyme extracts.
SE|63||ab|9|entity|C0036679|Diastasis|patf|||separation|||0|1000|964|974
SE|63||ab|9|entity|C0441655|Activities|acty|||activities|||0|1000|978|988
SE|63||ab|9|entity|C1547020|*Difference|qnco|||different|||0|836|1001|1010
SE|63||ab|9|entity|C1514468|product|qnco|||products|||0|836|1011|1019
SE|63||ab|9|entity|C0728938|Partial|qnco|||partial|||0|888|1036|1043
SE|63||ab|9|entity|C0243114|purification|lbpr,resa|||purification|||0|888|1044|1056
SE|63||ab|9|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|872|1060|1066
SE|63||ab|9|entity|C1555707|extract|idcn|||extracts|||0|872|1067|1075

SE|63||ab|10|text|1077|1080|5.

SE|63||ab|11|text|1080|1203|Product formation was unaffected by EDTA, CN-, sulphydryl reagents or glutathione but was reduced by boiling the extracts.
SE|63||ab|11|entity|C1514468|product|qnco|||Product|||0|888|1080|1087
SE|63||ab|11|entity|C1522492|Formation|ftcn|||formation|||0|888|1088|1097
SE|63||ab|11|entity|C0013618|Edetic Acid|irda,orch,phsu|||EDTA|||0|1000|1116|1120
SE|63||ab|11|entity|C0038738|Sulfhydryl Reagents|irda,phsu|||sulphydryl reagents|||0|1000|1127|1146
SE|63||ab|11|entity|C0017817|Glutathione|aapp,bacs|||glutathione|||0|1000|1150|1161
SE|63||ab|11|entity|C0242301|furuncle|dsyn|||boiling|||0|966|1181|1188
SE|63||ab|11|entity|C1555707|extract|idcn|||extracts|||0|966|1193|1201

SE|63||ab|12|text|1203|1206|6.

SE|63||ab|13|text|1206|1330|This system is compared with the 9-hydroperoxide-specific enzymic formation of divinyl ether derivatives by potato extracts.
SE|63||ab|13|entity|C0449913|System|ftcn|||system|||0|1000|1211|1217
SE|63||ab|13|entity|C0020281|Hydrogen Peroxide|inch,irda,phsu|||hydroperoxide|||0|764|1241|1254
SE|63||ab|13|entity|C1522492|Formation|ftcn|||formation|||0|764|1272|1281
SE|63||ab|13|entity|C0078264|vinyl ether|orch,phsu|||divinyl ether|||0|901|1285|1298
SE|63||ab|13|entity|C0243072|derivatives|chvs|||derivatives|||0|901|1299|1310
SE|63||ab|13|entity|C0032846|Potato|food|||potato|||0|872|1314|1320
SE|63||ab|13|entity|C1555707|extract|idcn|||extracts|||0|872|1321|1329


SE|64||ti|1|text|15|112|Partial purification and properties of microsomal phosphatidate phosphohydrolase from rat liver.
SE|64||ti|1|entity|C0728938|Partial|qnco|||Partial|||0|888|15|22
SE|64||ti|1|entity|C0243114|purification|lbpr,resa|||purification|||0|888|23|35
SE|64||ti|1|entity|C0871161|Property|qlco|||properties|||0|966|40|50
SE|64||ti|1|entity|C0026029|Microsomes|celc|||microsomal|||0|865|54|64
SE|64||ti|1|entity|C0031607|Phosphatidate Phosphatase|aapp,enzy|||phosphatidate phosphohydrolase|||0|865|65|95
SE|64||ti|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|888|101|104
SE|64||ti|1|entity|C0023884|Liver|bpoc|||liver|||0|888|105|110
SE|64||ti|1|relation|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|888|105|110|MOD/HEAD|PART_OF||101|110|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|888|101|104
SE|64||ti|1|relation|0|0|C0031607|Phosphatidate Phosphatase|aapp,gngm,enzy|aapp|||phosphatidate phosphohydrolase|||0|865|65|95|MOD/HEAD|PART_OF||54|95|0|0|C0026029|Microsomes|celc|celc|||microsomal|||0|865|54|64
SE|64||ti|1|relation|1|1|C0023884|Liver|bpoc|bpoc|||liver|||0|888|105|110|PREP|LOCATION_OF||96|100|3|1|C0031607|Phosphatidate Phosphatase|aapp,gngm,enzy|aapp|||phosphatidate phosphohydrolase|||0|865|65|95

SE|64||ab|1|text|118|295|Microsomal phosphatidate phosphohydrolase (phosphatidate phosphatase EC 3.1.3.4) was solubilized and fractionated to yield at least two distinct enzymatically active fractions.
SE|64||ab|1|entity|C0026029|Microsomes|celc|||Microsomal|||0|865|118|128
SE|64||ab|1|entity|C0031607|Phosphatidate Phosphatase|aapp,enzy|||phosphatidate phosphohydrolase|||0|865|129|159
SE|64||ab|1|entity|C0031607|Phosphatidate Phosphatase|aapp,enzy|||phosphatidate phosphatase|||0|747|161|186
SE|64||ab|1|entity|C0205448|Two|qnco|||two|||0|737|250|253
SE|64||ab|1|entity|C0205177|Active|ftcn|||active|||0|737|277|283
SE|64||ab|1|entity|C1264633|Fraction of|qnco|||fractions|||0|737|284|293
SE|64||ab|1|relation|0|0|C0031607|Phosphatidate Phosphatase|aapp,gngm,enzy|aapp|||phosphatidate phosphohydrolase|||0|865|129|159|MOD/HEAD|PART_OF||118|159|0|0|C0026029|Microsomes|celc|celc|||Microsomal|||0|865|118|128

SE|64||ab|2|text|295|430|One, denoted FA, was non-specific, had a relatively high Km for phosphatidic acid and was insensitive to inhibition by diacylglycerol.
SE|64||ab|2|entity|C0205447|One|qnco|||One|||0|1000|295|298
SE|64||ab|2|entity|C0205370|Unspecified|qlco|||non-specific|||0|1000|316|328
SE|64||ab|2|entity|C0205250|High|qlco|||high|||0|790|347|351
SE|64||ab|2|entity|C0031610|Phosphatidic Acid|lipd|||phosphatidic acid|||0|1000|359|376
SE|64||ab|2|entity|C0237677|Insensitivity|menp|||insensitive|||0|928|385|396
SE|64||ab|2|entity|C0043791|1,2-diacylglycerol|bacs,lipd,orch,phsu|||diacylglycerol|||0|1000|414|428

SE|64||ab|3|text|430|559|The second fraction, FB, was specific for phosphatidates, had a low Km, and was inhibited, non-competitively, by diacylglycerol.
SE|64||ab|3|entity|C0457385|seconds|tmco|||second|||0|694|434|440
SE|64||ab|3|entity|C0205251|low|qlco|||low|||0|888|494|497
SE|64||ab|3|entity|C0043791|1,2-diacylglycerol|bacs,lipd,orch,phsu|||diacylglycerol|||0|1000|543|557

SE|64||ab|4|text|559|608|FA exhibited a sigmoid substrate-activity curve.
SE|64||ab|4|entity|C0205134|Curved|spco|||curve|||0|714|601|606

SE|64||ab|5|text|608|835|The isolated FB aggregated to particles of about 10(6) in the absence of salts and could be dissociated by the addition of monovalent cations at ionic strength 0.4-0.6 to about 2-10(5) daltons and thereby doubled its activity.
SE|64||ab|5|entity|C0205409|Isolated|ftcn|||isolated|||0|888|612|620
SE|64||ab|5|entity|C0597177|particle|chvs|||particles|||0|966|638|647
SE|64||ab|5|entity|C0036140|Salts|chvs|||salts|||0|1000|681|686
SE|64||ab|5|entity|C0442796|Additive|qlco|||addition|||0|928|719|727
SE|64||ab|5|entity|C0007449|Cations, Monovalent|chvs|||monovalent cations|||0|1000|731|749
SE|64||ab|5|entity|C0086486|Ionic Strength|lbtr|||ionic strength|||0|827|753|767
SE|64||ab|5|entity|C0678223|dalton|qnco|||daltons|||0|966|793|800

SE|64||ab|6|text|835|885|Dissociation was time- and temperature-dependent.
SE|64||ab|6|entity|C0086168|Dissociation|mobd|||Dissociation|||0|1000|835|847
SE|64||ab|6|entity|C0040223|Time|tmco|||time|||0|1000|852|856
SE|64||ab|6|entity|C0039476|Temperature|qnco|||temperature|||0|888|862|873

SE|64||ab|7|text|885|904|F- was inhibitory.
SE|64||ab|7|entity|C0243077|inhibitors|chvf|||inhibitory|||0|928|892|902

SE|64||ab|8|text|904|1012|Divalent ions were not required for the activity of FA or FB and inhibited at concentrations exceeding 1 mM.
SE|64||ab|8|entity|C0022023|Ions|elii|||ions|||0|861|913|917
SE|64||ab|8|entity|C1518422|Not|ftcn|||not|||0|1000|923|926


SE|65||ti|1|text|15|27|Bile acids.
SE|65||ti|1|entity|C0005390|Bile Acids|bacs,strd|||Bile acids|||0|1000|15|25

SE|65||ti|2|text|27|34|XLVII.

SE|65||ti|3|text|34|117|12alpha-Hydroxylation of precursors of allo bile acids by rabbit liver microsomes.
SE|65||ti|3|entity|C0020365|Hydroxylation|npop|||Hydroxylation|||0|861|42|55
SE|65||ti|3|entity|C0005390|Bile Acids|bacs,strd|||bile acids|||0|901|78|88
SE|65||ti|3|entity|C0034493|Oryctolagus cuniculus|mamm|||rabbit|||0|901|92|98
SE|65||ti|3|entity|C0026030|Microsomes, Liver|celc|||liver microsomes|||0|901|99|115
SE|65||ti|3|relation|0|0|C0026030|Microsomes, Liver|celc|celc|||liver microsomes|||0|901|99|115|MOD/HEAD|PART_OF||92|115|0|0|C0034493|Oryctolagus cuniculus|mamm|mamm|||rabbit|||0|901|92|98

SE|65||ab|1|text|123|422|Rabbit liver microsomal preparations fortified with 0.1 mM NADPH effectively promote hydroxylation of [3beta-3H]- or [24-14C]allochenodeoxycholic acid or [5alpha,6alpha-3H2]5alpha-cholestane-3alpha,7alpha-diol to their respective 12alpha-hydroxyl derivatives in yields of about 25 or 65% in 60 min.
SE|65||ab|1|entity|C0034493|Oryctolagus cuniculus|mamm|||Rabbit|||0|834|123|129
SE|65||ab|1|entity|C0026029|Microsomes|celc|||microsomal|||0|834|136|146
SE|65||ab|1|entity|C0023899|Liver Extract|orch,phsu|||liver microsomal preparations|||0|834|130|159
SE|65||ab|1|entity|C0027303|NADP|bacs,nnon|||NADPH|||0|750|182|187
SE|65||ab|1|entity|C0020365|Hydroxylation|npop|||hydroxylation|||0|1000|208|221
SE|65||ab|1|entity|C0001128|Acids|chem|||acid|||0|861|269|273
SE|65||ab|1|entity|C0008366|Cholestanes|strd|||cholestane|||0|627|303|313
SE|65||ab|1|entity|C0017945|Glycol|orch|||diol|||0|861|328|332
SE|65||ab|1|entity|C0243072|derivatives|chvs|||derivatives|||0|812|370|381
SE|65||ab|1|entity|C0439232|Minute of time|tmco|||min|||0|861|417|420
SE|65||ab|1|relation|0|0|C0026029|Microsomes|celc|celc|||microsomal|||0|834|136|146|MOD/HEAD|LOCATION_OF||136|159|0|0|C0023899|Liver Extract|orch,phsu|orch|||liver microsomal preparations|||0|834|130|159
SE|65||ab|1|relation|2|1|C0027303|NADP|bacs,nnon|bacs|||NADPH|||0|750|182|187|VERB|AUGMENTS||200|207|11|1|C0020365|Hydroxylation|npop|npop|||hydroxylation|||0|1000|208|221

SE|65||ab|2|text|422|480|Minor amounts of other products are formed from the diol.
SE|65||ab|2|entity|C1265611|Quantity|qnco|||amounts|||0|872|428|435
SE|65||ab|2|entity|C1514468|product|qnco|||products|||0|966|445|453
SE|65||ab|2|entity|C0017945|Glycol|orch|||diol|||0|1000|474|478

SE|65||ab|3|text|480|597|The requirements for activity of rabbit liver microsomal 12alpha-hydroxylase resemble those of rat liver microsomes.
SE|65||ab|3|entity|C1514873|Requirement|idcn|||requirements|||0|966|484|496
SE|65||ab|3|entity|C0034493|Oryctolagus cuniculus|mamm|||rabbit|||0|843|513|519
SE|65||ab|3|entity|C0026030|Microsomes, Liver|celc|||liver microsomal|||0|843|520|536
SE|65||ab|3|entity|C0038315|Sterol 12-alpha-Hydroxylase|aapp,enzy|||12alpha-hydroxylase|||0|843|537|556
SE|65||ab|3|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|901|575|578
SE|65||ab|3|entity|C0026030|Microsomes, Liver|celc|||liver microsomes|||0|901|579|595
SE|65||ab|3|relation|0|0|C0026030|Microsomes, Liver|celc|celc|||liver microsomes|||0|901|579|595|MOD/HEAD|PART_OF||575|595|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|901|575|578

SE|65||ab|4|text|597|754|Of a number of enzyme inhibitors studied only p-chloromercuribenzoate demonstrated a marked ability to inhibit the reaction with either tritiated substrate.
SE|65||ab|4|entity|C0014432|Enzyme Inhibitors|phsu|||enzyme inhibitors|||0|1000|612|629
SE|65||ab|4|entity|C0008247|Chloromercuribenzoates|irda,orch|||chloromercuribenzoate|||0|773|645|666
SE|65||ab|4|entity|C0522501|Massive|qlco|||marked|||0|888|682|688
SE|65||ab|4|entity|C0085732|Ability|orga|||ability|||0|888|689|696
SE|65||ab|4|entity|C0443286|Reaction|ftcn|||reaction|||0|1000|712|720

SE|65||ab|5|text|754|863|There was no difference in the quantity of product produced from the tritiated acid or the 14C-labeled acid.
SE|65||ab|5|entity|C1547020|*Difference|qnco|||difference|||0|1000|767|777
SE|65||ab|5|entity|C1265611|Quantity|qnco|||quantity|||0|1000|785|793
SE|65||ab|5|entity|C1514468|product|qnco|||product|||0|1000|797|804
SE|65||ab|5|entity|C0001128|Acids|chem|||acid|||0|861|833|837
SE|65||ab|5|entity|C0181496|Labels|mnob|||labeled|||0|773|849|856
SE|65||ab|5|entity|C0001128|Acids|chem|||acid|||0|773|857|861

SE|65||ab|6|text|863|1026|No clear sex difference was found in activity of the enzyme, nor was an appreciable difference noted in activity of the enzyme between mature and immature animals.
SE|65||ab|6|entity|C0522503|Translucent|qlco|||clear|||0|901|866|871
SE|65||ab|6|entity|C0036866|Sex Characteristics|orga|||sex difference|||0|901|872|886
SE|65||ab|6|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|916|922
SE|65||ab|6|entity|C1547020|*Difference|qnco|||difference|||0|861|947|957
SE|65||ab|6|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|983|989
SE|65||ab|6|entity|C0205286|Mature|tmco|||mature|||0|1000|998|1004
SE|65||ab|6|entity|C0596750|immature animal|orga|||immature animals|||0|983|1009|1025


SE|66||ti|1|text|15|115|Partial purification and properties of a phenobarbital-induced aldehyde dehydrogenase of rat liver.
SE|66||ti|1|entity|C0728938|Partial|qnco|||Partial|||0|888|15|22
SE|66||ti|1|entity|C0243114|purification|lbpr,resa|||purification|||0|888|23|35
SE|66||ti|1|entity|C0871161|Property|qlco|||properties|||0|966|40|50
SE|66||ti|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital|||0|861|56|69
SE|66||ti|1|entity|C0205263|Induced|ftcn|||induced|||0|861|70|77
SE|66||ti|1|entity|C0684287|aldehyde dehydrogenases|aapp,enzy|||aldehyde dehydrogenase|||0|861|78|100
SE|66||ti|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|888|104|107
SE|66||ti|1|entity|C0023884|Liver|bpoc|||liver|||0|888|108|113
SE|66||ti|1|relation|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|888|108|113|MOD/HEAD|PART_OF||104|113|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|888|104|107
SE|66||ti|1|relation|2|0|C0031412|Phenobarbital|orch,phsu|orch|||phenobarbital|||0|861|56|69|ADJ|STIMULATES||70|77|2|0|C0684287|aldehyde dehydrogenases|aapp,gngm,enzy|gngm|||aldehyde dehydrogenase|||0|861|78|100
SE|66||ti|1|relation|3|1|C0684287|aldehyde dehydrogenases|aapp,gngm,enzy|aapp|||aldehyde dehydrogenase|||0|861|78|100|PREP|PART_OF||101|103|1|1|C0023884|Liver|bpoc|bpoc|||liver|||0|888|108|113

SE|66||ab|1|text|121|241|Properties of the phenobarbital induced cytoplasmic aldehyde dehydrogenase (EC 1.2.1.3) have been studied in rat liver.
SE|66||ab|1|entity|C0871161|Property|qlco|||Properties|||0|966|121|131
SE|66||ab|1|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital|||0|1000|139|152
SE|66||ab|1|entity|C0521449|Cytoplasmic|blor|||cytoplasmic|||0|901|161|172
SE|66||ab|1|entity|C0684287|aldehyde dehydrogenases|aapp,enzy|||aldehyde dehydrogenase|||0|901|173|195
SE|66||ab|1|entity|C0040676|Transferase|aapp,enzy|||EC 1.2|||0|853|197|203
SE|66||ab|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|888|230|233
SE|66||ab|1|entity|C0023884|Liver|bpoc|||liver|||0|888|234|239
SE|66||ab|1|relation|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|888|234|239|MOD/HEAD|PART_OF||230|239|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|888|230|233
SE|66||ab|1|relation|0|0|C0684287|aldehyde dehydrogenases|aapp,gngm,enzy|gngm|||aldehyde dehydrogenase|||0|901|173|195|MOD/HEAD|PART_OF||161|195|0|0|C0521449|Cytoplasmic|blor|blor|||cytoplasmic|||0|901|161|172
SE|66||ab|1|relation|2|1|C0031412|Phenobarbital|orch,phsu|orch|||phenobarbital|||0|1000|139|152|VERB|STIMULATES||153|160|2|1|C0684287|aldehyde dehydrogenases|aapp,gngm,enzy|gngm|||aldehyde dehydrogenase|||0|901|173|195

SE|66||ab|2|text|241|455|7-12-Fold higher levels were seen in the cytoplasmic activities after phenobarbital treatment in reactor compared to non-reactor animals with high concentrations of acetaldehyde (18 mM) and propionaldehyde (9 mM).
SE|66||ab|2|entity|C0332462|Fold|spco|||Fold|||0|725|246|250
SE|66||ab|2|entity|C0205250|High|qlco|||higher|||0|725|251|257
SE|66||ab|2|entity|C0441889|Levels|inpr|||levels|||0|725|258|264
SE|66||ab|2|entity|C0521449|Cytoplasmic|blor|||cytoplasmic|||0|888|282|293
SE|66||ab|2|entity|C0441655|Activities|acty|||activities|||0|888|294|304
SE|66||ab|2|entity|C0747568|PHENOBARBITAL TREATMENT|topp|||phenobarbital treatment|||0|1000|311|334
SE|66||ab|2|entity|C0003062|Animals|anim|||animals|||0|827|370|377
SE|66||ab|2|entity|C0205250|High|qlco|||high|||0|888|383|387
SE|66||ab|2|entity|C0000966|Acetaldehyde|orch|||acetaldehyde|||0|1000|406|418
SE|66||ab|2|entity|C0072184|propionaldehyde|hops,orch|||propionaldehyde|||0|1000|431|446
SE|66||ab|2|relation|6|3|C0000966|Acetaldehyde|orch|orch|||acetaldehyde|||0|1000|406|418|VERB|compared_with||346|354|6|5|C0072184|propionaldehyde|hops,orch|hops|||propionaldehyde|||0|1000|431|446

SE|66||ab|3|text|455|573|No difference was found with 0.12 mM acetaldehyde, 2 mM glycolaldehyde, 6 mM formaldehyde or 0.5 mM betaine aldehyde.
SE|66||ab|3|entity|C1547020|*Difference|qnco|||difference|||0|1000|458|468
SE|66||ab|3|entity|C0000966|Acetaldehyde|orch|||acetaldehyde|||0|750|492|504
SE|66||ab|3|entity|C0061633|glycolaldehyde|bacs,orch|||glycolaldehyde|||0|790|511|525
SE|66||ab|3|entity|C0016564|Formaldehyde|hops,orch|||formaldehyde|||0|790|532|544
SE|66||ab|3|entity|C0444499|0/5|qnco|||0.5|||0|857|548|551
SE|66||ab|3|entity|C0053516|betaine aldehyde|orch|||betaine aldehyde|||0|857|555|571

SE|66||ab|4|text|573|718|The reactor group also had slightly higher activity in the mitochondrial fraction with the high acetaldehyde and propionaldehyde concentrations.
SE|66||ab|4|entity|C0441833|Groups|inpr|||group|||0|861|585|590
SE|66||ab|4|entity|C0750482|SLIGHTLY|idcn|||slightly|||0|840|600|608
SE|66||ab|4|entity|C0205250|High|qlco|||higher|||0|840|609|615
SE|66||ab|4|entity|C0521451|Mitochondrial|ftcn|||mitochondrial|||0|694|632|645
SE|66||ab|4|entity|C0205250|High|qlco|||high|||0|888|664|668
SE|66||ab|4|entity|C0000966|Acetaldehyde|orch|||acetaldehyde|||0|888|669|681
SE|66||ab|4|entity|C0072184|propionaldehyde|hops,orch|||propionaldehyde|||0|888|686|701

SE|66||ab|5|text|718|815|In the microsomal fraction, the activities showed no differences at any substrate concentration.
SE|66||ab|5|entity|C0026029|Microsomes|celc|||microsomal|||0|623|725|735
SE|66||ab|5|entity|C0441655|Activities|acty|||activities|||0|1000|750|760
SE|66||ab|5|entity|C1547020|*Difference|qnco|||differences|||0|966|771|782

SE|66||ab|6|text|815|901|An induced aldehyde dehydrogenase was purified 70-fold by chromatographic techniques.
SE|66||ab|6|entity|C0205263|Induced|ftcn|||induced|||0|901|818|825
SE|66||ab|6|entity|C0684287|aldehyde dehydrogenases|aapp,enzy|||aldehyde dehydrogenase|||0|901|826|848
SE|66||ab|6|entity|C0332462|Fold|spco|||fold|||0|861|865|869
SE|66||ab|6|entity|C0008550|Chromatography|lbpr|||chromatographic|||0|853|873|888
SE|66||ab|6|entity|C0025664|Methodology|inpr|||techniques|||0|853|889|899

SE|66||ab|7|text|901|1021|It had different molecular and enzymic properties than the main high-Km enzyme normally present in rat liver cytoplasm.
SE|66||ab|7|entity|C1547020|*Difference|qnco|||different|||0|853|908|917
SE|66||ab|7|entity|C1521991|Molecular|qlco|||molecular|||0|853|918|927
SE|66||ab|7|entity|C0871161|Property|qlco|||properties|||0|827|940|950
SE|66||ab|7|entity|C0205225|Primary|qlco|||main|||0|833|960|964
SE|66||ab|7|entity|C0205250|High|qlco|||high|||0|833|965|969
SE|66||ab|7|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|833|973|979
SE|66||ab|7|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|851|1000|1003
SE|66||ab|7|entity|C0023884|Liver|bpoc|||liver|||0|851|1004|1009
SE|66||ab|7|entity|C0010834|Cytoplasm|celc|||cytoplasm|||0|851|1010|1019
SE|66||ab|7|relation|0|0|C0010834|Cytoplasm|celc|celc|||cytoplasm|||0|851|1010|1019|MOD/HEAD|PART_OF||1004|1019|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|851|1004|1009

SE|66||ab|8|text|1021|1101|The pI of the induced enzyme was about 7.0 as measured by isoelectric focusing.
SE|66||ab|8|entity|C0205263|Induced|ftcn|||induced|||0|888|1035|1042
SE|66||ab|8|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|888|1043|1049
SE|66||ab|8|entity|C0022169|Isoelectric Focusing|lbpr|||isoelectric focusing|||0|1000|1079|1099

SE|66||ab|9|text|1101|1224|It was active with several aliphatic and aromatic aldehydes but not with formaldehyde, glycolaldehyde or D-glyceraldehyde.
SE|66||ab|9|entity|C0205177|Active|ftcn|||active|||0|1000|1108|1114
SE|66||ab|9|entity|C0443302|Several|qnco|||several|||0|694|1120|1127
SE|66||ab|9|entity|C0772162|AROMATICS|orch,phsu|||aromatic|||0|888|1142|1150
SE|66||ab|9|entity|C0001992|Aldehydes|orch|||aldehydes|||0|888|1151|1160
SE|66||ab|9|entity|C1518422|Not|ftcn|||not|||0|1000|1165|1168
SE|66||ab|9|entity|C0016564|Formaldehyde|hops,orch|||formaldehyde|||0|1000|1174|1186
SE|66||ab|9|entity|C0061633|glycolaldehyde|bacs,orch|||glycolaldehyde|||0|1000|1188|1202
SE|66||ab|9|entity|C0017854|Glyceraldehyde|carb|||glyceraldehyde|||0|1000|1208|1222

SE|66||ab|10|text|1224|1305|The Km-values for propionaldehyde and acetaldehyde were in the millimolar range.
SE|66||ab|10|entity|C0042295|Values|qlco|||values|||0|888|1231|1237
SE|66||ab|10|entity|C0072184|propionaldehyde|hops,orch|||propionaldehyde|||0|1000|1242|1257
SE|66||ab|10|entity|C0000966|Acetaldehyde|orch|||acetaldehyde|||0|1000|1262|1274
SE|66||ab|10|entity|C0439279|millimole/liter|qnco|||millimolar|||0|888|1287|1297
SE|66||ab|10|entity|C1514721|Range|qnco|||range|||0|888|1298|1303

SE|66||ab|11|text|1305|1391|Millimolar concentrations of aromatic aldehydes caused a strong substrate inhibition.
SE|66||ab|11|entity|C0439279|millimole/liter|qnco|||Millimolar|||0|888|1305|1315
SE|66||ab|11|entity|C0772162|AROMATICS|orch,phsu|||aromatic|||0|888|1334|1342
SE|66||ab|11|entity|C0001992|Aldehydes|orch|||aldehydes|||0|888|1343|1352
SE|66||ab|11|entity|C0442821|Strong|qlco|||strong|||0|802|1362|1368

SE|66||ab|12|text|1391|1463|The enzyme was inhibited by submicromolar concentrations of disulfiram.
SE|66||ab|12|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|1395|1401
SE|66||ab|12|entity|C0012772|Disulfiram|orch,phsu|||disulfiram|||0|1000|1451|1461
SE|66||ab|12|relation|1|1|C0014442|Enzymes|enzy,orch|enzy|||enzyme|||0|1000|1395|1401|VERB|INHIBITS||1406|1415|2|2|C0012772|Disulfiram|orch,phsu|orch|||disulfiram|||0|1000|1451|1461

SE|66||ab|13|text|1463|1563|Estrone, deoxycorticosterone, progesterone and diethylstilbestrol also affected the enzyme activity.
SE|66||ab|13|entity|C0014942|Estrone|horm,phsu,strd|||Estrone|||0|1000|1463|1470
SE|66||ab|13|entity|C0011710|Deoxycorticosterone|horm,phsu,strd|||deoxycorticosterone|||0|1000|1472|1491
SE|66||ab|13|entity|C0033308|Progesterone|horm,phsu,strd|||progesterone|||0|1000|1493|1505
SE|66||ab|13|entity|C0012203|Diethylstilbestrol|hops,orch,phsu|||diethylstilbestrol|||0|1000|1510|1528
SE|66||ab|13|entity|C0243102|enzyme activity|moft|||enzyme activity|||0|1000|1547|1562
SE|66||ab|13|relation|4|1|C0011710|Deoxycorticosterone|horm,phsu,strd|phsu|||deoxycorticosterone|||0|1000|1472|1491|VERB|AFFECTS||1534|1542|1|1|C0243102|enzyme activity|moft|moft|||enzyme activity|||0|1000|1547|1562
SE|66||ab|13|relation|4|1|C0012203|Diethylstilbestrol|hops,orch,phsu|phsu|||diethylstilbestrol|||0|1000|1510|1528|VERB|AFFECTS||1534|1542|1|1|C0243102|enzyme activity|moft|moft|||enzyme activity|||0|1000|1547|1562
SE|66||ab|13|relation|4|1|C0014942|Estrone|horm,phsu,strd|phsu|||Estrone|||0|1000|1463|1470|VERB|AFFECTS||1534|1542|1|1|C0243102|enzyme activity|moft|moft|||enzyme activity|||0|1000|1547|1562
SE|66||ab|13|relation|4|1|C0033308|Progesterone|horm,phsu,strd|phsu|||progesterone|||0|1000|1493|1505|VERB|AFFECTS||1534|1542|1|1|C0243102|enzyme activity|moft|moft|||enzyme activity|||0|1000|1547|1562


SE|67||ti|1|text|15|51|Cholinesterases from plant tissues.
SE|67||ti|1|entity|C0008429|Cholinesterases|aapp,enzy|||Cholinesterases|||0|1000|15|30
SE|67||ti|1|entity|C0032098|Plants|plnt|||plant|||0|888|36|41
SE|67||ti|1|entity|C0040300|Body tissue|tisu|||tissues|||0|888|42|49
SE|67||ti|1|relation|0|0|C0040300|Body tissue|tisu|tisu|||tissues|||0|888|42|49|MOD/HEAD|PART_OF||36|49|0|0|C0032098|Plants|plnt|plnt|||plant|||0|888|36|41
SE|67||ti|1|relation|1|1|C0040300|Body tissue|tisu|tisu|||tissues|||0|888|42|49|PREP|LOCATION_OF||31|35|1|1|C0008429|Cholinesterases|aapp,gngm,enzy|aapp|||Cholinesterases|||0|1000|15|30

SE|67||ti|2|text|51|55|VI.

SE|67||ti|3|text|55|137|Preliminary characterization of enzymes from Solanum melongena L. and Zea mays L.
SE|67||ti|3|entity|C0439611|Preliminary|tmco|||Preliminary|||0|694|55|66
SE|67||ti|3|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|1000|87|94
SE|67||ti|3|entity|C1123002|Solanum melongena|plnt|||Solanum melongena|||0|884|100|117
SE|67||ti|3|entity|C0010028|Zea mays|plnt|||Zea mays|||0|884|125|133

SE|67||ab|1|text|143|250|Enzymes capable of hydrolyzing esters of thiocholine have been assayed in extracts of Solanum melongena L.
SE|67||ab|1|entity|C0014442|Enzymes|enzy,orch|||Enzymes|||0|1000|143|150
SE|67||ab|1|entity|C0014898|Esters|orch|||esters|||0|861|174|180
SE|67||ab|1|entity|C0039883|Thiocholine|irda,orch|||thiocholine|||0|1000|184|195
SE|67||ab|1|entity|C1555707|extract|idcn|||extracts|||0|966|217|225
SE|67||ab|1|entity|C1123002|Solanum melongena|plnt|||Solanum melongena|||0|884|229|246

SE|67||ab|2|text|250|277|(eggplant) and Zea Mays L.
SE|67||ab|2|entity|C0453111|Aubergine|food|||eggplant|||0|1000|251|259
SE|67||ab|2|entity|C0010028|Zea mays|plnt|||Zea Mays|||0|884|265|273

SE|67||ab|3|text|277|285|(corn).
SE|67||ab|3|entity|C0010028|Zea mays|plnt|||corn|||0|1000|278|282

SE|67||ab|4|text|285|480|The enzymes from both species are inhibited by the anti-cholinesterases neostigmine, physostigmine, and 284c51 and by AMO-1618, a plant growth retardant and they both have pH optima near pH 8.0.
SE|67||ab|4|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|1000|289|296
SE|67||ab|4|entity|C1548151|Species|idcn|||species|||0|1000|307|314
SE|67||ab|4|entity|C0008425|Cholinesterase Inhibitors|orch,phsu|||anti-cholinesterases|||0|901|336|356
SE|67||ab|4|entity|C0027679|Neostigmine|orch,phsu|||neostigmine|||0|901|357|368
SE|67||ab|4|entity|C0031849|Physostigmine|orch,phsu|||physostigmine|||0|1000|370|383
SE|67||ab|4|entity|C0051730|AMO-1618|orch,phsu|||AMO-1618|||0|1000|403|411
SE|67||ab|4|entity|C0597252|plant growth/development|orgf|||plant growth|||0|734|415|427
SE|67||ab|4|relation|0|0|C0027679|Neostigmine|orch,phsu|orch|||neostigmine|||0|901|357|368|MOD/HEAD|ISA||336|368|0|0|C0008425|Cholinesterase Inhibitors|orch,phsu|orch|||anti-cholinesterases|||0|901|336|356
SE|67||ab|4|relation|5|1|C0027679|Neostigmine|orch,phsu|orch|||neostigmine|||0|901|357|368|VERB|INHIBITS||319|328|2|2|C0014442|Enzymes|enzy,orch|enzy|||enzymes|||0|1000|289|296

SE|67||ab|5|text|480|636|The enzyme from eggplant is maximally active at a substrate concentration of 0.15 mM acetylthiocholine and is inhibited at higher substrate concentrations.
SE|67||ab|5|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|484|490
SE|67||ab|5|entity|C0453111|Aubergine|food|||eggplant|||0|1000|496|504
SE|67||ab|5|entity|C0205177|Active|ftcn|||active|||0|861|518|524
SE|67||ab|5|entity|C0001066|Acetylthiocholine|orch,phsu|||acetylthiocholine|||0|750|565|582
SE|67||ab|5|entity|C0205250|High|qlco|||higher|||0|785|603|609
SE|67||ab|5|relation|3|3|C0014442|Enzymes|enzy,orch|enzy|||enzyme|||0|1000|484|490|NOM|INTERACTS_WITH||530|539|2|1|C0001066|Acetylthiocholine|orch,phsu|orch|||acetylthiocholine|||0|750|565|582

SE|67||ab|6|text|636|845|On the basis of this last property, the magnitude of inhibition by the various inhibitors, and the substrate specificity, we conclude that the enzyme from eggplant, but not that from corn, is a cholinesterase.
SE|67||ab|6|entity|C1527178|Basis|ftcn|||basis|||0|1000|643|648
SE|67||ab|6|entity|C1517741|Last|qlco|||last|||0|888|657|661
SE|67||ab|6|entity|C0871161|Property|qlco|||property|||0|888|662|670
SE|67||ab|6|entity|C0449286|Degree or extent|qnco|||magnitude|||0|966|676|685
SE|67||ab|6|entity|C0243077|inhibitors|chvf|||inhibitors|||0|861|715|725
SE|67||ab|6|entity|C0038592|Substrate Specificity|qnco|||substrate specificity|||0|1000|735|756
SE|67||ab|6|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|779|785
SE|67||ab|6|entity|C0453111|Aubergine|food|||eggplant|||0|1000|791|799
SE|67||ab|6|entity|C1518422|Not|ftcn|||not|||0|1000|805|808
SE|67||ab|6|entity|C0010028|Zea mays|plnt|||corn|||0|1000|819|823
SE|67||ab|6|entity|C0008429|Cholinesterases|aapp,enzy|||cholinesterase|||0|1000|830|844


SE|97||ti|1|text|15|75|Hydrogen peroxide and iron: a microbial cellulolytic system?
SE|97||ti|1|entity|C0020281|Hydrogen Peroxide|inch,irda,phsu|||Hydrogen peroxide|||0|1000|15|32
SE|97||ti|1|entity|C0302583|Iron|bacs,elii,phsu|||iron|||0|1000|37|41
SE|97||ti|1|entity|C0599840|microbial|orgm|||microbial|||0|802|45|54
SE|97||ti|1|entity|C0449913|System|ftcn|||system|||0|802|68|74


SE|98||ti|1|text|15|46|Microbial sources of cellulase.
SE|98||ti|1|entity|C0599840|microbial|orgm|||Microbial|||0|872|15|24
SE|98||ti|1|entity|C0007641|CELLULASE|aapp,enzy,phsu|||cellulase|||0|1000|36|45


SE|99||ti|1|text|15|63|Mannosidosis: clinical and biochemical findings.
SE|99||ti|1|entity|C1257960|Mannosidase Deficiency Diseases|dsyn|||Mannosidosis|||0|1000|15|27
SE|99||ti|1|entity|C0205210|Clinical|qlco|||clinical|||0|1000|29|37
SE|99||ti|1|entity|C0428132|Biochemical finding|lbtr|||biochemical findings|||0|983|42|62


SE|100||ti|1|text|16|71|Bovine mannosidosis--a model lysosomal storage disease.
SE|100||ti|1|entity|C0007452|Cattle|mamm|||Bovine|||0|888|16|22
SE|100||ti|1|entity|C1257960|Mannosidase Deficiency Diseases|dsyn|||mannosidosis|||0|888|23|35
SE|100||ti|1|entity|C0026336|Study models|inpr,resd|||model|||0|916|39|44
SE|100||ti|1|entity|C0085078|Lysosomal Storage Diseases|dsyn|||lysosomal storage disease|||0|916|45|70
SE|100||ti|1|relation|0|0|C1257960|Mannosidase Deficiency Diseases|dsyn|dsyn|||mannosidosis|||0|888|23|35|MOD/HEAD|PROCESS_OF||16|35|0|0|C0007452|Cattle|mamm|mamm|||Bovine|||0|888|16|22


SE|101||ti|1|text|16|81|Ehlers-Danlos type V (X-linked form): a lysyl oxidase deficiency.
SE|101||ti|1|entity|C0013720|Ehlers-Danlos Syndrome|cgab,dsyn|||Danlos|||0|736|23|29
SE|101||ti|1|entity|C1547052|*Type|qnco|||type|||0|736|30|34
SE|101||ti|1|entity|C1522492|Formation|ftcn|||form|||0|736|47|51
SE|101||ti|1|entity|C0024375|Protein-Lysine 6-Oxidase|aapp,enzy|4015|LOX|lysyl oxidase|||0|901|56|69
SE|101||ti|1|entity|C0011155|Deficiency|ftcn|||deficiency|||0|901|70|80


SE|102||ti|1|text|16|43|Urinary alpha-L-fucosidase.
SE|102||ti|1|entity|C1524119|urinary|qlco|||Urinary|||0|916|16|23
SE|102||ti|1|entity|C0016787|Fucosidase|aapp,enzy|||alpha-L-fucosidase|||0|916|24|42


SE|108||ti|1|text|16|46|Symposium on malaria research.
SE|108||ti|1|entity|C0086047|Conferences|hcpp|||Symposium|||0|1000|16|25
SE|108||ti|1|entity|C0024530|Malaria|dsyn|||malaria|||0|888|29|36
SE|108||ti|1|entity|C0035168|research|resa|||research|||0|888|37|45


SE|109||ti|1|text|16|70|6th International Symposium on Maritime Medicine 1974.
SE|109||ti|1|entity|C1512888|International|idcn|||International|||0|790|20|33
SE|109||ti|1|entity|C0086047|Conferences|hcpp|||Symposium|||0|790|34|43
SE|109||ti|1|entity|C0013227|Pharmaceutical Preparations|phsu|||Medicine|||0|827|56|64


SE|110||ti|1|text|16|35|Polypsychopharmacy.


SE|111||ti|1|text|16|67|[Oxygen affinity of haemoglobin (author's transl)].
SE|111||ti|1|entity|C0369765|Oxygen affinity|moft|||Oxygen affinity|||0|1000|17|32
SE|111||ti|1|entity|C0019046|Hemoglobin|aapp,bacs|||haemoglobin|||0|1000|36|47
SE|111||ti|1|entity|C0221192|Author|idcn,prog|||author's|||0|694|49|57


SE|112||ti|1|text|16|51|PH changes on the surface of burns.
SE|112||ti|1|entity|C0205148|Surface|spco|||surface|||0|1000|34|41
SE|112||ti|1|entity|C0006434|Burn injury|inpo|||burns|||0|1000|45|50


SE|113||ti|1|text|16|156|Proceedings: The effects of glucagon on the hepatic arterial vasculature of the dog: an inhibition of the effects of vasoconstrictor agents.
SE|113||ti|1|entity|C1280500|Effect|qlco|||effects|||0|966|33|40
SE|113||ti|1|entity|C0017687|Glucagon|aapp,horm,nsba,phsu|||glucagon|||0|1000|44|52
SE|113||ti|1|entity|C0221464|Arterial|spco|||arterial|||0|901|68|76
SE|113||ti|1|entity|C1183745|Hepatic vasculature|bpoc|||hepatic arterial vasculature|||0|901|60|88
SE|113||ti|1|entity|C0012984|Canis familiaris|mamm|||dog|||0|1000|96|99
SE|113||ti|1|entity|C1280500|Effect|qlco|||effects|||0|966|122|129
SE|113||ti|1|entity|C0042397|Vasoconstrictor Agents|phsu|||vasoconstrictor agents|||0|1000|133|155
SE|113||ti|1|relation|4|1|C1183745|Hepatic vasculature|bpoc|bpoc|||hepatic arterial vasculature|||0|901|60|88|PREP|PART_OF||89|91|4|1|C0012984|Canis familiaris|mamm|mamm|||dog|||0|1000|96|99
SE|113||ti|1|relation|6|1|C0017687|Glucagon|aapp,gngm,horm,nsba,phsu|aapp|||glucagon|||0|1000|44|52|NOM|AFFECTS||33|40|6|2|C1183745|Hepatic vasculature|bpoc|bpoc|||hepatic arterial vasculature|||0|901|60|88


SE|114||ti|1|text|16|78|Proceedings: Central hypertensive action of histamine in rats.
SE|114||ti|1|entity|C0205099|Central|spco|||Central|||0|623|29|36
SE|114||ti|1|entity|C0857121|Hypertensive|fndg|||hypertensive|||0|623|37|49
SE|114||ti|1|entity|C0019588|Histamine|nsba,orch|||histamine|||0|1000|60|69
SE|114||ti|1|entity|C0034693|Rattus norvegicus|mamm|||rats|||0|1000|73|77
SE|114||ti|1|relation|1|1|C0034693|Rattus norvegicus|mamm|mamm|||rats|||0|1000|73|77|PREP|LOCATION_OF||70|72|3|1|C0019588|Histamine|nsba,orch|orch|||histamine|||0|1000|60|69


SE|115||ti|1|text|16|154|Proceedings: Response of identified ventromedial hypothalamic nucleus neurons to putative neurotransmitters applied by microiontophoresis.
SE|115||ti|1|entity|C0871261|response|clna|||Response|||0|1000|29|37
SE|115||ti|1|entity|C0205396|Identified|qlco|||identified|||0|875|41|51
SE|115||ti|1|entity|C1289551|Entire ventromedial hypothalamic nucleus|bpoc|||ventromedial hypothalamic nucleus|||0|875|52|85
SE|115||ti|1|entity|C0027882|Neurons|cell|||neurons|||0|875|86|93
SE|115||ti|1|entity|C0027908|Neurotransmitters|nsba|||neurotransmitters|||0|861|106|123
SE|115||ti|1|relation|0|0|C0027882|Neurons|cell|cell|||neurons|||0|875|86|93|MOD/HEAD|PART_OF||52|93|0|0|C1289551|Entire ventromedial hypothalamic nucleus|bpoc|bpoc|||ventromedial hypothalamic nucleus|||0|875|52|85


SE|116||ti|1|text|16|104|Proceedings: The mechanism of "adrenaline reversal" in the anaesthetized cat and rabbit.
SE|116||ti|1|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|1000|33|42
SE|116||ti|1|entity|C0014563|Epinephrine|horm,nsba,orch,phsu|||adrenaline|||0|694|47|57
SE|116||ti|1|entity|C0007450|Felis catus|mamm|||cat|||0|861|89|92
SE|116||ti|1|entity|C0034493|Oryctolagus cuniculus|mamm|||rabbit|||0|1000|97|103


SE|117||ti|1|text|16|86|Proceedings: Is ATP an inhibitory neurotransmitter in the rat stomach.
SE|117||ti|1|entity|||gngm|51761|ATP8A2|ATP|||0|1000|32|35
SE|117||ti|1|entity|C0243077|inhibitors|chvf|||inhibitory|||0|853|39|49
SE|117||ti|1|entity|C0027908|Neurotransmitters|nsba|||neurotransmitter|||0|853|50|66
SE|117||ti|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|888|74|77
SE|117||ti|1|entity|C0038351|Stomach|bpoc|||stomach|||0|888|78|85
SE|117||ti|1|relation|0|0|C0038351|Stomach|bpoc|bpoc|||stomach|||0|888|78|85|MOD/HEAD|PART_OF||74|85|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|888|74|77
SE|117||ti|1|relation|1|1|C0038351|Stomach|bpoc|bpoc|||stomach|||0|888|78|85|PREP|LOCATION_OF||67|69|3|2|||gngm,aapp|aapp|51761|ATP8A2|ATP|||0|1000|32|35


SE|118||ti|1|text|16|192|Proceedings: Comparison of the effects of selective alpha and beta-receptor agonists on intracellular cyclic AMP levels and glycogen phosphorylase activity in guinea-pig liver.
SE|118||ti|1|entity|C1280500|Effect|qlco|||effects|||0|966|47|54
SE|118||ti|1|entity|C0439095|Alpha|inpr|||alpha|||0|861|68|73
SE|118||ti|1|entity|C0597357|receptor|aapp,rcpt|||receptor|||0|790|83|91
SE|118||ti|1|entity|C0243192|agonists|phsu|||agonists|||0|790|92|100
SE|118||ti|1|entity|C0175996|Protoplasm|celc|||intracellular|||0|861|104|117
SE|118||ti|1|entity|C0001455|Cyclic AMP|bacs,nnon|||cyclic AMP|||0|861|118|128
SE|118||ti|1|entity|C0441889|Levels|inpr|||levels|||0|861|129|135
SE|118||ti|1|entity|C1152162|glycogen phosphorylase activity|moft|||glycogen phosphorylase activity|||0|1000|140|171
SE|118||ti|1|entity|C0085979|Cavia|mamm|||guinea-pig|||0|901|175|185
SE|118||ti|1|entity|C0023884|Liver|bpoc|||liver|||0|901|186|191
SE|118||ti|1|relation|0|0|C0001455|Cyclic AMP|bacs,nnon|bacs|||cyclic AMP|||0|861|118|128|MOD/HEAD|PART_OF||104|128|0|0|C0175996|Protoplasm|celc|celc|||intracellular|||0|861|104|117
SE|118||ti|1|relation|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|901|186|191|MOD/HEAD|PART_OF||175|191|0|0|C0085979|Cavia|mamm|mamm|||guinea-pig|||0|901|175|185
SE|118||ti|1|relation|1|1|C0023884|Liver|bpoc|bpoc|||liver|||0|901|186|191|PREP|LOCATION_OF||172|174|7|2|C0001455|Cyclic AMP|bacs,nnon|bacs|||cyclic AMP|||0|861|118|128


SE|119||ti|1|text|16|128|Proceedings: The role of dopamine in rotational behaviour produced by unilateral lesions of the locus coeruleus.
SE|119||ti|1|entity|C0035820|Role|socb|||role|||0|1000|33|37
SE|119||ti|1|entity|C0013030|Dopamine|nsba,orch,phsu|||dopamine|||0|1000|41|49
SE|119||ti|1|entity|C0871276|Rotational Behavior|orgf|||rotational behaviour|||0|1000|53|73
SE|119||ti|1|entity|C0205092|Unilateral|spco|||unilateral|||0|888|86|96
SE|119||ti|1|entity|C0221198|Lesion|fndg|||lesions|||0|888|97|104
SE|119||ti|1|entity|C0023951|Structure of locus ceruleus|bpoc|||locus coeruleus|||0|1000|112|127
SE|119||ti|1|relation|1|1|C0023951|Structure of locus ceruleus|bpoc|bpoc|||locus coeruleus|||0|1000|112|127|PREP|LOCATION_OF||105|107|5|1|C0221198|Lesion|fndg|fndg|||lesions|||0|888|97|104
SE|119||ti|1|relation|4|1|C0013030|Dopamine|nsba,orch,phsu|nsba|||dopamine|||0|1000|41|49|NOM|AFFECTS||33|37|4|2|C0871276|Rotational Behavior|orgf|orgf|||rotational behaviour|||0|1000|53|73


SE|120||ti|1|text|16|112|Proceedings: Do anti-psychotic drugs act by dopamine receptor blockade in the nucleus accumbens.
SE|120||ti|1|entity|C0033975|Psychotic Disorders|mobd|||psychotic|||0|790|37|46
SE|120||ti|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs|||0|790|47|52
SE|120||ti|1|entity|C0034798|Dopamine Receptor|aapp,rcpt|||dopamine receptor|||0|734|60|77
SE|120||ti|1|entity|C0028633|Nucleus Accumbens|bpoc|||nucleus accumbens|||0|1000|94|111
SE|120||ti|1|relation|2|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs|||0|790|47|52|NOM|INHIBITS||78|86|2|0|C0034798|Dopamine Receptor|aapp,gngm,rcpt|gngm|||dopamine receptor|||0|734|60|77


SE|121||ti|1|text|16|132|Proceedings: Evaluation of narcotic and narcotic antagonist analgesic drugs in the dog dental pulp stimulation test.
SE|121||ti|1|entity|C0220825|Evaluation|ftcn|||Evaluation|||0|1000|29|39
SE|121||ti|1|entity|C0027415|Narcotics|hops,phsu|||narcotic|||0|1000|43|51
SE|121||ti|1|entity|C0027410|Narcotic Antagonists|phsu|||narcotic antagonist|||0|888|56|75
SE|121||ti|1|entity|C0002771|Analgesics|phsu|||analgesic drugs|||0|888|76|91
SE|121||ti|1|entity|C0012984|Canis familiaris|mamm|||dog|||0|875|99|102
SE|121||ti|1|entity|C0011410|Dental Pulp Test|diap|||dental pulp stimulation test|||0|875|103|131


SE|122||ti|1|text|16|41|Meso-appendicular testis.
SE|122||ti|1|entity|C0598782|appendage|bpoc|||appendicular|||0|754|21|33
SE|122||ti|1|entity|C0039597|Testis|bpoc|||testis|||0|754|34|40


SE|126||ti|1|text|16|68|Phobias complicating treatment of uterine carcinoma.
SE|126||ti|1|entity|C0349231|Phobic anxiety disorder|mobd,sosy|||Phobias|||0|1000|16|23
SE|126||ti|1|entity|C0848454|Uterine carcinoma|neop|||uterine carcinoma|||0|1000|50|67


SE|127||ti|1|text|16|84|Editorial: Childhood poisoning: prevention and first-aid management.
SE|127||ti|1|entity|C0231335|Childhood|tmco|||Childhood|||0|888|27|36
SE|127||ti|1|entity|C0032343|Poisoning|inpo|||poisoning|||0|888|37|46
SE|127||ti|1|entity|C0199176|Prophylactic treatment|topp|||prevention|||0|1000|48|58
SE|127||ti|1|entity|C0016143|First Aid|topp|||first-aid|||0|901|63|72


SE|130||ti|1|text|16|95|Uptake of radiolabeled glucose analogues by organotypic pia arachnoid cultures.
SE|130||ti|1|entity|C0243144|uptake|phsf|||Uptake|||0|1000|16|22
SE|130||ti|1|entity|C1527121|Radiolabeled|qlco|||radiolabeled|||0|890|26|38
SE|130||ti|1|entity|C0596619|glucose analog|carb|||glucose analogues|||0|890|39|56
SE|130||ti|1|entity|C0228126|Leptomeninges|bpoc|||pia arachnoid|||0|824|72|85
SE|130||ti|1|entity|C0010453|Anthropological Culture|idcn|||cultures|||0|824|86|94


SE|131||ti|1|text|16|66|Processing of tRNA precursors in higher organisms.
SE|131||ti|1|entity|C1522240|Process|phpr|||Processing|||0|966|16|26
SE|131||ti|1|entity|C0041133|RNA, Transfer, Precursors|bacs,nnon|||tRNA precursors|||0|983|30|45
SE|131||ti|1|entity|C0205250|High|qlco|||higher|||0|872|49|55
SE|131||ti|1|entity|C0029235|Organism|orgm|||organisms|||0|872|56|65


SE|144||ti|1|text|16|193|Isolation and characterization of an unsubstituted 2,3-unsaturated sugar, trans-2,3-dideoxy-D-glycero-pent-2-enose, produced by thermal dehydration of 2-deoxy-D-erythro-pentose.
SE|144||ti|1|entity|C0204727|Isolation procedure|topp|||Isolation|||0|1000|16|25
SE|144||ti|1|entity|C0522535|Unsaturated|qnco|||unsaturated|||0|851|71|82
SE|144||ti|1|entity|C0242209|Sugars|carb,phsu|||sugar|||0|851|83|88
SE|144||ti|1|entity|||gngm|5409|PNMT|pent|||0|1000|118|122
SE|144||ti|1|entity|C0011175|Dehydration|dsyn|||dehydration|||0|861|152|163
SE|144||ti|1|entity|C0699343|Erythro|antb,carb|||erythro|||0|888|177|184
SE|144||ti|1|entity|C0030894|Pentoses|carb|||pentose|||0|888|185|192


SE|145||ti|1|text|16|88|Prophylactic antiarrhythmic drug therapy in acute myocardial infarction.
SE|145||ti|1|entity|C0003195|Anti-Arrhythmia Agents|phsu|||antiarrhythmic|||0|905|29|43
SE|145||ti|1|entity|C0420172|Prophylactic drug therapy NOS|topp|||Prophylactic antiarrhythmic drug therapy|||0|905|16|56
SE|145||ti|1|entity|C0155626|Acute myocardial infarction|dsyn|||acute myocardial infarction|||0|1000|60|87
SE|145||ti|1|relation|0|0|C0420172|Prophylactic drug therapy NOS|topp|topp|||Prophylactic antiarrhythmic drug therapy|||0|905|16|56|MOD/HEAD|USES||29|56|0|0|C0003195|Anti-Arrhythmia Agents|phsu|phsu|||antiarrhythmic|||0|905|29|43
SE|145||ti|1|relation|1|1|C0420172|Prophylactic drug therapy NOS|topp|topp|||Prophylactic antiarrhythmic drug therapy|||0|905|16|56|PREP|TREATS||57|59|1|1|C0155626|Acute myocardial infarction|dsyn|dsyn|||acute myocardial infarction|||0|1000|60|87


SE|146||ti|1|text|16|111|[Influence of beta-blocking agents on experimental atherosclerosis of cocks (author's transl)].
SE|146||ti|1|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-blocking agents|||0|983|30|50
SE|146||ti|1|entity|C1517004|Experimental|ftcn|||experimental|||0|888|54|66
SE|146||ti|1|entity|C0004153|Atherosclerosis|dsyn|||atherosclerosis|||0|888|67|82
SE|146||ti|1|entity|C0221192|Author|idcn,prog|||author's|||0|694|93|101


SE|147||ti|1|text|16|81|Cytotoxic interaction between gorgonian explants: mode of action.
SE|147||ti|1|entity|C1511636|cytotoxic|ftcn|||Cytotoxic|||0|888|16|25
SE|147||ti|1|entity|C1222973|Gorgonia|invt|||gorgonian|||0|623|46|55
SE|147||ti|1|entity|C1513371|Mode|ftcn|||mode|||0|1000|66|70


SE|163||ti|1|text|16|82|Measurement of total alkaline phosphatase activity in human serum.
SE|163||ti|1|entity|C0242485|Measurement|ftcn|||Measurement|||0|1000|16|27
SE|163||ti|1|entity|C0439175|% of total|qnco|||total|||0|916|31|36
SE|163||ti|1|entity|C1149888|alkaline phosphatase activity|moft|||alkaline phosphatase activity|||0|916|37|66
SE|163||ti|1|entity|C0020114|Human|humn|||human|||0|888|70|75
SE|163||ti|1|entity|C0229671|Serum|bdsu|||serum|||0|888|76|81
SE|163||ti|1|relation|0|0|C0229671|Serum|bdsu|bdsu|||serum|||0|888|76|81|MOD/HEAD|PART_OF||70|81|0|0|C0020114|Human|grup,humn|humn|||human|||0|888|70|75


SE|164||ti|1|text|16|122|Problems associated with the determination of arylsulfatase A and B using nitrocatechol sulfate substrate.
SE|164||ti|1|entity|C1546466|Problems|idcn|||Problems|||0|1000|16|24
SE|164||ti|1|entity|C0680730|Adjudication|gora|||determination|||0|1000|45|58
SE|164||ti|1|entity|C0007804|Cerebroside-Sulfatase|aapp,enzy|410|ARSA|arylsulfatase A|||0|1000|62|77
SE|164||ti|1|entity|C0038720|Sulfates, Inorganic|inch|||sulfate|||0|660|104|111


SE|166||ti|1|text|16|56|[Inborn error of glycolipid metabolism].
SE|166||ti|1|entity|C0743559|error|qlco|||error|||0|861|24|29
SE|166||ti|1|entity|C1158409|glycolipid metabolism|moft|||glycolipid metabolism|||0|1000|33|54


SE|169||ti|1|text|16|66|Some pharmacologic aspects of the antihistamines.
SE|169||ti|1|entity|C0205464|pharmacological|ftcn|||pharmacologic|||0|872|21|34
SE|169||ti|1|entity|C1547011|Aspect|qnco|||aspects|||0|872|35|42
SE|169||ti|1|entity|C0003360|Antihistamines|phsu|||antihistamines|||0|1000|50|64

SE|169||ti|2|text|66|108|A survey of current clinical applications.
SE|169||ti|2|entity|C0038951|Surveys|resa|||survey|||0|1000|68|74
SE|169||ti|2|entity|C0521116|Current|tmco|||current|||0|840|78|85
SE|169||ti|2|entity|C0205210|Clinical|qlco|||clinical|||0|840|86|94


SE|172||ti|1|text|16|74|Meal to pellet intervals in 14 species of captive raptors.
SE|172||ti|1|entity|C1272706|Interval|tmco|||intervals|||0|827|31|40
SE|172||ti|1|entity|C1548151|Species|idcn|||species|||0|861|47|54
SE|172||ti|1|entity|C0600536|Raptors|bird|||raptors|||0|861|66|73


SE|174||ti|1|text|16|69|Studies on the lipid content of pigeon breast muscle.
SE|174||ti|1|entity|C0008972|Clinical Research|resa|||Studies|||0|966|16|23
SE|174||ti|1|entity|C0023779|Lipids|lipd|||lipid|||0|694|31|36
SE|174||ti|1|entity|C0158731|Congenital pectus carinatum|cgab|||pigeon breast|||0|901|48|61
SE|174||ti|1|entity|C0026845|Muscle|tisu|||muscle|||0|901|62|68
SE|174||ti|1|relation|2|1|C0023779|Lipids|lipd|lipd|||lipid|||0|694|31|36|PREP|PART_OF||45|47|1|1|C0026845|Muscle|tisu|tisu|||muscle|||0|901|62|68


SE|173||ti|1|text|16|130|Secretion of sulfuric acid in Cassidaria echinophora Lamarck (Mollusca: Mesogastropoda, marine carnivorous snail).
SE|173||ti|1|entity|C0015283|Exocytosis|celf|||Secretion|||0|1000|16|25
SE|173||ti|1|entity|C0038784|Sulfuric acid|inch,phsu|||sulfuric acid|||0|1000|29|42
SE|173||ti|1|entity|C1035206|Echinophora|plnt|||echinophora|||0|660|57|68
SE|173||ti|1|entity|C0026391|Mollusca|invt|||Mollusca|||0|1000|78|86
SE|173||ti|1|entity|C0524645|Marines|prog|||marine|||0|816|104|110
SE|173||ti|1|entity|C0007266|Carnivora|mamm|||carnivorous|||0|816|111|122
SE|173||ti|1|entity|C0037378|Snails|invt|||snail|||0|816|123|128


SE|175||ti|1|text|16|115|Seasonal variation in diet, volatile fatty acid production and size of the cecum of roch ptarmigan.
SE|175||ti|1|entity|C0036496|Seasonal Variation|tmco|||Seasonal variation|||0|1000|16|34
SE|175||ti|1|entity|C0012155|Diet|food|||diet|||0|1000|38|42
SE|175||ti|1|entity|C0015691|Fatty Acids, Volatile|bacs,lipd|||volatile fatty acid|||0|916|44|63
SE|175||ti|1|entity|C0033268|production|ocac|||production|||0|916|64|74
SE|175||ti|1|entity|C0456389|size|spco|||size|||0|1000|79|83
SE|175||ti|1|entity|C0007531|Cecum|bpoc|||cecum|||0|1000|91|96


SE|176||ti|1|text|16|113|The auditory system of the goldfish (Carassius auratus): effects of intense acoustic stimulation.
SE|176||ti|1|entity|C0587901|Auditory system|bdsy|||auditory system|||0|1000|20|35
SE|176||ti|1|entity|C0018038|Goldfish|fish|||goldfish|||0|1000|43|51
SE|176||ti|1|entity|C0018038|Goldfish|fish|||Carassius auratus|||0|1000|53|70
SE|176||ti|1|entity|C1280500|Effect|qlco|||effects|||0|966|73|80
SE|176||ti|1|entity|C0001164|Acoustic Stimulation|diap|||acoustic stimulation|||0|901|92|112


SE|177||ti|1|text|16|118|Volatile fatty acids and metabolizable energy derived from cecal fermentation in the willow ptarmigan.
SE|177||ti|1|entity|C0015691|Fatty Acids, Volatile|bacs,lipd|||Volatile fatty acids|||0|1000|16|36
SE|177||ti|1|entity|C0424589|Vitality|fndg|||energy|||0|861|55|61
SE|177||ti|1|entity|C0521375|Ceco-|spco|||cecal|||0|888|75|80
SE|177||ti|1|entity|C0015852|Fermentation|moft|||fermentation|||0|888|81|93
SE|177||ti|1|entity|C0995181|Willow|plnt|||willow|||0|861|101|107


SE|178||ti|1|text|16|104|A comparison of intestinal amino acid absorption in various avian and mammalian species.
SE|178||ti|1|entity|C0002520|Amino Acids|aapp,bacs,phsu|||amino acid|||0|901|43|53
SE|178||ti|1|entity|C0021826|Intestinal Absorption|ortf|||intestinal amino acid absorption|||0|901|32|64
SE|178||ti|1|entity|C0005595|Aves|bird|||avian|||0|861|76|81
SE|178||ti|1|entity|C1548151|Species|idcn|||species|||0|861|96|103
SE|178||ti|1|relation|2|1|C0021826|Intestinal Absorption|ortf|ortf|||intestinal amino acid absorption|||0|901|32|64|PREP|PROCESS_OF||65|67|2|1|C0005595|Aves|bird|bird|||avian|||0|861|76|81


SE|179||ti|1|text|16|96|Holeuryhalinity and its mechanisms in a cirriped crustacean, Balanus improvisus.
SE|179||ti|1|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|1000|40|50
SE|179||ti|1|entity|C0010395|Crustacea|invt|||crustacean|||0|861|65|75
SE|179||ti|1|entity|C1095695|Balanus improvisus|invt|||Balanus improvisus|||0|1000|77|95


SE|180||ti|1|text|16|140|A comparative study on the regulation of osmotic, ionic and organic-solute concentrations in the blood of aquatic organisms.
SE|180||ti|1|entity|C0008972|Clinical Research|resa|||study|||0|861|30|35
SE|180||ti|1|entity|C0851285|Regulation|gora|||regulation|||0|1000|43|53
SE|180||ti|1|entity|C0311417|Osmotic|ftcn|||osmotic|||0|853|57|64
SE|180||ti|1|entity|C0022023|Ions|elii|||ionic|||0|853|66|71
SE|180||ti|1|entity|C0747055|ORGANIC|qlco|||organic|||0|851|76|83
SE|180||ti|1|entity|C0597488|solute|chvs|||solute|||0|851|84|90
SE|180||ti|1|entity|C0005767|Blood|tisu|||blood|||0|1000|113|118
SE|180||ti|1|entity|C0596121|aquatic organism|orgm|||aquatic organisms|||0|983|122|139
SE|180||ti|1|relation|2|1|C0005767|Blood|tisu|tisu|||blood|||0|1000|113|118|PREP|LOCATION_OF||106|108|4|2|C0022023|Ions|elii|elii|||ionic|||0|853|66|71
SE|180||ti|1|relation|5|1|C0005767|Blood|tisu|tisu|||blood|||0|1000|113|118|PREP|PART_OF||119|121|1|1|C0596121|aquatic organism|orgm|orgm|||aquatic organisms|||0|983|122|139


SE|182||ti|1|text|16|61|The respiratory quotient of Gammarus pulex L.
SE|182||ti|1|entity|C0429702|Respiratory quotient|lbtr|||respiratory quotient|||0|1000|20|40
SE|182||ti|1|entity|C1016815|Gammarus pulex|invt|||Gammarus pulex|||0|884|44|58


SE|181||ti|1|text|16|93|Aestivation and thermoregulation in the Texas tortoise, Gopherus berlandieri.
SE|181||ti|1|entity|C0014906|Estivation|orgf|||Aestivation|||0|1000|16|27
SE|181||ti|1|entity|C0039711|Texas|geoa|||Texas|||0|888|56|61
SE|181||ti|1|entity|C0041412|Turtles|rept|||tortoise|||0|888|62|70


SE|183||ti|1|text|16|62|Water balance of small lactating rodents--II.
SE|183||ti|1|entity|C0016284|Fluid Balance|orgf|||Water balance|||0|1000|16|29
SE|183||ti|1|entity|C0700321|Small|qnco|||small|||0|840|33|38
SE|183||ti|1|entity|C0022924|Lactates|orch|||lactating|||0|840|39|48
SE|183||ti|1|entity|C0035804|Rodent|mamm|||rodents|||0|840|49|56

SE|183||ti|2|text|62|154|Concentration and composition of milk of females on ad libitum and restricted water intakes.
SE|183||ti|2|entity|C0486616|Composition|clna|||composition|||0|1000|80|91
SE|183||ti|2|entity|C0026131|Milk|bdsu|||milk|||0|1000|95|99
SE|183||ti|2|entity|C0015780|Female|orga|||females|||0|1000|103|110
SE|183||ti|2|entity|C0443288|Restricted|ftcn|||restricted|||0|890|129|139
SE|183||ti|2|entity|C0013123|Water consumption|orgf|||water intakes|||0|890|140|153


SE|184||ti|1|text|16|115|Insect morphogenetic hormones and developmental mechanisms in the nematode, Nematospiroides dubius.
SE|184||ti|1|entity|C0026559|Morphogenesis|orgf|||morphogenetic|||0|877|23|36
SE|184||ti|1|entity|C0021571|Insect Hormones|horm|||Insect morphogenetic hormones|||0|877|16|45
SE|184||ti|1|entity|C0458003|Developmental|qlco|||developmental|||0|888|50|63
SE|184||ti|1|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|888|64|74
SE|184||ti|1|entity|C0027581|Nematoda|invt|||nematode|||0|1000|82|90
SE|184||ti|1|entity|C0027586|Nematospiroides dubius|invt|||Nematospiroides dubius|||0|1000|92|114


SE|185||ti|1|text|16|107|Osmotic interrelationship between blood and gut fluid in the isopod Porcellio scaber Latr.
SE|185||ti|1|entity|C0311417|Osmotic|ftcn|||Osmotic|||0|694|16|23
SE|185||ti|1|entity|C0005767|Blood|tisu|||blood|||0|1000|50|55
SE|185||ti|1|entity|C0699819|Gut|bpoc|||gut|||0|888|60|63
SE|185||ti|1|entity|C0302908|Liquid substance|sbst|||fluid|||0|888|64|69
SE|185||ti|1|entity|C0598806|Isopoda|invt|||isopod|||0|641|77|83
SE|185||ti|1|entity|C1084675|Porcellio scaber|invt|||Porcellio scaber|||0|641|84|100

SE|185||ti|2|text|107|119|(Crustacea).
SE|185||ti|2|entity|C0010395|Crustacea|invt|||Crustacea|||0|1000|108|117


SE|186||ti|1|text|16|99|Effects of thermal stimulation to the spinal cord on heart rate in cyprinid fishes.
SE|186||ti|1|entity|C1280500|Effect|qlco|||Effects|||0|966|16|23
SE|186||ti|1|entity|C0037925|Spinal Cord|bpoc|||spinal cord|||0|1000|54|65
SE|186||ti|1|entity|C0018810|heart rate|orga|||heart rate|||0|1000|69|79
SE|186||ti|1|entity|C0016163|Fishes|fish|||fishes|||0|861|92|98


SE|187||ti|1|text|16|111|The long-term monitoring of ventilation rhythms of the polychaetous annelid Nereis virens sars.
SE|187||ti|1|entity|C0443252|Long-term|tmco|||long-term|||0|734|20|29
SE|187||ti|1|entity|C0035203|Respiration|phsf|||ventilation|||0|872|44|55
SE|187||ti|1|entity|C0871269|Rhythm|tmco|||rhythms|||0|872|56|63
SE|187||ti|1|entity|C0003096|Annelida|invt|||annelid|||0|798|84|91
SE|187||ti|1|entity|C0998000|Nereis virens|invt|||Nereis virens|||0|798|92|105
SE|187||ti|1|entity|C1175175|Severe Acute Respiratory Syndrome|dsyn|||sars|||0|798|106|110


SE|188||ti|1|text|16|84|Diving bradycardia in four species of North American aquatic snakes.
SE|188||ti|1|entity|C0428977|Bradycardia|fndg|||bradycardia|||0|1000|23|34
SE|188||ti|1|entity|C0205450|Four|qnco|||four|||0|888|38|42
SE|188||ti|1|entity|C1548151|Species|idcn|||species|||0|888|43|50
SE|188||ti|1|entity|C0596070|American|popg|||American|||0|763|60|68
SE|188||ti|1|entity|C0037382|Snakes|rept|||snakes|||0|763|77|83


SE|189||ti|1|text|16|120|Respiratory responses of Gillichthys mirabilis to changes in temperature, dissolved oxygen and salinity.
SE|189||ti|1|entity|C0521346|respiratory|ftcn|||Respiratory|||0|888|16|27
SE|189||ti|1|entity|C0871261|response|clna|||responses|||0|888|28|37
SE|189||ti|1|entity|C0329512|Gillichthys mirabilis|fish|||Gillichthys mirabilis|||0|1000|41|62
SE|189||ti|1|entity|C0039476|Temperature|qnco|||temperature|||0|1000|77|88
SE|189||ti|1|entity|C1549535|Dissolve|ftcn|||dissolved|||0|872|90|99
SE|189||ti|1|entity|C0030054|Oxygen|elii,phsu|||oxygen|||0|872|100|106
SE|189||ti|1|entity|C0036082|Saline|clnd|||salinity|||0|928|111|119


SE|190||ti|1|text|16|109|The pronephroi as the site of presumptive interrenal cells in the hagfish Myxine glutinosa L.
SE|190||ti|1|entity|C0231048|Pronephric structure|emst|||pronephroi|||0|916|20|30
SE|190||ti|1|entity|C0205145|Site|spco|||site|||0|1000|38|42
SE|190||ti|1|entity|C0007634|Cells|cell|||cells|||0|827|69|74
SE|190||ti|1|entity|C0018492|Hagfish|invt|||hagfish|||0|850|82|89
SE|190||ti|1|entity|C0327586|Myxine glutinosa|fish|||Myxine glutinosa|||0|850|90|106


SE|191||ti|1|text|16|87|Excreta analysis on additional cockroach species and the house cricket.
SE|191||ti|1|entity|C0936012|Analysis|resa|||analysis|||0|861|24|32
SE|191||ti|1|entity|C1524062|Additional|ftcn|||additional|||0|851|36|46
SE|191||ti|1|entity|C0009208|Dictyoptera|invt|||cockroach|||0|851|47|56
SE|191||ti|1|entity|C1548151|Species|idcn|||species|||0|851|57|64
SE|191||ti|1|entity|C1054662|Gryllinae|invt|||house cricket|||0|966|73|86


SE|192||ti|1|text|16|86|Interrelationships between water and metabolism in Artemia cysts--II.
SE|192||ti|1|entity|C0020311|Hydrotherapy|topp|||water|||0|1000|43|48
SE|192||ti|1|entity|C0025519|Metabolism|orgf|||metabolism|||0|1000|53|63
SE|192||ti|1|entity|C0003831|Artemia|invt|||Artemia|||0|888|67|74
SE|192||ti|1|entity|C0010709|Cyst|anab|||cysts|||0|888|75|80
SE|192||ti|1|relation|3|2|C0020311|Hydrotherapy|topp|topp|||water|||0|1000|43|48|PREP|TREATS||64|66|2|1|C0010709|Cyst|anab|anab|||cysts|||0|888|75|80

SE|192||ti|2|text|86|100|Carbohydrates.
SE|192||ti|2|entity|C0007004|Carbohydrates|carb|||Carbohydrates|||0|1000|86|99


SE|193||ti|1|text|16|87|Interrelationships between water and metabolism in Artemia cysts--III.
SE|193||ti|1|entity|C0020311|Hydrotherapy|topp|||water|||0|1000|43|48
SE|193||ti|1|entity|C0025519|Metabolism|orgf|||metabolism|||0|1000|53|63
SE|193||ti|1|entity|C0003831|Artemia|invt|||Artemia|||0|888|67|74
SE|193||ti|1|entity|C0010709|Cyst|anab|||cysts|||0|888|75|80
SE|193||ti|1|entity|C0439070|III|inpr|||III|||0|1000|82|85
SE|193||ti|1|relation|3|2|C0020311|Hydrotherapy|topp|topp|||water|||0|1000|43|48|PREP|TREATS||64|66|2|1|C0010709|Cyst|anab|anab|||cysts|||0|888|75|80

SE|193||ti|2|text|87|99|Respiration.
SE|193||ti|2|entity|C0035203|Respiration|phsf|||Respiration|||0|1000|87|98


SE|194||ti|1|text|16|60|Studies on avian erythrocyte metabolism--I.
SE|194||ti|1|entity|C0008972|Clinical Research|resa|||Studies|||0|966|16|23
SE|194||ti|1|entity|C0005595|Aves|bird|||avian|||0|851|27|32
SE|194||ti|1|entity|C0014792|Erythrocytes|cell|||erythrocyte|||0|851|33|44
SE|194||ti|1|entity|C0025519|Metabolism|orgf|||metabolism|||0|851|45|55

SE|194||ti|2|text|60|187|Procedure for separation and quantitation of the major phosphorylated metabolic intermediates by anion exchange chromatography.
SE|194||ti|2|entity|C0184661|Procedures|hlca|||Procedure|||0|1000|60|69
SE|194||ti|2|entity|C0036679|Diastasis|patf|||separation|||0|1000|74|84
SE|194||ti|2|entity|C0205164|Major|qlco|||major|||0|764|109|114
SE|194||ti|2|entity|C0311400|Metabolic|ftcn|||metabolic|||0|764|130|139
SE|194||ti|2|entity|C0205103|Intermediate|spco|||intermediates|||0|764|140|153
SE|194||ti|2|entity|C0003075|Anions|elii|||anion|||0|851|157|162
SE|194||ti|2|entity|C0678640|exchange|socb|||exchange|||0|851|163|171
SE|194||ti|2|entity|C0008550|Chromatography|lbpr|||chromatography|||0|851|172|186
SE|194||ti|2|relation|1|1|C0184661|Procedures|hlca|hlca|||Procedure|||0|1000|60|69|PREP|TREATS||70|73|4|1|C0036679|Diastasis|patf|patf|||separation|||0|1000|74|84


SE|196||ti|1|text|16|120|Evaluation of amplitude and frequency changes of miniature potentials with a poor signal-to-noise ratio.
SE|196||ti|1|entity|C0220825|Evaluation|ftcn|||Evaluation|||0|1000|16|26
SE|196||ti|1|entity|C0439603|Frequencies (time pattern)|tmco|||frequency|||0|1000|44|53
SE|196||ti|1|entity|C0237399|Potential|qlco|||potentials|||0|827|75|85
SE|196||ti|1|entity|C0032854|Poverty|grpa|||poor|||0|749|93|97
SE|196||ti|1|entity|C0037083|Signal Transduction|celf|||signal|||0|749|98|104
SE|196||ti|1|entity|C0028263|Noise|phpr|||noise|||0|749|108|113
SE|196||ti|1|entity|C0456603|Ratio|inpr|||ratio|||0|749|114|119


SE|195||ti|1|text|16|99|Effect of different prostaglandins on the permeability of the toad urinary bladder.
SE|195||ti|1|entity|C1280500|Effect|qlco|||Effect|||0|1000|16|22
SE|195||ti|1|entity|C1547020|*Difference|qnco|||different|||0|853|26|35
SE|195||ti|1|entity|C0033554|Prostaglandins|bacs,eico,phsu|||prostaglandins|||0|853|36|50
SE|195||ti|1|entity|C0031164|Permeability|npop|||permeability|||0|1000|58|70
SE|195||ti|1|entity|C0327011|Toad|amph|||toad|||0|901|78|82
SE|195||ti|1|entity|C0005682|Bladder|bpoc|||urinary bladder|||0|901|83|98
SE|195||ti|1|relation|0|0|C0005682|Bladder|bpoc|bpoc|||urinary bladder|||0|901|83|98|MOD/HEAD|PART_OF||78|98|0|0|C0327011|Toad|amph|amph|||toad|||0|901|78|82
SE|195||ti|1|relation|3|1|C0033554|Prostaglandins|bacs,eico,phsu|bacs|||prostaglandins|||0|853|36|50|NOM|AFFECTS||16|22|3|2|C0031164|Permeability|npop|npop|||permeability|||0|1000|58|70


SE|197||ti|1|text|16|139|Practolol, caffeine and calcium in the regulation of mechanical activity of the cardiac ventricle in Myxine glutinosa (L.).
SE|197||ti|1|entity|C0032896|Practolol|orch,phsu|||Practolol|||0|1000|16|25
SE|197||ti|1|entity|C0006644|Caffeine|orch,phsu|||caffeine|||0|1000|27|35
SE|197||ti|1|entity|C0006675|Calcium|bacs,elii|||calcium|||0|1000|40|47
SE|197||ti|1|entity|C0851285|Regulation|gora|||regulation|||0|1000|55|65
SE|197||ti|1|entity|C0018827|Heart Ventricle|bpoc|||cardiac ventricle|||0|1000|96|113
SE|197||ti|1|entity|C0327586|Myxine glutinosa|fish|||Myxine glutinosa|||0|1000|117|133


SE|198||ti|1|text|16|94|Asymmetric distribution of aspartate in ganglia and single neurons of Aplysia.
SE|198||ti|1|entity|C0332514|Asymmetry|spco|||Asymmetric|||0|888|16|26
SE|198||ti|1|entity|C0520511|Distributing|idcn|||distribution|||0|888|27|39
SE|198||ti|1|entity|C0085845|Aspartate|aapp,bacs|||aspartate|||0|1000|43|52
SE|198||ti|1|entity|C0017067|Ganglia|bpoc|||ganglia|||0|1000|56|63
SE|198||ti|1|entity|C0037179|Unmarried person|popg|||single|||0|888|68|74
SE|198||ti|1|entity|C0027882|Neurons|cell|||neurons|||0|888|75|82
SE|198||ti|1|entity|C0003577|Aplysia|invt|||Aplysia|||0|1000|86|93
SE|198||ti|1|relation|3|1|C0017067|Ganglia|bpoc|bpoc|||ganglia|||0|1000|56|63|PREP|LOCATION_OF||53|55|2|1|C0085845|Aspartate|aapp,gngm,bacs|aapp|||aspartate|||0|1000|43|52


SE|199||ti|1|text|16|127|Electrophysiological actions of convulsants and anticonvulsants on neurons of the leech subesophageal ganglion.
SE|199||ti|1|entity|C0009950|Convulsants|hops,phsu|||convulsants|||0|1000|48|59
SE|199||ti|1|entity|C0003286|Anticonvulsants|phsu|||anticonvulsants|||0|1000|64|79
SE|199||ti|1|entity|C0027882|Neurons|cell|||neurons|||0|1000|83|90
SE|199||ti|1|entity|C0023209|Leeches|invt|||leech|||0|802|98|103
SE|199||ti|1|entity|C0017067|Ganglia|bpoc|||ganglion|||0|802|118|126
SE|199||ti|1|relation|2|1|C0027882|Neurons|cell|cell|||neurons|||0|1000|83|90|PREP|LOCATION_OF||80|82|3|2|C0003286|Anticonvulsants|phsu|phsu|||anticonvulsants|||0|1000|64|79
SE|199||ti|1|relation|2|1|C0027882|Neurons|cell|cell|||neurons|||0|1000|83|90|PREP|LOCATION_OF||80|82|3|2|C0009950|Convulsants|hops,phsu|hops|||convulsants|||0|1000|48|59
SE|199||ti|1|relation|4|1|C0027882|Neurons|cell|cell|||neurons|||0|1000|83|90|PREP|PART_OF||91|93|1|1|C0017067|Ganglia|bpoc|bpoc|||ganglion|||0|802|118|126


SE|200||ti|1|text|16|168|The relative importance of monoamine oxidase and catechol-O-methyl transferase on the physiologic response to administered norepinephrine in the turkey.
SE|200||ti|1|entity|C0205345|Relative|qlco|||relative|||0|694|20|28
SE|200||ti|1|entity|C0026454|Monoamine Oxidase|aapp,enzy|||monoamine oxidase|||0|1000|43|60
SE|200||ti|1|entity|C0007413|Catechols|orch|||catechol|||0|775|65|73
SE|200||ti|1|entity|C0040676|Transferase|aapp,enzy|||transferase|||0|775|83|94
SE|200||ti|1|entity|C1546213|Physiologic Responses|fndg|||physiologic response|||0|983|102|122
SE|200||ti|1|entity|C0028351|Norepinephrine|nsba,orch,phsu|||norepinephrine|||0|861|139|153
SE|200||ti|1|entity|C0325628|Meleagris gallopavo|bird|||turkey|||0|1000|161|167


SE|201||ti|1|text|16|137|The cardiac cycle and the effects of neurohumors on myocardial contractility in the Asiatic eel Anguilla japonica, Timm.
SE|201||ti|1|entity|C0018787|Heart|bpoc|||cardiac|||0|888|20|27
SE|201||ti|1|entity|C0750729|Course|tmco|||cycle|||0|888|28|33
SE|201||ti|1|entity|C1280500|Effect|qlco|||effects|||0|966|42|49
SE|201||ti|1|entity|C0949369|Neurohumors|nsba|||neurohumors|||0|1000|53|64
SE|201||ti|1|entity|C0027045|Myocardial Contraction|ortf|||myocardial contractility|||0|950|68|92
SE|201||ti|1|entity|C0013671|Eels|fish|||eel|||0|824|108|111
SE|201||ti|1|entity|C0327782|Anguilla japonica|fish|||Anguilla japonica|||0|824|112|129
SE|201||ti|1|relation|0|0|C0327782|Anguilla japonica|fish|fish|||Anguilla japonica|||0|824|112|129|MOD/HEAD|ISA||108|129|0|0|C0013671|Eels|fish|fish|||eel|||0|824|108|111
SE|201||ti|1|relation|4|1|C0027045|Myocardial Contraction|ortf|ortf|||myocardial contractility|||0|950|68|92|PREP|PROCESS_OF||93|95|2|1|C0327782|Anguilla japonica|fish|fish|||Anguilla japonica|||0|824|112|129
SE|201||ti|1|relation|4|1|C0949369|Neurohumors|nsba|nsba|||neurohumors|||0|1000|53|64|NOM|AFFECTS||42|49|4|2|C0027045|Myocardial Contraction|ortf|ortf|||myocardial contractility|||0|950|68|92

SE|201||ti|2|text|137|145|& Schle.


SE|202||ti|1|text|16|128|Characteristics of the noradrenergic innervation of the left atrium in the chick (Gallus gallus domesticus, L.).
SE|202||ti|1|entity|C1521970|Characteristics|grpa|||Characteristics|||0|1000|16|31
SE|202||ti|1|entity|C0599861|noradrenergic|moft|||noradrenergic|||0|888|39|52
SE|202||ti|1|entity|C0021516|nerve supply|ortf|||innervation|||0|888|53|64
SE|202||ti|1|entity|C0225860|Left atrial structure|bpoc|||left atrium|||0|1000|72|83
SE|202||ti|1|entity|C0008051|Chickens|bird|||Gallus gallus domesticus|||0|1000|98|122


SE|203||ti|1|text|16|66|Responsiveness of neurogenic hearts to octopamine.
SE|203||ti|1|entity|C0205342|Responsive|ftcn|||Responsiveness|||0|928|16|30
SE|203||ti|1|entity|C0018787|Heart|bpoc|||hearts|||0|861|45|51
SE|203||ti|1|entity|C0028403|Octopamine|nsba,orch,phsu|||octopamine|||0|1000|55|65


SE|204||ti|1|text|16|65|Action of kainic acid on a glutamatergic synapse.
SE|204||ti|1|entity|C0022471|Kainic Acid|orch,phsu|||kainic acid|||0|1000|26|37
SE|204||ti|1|entity|C0039062|Synapses|bsoj|||synapse|||0|861|57|64


SE|205||ti|1|text|16|273|The effects of 5-hydroxytryptamine depletors and monoamine oxidase inhibitors on color changes of the fiddler crab, Uca pugilator: further evidence in support of the hypothesis that 5-hydroxytryptamine controls the release of red pigment-dispersing hormone.
SE|205||ti|1|entity|C1280500|Effect|qlco|||effects|||0|966|20|27
SE|205||ti|1|entity|C0036751|Serotonin|nsba,orch|||5-hydroxytryptamine|||0|734|31|50
SE|205||ti|1|entity|C0026457|Monoamine Oxidase Inhibitors|phsu|||monoamine oxidase inhibitors|||0|1000|65|93
SE|205||ti|1|entity|C0009393|Color|npop|||color|||0|1000|97|102
SE|205||ti|1|entity|C0010260|Crabs|invt|||crab|||0|861|126|130
SE|205||ti|1|entity|C0998281|Celuca pugilator|invt|||Uca pugilator|||0|1000|132|145
SE|205||ti|1|entity|C1517331|Further|spco|||further|||0|694|147|154
SE|205||ti|1|entity|C1512571|Hypothesis|idcn|||hypothesis|||0|1000|182|192
SE|205||ti|1|entity|C0036751|Serotonin|nsba,orch|||5-hydroxytryptamine|||0|1000|198|217
SE|205||ti|1|entity|C0332575|Redness|fndg|||red|||0|888|242|245
SE|205||ti|1|entity|C0031916|Pigment|chvf|||pigment|||0|888|246|253
SE|205||ti|1|entity|C0019932|Hormones|horm|||hormone|||0|1000|265|272


SE|206||ti|1|text|16|77|Evidence of a gastrin-like substance in Rhinobatus productus.
SE|206||ti|1|entity|C0376180|Gastrin|aapp,horm|||gastrin|||0|1000|30|37
SE|206||ti|1|entity|C0439861|Substance|sbst|||substance|||0|1000|43|52


SE|207||ti|1|text|16|142|5-hydroxytryptamine as a possible inhibitory neurotransmitter in the central nervous system of the leech, Haemopis sanguisuga.
SE|207||ti|1|entity|C0036751|Serotonin|nsba,orch|||5-hydroxytryptamine|||0|1000|16|35
SE|207||ti|1|entity|C0332149|Possible|qlco|||possible|||0|828|41|49
SE|207||ti|1|entity|C0243077|inhibitors|chvf|||inhibitory|||0|828|50|60
SE|207||ti|1|entity|C0027908|Neurotransmitters|nsba|||neurotransmitter|||0|828|61|77
SE|207||ti|1|entity|C0927232|Neuraxis|bdsy|||central nervous system|||0|1000|85|107
SE|207||ti|1|entity|C0023209|Leeches|invt|||leech|||0|1000|115|120
SE|207||ti|1|entity|C1016352|Haemopis sanguisuga|invt|||Haemopis sanguisuga|||0|1000|122|141


SE|208||ti|1|text|16|58|Gastrin-like activity in an Indian python.
SE|208||ti|1|entity|C0376180|Gastrin|aapp,horm|||Gastrin|||0|1000|16|23
SE|208||ti|1|entity|C0327302|Python molurus|rept|||Indian python|||0|1000|44|57


SE|209||ti|1|text|16|55|Kinetics of antibody--hapten reactions.
SE|209||ti|1|entity|C0022702|Kinetics|idcn|||Kinetics|||0|1000|16|24
SE|209||ti|1|entity|C0003241|Antibodies|aapp,imft|||antibody|||0|1000|28|36
SE|209||ti|1|entity|C0018593|Haptens|imft|||hapten|||0|872|38|44
SE|209||ti|1|entity|C0443286|Reaction|ftcn|||reactions|||0|872|45|54


SE|210||ti|1|text|16|78|Influence of pH and hypoxia on the success of defibrillation.
SE|210||ti|1|entity|C0242184|Hypoxia|patf|||hypoxia|||0|1000|36|43
SE|210||ti|1|entity|C0597535|Success|socb|||success|||0|1000|51|58
SE|210||ti|1|entity|C0013778|Electric Countershock|topp|||defibrillation|||0|1000|62|76

SE|210||ab|1|text|84|308|Clinical impressions about the problem of defibrillation during states of acid-base imbalance and hypoxia have been influenced by studies involving the effect of these derangements on the ventricular fibrillation threshold.
SE|210||ab|1|entity|C0205210|Clinical|qlco|||Clinical|||0|872|84|92
SE|210||ab|1|entity|C0596764|impression|inbe|||impressions|||0|872|93|104
SE|210||ab|1|entity|C0013778|Electric Countershock|topp|||defibrillation|||0|1000|126|140
SE|210||ab|1|entity|C1442792|State|ftcn|||states|||0|966|148|154
SE|210||ab|1|entity|C0001118|Acid-Base Imbalance|patf|||acid-base imbalance|||0|1000|158|177
SE|210||ab|1|entity|C0242184|Hypoxia|patf|||hypoxia|||0|1000|182|189
SE|210||ab|1|entity|C0008972|Clinical Research|resa|||studies|||0|966|214|221
SE|210||ab|1|entity|C1280500|Effect|qlco|||effect|||0|1000|236|242
SE|210||ab|1|entity|C0042510|Ventricular Fibrillation|dsyn|||ventricular fibrillation|||0|901|272|296
SE|210||ab|1|entity|C0449864|Threshold|ftcn|||threshold|||0|901|297|306

SE|210||ab|2|text|308|501|Based on body weight, energy requirements for defibrillation in normal dogs were compared to requirements in dogs subjected to commonly encountered acid-base disturbances and severe hypoxemia.
SE|210||ab|2|entity|C0005910|Body Weight|orga|||body weight|||0|1000|317|328
SE|210||ab|2|entity|C0489460|Energy requirement|qnco|||energy requirements|||0|983|330|349
SE|210||ab|2|entity|C0013778|Electric Countershock|topp|||defibrillation|||0|1000|354|368
SE|210||ab|2|entity|C0205307|Normal|qlco|||normal|||0|888|372|378
SE|210||ab|2|entity|C0012984|Canis familiaris|mamm|||dogs|||0|888|379|383
SE|210||ab|2|entity|C1514873|Requirement|idcn|||requirements|||0|966|401|413
SE|210||ab|2|entity|C0012984|Canis familiaris|mamm|||dogs|||0|1000|417|421
SE|210||ab|2|entity|C0545082|Visit|ftcn|||encountered|||0|535|444|455
SE|210||ab|2|entity|C0001128|Acids|chem|||acid|||0|535|456|460
SE|210||ab|2|entity|C0205082|Severe|qlco|||severe|||0|888|483|489
SE|210||ab|2|entity|C0700292|Hypoxemia|fndg|||hypoxemia|||0|888|490|499
SE|210||ab|2|relation|3|1|C0013778|Electric Countershock|topp|topp|||defibrillation|||0|1000|354|368|PREP|TREATS||369|371|5|1|C0012984|Canis familiaris|mamm|mamm|||dogs|||0|888|379|383
SE|210||ab|2|relation|5|3|C0013778|Electric Countershock|topp|topp|||defibrillation|||0|1000|354|368|PREP|TREATS||414|416|3|1|C0012984|Canis familiaris|mamm|mamm|||dogs|||0|1000|417|421

SE|210||ab|3|text|501|540|No significant differences were found.
SE|210||ab|3|entity|C0750502|Significant|idcn|||significant|||0|872|504|515
SE|210||ab|3|entity|C1547020|*Difference|qnco|||differences|||0|872|516|527

SE|210||ab|4|text|540|656|Seventy-five percent of all animals in the study were electrically converted with low-to-moderate levels of energy.
SE|210||ab|4|entity|C0205451|Five|qnco|||five|||0|660|548|552
SE|210||ab|4|entity|C0003062|Animals|anim|||animals|||0|1000|568|575
SE|210||ab|4|entity|C0008972|Clinical Research|resa|||study|||0|1000|583|588
SE|210||ab|4|entity|C0205251|low|qlco|||low|||0|791|622|625
SE|210||ab|4|entity|C0441889|Levels|inpr|||levels|||0|791|638|644
SE|210||ab|4|entity|C0424589|Vitality|fndg|||energy|||0|1000|648|654

SE|210||ab|5|text|656|803|The incidence of spontaneous resumption of circulation following defibrillation was lowest in animals subjected to metabolic acidosis and hypoxia.
SE|210||ab|5|entity|C0021149|Incidence|qnco|||incidence|||0|1000|660|669
SE|210||ab|5|entity|C0205359|Spontaneous|ftcn|||spontaneous|||0|694|673|684
SE|210||ab|5|entity|C0013778|Electric Countershock|topp|||defibrillation|||0|1000|721|735
SE|210||ab|5|entity|C0205251|low|qlco|||lowest|||0|966|740|746
SE|210||ab|5|entity|C0003062|Animals|anim|||animals|||0|1000|750|757
SE|210||ab|5|entity|C0220981|Metabolic acidosis|patf|||metabolic acidosis|||0|1000|771|789
SE|210||ab|5|entity|C0242184|Hypoxia|patf|||hypoxia|||0|1000|794|801

SE|210||ab|6|text|803|999|The results suggest that pH and blood gas alterations, previously shown to influence the normal ventricular fibrillation threshold, do not significantly affect the normal defibrillation threshold.
SE|210||ab|6|entity|C1274040|result|ftcn|||results|||0|966|807|814
SE|210||ab|6|entity|C0005800|Blood Gas Analysis|lbpr|||blood gas|||0|890|835|844
SE|210||ab|6|entity|C1515926|Alteration|idcn|||alterations|||0|890|845|856
SE|210||ab|6|entity|C0205307|Normal|qlco|||normal|||0|861|892|898
SE|210||ab|6|entity|C0042510|Ventricular Fibrillation|dsyn|||ventricular fibrillation|||0|861|899|923
SE|210||ab|6|entity|C0449864|Threshold|ftcn|||threshold|||0|861|924|933
SE|210||ab|6|entity|C1518422|Not|ftcn|||not|||0|1000|938|941
SE|210||ab|6|entity|C0205307|Normal|qlco|||normal|||0|851|967|973
SE|210||ab|6|entity|C0013778|Electric Countershock|topp|||defibrillation|||0|851|974|988
SE|210||ab|6|entity|C0449864|Threshold|ftcn|||threshold|||0|851|989|998


SE|211||ti|1|text|16|72|Effects of maleate on renal reabsorption of bicarbonate.
SE|211||ti|1|entity|C1280500|Effect|qlco|||Effects|||0|966|16|23
SE|211||ti|1|entity|C0024572|Maleates|orch|||maleate|||0|1000|27|34
SE|211||ti|1|entity|C0022646|Kidney|bpoc|||renal|||0|694|38|43
SE|211||ti|1|entity|C0005367|Bicarbonates|inch|||bicarbonate|||0|1000|60|71


SE|212||ti|1|text|16|84|Bicarbonate inhibition of rat kidney aconitate hydratase isoenzymes.
SE|212||ti|1|entity|C0005367|Bicarbonates|inch|||Bicarbonate|||0|888|16|27
SE|212||ti|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|840|42|45
SE|212||ti|1|entity|C0022646|Kidney|bpoc|||kidney|||0|840|46|52
SE|212||ti|1|entity|C0001156|Aconitate Hydratase|aapp,enzy|||aconitate hydratase|||0|840|53|72
SE|212||ti|1|entity|C0022173|Isoenzymes|aapp,enzy|||isoenzymes|||0|840|73|83
SE|212||ti|1|relation|0|0|C0001156|Aconitate Hydratase|aapp,gngm,enzy|aapp|||aconitate hydratase|||0|840|53|72|MOD/HEAD|PART_OF||46|72|0|0|C0022646|Kidney|bpoc|bpoc|||kidney|||0|840|46|52
SE|212||ti|1|relation|0|0|C0005367|Bicarbonates|inch|inch|||Bicarbonate|||0|888|16|27|NOM|INHIBITS||28|38|1|1|C0001156|Aconitate Hydratase|aapp,gngm,enzy|gngm|||aconitate hydratase|||0|840|53|72


SE|213||ti|1|text|16|106|Metabolic studies in experimental renal dysfunction resulting from maleate administration.
SE|213||ti|1|entity|C0280606|metabolic abnormality assessment|diap|||Metabolic studies|||0|1000|16|33
SE|213||ti|1|entity|C1517004|Experimental|ftcn|||experimental|||0|882|37|49
SE|213||ti|1|entity|C0151746|Abnormal renal function|patf|||renal dysfunction|||0|882|50|67
SE|213||ti|1|entity|C0024572|Maleates|orch|||maleate|||0|888|83|90
SE|213||ti|1|relation|1|1|C0280606|metabolic abnormality assessment|diap|diap|||Metabolic studies|||0|1000|16|33|PREP|DIAGNOSES||34|36|2|1|C0151746|Abnormal renal function|patf|patf|||renal dysfunction|||0|882|50|67


SE|214||ti|1|text|16|57|Multiple endocrine adenomatosis-I and II.
SE|214||ti|1|entity|C0027662|Multiple Endocrine Neoplasia|neop|||Multiple endocrine adenomatosis|||0|1000|16|47


SE|215||ti|1|text|16|99|A randomized double-blind study of timolol in patients with essential hypertension.
SE|215||ti|1|entity|C1514720|Randomized|ftcn|||randomized|||0|916|18|28
SE|215||ti|1|entity|C0013072|Double-Blind Method|resa|||double-blind study|||0|916|29|47
SE|215||ti|1|entity|C0040233|Timolol|orch,phsu|||timolol|||0|1000|51|58
SE|215||ti|1|entity|C0030705|Patients|podg|||patients|||0|1000|62|70
SE|215||ti|1|entity|C0085580|Essential Hypertension|dsyn|||essential hypertension|||0|1000|76|98
SE|215||ti|1|relation|0|0|C0040233|Timolol|orch,phsu|phsu|||timolol|||0|1000|51|58|INFER|TREATS(INFER)||59|61|0|0|C0085580|Essential Hypertension|dsyn|dsyn|||essential hypertension|||0|1000|76|98
SE|215||ti|1|relation|1|1|C0085580|Essential Hypertension|dsyn|dsyn|||essential hypertension|||0|1000|76|98|PREP|PROCESS_OF||71|75|3|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|62|70
SE|215||ti|1|relation|2|1|C0040233|Timolol|orch,phsu|phsu|||timolol|||0|1000|51|58|PREP|TREATS||59|61|2|1|C0030705|Patients|podg,humn|podg|||patients|||0|1000|62|70


SE|216||ti|1|text|16|85|[Observation of permanent teeth adjacent to teeth damaged by trauma].
SE|216||ti|1|entity|C0348070|Structure of permanent tooth|bpoc|||permanent teeth|||0|1000|32|47
SE|216||ti|1|entity|C0205117|Adjacent|spco|||adjacent|||0|1000|48|56
SE|216||ti|1|entity|C0040426|Tooth structure|bpoc|||teeth|||0|1000|60|65
SE|216||ti|1|entity|C0043251|Wounds and Injuries|inpo|||trauma|||0|1000|77|83


SE|217||ti|1|text|16|124|Idiopathic hypertrophic subaortic stenosis (hypertrophic obstructive cardiomyopathy) changing concepts-1975.
SE|217||ti|1|entity|C0700053|Idiopathic hypertrophic subaortic stenosis|dsyn|||Idiopathic hypertrophic subaortic stenosis|||0|1000|16|58
SE|217||ti|1|entity|C0007194|Hypertrophic Cardiomyopathy|dsyn|||hypertrophic obstructive cardiomyopathy|||0|1000|60|99
SE|217||ti|1|entity|C0392747|Changing|ftcn|||changing|||0|790|101|109
SE|217||ti|1|entity|C0178566|concept|idcn|||concepts|||0|790|110|118
SE|217||ti|1|relation|0|0|C0700053|Idiopathic hypertrophic subaortic stenosis|dsyn|dsyn|||Idiopathic hypertrophic subaortic stenosis|||0|1000|16|58|SPEC|ISA||16|99|0|0|C0007194|Hypertrophic Cardiomyopathy|dsyn|dsyn|||hypertrophic obstructive cardiomyopathy|||0|1000|60|99


SE|218||ti|1|text|16|68|Pleural effusion associated with aortitis syndrome.
SE|218||ti|1|entity|C0032227|Pleural effusion disorder|patf|||Pleural effusion|||0|1000|16|32
SE|218||ti|1|entity|C0003510|Aortitis Syndrome|dsyn|||aortitis syndrome|||0|1000|49|66
SE|218||ti|1|relation|1|1|C0003510|Aortitis Syndrome|dsyn|dsyn|||aortitis syndrome|||0|1000|49|66|VERB|COEXISTS_WITH||33|43|1|1|C0032227|Pleural effusion disorder|patf|patf|||Pleural effusion|||0|1000|16|32

SE|218||ab|1|text|74|242|A patient with aortitis syndrome had a pleural effusion which subsided but reappeared with an exacerbation of aortitis symptoms while under antituberculosis treatment.
SE|218||ab|1|entity|C0030705|Patients|podg|||patient|||0|1000|76|83
SE|218||ab|1|entity|C0003510|Aortitis Syndrome|dsyn|||aortitis syndrome|||0|1000|89|106
SE|218||ab|1|entity|C0032227|Pleural effusion disorder|patf|||pleural effusion|||0|1000|113|129
SE|218||ab|1|entity|C0003509|Aortitis|dsyn|||aortitis|||0|888|184|192
SE|218||ab|1|entity|C1457887|Symptoms|sosy|||symptoms|||0|888|193|201
SE|218||ab|1|entity|C0003448|Antitubercular Agents|phsu|||antituberculosis|||0|888|214|230
SE|218||ab|1|relation|4|1|C0032227|Pleural effusion disorder|patf|patf|||pleural effusion|||0|1000|113|129|AUX|PROCESS_OF||107|110|2|2|C0030705|Patients|podg,humn|humn|||patient|||0|1000|76|83
SE|218||ab|1|relation|5|0|C0003448|Antitubercular Agents|phsu|phsu|||antituberculosis|||0|888|214|230|NOM|TREATS||231|240|5|1|C1457887|Symptoms|sosy|sosy|||symptoms|||0|888|193|201
SE|218||ab|1|relation|5|1|C0003510|Aortitis Syndrome|dsyn|dsyn|||aortitis syndrome|||0|1000|89|106|PREP|PROCESS_OF||84|88|1|1|C0030705|Patients|podg,humn|humn|||patient|||0|1000|76|83

SE|218||ab|2|text|242|335|The character of the fluid was that of an exudate, and the glucose concentration was normal.
SE|218||ab|2|entity|C0302908|Liquid substance|sbst|||fluid|||0|1000|263|268
SE|218||ab|2|entity|C0015388|Exudate|bdsu|||exudate|||0|1000|284|291
SE|218||ab|2|entity|C0427743|Glucose concentration, test strip measurement|lbpr|||glucose concentration|||0|1000|301|322
SE|218||ab|2|entity|C0205307|Normal|qlco|||normal|||0|1000|327|333

SE|218||ab|3|text|335|447|Clinical and laboratory features of the case suggest that the effusion was part of the aortitis syndrome per se.
SE|218||ab|3|entity|C0205210|Clinical|qlco|||Clinical|||0|1000|335|343
SE|218||ab|3|entity|C0022877|Laboratory|mnob,orgt|||laboratory|||0|1000|348|358
SE|218||ab|3|entity|C0013687|effusion|patf|||effusion|||0|1000|397|405
SE|218||ab|3|entity|C0449719|Part|spco|||part|||0|1000|410|414
SE|218||ab|3|entity|C0003510|Aortitis Syndrome|dsyn|||aortitis syndrome|||0|1000|422|439


SE|219||ti|1|text|16|49|The metabolic fate of securinine.
SE|219||ti|1|entity|C0311400|Metabolic|ftcn|||metabolic|||0|853|20|29
SE|219||ti|1|entity|C1302234|Fatal|qlco|||fate|||0|853|30|34
SE|219||ti|1|entity|C0074259|securinine|orch,phsu|||securinine|||0|1000|38|48


SE|220||ti|1|text|16|84|[Transplantation and preservation of tissue-typized skin in burns].
SE|220||ti|1|entity|C0040732|Transplantation|topp|||Transplantation|||0|1000|17|32
SE|220||ti|1|entity|C0033085|Preservation, Biological|lbpr|||preservation|||0|1000|37|49
SE|220||ti|1|entity|C0037267|Integumentary system|bdsy|||skin|||0|827|68|72
SE|220||ti|1|entity|C0006434|Burn injury|inpo|||burns|||0|1000|76|81
SE|220||ti|1|relation|3|2|C0033085|Preservation, Biological|lbpr|lbpr|||preservation|||0|1000|37|49|PREP|DIAGNOSES||73|75|1|1|C0006434|Burn injury|inpo|inpo|||burns|||0|1000|76|81

SE|220||ab|1|text|90|250|At the Department of Plastic Surgery and Burns, Berufsgenossenschaftliche Unfalklinik Ludwigshafen-Oggersheim, a skinbank with typed skin has been established.
SE|220||ab|1|entity|C0038911|Plastic Surgery Specialty|bmod|||Plastic Surgery|||0|1000|111|126
SE|220||ab|1|entity|C0006434|Burn injury|inpo|||Burns|||0|1000|131|136
SE|220||ab|1|entity|C0332307|Type - attribute|qlco|||typed|||0|853|217|222
SE|220||ab|1|entity|C0037267|Integumentary system|bdsy|||skin|||0|853|223|227

SE|220||ab|2|text|250|333|The storage system consists of deep-freezing at -196 degrees C in liquid nitrogen.
SE|220||ab|2|entity|C0449913|System|ftcn|||system|||0|888|262|268
SE|220||ab|2|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|303|312
SE|220||ab|2|entity|C0260055|Liquid nitrogen|elii|||liquid nitrogen|||0|1000|316|331

SE|220||ab|3|text|333|436|The transplantation of HL-A typed skin was evaluated from the clinical and histological point of view.
SE|220||ab|3|entity|C0040732|Transplantation|topp|||transplantation|||0|1000|337|352
SE|220||ab|3|entity|C0332307|Type - attribute|qlco|||typed|||0|714|361|366
SE|220||ab|3|entity|C0037267|Integumentary system|bdsy|||skin|||0|714|367|371
SE|220||ab|3|entity|C0205210|Clinical|qlco|||clinical|||0|1000|395|403
SE|220||ab|3|entity|C0205462|Histologic|ftcn|||histological|||0|694|408|420
SE|220||ab|3|entity|C0449911|View|orga|||view|||0|1000|430|434
SE|220||ab|3|relation|4|1|C0037267|Integumentary system|bdsy|bdsy|||skin|||0|714|367|371|PREP|LOCATION_OF||353|355|1|1|C0040732|Transplantation|topp|topp|||transplantation|||0|1000|337|352

SE|220||ab|4|text|436|523|Due to the effort necessary for such an undertaking this method is critically reviewed.
SE|220||ab|4|entity|C0041666|Undertaking|ocdi|||undertaking|||0|1000|476|487
SE|220||ab|4|entity|C0025663|Methods|inpr|||method|||0|1000|493|499


SE|221||ti|1|text|16|88|[Polyploidization and fusion of insect cells exposed to concanavalin A].
SE|221||ti|1|entity|C0332466|Fused structure|ftcn|||fusion|||0|1000|38|44
SE|221||ti|1|entity|C0021585|Insecta|invt|||insect|||0|888|48|54
SE|221||ti|1|entity|C0007634|Cells|cell|||cells|||0|888|55|60
SE|221||ti|1|entity|C0009630|Concanavalin A|aapp,bacs|||concanavalin A|||0|1000|72|86


SE|222||ti|1|text|16|117|[Ability of antilymphocyte sera to counteract the allogeneic inhibition of hematopoietic stem cells].
SE|222||ti|1|entity|C0085732|Ability|orga|||Ability|||0|1000|17|24
SE|222||ti|1|entity|C0003372|Antilymphocyte Serum|imft,phsu|||antilymphocyte sera|||0|1000|28|47
SE|222||ti|1|entity|C0301905|Allogeneic inhibition|phsf|||allogeneic inhibition|||0|1000|66|87
SE|222||ti|1|entity|C0018956|Hematopoietic stem cells|cell|||hematopoietic stem cells|||0|1000|91|115
SE|222||ti|1|relation|2|1|C0003372|Antilymphocyte Serum|imft,phsu|imft|||antilymphocyte sera|||0|1000|28|47|VERB|DISRUPTS||51|61|2|1|C0301905|Allogeneic inhibition|phsf|phsf|||allogeneic inhibition|||0|1000|66|87


SE|223||ti|1|text|16|160|[Microenvironment of enzymes as 1 of the factors determining enzyme stability. Stabilization of soluble and immobilized horseradish peroxidase].
SE|223||ti|1|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|1000|37|44
SE|223||ti|1|entity|C1521761|Factor|ftcn|||factors|||0|966|57|64
SE|223||ti|1|entity|C0014439|Enzyme Stability|qlco|||enzyme stability|||0|901|77|93
SE|223||ti|1|entity|C1293130|Stabilization|topp|||Stabilization|||0|901|95|108
SE|223||ti|1|entity|C0019941|Horseradish Peroxidase|aapp,enzy,irda|||horseradish peroxidase|||0|901|136|158


SE|224||ti|1|text|16|167|[3d regional meeting of the specialty field of supervisory nurses in Baden-Wurttemberg, Northern Group. June 25, 1975 in district hospital Heidenheim].
SE|224||ti|1|entity|C0205147|Region|spco|||regional|||0|840|20|28
SE|224||ti|1|entity|C0556656|Meetings|hlca|||meeting|||0|840|29|36
SE|224||ti|1|entity|C0037778|Medical Specialities|bmod|||specialty|||0|888|44|53
SE|224||ti|1|entity|C1521738|Field|cnce|||field|||0|888|54|59
SE|224||ti|1|entity|C0403172|Supervisor NOS|prog|||supervisory|||0|853|63|74
SE|224||ti|1|entity|C0028661|Nurses|prog|||nurses|||0|853|75|81
SE|224||ti|1|entity|C0441833|Groups|inpr|||Group|||0|812|113|118
SE|224||ti|1|entity|C0020006|Hospitals, District|hcro|||district hospital|||0|734|137|154


SE|225||ti|1|text|16|58|[Adverse effects of anti-epileptic drugs].
SE|225||ti|1|entity|C0879626|Adverse effects|patf|||Adverse effects|||0|1000|17|32
SE|225||ti|1|entity|C0014544|Epilepsy|dsyn|||epileptic|||0|790|41|50
SE|225||ti|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs|||0|790|51|56


SE|226||ti|1|text|16|84|Charge properties of human pituitary and amniotic fluid prolactins.
SE|226||ti|1|entity|C0871161|Property|qlco|||properties|||0|827|23|33
SE|226||ti|1|entity|C0020114|Human|humn|||human|||0|694|37|42
SE|226||ti|1|entity|C0002638|Amniotic Fluid|bdsu|||amniotic fluid|||0|884|57|71
SE|226||ti|1|entity|C0033371|Prolactin|aapp,horm|||prolactins|||0|884|72|82
SE|226||ti|1|relation|0|0|C0002638|Amniotic Fluid|bdsu|bdsu|||amniotic fluid|||0|884|57|71|MOD/HEAD|LOCATION_OF||57|82|0|0|C0033371|Prolactin|aapp,gngm,horm|aapp|||prolactins|||0|884|72|82

SE|226||ab|1|text|90|263|The apparent isoelectric points (pI) in isoelectric focusing (IF) of human pituitary and amniotic fluid prolactin (hPRL), both non-iodinated and iodinated, were determined.
SE|226||ab|1|entity|C0750489|APPARENT|idcn|||apparent|||0|901|94|102
SE|226||ab|1|entity|C0022171|Isoelectric Point|qnco|||isoelectric points|||0|901|103|121
SE|226||ab|1|entity|C0022169|Isoelectric Focusing|lbpr|||isoelectric focusing|||0|1000|130|150
SE|226||ab|1|entity|C0020114|Human|humn|||human|||0|694|159|164
SE|226||ab|1|entity|C0002638|Amniotic Fluid|bdsu|||amniotic fluid|||0|901|179|193
SE|226||ab|1|entity|C0033371|Prolactin|aapp,horm|||prolactin|||0|901|194|203
SE|226||ab|1|entity|||gngm|5618|PRLR|hPRL|||0|1000|205|209
SE|226||ab|1|relation|0|0|C0002638|Amniotic Fluid|bdsu|bdsu|||amniotic fluid|||0|901|179|193|MOD/HEAD|LOCATION_OF||179|203|0|0|C0033371|Prolactin|aapp,gngm,horm|aapp|||prolactin|||0|901|194|203

SE|226||ab|2|text|263|438|Unresolved mixtures of pituitary hPRL isohormones E and F, and of at least five isohormones found in amniotic fluid, and plasma hPRL exhibit an average pI value of 6.5 - 6.7.
SE|226||ab|2|entity|C0443342|Unresolved|qlco|||Unresolved|||0|872|263|273
SE|226||ab|2|entity|C0439962|Mixture|sbst|||mixtures|||0|872|274|282
SE|226||ab|2|entity|||gngm|5618|PRLR|hPRL|||0|779|296|300
SE|226||ab|2|entity|C0205451|Five|qnco|||five|||0|660|338|342
SE|226||ab|2|entity|C0002638|Amniotic Fluid|bdsu|||amniotic fluid|||0|1000|364|378
SE|226||ab|2|entity|C0032105|Plasma|bdsu|||plasma|||0|694|384|390
SE|226||ab|2|entity|||gngm|5618|PRLR|hPRL|||0|694|391|395
SE|226||ab|2|entity|C1510992|Average|qnco|||average|||0|1000|407|414
SE|226||ab|2|relation|0|0|C0032105|Plasma|bdsu|bdsu|||plasma|||0|694|384|390|MOD/HEAD|LOCATION_OF||384|395|0|0|||gngm,aapp|aapp|5618|PRLR|hPRL|||0|694|391|395

SE|226||ab|3|text|438|582|Transient state pH values observed or previously reported for hPRL components range from pH 5.9 to 6.8 after correction to standard conditions.
SE|226||ab|3|entity|C0040704|Transient Population Group|popg|||Transient|||0|833|438|447
SE|226||ab|3|entity|C1442792|State|ftcn|||state|||0|833|448|453
SE|226||ab|3|entity|C0042295|Values|qlco|||values|||0|833|457|463
SE|226||ab|3|entity|||gngm|5618|PRLR|hPRL|||0|773|500|504
SE|226||ab|3|entity|C1524073|Component, LOINC Axis 1|clas|||components|||0|773|505|515
SE|226||ab|3|entity|C1514721|Range|qnco|||range|||0|773|516|521
SE|226||ab|3|entity|C1546923|Correction|tmco|||correction|||0|1000|547|557
SE|226||ab|3|entity|C1442989|STANDARD|ftcn|||standard|||0|872|561|569
SE|226||ab|3|entity|C0348080|Condition|qlco|||conditions|||0|872|570|580

SE|226||ab|4|text|582|674|At pH 8.1, the major isohormone, hPRL-F, carriers a charge of 2.2 net protons per molecule.
SE|226||ab|4|entity|C0205164|Major|qlco|||major|||0|694|597|602
SE|226||ab|4|entity|||gngm|5618|PRLR|hPRL|||0|1000|615|619
SE|226||ab|4|entity|C0560175|Carrier of disorder|fndg|||carriers|||0|966|623|631
SE|226||ab|4|entity|C0812375|ELK3 gene|gngm|2004,131096|ELK3,KCNH8|net|||0|750|648|651
SE|226||ab|4|entity|C0033727|Protons|elii|||protons|||0|750|652|659
SE|226||ab|4|entity|C0567416|Molecule|sbst|||molecule|||0|1000|664|672

SE|226||ab|5|text|674|824|The net charge differences among isohormones E, F and G are compatible with acquisition or loss of single charged groups per 20,000 molecular weight.
SE|226||ab|5|entity|C0812375|ELK3 gene|gngm|2004,131096|ELK3,KCNH8|net|||0|785|678|681
SE|226||ab|5|entity|C1547020|*Difference|qnco|||differences|||0|785|689|700
SE|226||ab|5|entity|C1524057|Compatible|qlco|||compatible|||0|1000|734|744
SE|226||ab|5|entity|C1517945|Loss|qnco|||loss|||0|1000|765|769
SE|226||ab|5|entity|C0037179|Unmarried person|popg|||single|||0|840|773|779
SE|226||ab|5|entity|C0007961|charge amounts|qnco|||charged|||0|840|780|787
SE|226||ab|5|entity|C0441833|Groups|inpr|||groups|||0|840|788|794
SE|226||ab|5|entity|C0026385|Molecular Weight|qnco|||molecular weight|||0|861|806|822

SE|226||ab|6|text|824|1046|This net charge is similar to that of the least prolactin-bioactive major isohormone of human growth hormone (hGH-B), while the hGH with a bioactivity comparable to that of hPRL exhibits a net charge of 3.4 valence units.
SE|226||ab|6|entity|C0812375|ELK3 gene|gngm|2004,131096|ELK3,KCNH8|net|||0|694|829|832
SE|226||ab|6|entity|C0033371|Prolactin|aapp,horm|||prolactin|||0|575|872|881
SE|226||ab|6|entity|C0205164|Major|qlco|||major|||0|575|892|897
SE|226||ab|6|entity|C0169964|Somatropin|aapp,horm,phsu|||human growth hormone|||0|1000|912|932
SE|226||ab|6|entity|C0169964|Somatropin|aapp,horm,phsu|||hGH|||0|872|934|937
SE|226||ab|6|entity|C0169964|Somatropin|aapp,horm,phsu|||hGH|||0|1000|952|955
SE|226||ab|6|entity|||gngm|5618|PRLR|hPRL|||0|1000|997|1001
SE|226||ab|6|entity|C0812375|ELK3 gene|gngm|2004,131096|ELK3,KCNH8|net|||0|694|1013|1016
SE|226||ab|6|entity|C0442757|3/4|fndg|||3.4|||0|824|1027|1030
SE|226||ab|6|entity|C0439148|Unit|qnco|||units|||0|824|1039|1044

SE|226||ab|7|text|1046|1167|The "large" isohormones J and H increased net charges, by a factor of 2-3, in direct proportion to their size increments.
SE|226||ab|7|entity|C0549177|Large|qnco|||large|||0|785|1051|1056
SE|226||ab|7|entity|C0812375|ELK3 gene|gngm|2004,131096|ELK3,KCNH8|net|||0|888|1088|1091
SE|226||ab|7|entity|C0007961|charge amounts|qnco|||charges|||0|888|1092|1099
SE|226||ab|7|entity|C1521761|Factor|ftcn|||factor|||0|1000|1106|1112
SE|226||ab|7|entity|C0205351|Proportional|qlco|||proportion|||0|789|1131|1141
SE|226||ab|7|entity|C0456389|size|spco|||size|||0|694|1151|1155


SE|227||ti|1|text|16|120|Human and monkey prolactin and growth hormone: separation of polymorphic forms by isoelectric focusing.
SE|227||ti|1|entity|C0020114|Human|humn|||Human|||0|1000|16|21
SE|227||ti|1|entity|C0026447|Monkeys|mamm|||monkey|||0|888|26|32
SE|227||ti|1|entity|C0033371|Prolactin|aapp,horm|5617|PRL|prolactin|||0|888|33|42
SE|227||ti|1|entity|C0037663|Somatotropin|aapp,horm,phsu|||growth hormone|||0|1000|47|61
SE|227||ti|1|entity|C0036679|Diastasis|patf|||separation|||0|1000|63|73
SE|227||ti|1|entity|C0027950|neutrophil|cell|||polymorphic|||0|853|77|88
SE|227||ti|1|entity|C0022169|Isoelectric Focusing|lbpr|||isoelectric focusing|||0|1000|98|118
SE|227||ti|1|relation|0|0|C0033371|Prolactin|aapp,gngm,horm|aapp|5617|PRL|prolactin|||0|888|33|42|MOD/HEAD|PART_OF||26|42|0|0|C0026447|Monkeys|mamm|mamm|||monkey|||0|888|26|32

SE|227||ab|1|text|126|324|The feasibility of using isoelectric focusing for the separation of primate pituitary growth hormone from prolactin and for the characterization of polymorphic forms of these hormones was explored.
SE|227||ab|1|entity|C0022169|Isoelectric Focusing|lbpr|||isoelectric focusing|||0|1000|151|171
SE|227||ab|1|entity|C0036679|Diastasis|patf|||separation|||0|1000|180|190
SE|227||ab|1|entity|C0033147|Primates|mamm|||primate|||0|916|194|201
SE|227||ab|1|entity|C0037663|Somatotropin|aapp,horm,phsu|||pituitary growth hormone|||0|916|202|226
SE|227||ab|1|entity|C0033371|Prolactin|aapp,horm|5617|PRL|prolactin|||0|1000|232|241
SE|227||ab|1|entity|C0027950|neutrophil|cell|||polymorphic|||0|853|274|285
SE|227||ab|1|entity|C0019932|Hormones|horm|||hormones|||0|1000|301|309
SE|227||ab|1|relation|0|0|C0037663|Somatotropin|aapp,gngm,horm,phsu|aapp|||pituitary growth hormone|||0|916|202|226|MOD/HEAD|PART_OF||194|226|0|0|C0033147|Primates|mamm|mamm|||primate|||0|916|194|201

SE|227||ab|2|text|324|524|In a pH 3--10 gradient, extracts of both human and cynomolgus monkey pituitaries were each resolved into 4 growth hormone components and at least 3 prolactin components, as shown by radioimmunoassay.
SE|227||ab|2|entity|C0601906|PH.3|phsu|||pH 3|||0|1000|329|333
SE|227||ab|2|entity|C0439182|% gradient|qnco|||gradient|||0|861|338|346
SE|227||ab|2|entity|C0020114|Human|humn|||human|||0|1000|365|370
SE|227||ab|2|entity|C0024399|Macaca fascicularis|mamm|||cynomolgus monkey|||0|734|375|392
SE|227||ab|2|entity|C0037663|Somatotropin|aapp,horm,phsu|||growth hormone|||0|808|431|445
SE|227||ab|2|entity|C1524073|Component, LOINC Axis 1|clas|||components|||0|808|446|456
SE|227||ab|2|entity|C0033371|Prolactin|aapp,horm|5617|PRL|prolactin|||0|733|472|481
SE|227||ab|2|entity|C1524073|Component, LOINC Axis 1|clas|||components|||0|733|482|492
SE|227||ab|2|entity|C0034580|Radioimmunoassay|lbpr|||radioimmunoassay|||0|1000|506|522

SE|227||ab|3|text|524|750|In narrower gradients (of 2--3 pH units) greater resolution was achieved; the principal growth hormone components were well separated from the principal prolactin components but there was overlapping of some minor components.
SE|227||ab|3|entity|C0332463|Narrowed structure|spco|||narrower|||0|855|527|535
SE|227||ab|3|entity|C0439182|% gradient|qnco|||gradients|||0|855|536|545
SE|227||ab|3|entity|C0439148|Unit|qnco|||units|||0|851|558|563
SE|227||ab|3|entity|C0443228|Largest|qnco|||greater|||0|888|565|572
SE|227||ab|3|entity|C1514893|Resolution|ftcn|||resolution|||0|888|573|583
SE|227||ab|3|entity|C0205225|Primary|qlco|||principal|||0|850|602|611
SE|227||ab|3|entity|C0037663|Somatotropin|aapp,horm,phsu|||growth hormone|||0|850|612|626
SE|227||ab|3|entity|C1524073|Component, LOINC Axis 1|clas|||components|||0|850|627|637
SE|227||ab|3|entity|C0205170|Good|qlco|||well|||0|1000|643|647
SE|227||ab|3|entity|C0205225|Primary|qlco|||principal|||0|840|667|676
SE|227||ab|3|entity|C0033371|Prolactin|aapp,horm|5617|PRL|prolactin|||0|840|677|686
SE|227||ab|3|entity|C1524073|Component, LOINC Axis 1|clas|||components|||0|840|687|697
SE|227||ab|3|entity|C1524073|Component, LOINC Axis 1|clas|||components|||0|872|738|748

SE|227||ab|4|text|750|902|A partially purified human prolactin preparation was found to contain 4 prolactin components, one of which had a prolactin/growth hormone ratio of 760.
SE|227||ab|4|entity|C0020114|Human|humn|||human|||0|785|771|776
SE|227||ab|4|entity|C0304823|Prolactin preparation|aapp,horm,phsu|5617|PRL|prolactin preparation|||0|785|777|798
SE|227||ab|4|entity|C0033371|Prolactin|aapp,horm|5617|PRL|prolactin|||0|773|822|831
SE|227||ab|4|entity|C1524073|Component, LOINC Axis 1|clas|||components|||0|773|832|842
SE|227||ab|4|entity|C0205447|One|qnco|||one|||0|1000|844|847
SE|227||ab|4|entity|C0033371|Prolactin|aapp,horm|5617|PRL|prolactin|||0|861|863|872
SE|227||ab|4|entity|C0037663|Somatotropin|aapp,horm,phsu|||growth hormone|||0|861|873|887
SE|227||ab|4|entity|C0456603|Ratio|inpr|||ratio|||0|861|888|893
SE|227||ab|4|relation|0|0|C0304823|Prolactin preparation|aapp,gngm,horm,phsu|aapp|5617|PRL|prolactin preparation|||0|785|777|798|MOD/HEAD|PART_OF||771|798|0|0|C0020114|Human|grup,humn|humn|||human|||0|785|771|776

SE|227||ab|5|text|902|1089|Clinical grade human growth hormone was also resolved into at least 5 prolactin and 5 growth hormone components, many of which had higher pI values than those found in pituitary extract.
SE|227||ab|5|entity|C0205210|Clinical|qlco|||Clinical|||0|875|902|910
SE|227||ab|5|entity|C0169964|Somatropin|aapp,horm,phsu|||human growth hormone|||0|875|917|937
SE|227||ab|5|entity|C0033371|Prolactin|aapp,horm|5617|PRL|prolactin|||0|827|972|981
SE|227||ab|5|entity|C0037663|Somatotropin|aapp,horm,phsu|||growth hormone|||0|850|988|1002
SE|227||ab|5|entity|C1524073|Component, LOINC Axis 1|clas|||components|||0|850|1003|1013
SE|227||ab|5|entity|C0205250|High|qlco|||higher|||0|840|1033|1039
SE|227||ab|5|entity|C0042295|Values|qlco|||values|||0|840|1043|1049
SE|227||ab|5|entity|C1555707|extract|idcn|||extract|||0|861|1080|1087

SE|227||ab|6|text|1089|1214|Under the conditions used, both growth hormone and prolactin were found to be polymorphic with respect to isoelectric point.
SE|227||ab|6|entity|C0348080|Condition|qlco|||conditions|||0|966|1099|1109
SE|227||ab|6|entity|C0037663|Somatotropin|aapp,horm,phsu|||growth hormone|||0|1000|1121|1135
SE|227||ab|6|entity|C0033371|Prolactin|aapp,horm|5617|PRL|prolactin|||0|1000|1140|1149
SE|227||ab|6|entity|C0027950|neutrophil|cell|||polymorphic|||0|928|1167|1178
SE|227||ab|6|entity|C0022171|Isoelectric Point|qnco|||isoelectric point|||0|1000|1195|1212

SE|227||ab|7|text|1214|1326|Some of the human prolactin components were found to contain less than 0.2% growth hormone by radioimmunoassay.
SE|227||ab|7|entity|C0020114|Human|humn|||human|||0|840|1226|1231
SE|227||ab|7|entity|C0033371|Prolactin|aapp,horm|5617|PRL|prolactin|||0|840|1232|1241
SE|227||ab|7|entity|C1524073|Component, LOINC Axis 1|clas|||components|||0|840|1242|1252
SE|227||ab|7|entity|C0037663|Somatotropin|aapp,horm,phsu|||growth hormone|||0|861|1290|1304
SE|227||ab|7|entity|C0034580|Radioimmunoassay|lbpr|||radioimmunoassay|||0|1000|1308|1324

SE|227||ab|8|text|1326|1389|Monkey growth hormone containing 0.01% prolactin was isolated.
SE|227||ab|8|entity|C0026447|Monkeys|mamm|||Monkey|||0|901|1326|1332
SE|227||ab|8|entity|C0037663|Somatotropin|aapp,horm,phsu|||growth hormone|||0|901|1333|1347
SE|227||ab|8|entity|C0033371|Prolactin|aapp,horm|5617|PRL|prolactin|||0|827|1365|1374
SE|227||ab|8|relation|0|0|C0037663|Somatotropin|aapp,gngm,horm,phsu|aapp|||growth hormone|||0|901|1333|1347|MOD/HEAD|PART_OF||1326|1347|0|0|C0026447|Monkeys|mamm|mamm|||Monkey|||0|901|1326|1332

SE|227||ab|9|text|1389|1552|These findings demonstrate that isoelectric focusing is useful for the preparation of both growth hormone and prolactin which are essentially free of one another.
SE|227||ab|9|entity|C0243095|Finding|ftcn|||findings|||0|1000|1395|1403
SE|227||ab|9|entity|C0022169|Isoelectric Focusing|lbpr|||isoelectric focusing|||0|1000|1421|1441
SE|227||ab|9|entity|C1521827|Preparation|ftcn|||preparation|||0|1000|1460|1471
SE|227||ab|9|entity|C0037663|Somatotropin|aapp,horm,phsu|||growth hormone|||0|1000|1480|1494
SE|227||ab|9|entity|C0033371|Prolactin|aapp,horm|5617|PRL|prolactin|||0|1000|1499|1508
SE|227||ab|9|entity|C0205447|One|qnco|||one|||0|1000|1539|1542

SE|227||ab|10|text|1552|1729|Furthermore, the polymorphic forms were repeatedly found in preparations obtained by several methods and from 2 different species, suggesting that these forms are not artifacts.
SE|227||ab|10|entity|C0027950|neutrophil|cell|||polymorphic|||0|853|1569|1580
SE|227||ab|10|entity|C1521827|Preparation|ftcn|||preparations|||0|966|1612|1624
SE|227||ab|10|entity|C0443302|Several|qnco|||several|||0|888|1637|1644
SE|227||ab|10|entity|C0025663|Methods|inpr|||methods|||0|888|1645|1652
SE|227||ab|10|entity|C1547020|*Difference|qnco|||different|||0|754|1664|1673
SE|227||ab|10|entity|C1548151|Species|idcn|||species|||0|754|1674|1681
SE|227||ab|10|entity|C1518422|Not|ftcn|||not|||0|694|1715|1718


SE|228||ti|1|text|16|53|The interaction of SO2 with proteins.
SE|228||ti|1|entity|C0038777|Sulfur Dioxide|hops,inch|||SO2|||0|1000|35|38
SE|228||ti|1|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|1000|44|52
SE|228||ti|1|relation|2|2|C0033684|Proteins|aapp,gngm,bacs|aapp|||proteins|||0|1000|44|52|NOM|INTERACTS_WITH||20|31|2|1|C0038777|Sulfur Dioxide|hops,inch|hops|||SO2|||0|1000|35|38


SE|229||ti|1|text|16|118|Ecological observation of the 137Cs-contamination in beef of animals from the southern-Bavarian area.
SE|229||ti|1|entity|C0013546|Ecology|ocdi|||Ecological|||0|623|16|26
SE|229||ti|1|entity|C0259846|adulteration|hcpp|||contamination|||0|861|52|65
SE|229||ti|1|entity|C0452849|Beef|food|||beef|||0|1000|69|73
SE|229||ti|1|entity|C0003062|Animals|anim|||animals|||0|1000|77|84
SE|229||ti|1|entity|C0205146|Area|spco|||area|||0|827|112|116

SE|229||ab|1|text|124|355|Certain climatic and edaphic conformations in the Bavarian sub-alpine mountains and in the Alps favor above all the development of a land utilization system and farm structures similar to those in the northern part of Scandinavia.
SE|229||ab|1|entity|C0008946|Climate|npop|||climatic|||0|853|132|140
SE|229||ab|1|entity|C0542339|Inferior|spco|||sub|||0|747|183|186
SE|229||ab|1|entity|C0442533|Mountain|spco|||mountains|||0|747|194|203
SE|229||ab|1|entity|C1527148|Development|ftcn|||development|||0|1000|240|251
SE|229||ab|1|entity|C1552507|Land|hcro|||land|||0|802|257|261
SE|229||ab|1|entity|C0449913|System|ftcn|||system|||0|802|274|280
SE|229||ab|1|entity|C0557759|Farming environment|geoa|||farm|||0|1000|285|289
SE|229||ab|1|entity|C0449719|Part|spco|||part|||0|827|334|338
SE|229||ab|1|entity|C0036273|Scandinavia|geoa|||Scandinavia|||0|1000|342|353

SE|229||ab|2|text|355|798|In 1963/64, the years of the highest environmental contamination up to the present, we established in 600 beef samples from the round or shoulder of male and female cattle (mainly Highland cattle) close connections between the 137Cs-contamination of green crop and the long lastnig yearly precipitation quantities, as well as certain relations between the 137Cs-contamination of meat and differences in the feeding and keeping of the animals.
SE|229||ab|2|entity|C0439234|year|tmco|||years|||0|1000|371|376
SE|229||ab|2|entity|C1522410|Highest|qlco|||highest|||0|901|384|391
SE|229||ab|2|entity|C0014419|Environmental Pollution|eehu|||environmental contamination|||0|901|392|419
SE|229||ab|2|entity|C0150312|Present|qnco|||present|||0|1000|430|437
SE|229||ab|2|entity|C0452849|Beef|food|||beef|||0|660|461|465
SE|229||ab|2|entity|C0037004|Shoulder|bpoc|||shoulder|||0|1000|492|500
SE|229||ab|2|entity|C0015780|Female|orga|||female|||0|888|513|519
SE|229||ab|2|entity|C0007452|Cattle|mamm|||cattle|||0|888|520|526
SE|229||ab|2|entity|C0454911|Highland|geoa|||Highland|||0|790|535|543
SE|229||ab|2|entity|C0007452|Cattle|mamm|||cattle|||0|790|544|550
SE|229||ab|2|entity|C0449379|Connection|inpr|||connections|||0|966|558|569
SE|229||ab|2|entity|C0259846|adulteration|hcpp|||contamination|||0|861|588|601
SE|229||ab|2|entity|C0205166|Long|qlco|||long|||0|766|624|628
SE|229||ab|2|entity|C0332181|Annual|tmco|||yearly|||0|766|637|643
SE|229||ab|2|entity|C0032931|Precipitation|npop|||precipitation|||0|766|644|657
SE|229||ab|2|entity|C1265611|Quantity|qnco|||quantities|||0|766|658|668
SE|229||ab|2|entity|C0869014|Relations|socb|||relations|||0|888|689|698
SE|229||ab|2|entity|C0259846|adulteration|hcpp|||contamination|||0|861|717|730
SE|229||ab|2|entity|C0025017|Meat|food|||meat|||0|1000|734|738
SE|229||ab|2|entity|C1547020|*Difference|qnco|||differences|||0|966|743|754
SE|229||ab|2|entity|C0003062|Animals|anim|||animals|||0|1000|789|796

SE|229||ab|3|text|798|971|During summer-seasons (April-October), beef of cattle from pastures with heavy rainfall (Alps) was contaiminated by 137Cs up to 15 times more than that of confined animals.
SE|229||ab|3|entity|C0241301|summer|tmco|||summer|||0|888|805|811
SE|229||ab|3|entity|C0036497|Seasons|tmco|||seasons|||0|888|812|819
SE|229||ab|3|entity|C1332090|ANP32B gene|gngm|10541|ANP32B|April|||0|694|821|826
SE|229||ab|3|entity|C0452849|Beef|food|||beef|||0|1000|837|841
SE|229||ab|3|entity|C0007452|Cattle|mamm|||cattle|||0|1000|845|851
SE|229||ab|3|entity|C0040223|Time|tmco|||times|||0|793|929|934
SE|229||ab|3|entity|C0003062|Animals|anim|||animals|||0|861|962|969

SE|229||ab|4|text|971|1100|Hereby the rate of 137Cs-contamination in the meat of grazing cattle was nearly proportional to the quantities of precipitation.
SE|229||ab|4|entity|C1521828|Rate|qnco|||rate|||0|1000|982|986
SE|229||ab|4|entity|C0259846|adulteration|hcpp|||contamination|||0|861|996|1009
SE|229||ab|4|entity|C0025017|Meat|food|||meat|||0|1000|1017|1021
SE|229||ab|4|entity|C0043242|Superficial abrasion|inpo|||grazing|||0|872|1025|1032
SE|229||ab|4|entity|C0007452|Cattle|mamm|||cattle|||0|872|1033|1039
SE|229||ab|4|entity|C0205351|Proportional|qlco|||proportional|||0|861|1051|1063
SE|229||ab|4|entity|C1265611|Quantity|qnco|||quantities|||0|1000|1071|1081
SE|229||ab|4|entity|C0032931|Precipitation|npop|||precipitation|||0|1000|1085|1098

SE|229||ab|5|text|1100|1351|When confined cattle were fed on pastures in autumn after harvesting for 2 to 3 weeks, a quick increase of 137Cs-contamination of the meat was caused within this time up to values which in this district were otherwise only observed in grazing cattle.
SE|229||ab|5|entity|C0007452|Cattle|mamm|||cattle|||0|861|1114|1120
SE|229||ab|5|entity|C1442462|3 Weeks|tmco|||3 weeks|||0|1000|1178|1185
SE|229||ab|5|entity|C0439831|Rapid|qlco|||quick|||0|888|1189|1194
SE|229||ab|5|entity|C0442805|Increase|ftcn|||increase|||0|888|1195|1203
SE|229||ab|5|entity|C0259846|adulteration|hcpp|||contamination|||0|861|1213|1226
SE|229||ab|5|entity|C0025017|Meat|food|||meat|||0|1000|1234|1238
SE|229||ab|5|entity|C0040223|Time|tmco|||time|||0|1000|1262|1266
SE|229||ab|5|entity|C0042295|Values|qlco|||values|||0|1000|1273|1279
SE|229||ab|5|entity|C0043242|Superficial abrasion|inpo|||grazing|||0|872|1335|1342
SE|229||ab|5|entity|C0007452|Cattle|mamm|||cattle|||0|872|1343|1349

SE|229||ab|6|text|1351|1516|The lower 137Cs-content in meat of cattle housed during the summer season is due to the more varied fodder, which is at that time less contaminated than green crop.
SE|229||ab|6|entity|C0441994|Lower|ftcn|||lower|||0|660|1355|1360
SE|229||ab|6|entity|C0025017|Meat|food|||meat|||0|1000|1378|1382
SE|229||ab|6|entity|C0007452|Cattle|mamm|||cattle|||0|1000|1386|1392
SE|229||ab|6|entity|C0241301|summer|tmco|||summer|||0|888|1411|1417
SE|229||ab|6|entity|C0036497|Seasons|tmco|||season|||0|888|1418|1424
SE|229||ab|6|entity|C0205172|More|ftcn|||more|||0|660|1439|1443
SE|229||ab|6|entity|C0040223|Time|tmco|||time|||0|1000|1476|1480

SE|229||ab|7|text|1516|1791|During the winter season (November to March), the highest contaminations in the meat of confined (Bohemian Forest) or grazing cattle (Alps) was measured when the animals in these districts were almost exclusively fed with fodder from the own farmground or with leafy silage.
SE|229||ab|7|entity|C0241737|winter|tmco|||winter|||0|888|1527|1533
SE|229||ab|7|entity|C0036497|Seasons|tmco|||season|||0|888|1534|1540
SE|229||ab|7|entity|C1522410|Highest|qlco|||highest|||0|872|1566|1573
SE|229||ab|7|entity|C0259846|adulteration|hcpp|||contaminations|||0|872|1574|1588
SE|229||ab|7|entity|C0025017|Meat|food|||meat|||0|1000|1596|1600
SE|229||ab|7|entity|C0086312|Forests|geoa|||Forest|||0|861|1623|1629
SE|229||ab|7|entity|C0043242|Superficial abrasion|inpo|||grazing|||0|872|1634|1641
SE|229||ab|7|entity|C0007452|Cattle|mamm|||cattle|||0|872|1642|1648
SE|229||ab|7|entity|C0003062|Animals|anim|||animals|||0|1000|1678|1685
SE|229||ab|7|entity|C1546511|Owner|idcn|||own|||0|623|1754|1757
SE|229||ab|7|entity|C0242724|Plant Leaves|plnt|||leafy|||0|853|1777|1782
SE|229||ab|7|entity|C0037092|Silage|food|||silage|||0|853|1783|1789

SE|229||ab|8|text|1791|1957|The highest contamination was almost regularly noticed in January, February and March, as generally during these months the highly contaminated first cut hay is fed.
SE|229||ab|8|entity|C1522410|Highest|qlco|||highest|||0|888|1795|1802
SE|229||ab|8|entity|C0259846|adulteration|hcpp|||contamination|||0|888|1803|1816
SE|229||ab|8|entity|C0439231|month|tmco|||months|||0|1000|1904|1910
SE|229||ab|8|entity|C1279901|Firstly|qlco|||first|||0|1000|1935|1940
SE|229||ab|8|entity|C1440666|HAY|imft|||hay|||0|1000|1945|1948

SE|229||ab|9|text|1957|2033|Here the meat was often even more contaminated than that of grazing cattle.
SE|229||ab|9|entity|C0025017|Meat|food|||meat|||0|1000|1966|1970
SE|229||ab|9|entity|C0332183|Frequent|tmco|||often|||0|861|1975|1980
SE|229||ab|9|entity|C0205172|More|ftcn|||more|||0|1000|1986|1990
SE|229||ab|9|entity|C0043242|Superficial abrasion|inpo|||grazing|||0|872|2017|2024
SE|229||ab|9|entity|C0007452|Cattle|mamm|||cattle|||0|872|2025|2031

SE|229||ab|10|text|2033|2459|After the quick decrease of 137Cs in fallout noticed in the years 1964 and 1965, in 1965/66 a dependance in the 137Cs-contamination of beef on the methods of keeping and feeding could still be observed in only the extreme cases (Alps, Bavarian- and Bohemian Forest); though in general, meat of animals from districts with heavy rainfall was slightly more contaminated than meat of animals from regions with less precipitation.
SE|229||ab|10|entity|C0439831|Rapid|qlco|||quick|||0|888|2043|2048
SE|229||ab|10|entity|C0547047|Decrease|qnco|||decrease|||0|888|2049|2057
SE|229||ab|10|entity|C0439234|year|tmco|||years|||0|861|2093|2098
SE|229||ab|10|entity|C0439857|Dependence|mobd|||dependance|||0|1000|2127|2137
SE|229||ab|10|entity|C0259846|adulteration|hcpp|||contamination|||0|861|2151|2164
SE|229||ab|10|entity|C0452849|Beef|food|||beef|||0|1000|2168|2172
SE|229||ab|10|entity|C0025663|Methods|inpr|||methods|||0|1000|2180|2187
SE|229||ab|10|entity|C0205403|Extreme|qlco|||extreme|||0|888|2247|2254
SE|229||ab|10|entity|C0868928|Case (situation)|ftcn|||cases|||0|888|2255|2260
SE|229||ab|10|entity|C0086312|Forests|geoa|||Forest|||0|861|2291|2297
SE|229||ab|10|entity|C0205246|Generalized|spco|||general|||0|888|2310|2317
SE|229||ab|10|entity|C0025017|Meat|food|||meat|||0|888|2319|2323
SE|229||ab|10|entity|C0003062|Animals|anim|||animals|||0|1000|2327|2334
SE|229||ab|10|entity|C0750482|SLIGHTLY|idcn|||slightly|||0|1000|2374|2382
SE|229||ab|10|entity|C0205172|More|ftcn|||more|||0|1000|2383|2387
SE|229||ab|10|entity|C0025017|Meat|food|||meat|||0|1000|2406|2410
SE|229||ab|10|entity|C0003062|Animals|anim|||animals|||0|1000|2414|2421
SE|229||ab|10|entity|C0205147|Region|spco|||regions|||0|966|2427|2434
SE|229||ab|10|entity|C0032931|Precipitation|npop|||precipitation|||0|861|2445|2458


SE|230||ti|1|text|16|83|Liver microsomal beta-glucuronidase and UDP-glucuronyltransferase.
SE|230||ti|1|entity|C0026030|Microsomes, Liver|celc|||Liver microsomal|||0|865|16|32
SE|230||ti|1|entity|C0017776|Beta-glucuronidase|aapp,enzy,irda|||beta-glucuronidase|||0|865|33|51
SE|230||ti|1|entity|C0041986|Uridine Diphosphate|bacs,carb,nnon|||UDP|||0|888|56|59
SE|230||ti|1|entity|C0041560|Glucuronosyltransferase|aapp,enzy|||glucuronyltransferase|||0|888|60|81
SE|230||ti|1|relation|0|0|C0017776|Beta-glucuronidase|aapp,gngm,enzy,irda|aapp|||beta-glucuronidase|||0|865|33|51|MOD/HEAD|PART_OF||16|51|0|0|C0026030|Microsomes, Liver|celc|celc|||Liver microsomal|||0|865|16|32

SE|230||ab|1|text|89|200|Both UDP-glucuronyltransferase (GT) and beta-glucuronidase (betaG) were assayed in untreated liver microsomes.
SE|230||ab|1|entity|C0041986|Uridine Diphosphate|bacs,carb,nnon|||UDP|||0|888|94|97
SE|230||ab|1|entity|C0041560|Glucuronosyltransferase|aapp,enzy|||glucuronyltransferase|||0|888|98|119
SE|230||ab|1|entity|C0017776|Beta-glucuronidase|aapp,enzy,irda|||beta-glucuronidase|||0|1000|129|147
SE|230||ab|1|entity|C0026030|Microsomes, Liver|celc|||liver microsomes|||0|901|182|198
SE|230||ab|1|relation|1|1|C0026030|Microsomes, Liver|celc|celc|||liver microsomes|||0|901|182|198|PREP|LOCATION_OF||169|171|2|1|C0017776|Beta-glucuronidase|aapp,gngm,enzy,irda|aapp|||beta-glucuronidase|||0|1000|129|147
SE|230||ab|1|relation|1|1|C0026030|Microsomes, Liver|celc|celc|||liver microsomes|||0|901|182|198|PREP|LOCATION_OF||169|171|2|1|C0041560|Glucuronosyltransferase|aapp,gngm,enzy|aapp|||glucuronyltransferase|||0|888|98|119

SE|230||ab|2|text|200|368|Optimum assay conditions were established with rat liver microsomes using p-nitrophenol (pNP) and its glucuronide (pNPGA) at the pH optima of GT (7.5) and betaG (4.5).
SE|230||ab|2|entity|C1510438|Assay|lbpr|||assay|||0|773|208|213
SE|230||ab|2|entity|C0348080|Condition|qlco|||conditions|||0|773|214|224
SE|230||ab|2|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|901|247|250
SE|230||ab|2|entity|C0026030|Microsomes, Liver|celc|||liver microsomes|||0|901|251|267
SE|230||ab|2|entity|C0048581|4-nitrophenol|hops,irda,orch|||p-nitrophenol|||0|1000|274|287
SE|230||ab|2|entity|C0812407|glucuronide|carb|||glucuronide|||0|1000|302|313
SE|230||ab|2|entity|C0041560|Glucuronosyltransferase|aapp,enzy|||GT|||0|1000|342|344
SE|230||ab|2|entity|C0017776|Beta-glucuronidase|aapp,enzy,irda|||betaG|||0|1000|355|360
SE|230||ab|2|entity|C0450367|4/5|qnco|||4.5|||0|1000|362|365
SE|230||ab|2|relation|0|0|C0026030|Microsomes, Liver|celc|celc|||liver microsomes|||0|901|251|267|MOD/HEAD|PART_OF||247|267|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|901|247|250

SE|230||ab|3|text|368|597|The activities of the two enzymes were compared using microsomes from rats, mice, pigs, cattle and horses, with pNP, pNPGA, and phenolphthalein as substrate, in the presence of various cofactors and inhibitors at pH 7.5 and 4.5.
SE|230||ab|3|entity|C0441655|Activities|acty|||activities|||0|1000|372|382
SE|230||ab|3|entity|C0205448|Two|qnco|||two|||0|888|390|393
SE|230||ab|3|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|888|394|401
SE|230||ab|3|entity|C0026029|Microsomes|celc|||microsomes|||0|1000|422|432
SE|230||ab|3|entity|C0034693|Rattus norvegicus|mamm|||rats|||0|1000|438|442
SE|230||ab|3|entity|C0026809|Mus|mamm|||mice|||0|1000|444|448
SE|230||ab|3|entity|C0039005|Family suidae|mamm|||pigs|||0|1000|450|454
SE|230||ab|3|entity|C0007452|Cattle|mamm|||cattle|||0|1000|456|462
SE|230||ab|3|entity|C0019944|Equus caballus|mamm|||horses|||0|1000|467|473
SE|230||ab|3|entity|C0048581|4-nitrophenol|hops,irda,orch|||pNP|||0|1000|480|483
SE|230||ab|3|entity|C0600489|Phenolphthalein|irda,orch,phsu|||phenolphthalein|||0|1000|496|511
SE|230||ab|3|entity|C0178555|cofactor|bacs|||cofactors|||0|827|553|562
SE|230||ab|3|entity|C0243077|inhibitors|chvf|||inhibitors|||0|1000|567|577
SE|230||ab|3|entity|C0450367|4/5|qnco|||4.5|||0|1000|592|595
SE|230||ab|3|relation|12|2|C0048581|4-nitrophenol|hops,irda,orch|irda|||pNP|||0|1000|480|483|NOM|COEXISTS_WITH||533|541|2|1|C0178555|cofactor|bacs|bacs|||cofactors|||0|827|553|562
SE|230||ab|3|relation|12|2|C0600489|Phenolphthalein|irda,orch,phsu|orch|||phenolphthalein|||0|1000|496|511|NOM|COEXISTS_WITH||533|541|2|1|C0178555|cofactor|bacs|bacs|||cofactors|||0|827|553|562
SE|230||ab|3|relation|13|7|C0048581|4-nitrophenol|hops,irda,orch|hops|||pNP|||0|1000|480|483|VERB|compared_with||407|415|13|9|C0600489|Phenolphthalein|irda,orch,phsu|irda|||phenolphthalein|||0|1000|496|511

SE|230||ab|4|text|597|778|These data disclose pronounced differences with respect to species, substrate and other experimental conditions, thereby precluding the establishment of general optimum conditions.
SE|230||ab|4|entity|C1511726|Data|idcn|||data|||0|1000|603|607
SE|230||ab|4|entity|C1547020|*Difference|qnco|||differences|||0|827|628|639
SE|230||ab|4|entity|C1548151|Species|idcn|||species|||0|1000|656|663
SE|230||ab|4|entity|C1517004|Experimental|ftcn|||experimental|||0|872|685|697
SE|230||ab|4|entity|C0348080|Condition|qlco|||conditions|||0|872|698|708
SE|230||ab|4|entity|C0205246|Generalized|spco|||general|||0|785|750|757
SE|230||ab|4|entity|C0348080|Condition|qlco|||conditions|||0|785|766|776

SE|230||ab|5|text|778|1025|The two enzymes were also assayed under strictly identical conditions using pNP and pNPGA and rat liver microsomes at pH 7.5 in the presence and absence of UDP-glucuronate disodium (UDPGA), activators (ATP;UDP-N-acetylglucosamine) and inhibitors.
SE|230||ab|5|entity|C0205448|Two|qnco|||two|||0|888|782|785
SE|230||ab|5|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|888|786|793
SE|230||ab|5|entity|C0205280|Identical|qlco|||identical|||0|773|827|836
SE|230||ab|5|entity|C0348080|Condition|qlco|||conditions|||0|773|837|847
SE|230||ab|5|entity|C0048581|4-nitrophenol|hops,irda,orch|||pNP|||0|1000|854|857
SE|230||ab|5|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|901|872|875
SE|230||ab|5|entity|C0026030|Microsomes, Liver|celc|||liver microsomes|||0|901|876|892
SE|230||ab|5|entity|C0041986|Uridine Diphosphate|bacs,carb,nnon|||UDP|||0|583|934|937
SE|230||ab|5|entity|C0017774|Glucuronates|bacs,carb|||glucuronate|||0|583|938|949
SE|230||ab|5|entity|C1366628|ATP8A2 gene|gngm|51761|ATP8A2|ATP|||0|1000|980|983
SE|230||ab|5|entity|C0041993|Uridine Diphosphate N-Acetylglucosamine|bacs,carb,nnon|||UDP-N-acetylglucosamine|||0|1000|984|1007
SE|230||ab|5|entity|C0243077|inhibitors|chvf|||inhibitors|||0|1000|1013|1023
SE|230||ab|5|relation|0|0|C0026030|Microsomes, Liver|celc|celc|||liver microsomes|||0|901|876|892|MOD/HEAD|PART_OF||872|892|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|901|872|875

SE|230||ab|6|text|1025|1181|When provided with a functional level of UDPGA, both enzymes proved active under those conditions, and a conjugation-deconjugation interplay was indicated.
SE|230||ab|6|entity|C0205245|Functional|ftcn|||functional|||0|694|1046|1056
SE|230||ab|6|entity|C0041986|Uridine Diphosphate|bacs,carb,nnon|||UDPGA|||0|750|1066|1071
SE|230||ab|6|entity|C0017774|Glucuronates|bacs,carb|||UDPGA|||0|750|1066|1071
SE|230||ab|6|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|1000|1078|1085
SE|230||ab|6|entity|C0205177|Active|ftcn|||active|||0|1000|1093|1099
SE|230||ab|6|entity|C0348080|Condition|qlco|||conditions|||0|966|1112|1122
SE|230||ab|6|entity|C1160466|conjugation|celf|||conjugation|||0|660|1130|1141

SE|230||ab|7|text|1181|1271|The two processes could be selectively and totally inhibited by Zn2+ and saccharolactone.
SE|230||ab|7|entity|C0205448|Two|qnco|||two|||0|872|1185|1188
SE|230||ab|7|entity|C1522240|Process|phpr|||processes|||0|872|1189|1198
SE|230||ab|7|entity|C0073923|saccharolactone|carb,phsu|||saccharolactone|||0|1000|1254|1269

SE|230||ab|8|text|1271|1465|The results suggest that conjugation-deconjugation-reconjugation cycles may be operative in the metabolism of drugs in vivo, taking place already at the level of the liver endoplasmic reticulum.
SE|230||ab|8|entity|C1274040|result|ftcn|||results|||0|966|1275|1282
SE|230||ab|8|entity|C1160466|conjugation|celf|||conjugation|||0|775|1296|1307
SE|230||ab|8|entity|C0750729|Course|tmco|||cycles|||0|775|1336|1342
SE|230||ab|8|entity|C0025519|Metabolism|orgf|||metabolism|||0|1000|1367|1377
SE|230||ab|8|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs|||0|1000|1381|1386
SE|230||ab|8|entity|C1515655|in vivo|spco|||in vivo|||0|1000|1387|1394
SE|230||ab|8|entity|C0023884|Liver|bpoc|||liver|||0|901|1437|1442
SE|230||ab|8|entity|C0014239|Endoplasmic Reticulum|celc|||endoplasmic reticulum|||0|901|1443|1464
SE|230||ab|8|relation|0|0|C0014239|Endoplasmic Reticulum|celc|celc|||endoplasmic reticulum|||0|901|1443|1464|MOD/HEAD|PART_OF||1437|1464|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|901|1437|1442


SE|231||ti|1|text|16|86|Biochemical aspects of renal ammonia formation in metabolic acidosis.
SE|231||ti|1|entity|C0205474|Biochemical|ftcn|||Biochemical|||0|872|16|27
SE|231||ti|1|entity|C1547011|Aspect|qnco|||aspects|||0|872|28|35
SE|231||ti|1|entity|C0022646|Kidney|bpoc|||renal|||0|851|39|44
SE|231||ti|1|entity|C0002607|Ammonia|bacs,inch|||ammonia|||0|851|45|52
SE|231||ti|1|entity|C1522492|Formation|ftcn|||formation|||0|851|53|62
SE|231||ti|1|entity|C0220981|Metabolic acidosis|patf|||metabolic acidosis|||0|1000|66|84
SE|231||ti|1|relation|0|0|C0002607|Ammonia|bacs,inch|bacs|||ammonia|||0|851|45|52|MOD/HEAD|PART_OF||39|52|0|0|C0022646|Kidney|bpoc|bpoc|||renal|||0|851|39|44
SE|231||ti|1|relation|2|1|C0002607|Ammonia|bacs,inch|bacs|||ammonia|||0|851|45|52|PREP|ASSOCIATED_WITH||63|65|1|1|C0220981|Metabolic acidosis|patf|patf|||metabolic acidosis|||0|1000|66|84

SE|231||ab|1|text|92|266|In omnivorous creatures, the diet is acidogenic, especially as a result of the meat content, which gives rise to phosphoric and sulphuric acids, i.e., to metabolic acidosis.
SE|231||ab|1|entity|C0012155|Diet|food|||diet|||0|1000|121|125
SE|231||ab|1|entity|C0001128|Acids|chem|||acidogenic|||0|789|129|139
SE|231||ab|1|entity|C0025017|Meat|food|||meat|||0|694|171|175
SE|231||ab|1|entity|C0031705|Phosphorus|elii,phsu|||phosphoric|||0|928|205|215
SE|231||ab|1|entity|C0038786|Sulfuric Acids|chvs|||sulphuric acids|||0|1000|220|235
SE|231||ab|1|entity|C0220981|Metabolic acidosis|patf|||metabolic acidosis|||0|1000|246|264

SE|231||ab|2|text|266|373|In the short term, metabolic acids are buffered by tissue proteins and bicarbonate (the 'alkali reserve').
SE|231||ab|2|entity|C0443303|Short-term|tmco|||short term|||0|861|273|283
SE|231||ab|2|entity|C0311400|Metabolic|ftcn|||metabolic|||0|861|285|294
SE|231||ab|2|entity|C0001128|Acids|chem|||acids|||0|861|295|300
SE|231||ab|2|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|861|324|332
SE|231||ab|2|entity|C0005367|Bicarbonates|inch|||bicarbonate|||0|1000|337|348
SE|231||ab|2|entity|C0002055|Alkalies|inch|||alkali|||0|1000|355|361

SE|231||ab|3|text|373|532|In the longer term, acid must be excreted, or neutralized with base which is also generated from the diet, by conversion of dietary amino-nitrogen to ammonia.
SE|231||ab|3|entity|C0443252|Long-term|tmco|||longer term|||0|890|380|391
SE|231||ab|3|entity|C0001128|Acids|chem|||acid|||0|890|393|397
SE|231||ab|3|entity|C0012155|Diet|food|||diet|||0|1000|474|478
SE|231||ab|3|entity|C0439836|Conversions|spco|||conversion|||0|966|483|493
SE|231||ab|3|entity|C0028158|Nitrogen|elii|||nitrogen|||0|827|511|519
SE|231||ab|3|entity|C0002607|Ammonia|bacs,inch|||ammonia|||0|1000|523|530
SE|231||ab|3|relation|2|1|C0028158|Nitrogen|elii|elii|||nitrogen|||0|827|511|519|NOM|INTERACTS_WITH||483|493|2|2|C0002607|Ammonia|bacs,inch|bacs|||ammonia|||0|1000|523|530

SE|231||ab|4|text|532|818|The final steps of this process occur in the kidney, which converts circulating glutamine to ammonia, and to carbon products such as glucose and carbon dioxide, by metabolic reactions which adapt during acidosis to generate more ammonia and maintain an increased renal ammonia content.
SE|231||ab|4|entity|C0205088|End-stage|tmco|||final|||0|872|536|541
SE|231||ab|4|entity|C1261552|Step|ftcn|||steps|||0|872|542|547
SE|231||ab|4|entity|C1522240|Process|phpr|||process|||0|1000|556|563
SE|231||ab|4|entity|C0022646|Kidney|bpoc|||kidney|||0|1000|577|583
SE|231||ab|4|entity|C0175630|Circulating|ftcn|||circulating|||0|888|600|611
SE|231||ab|4|entity|C0017797|Glutamine|aapp,bacs|||glutamine|||0|888|612|621
SE|231||ab|4|entity|C0002607|Ammonia|bacs,inch|||ammonia|||0|1000|625|632
SE|231||ab|4|entity|C0007009|Carbon|elii|||carbon|||0|872|641|647
SE|231||ab|4|entity|C1514468|product|qnco|||products|||0|872|648|656
SE|231||ab|4|entity|C0017725|Glucose|bacs,carb,phsu|||glucose|||0|1000|665|672
SE|231||ab|4|entity|C0007012|Carbon Dioxide|bacs,inch|||carbon dioxide|||0|1000|677|691
SE|231||ab|4|entity|C0311400|Metabolic|ftcn|||metabolic|||0|872|696|705
SE|231||ab|4|entity|C0443286|Reaction|ftcn|||reactions|||0|872|706|715
SE|231||ab|4|entity|C0001122|Acidosis|patf|||acidosis|||0|1000|735|743
SE|231||ab|4|entity|C0205172|More|ftcn|||more|||0|888|756|760
SE|231||ab|4|entity|C0002607|Ammonia|bacs,inch|||ammonia|||0|888|761|768
SE|231||ab|4|entity|C0205217|Increased|qnco|||increased|||0|608|785|794
SE|231||ab|4|entity|C0022646|Kidney|bpoc|||renal|||0|608|795|800
SE|231||ab|4|entity|C0002607|Ammonia|bacs,inch|||ammonia|||0|608|801|808
SE|231||ab|4|relation|0|0|C0002607|Ammonia|bacs,inch|bacs|||ammonia|||0|608|801|808|MOD/HEAD|PART_OF||795|808|0|0|C0022646|Kidney|bpoc|bpoc|||renal|||0|608|795|800
SE|231||ab|4|relation|10|1|C0001122|Acidosis|patf|patf|||acidosis|||0|1000|735|743|VERB|PRODUCES||747|755|2|1|C0002607|Ammonia|bacs,inch|bacs|||ammonia|||0|888|761|768

SE|231||ab|5|text|818|1027|The complex mechanisms which govern the formation of ammonia, glucose and carbon dioxide from glutamine, involving the reactions of amino acids, the tricarboxylic acid cycle, and gluconeogenesis, are reviewed.
SE|231||ab|5|entity|C0439855|Complex|qlco|||complex|||0|888|822|829
SE|231||ab|5|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|888|830|840
SE|231||ab|5|entity|C1522492|Formation|ftcn|||formation|||0|1000|858|867
SE|231||ab|5|entity|C0002607|Ammonia|bacs,inch|||ammonia|||0|1000|871|878
SE|231||ab|5|entity|C0017725|Glucose|bacs,carb,phsu|||glucose|||0|1000|880|887
SE|231||ab|5|entity|C0007012|Carbon Dioxide|bacs,inch|||carbon dioxide|||0|1000|892|906
SE|231||ab|5|entity|C0017797|Glutamine|aapp,bacs|||glutamine|||0|1000|912|921
SE|231||ab|5|entity|C0443286|Reaction|ftcn|||reactions|||0|966|937|946
SE|231||ab|5|entity|C0002520|Amino Acids|aapp,bacs,phsu|||amino acids|||0|1000|950|961
SE|231||ab|5|entity|C0008858|Citric Acid Cycle|moft|||tricarboxylic acid cycle|||0|1000|967|991
SE|231||ab|5|entity|C0017715|Gluconeogenesis|moft|||gluconeogenesis|||0|1000|997|1012
SE|231||ab|5|relation|6|1|C0017797|Glutamine|aapp,gngm,bacs|aapp|||glutamine|||0|1000|912|921|VERB|INTERACTS_WITH||923|932|4|2|C0002520|Amino Acids|aapp,gngm,bacs,phsu|aapp|||amino acids|||0|1000|950|961


SE|232||ti|1|text|16|115|Studies on the mechanism of the changes in serum and liver gamma-glutamyl transpeptidase activity.
SE|232||ti|1|entity|C0008972|Clinical Research|resa|||Studies|||0|966|16|23
SE|232||ti|1|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|1000|31|40
SE|232||ti|1|entity|C0229671|Serum|bdsu|||serum|||0|1000|59|64
SE|232||ti|1|entity|C0023884|Liver|bpoc|||liver|||0|875|69|74
SE|232||ti|1|entity|C0017040|Gamma-glutamyl transferase|aapp,enzy|||gamma-glutamyl transpeptidase|||0|875|75|104
SE|232||ti|1|relation|0|0|C0017040|Gamma-glutamyl transferase|aapp,gngm,enzy|aapp|||gamma-glutamyl transpeptidase|||0|875|75|104|MOD/HEAD|PART_OF||69|104|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|875|69|74

SE|232||ti|2|text|115|118|I.

SE|232||ti|3|text|118|168|Experimental extrahepatic cholestasis in rabbits.
SE|232||ti|3|entity|C1517004|Experimental|ftcn|||Experimental|||0|901|118|130
SE|232||ti|3|entity|C0005398|Cholestasis, Extrahepatic|dsyn|||extrahepatic cholestasis|||0|901|131|155
SE|232||ti|3|entity|C0034493|Oryctolagus cuniculus|mamm|||rabbits|||0|1000|159|166
SE|232||ti|3|relation|1|1|C0005398|Cholestasis, Extrahepatic|dsyn|dsyn|||extrahepatic cholestasis|||0|901|131|155|PREP|PROCESS_OF||156|158|1|1|C0034493|Oryctolagus cuniculus|mamm|mamm|||rabbits|||0|1000|159|166

SE|232||ab|1|text|174|465|Serum, liver and renal gamma-glutamyl transpeptidase (GGT) activities were studied in four groups of rabbits: controls, rabbits with obstructive extrahepatic cholestasis, rabbits with obstructive anuria, and animals with combined obstructive extrahepatic cholestasis and obstructive anuria.
SE|232||ab|1|entity|C0229671|Serum|bdsu|||Serum|||0|1000|174|179
SE|232||ab|1|entity|C0023884|Liver|bpoc|||liver|||0|1000|181|186
SE|232||ab|1|entity|C0022646|Kidney|bpoc|||renal|||0|875|191|196
SE|232||ab|1|entity|C0017040|Gamma-glutamyl transferase|aapp,enzy|||gamma-glutamyl transpeptidase|||0|875|197|226
SE|232||ab|1|entity|C0441655|Activities|acty|||activities|||0|875|233|243
SE|232||ab|1|entity|C0205450|Four|qnco|||four|||0|888|260|264
SE|232||ab|1|entity|C0441833|Groups|inpr|||groups|||0|888|265|271
SE|232||ab|1|entity|C0034493|Oryctolagus cuniculus|mamm|||rabbits|||0|1000|275|282
SE|232||ab|1|entity|C0243148|control|ftcn|||controls|||0|966|284|292
SE|232||ab|1|entity|C0034493|Oryctolagus cuniculus|mamm|||rabbits|||0|1000|294|301
SE|232||ab|1|entity|C0549186|Obstructed|ftcn|||obstructive|||0|901|307|318
SE|232||ab|1|entity|C0005398|Cholestasis, Extrahepatic|dsyn|||extrahepatic cholestasis|||0|901|319|343
SE|232||ab|1|entity|C0034493|Oryctolagus cuniculus|mamm|||rabbits|||0|1000|345|352
SE|232||ab|1|entity|C0549186|Obstructed|ftcn|||obstructive|||0|888|358|369
SE|232||ab|1|entity|C0003460|Anuria|dsyn|||anuria|||0|888|370|376
SE|232||ab|1|entity|C0003062|Animals|anim|||animals|||0|1000|382|389
SE|232||ab|1|entity|C0205195|Combined|qlco|||combined|||0|861|395|403
SE|232||ab|1|entity|C0549186|Obstructed|ftcn|||obstructive|||0|861|404|415
SE|232||ab|1|entity|C0005398|Cholestasis, Extrahepatic|dsyn|||extrahepatic cholestasis|||0|861|416|440
SE|232||ab|1|entity|C0549186|Obstructed|ftcn|||obstructive|||0|888|445|456
SE|232||ab|1|entity|C0003460|Anuria|dsyn|||anuria|||0|888|457|463
SE|232||ab|1|relation|0|0|C0017040|Gamma-glutamyl transferase|aapp,gngm,enzy|aapp|||gamma-glutamyl transpeptidase|||0|875|197|226|MOD/HEAD|PART_OF||191|226|0|0|C0022646|Kidney|bpoc|bpoc|||renal|||0|875|191|196
SE|232||ab|1|relation|2|1|C0003460|Anuria|dsyn|dsyn|||anuria|||0|888|457|463|PREP|PROCESS_OF||390|394|11|1|C0003062|Animals|anim|anim|||animals|||0|1000|382|389
SE|232||ab|1|relation|2|1|C0005398|Cholestasis, Extrahepatic|dsyn|dsyn|||extrahepatic cholestasis|||0|861|416|440|PREP|PROCESS_OF||390|394|11|1|C0003062|Animals|anim|anim|||animals|||0|1000|382|389
SE|232||ab|1|relation|4|1|C0003460|Anuria|dsyn|dsyn|||anuria|||0|888|370|376|PREP|PROCESS_OF||353|357|9|1|C0034493|Oryctolagus cuniculus|mamm|mamm|||rabbits|||0|1000|345|352
SE|232||ab|1|relation|6|1|C0005398|Cholestasis, Extrahepatic|dsyn|dsyn|||extrahepatic cholestasis|||0|901|319|343|PREP|PROCESS_OF||302|306|7|1|C0034493|Oryctolagus cuniculus|mamm|mamm|||rabbits|||0|1000|294|301

SE|232||ab|2|text|465|685|Serum GGT was essentially increased in rabbits with obstructive extrahepatic cholestasis, showing peak values in the combined cholestasis + obstructive anuria group, and practically normal values in animals with anuria.
SE|232||ab|2|entity|C0229671|Serum|bdsu|||Serum|||0|916|465|470
SE|232||ab|2|entity|C0017040|Gamma-glutamyl transferase|aapp,enzy|||GGT|||0|916|471|474
SE|232||ab|2|entity|C0034493|Oryctolagus cuniculus|mamm|||rabbits|||0|1000|504|511
SE|232||ab|2|entity|C0549186|Obstructed|ftcn|||obstructive|||0|901|517|528
SE|232||ab|2|entity|C0005398|Cholestasis, Extrahepatic|dsyn|||extrahepatic cholestasis|||0|901|529|553
SE|232||ab|2|entity|C0042295|Values|qlco|||values|||0|861|568|574
SE|232||ab|2|entity|C0205195|Combined|qlco|||combined|||0|822|582|590
SE|232||ab|2|entity|C0008370|Cholestasis|dsyn|||cholestasis|||0|822|591|602
SE|232||ab|2|entity|C0549186|Obstructed|ftcn|||obstructive|||0|822|605|616
SE|232||ab|2|entity|C0003460|Anuria|dsyn|||anuria|||0|822|617|623
SE|232||ab|2|entity|C0441833|Groups|inpr|||group|||0|822|624|629
SE|232||ab|2|entity|C0086715|Normal Range|qnco|||normal values|||0|901|647|660
SE|232||ab|2|entity|C0003062|Animals|anim|||animals|||0|1000|664|671
SE|232||ab|2|entity|C0003460|Anuria|dsyn|||anuria|||0|1000|677|683
SE|232||ab|2|relation|0|0|C0229671|Serum|bdsu|bdsu|||Serum|||0|916|465|470|MOD/HEAD|LOCATION_OF||465|474|0|0|C0017040|Gamma-glutamyl transferase|aapp,gngm,enzy|aapp|||GGT|||0|916|471|474
SE|232||ab|2|relation|1|1|C0003460|Anuria|dsyn|dsyn|||anuria|||0|1000|677|683|PREP|PROCESS_OF||672|676|7|1|C0003062|Animals|anim|anim|||animals|||0|1000|664|671
SE|232||ab|2|relation|6|1|C0005398|Cholestasis, Extrahepatic|dsyn|dsyn|||extrahepatic cholestasis|||0|901|529|553|PREP|PROCESS_OF||512|516|2|1|C0034493|Oryctolagus cuniculus|mamm|mamm|||rabbits|||0|1000|504|511
SE|232||ab|2|relation|7|1|C0034493|Oryctolagus cuniculus|mamm|mamm|||rabbits|||0|1000|504|511|PREP|LOCATION_OF||501|503|1|1|C0017040|Gamma-glutamyl transferase|aapp,gngm,enzy|aapp|||GGT|||0|916|471|474

SE|232||ab|3|text|685|847|Liver GGT was increased in both cholestasis groups, but the increase was less prominent than the increase in serum GGT and there was no correlation between them.
SE|232||ab|3|entity|C0023884|Liver|bpoc|||Liver|||0|916|685|690
SE|232||ab|3|entity|C0017040|Gamma-glutamyl transferase|aapp,enzy|||GGT|||0|916|691|694
SE|232||ab|3|entity|C0008370|Cholestasis|dsyn|||cholestasis|||0|888|717|728
SE|232||ab|3|entity|C0441833|Groups|inpr|||groups|||0|888|729|735
SE|232||ab|3|entity|C0442805|Increase|ftcn|||increase|||0|1000|745|753
SE|232||ab|3|entity|C0205402|Prominent|qlco|||prominent|||0|861|763|772
SE|232||ab|3|entity|C0442805|Increase|ftcn|||increase|||0|1000|782|790
SE|232||ab|3|entity|C0229671|Serum|bdsu|||serum|||0|916|794|799
SE|232||ab|3|entity|C0017040|Gamma-glutamyl transferase|aapp,enzy|||GGT|||0|916|800|803
SE|232||ab|3|relation|0|0|C0017040|Gamma-glutamyl transferase|aapp,gngm,enzy|aapp|||GGT|||0|916|691|694|MOD/HEAD|PART_OF||685|694|0|0|C0023884|Liver|bpoc|bpoc|||Liver|||0|916|685|690
SE|232||ab|3|relation|0|0|C0229671|Serum|bdsu|bdsu|||serum|||0|916|794|799|MOD/HEAD|LOCATION_OF||794|803|0|0|C0017040|Gamma-glutamyl transferase|aapp,gngm,enzy|aapp|||GGT|||0|916|800|803

SE|232||ab|4|text|847|1008|In both anuric groups renal GGT was reduced, probably as a result of inhibited enzyme synthesis secondary to the altered conditions for adequate renal function.
SE|232||ab|4|entity|C0003460|Anuria|dsyn|||anuric|||0|833|855|861
SE|232||ab|4|entity|C0441833|Groups|inpr|||groups|||0|833|862|868
SE|232||ab|4|entity|C0022646|Kidney|bpoc|||renal|||0|833|869|874
SE|232||ab|4|entity|C0017040|Gamma-glutamyl transferase|aapp,enzy|||GGT|||0|833|875|878
SE|232||ab|4|entity|C0332148|Probable diagnosis|qlco|||probably|||0|1000|892|900
SE|232||ab|4|entity|C0311403|Inhibited|qlco|||inhibited|||0|851|916|925
SE|232||ab|4|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|851|926|932
SE|232||ab|4|entity|C0869032|Synthesis|phpr|||synthesis|||0|851|933|942
SE|232||ab|4|entity|C1522484|metastatic qualifier|qnco|||secondary|||0|1000|943|952
SE|232||ab|4|entity|C0205349|Altered|ftcn|||altered|||0|872|960|967
SE|232||ab|4|entity|C0348080|Condition|qlco|||conditions|||0|872|968|978
SE|232||ab|4|entity|C0205411|Adequate|qlco|||adequate|||0|901|983|991
SE|232||ab|4|entity|C0232804|Renal function|ortf|||renal function|||0|901|992|1006
SE|232||ab|4|relation|0|0|C0017040|Gamma-glutamyl transferase|aapp,gngm,enzy|aapp|||GGT|||0|833|875|878|MOD/HEAD|PART_OF||869|878|0|0|C0022646|Kidney|bpoc|bpoc|||renal|||0|833|869|874

SE|232||ab|5|text|1008|1125|The results obtained are suggestive of a probable renal involvement in the formation of the serum GGT activity level.
SE|232||ab|5|entity|C1274040|result|ftcn|||results|||0|966|1012|1019
SE|232||ab|5|entity|C0022646|Kidney|bpoc|||renal|||0|660|1058|1063
SE|232||ab|5|entity|C1522492|Formation|ftcn|||formation|||0|1000|1083|1092
SE|232||ab|5|entity|C0229671|Serum|bdsu|||serum|||0|864|1100|1105
SE|232||ab|5|entity|C0017040|Gamma-glutamyl transferase|aapp,enzy|||GGT|||0|864|1106|1109
SE|232||ab|5|entity|C0683317|activity level|fndg|||activity level|||0|864|1110|1124


SE|233||ti|1|text|16|115|Studies on the mechanism of the changes in serum and liver gamma-glutamyl transpeptidase activity.
SE|233||ti|1|entity|C0008972|Clinical Research|resa|||Studies|||0|966|16|23
SE|233||ti|1|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|1000|31|40
SE|233||ti|1|entity|C0229671|Serum|bdsu|||serum|||0|1000|59|64
SE|233||ti|1|entity|C0023884|Liver|bpoc|||liver|||0|875|69|74
SE|233||ti|1|entity|C0017040|Gamma-glutamyl transferase|aapp,enzy|||gamma-glutamyl transpeptidase|||0|875|75|104
SE|233||ti|1|relation|0|0|C0017040|Gamma-glutamyl transferase|aapp,gngm,enzy|aapp|||gamma-glutamyl transpeptidase|||0|875|75|104|MOD/HEAD|PART_OF||69|104|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|875|69|74

SE|233||ti|2|text|115|119|II.

SE|233||ti|3|text|119|172|Experimental hexachlorobenzene porphyria in rabbits.
SE|233||ti|3|entity|C1517004|Experimental|ftcn|||Experimental|||0|851|119|131
SE|233||ti|3|entity|C0019432|Hexachlorobenzene|hops,orch|||hexachlorobenzene|||0|851|132|149
SE|233||ti|3|entity|C0032708|Porphyrias|dsyn|||porphyria|||0|851|150|159
SE|233||ti|3|entity|C0034493|Oryctolagus cuniculus|mamm|||rabbits|||0|1000|163|170
SE|233||ti|3|relation|1|1|C0032708|Porphyrias|dsyn|dsyn|||porphyria|||0|851|150|159|PREP|PROCESS_OF||160|162|1|1|C0034493|Oryctolagus cuniculus|mamm|mamm|||rabbits|||0|1000|163|170

SE|233||ab|1|text|178|368|The mechanism responsible for the changes in serum and liver gamma-glutamyl transpeptidase (gamma-GT) activity was studied in a model of experimental hexachlorobenzene porphyria in rabbits.
SE|233||ab|1|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|1000|182|191
SE|233||ab|1|entity|C0229671|Serum|bdsu|||serum|||0|1000|223|228
SE|233||ab|1|entity|C0023884|Liver|bpoc|||liver|||0|875|233|238
SE|233||ab|1|entity|C0017040|Gamma-glutamyl transferase|aapp,enzy|||gamma-glutamyl transpeptidase|||0|875|239|268
SE|233||ab|1|entity|C0026336|Study models|inpr,resd|||model|||0|1000|306|311
SE|233||ab|1|entity|C1517004|Experimental|ftcn|||experimental|||0|851|315|327
SE|233||ab|1|entity|C0019432|Hexachlorobenzene|hops,orch|||hexachlorobenzene|||0|851|328|345
SE|233||ab|1|entity|C0032708|Porphyrias|dsyn|||porphyria|||0|851|346|355
SE|233||ab|1|entity|C0034493|Oryctolagus cuniculus|mamm|||rabbits|||0|1000|359|366
SE|233||ab|1|relation|0|0|C0017040|Gamma-glutamyl transferase|aapp,gngm,enzy|aapp|||gamma-glutamyl transpeptidase|||0|875|239|268|MOD/HEAD|PART_OF||233|268|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|875|233|238
SE|233||ab|1|relation|7|1|C0032708|Porphyrias|dsyn|dsyn|||porphyria|||0|851|346|355|PREP|PROCESS_OF||356|358|1|1|C0034493|Oryctolagus cuniculus|mamm|mamm|||rabbits|||0|1000|359|366

SE|233||ab|2|text|368|537|Porphyria followed the administration of hexachlorobenzene in doses of 280 mumol - kg-1 body weight, which were given daily through a gastric tube over a 20-day period.
SE|233||ab|2|entity|C0032708|Porphyrias|dsyn|||Porphyria|||0|1000|368|377
SE|233||ab|2|entity|C0019432|Hexachlorobenzene|hops,orch|||hexachlorobenzene|||0|1000|409|426
SE|233||ab|2|entity|C1446466|Dose|qnco|||doses|||0|1000|430|435
SE|233||ab|2|entity|C1508277|KG BODY WEIGHT|orga|||kg-1 body weight|||0|867|451|467
SE|233||ab|2|entity|C0332173|Daily|tmco|||daily|||0|1000|486|491
SE|233||ab|2|entity|C1546658|Tube, Gastric|inpr|||gastric tube|||0|1000|502|514
SE|233||ab|2|entity|C0205136|Over|spco|||over|||0|1000|515|519
SE|233||ab|2|entity|C0439228|day|tmco|||day|||0|790|525|528
SE|233||ab|2|entity|C0439531|/period|tmco|||period|||0|790|529|535

SE|233||ab|3|text|537|839|Serum gamma-GT activity and the activities of the lysosomal enzymes beta-N-acetylglucosaminidase and alpha-mannosidase were increased, whereas L-aspartate: 2-oxoglutarate aminotransferase and L-alanine: 2-oxoglutarate aminotransferase and L-alanine: 2-oxoglutarate aminotransferase remained unaltered.
SE|233||ab|3|entity|C0229671|Serum|bdsu|||Serum|||0|875|537|542
SE|233||ab|3|entity|C0017040|Gamma-glutamyl transferase|aapp,enzy|||gamma-GT|||0|875|543|551
SE|233||ab|3|entity|C0441655|Activities|acty|||activities|||0|1000|569|579
SE|233||ab|3|entity|C0391845|Lysosomal enzyme|aapp,enzy|||lysosomal enzymes|||0|893|587|604
SE|233||ab|3|entity|C0001057|Beta-N-Acetylglucosaminidase|aapp,enzy|||beta-N-acetylglucosaminidase|||0|893|605|633
SE|233||ab|3|entity|C0051350|Alpha-mannosidase|aapp,enzy|||alpha-mannosidase|||0|1000|638|655
SE|233||ab|3|entity|C0085845|Aspartate|aapp,bacs|||L-aspartate|||0|1000|680|691
SE|233||ab|3|entity|C1291208|2-Oxoglutarate|orch,phsu|||2-oxoglutarate|||0|901|693|707
SE|233||ab|3|entity|C0002594|Transaminases|aapp,enzy|||aminotransferase|||0|901|708|724
SE|233||ab|3|entity|C0001898|Alanine|aapp,bacs|||L-alanine|||0|1000|729|738
SE|233||ab|3|entity|C1291208|2-Oxoglutarate|orch,phsu|||2-oxoglutarate|||0|901|740|754
SE|233||ab|3|entity|C0002594|Transaminases|aapp,enzy|||aminotransferase|||0|901|755|771
SE|233||ab|3|entity|C0001898|Alanine|aapp,bacs|||L-alanine|||0|1000|776|785
SE|233||ab|3|entity|C1291208|2-Oxoglutarate|orch,phsu|||2-oxoglutarate|||0|901|787|801
SE|233||ab|3|entity|C0002594|Transaminases|aapp,enzy|||aminotransferase|||0|901|802|818
SE|233||ab|3|relation|0|0|C0229671|Serum|bdsu|bdsu|||Serum|||0|875|537|542|MOD/HEAD|LOCATION_OF||537|551|0|0|C0017040|Gamma-glutamyl transferase|aapp,gngm,enzy|aapp|||gamma-GT|||0|875|543|551

SE|233||ab|4|text|839|1014|There was a considerable increase in liver microsomal protein, gamma-GT, cytochrome P-450, anilinehydroxylase, aminopyrine-demethylase and delta-aminolevulinic acid synthase.
SE|233||ab|4|entity|C0442805|Increase|ftcn|||increase|||0|861|864|872
SE|233||ab|4|entity|C0026030|Microsomes, Liver|celc|||liver microsomal|||0|877|876|892
SE|233||ab|4|entity|C0033684|Proteins|aapp,bacs|||protein|||0|877|893|900
SE|233||ab|4|entity|C0017040|Gamma-glutamyl transferase|aapp,enzy|||gamma-GT|||0|1000|902|910
SE|233||ab|4|entity|C0010762|Cytochrome P450|aapp,enzy|||cytochrome P-450|||0|1000|912|928
SE|233||ab|4|entity|C0002586|Aminopyrine|orch,phsu|||aminopyrine|||0|694|950|961
SE|233||ab|4|entity|C0002563|Aminolevulinic Acid|aapp,bacs,phsu|||delta-aminolevulinic acid|||0|756|978|1003
SE|233||ab|4|relation|6|2|C0017040|Gamma-glutamyl transferase|aapp,gngm,enzy|aapp|||gamma-GT|||0|1000|902|910|NOM|AUGMENTS||864|872|6|1|C0026030|Microsomes, Liver|celc|celc|||liver microsomal|||0|877|876|892

SE|233||ab|5|text|1014|1132|In the liver gamma-GT was detected in the microsomes as well as in the cytoplasm where enzymatic activity was higher.
SE|233||ab|5|entity|C0023884|Liver|bpoc|||liver|||0|916|1021|1026
SE|233||ab|5|entity|C0017040|Gamma-glutamyl transferase|aapp,enzy|||gamma-GT|||0|916|1027|1035
SE|233||ab|5|entity|C0026029|Microsomes|celc|||microsomes|||0|1000|1056|1066
SE|233||ab|5|entity|C0010834|Cytoplasm|celc|||cytoplasm|||0|801|1085|1094
SE|233||ab|5|entity|C0243102|enzyme activity|moft|||enzymatic activity|||0|801|1101|1119
SE|233||ab|5|entity|C0205250|High|qlco|||higher|||0|966|1124|1130
SE|233||ab|5|relation|0|0|C0017040|Gamma-glutamyl transferase|aapp,gngm,enzy|aapp|||gamma-GT|||0|916|1027|1035|MOD/HEAD|PART_OF||1021|1035|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|916|1021|1026
SE|233||ab|5|relation|3|1|C0026029|Microsomes|celc|celc|||microsomes|||0|1000|1056|1066|PREP|LOCATION_OF||1049|1051|1|1|C0017040|Gamma-glutamyl transferase|aapp,gngm,enzy|aapp|||gamma-GT|||0|916|1027|1035

SE|233||ab|6|text|1132|1316|The high correlation coefficient between liver gamma-GT, cytochrome P-450 and delta-aminolevulinic acid synthase witnesses a hexachlorobenzene-induced gamma-GT formation in the liver.
SE|233||ab|6|entity|C0205250|High|qlco|||high|||0|802|1136|1140
SE|233||ab|6|entity|C1547015|*Coefficient|qnco|||coefficient|||0|802|1153|1164
SE|233||ab|6|entity|C0023884|Liver|bpoc|||liver|||0|916|1173|1178
SE|233||ab|6|entity|C0017040|Gamma-glutamyl transferase|aapp,enzy|||gamma-GT|||0|916|1179|1187
SE|233||ab|6|entity|C0010762|Cytochrome P450|aapp,enzy|||cytochrome P-450|||0|1000|1189|1205
SE|233||ab|6|entity|C0002563|Aminolevulinic Acid|aapp,bacs,phsu|||delta-aminolevulinic acid|||0|756|1210|1235
SE|233||ab|6|entity|C0019432|Hexachlorobenzene|hops,orch|||hexachlorobenzene|||0|851|1257|1274
SE|233||ab|6|entity|C0205263|Induced|ftcn|||induced|||0|851|1275|1282
SE|233||ab|6|entity|C0017040|Gamma-glutamyl transferase|aapp,enzy|||gamma-GT|||0|851|1283|1291
SE|233||ab|6|entity|C1522492|Formation|ftcn|||formation|||0|851|1292|1301
SE|233||ab|6|entity|C0023884|Liver|bpoc|||liver|||0|1000|1309|1314
SE|233||ab|6|relation|0|0|C0017040|Gamma-glutamyl transferase|aapp,gngm,enzy|aapp|||gamma-GT|||0|916|1179|1187|MOD/HEAD|PART_OF||1173|1187|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|916|1173|1178
SE|233||ab|6|relation|1|1|C0023884|Liver|bpoc|bpoc|||liver|||0|1000|1309|1314|PREP|LOCATION_OF||1302|1304|5|1|C0017040|Gamma-glutamyl transferase|aapp,gngm,enzy|aapp|||gamma-GT|||0|851|1283|1291
SE|233||ab|6|relation|4|0|C0019432|Hexachlorobenzene|hops,orch|hops|||hexachlorobenzene|||0|851|1257|1274|ADJ|STIMULATES||1275|1282|4|0|C0017040|Gamma-glutamyl transferase|aapp,gngm,enzy|gngm|||gamma-GT|||0|851|1283|1291

SE|233||ab|7|text|1316|1414|A statistically significant correlation between serum and liver gamma-GT activity was also found.
SE|233||ab|7|entity|C1514961|Statistically Significant|qnco|||statistically significant|||0|734|1318|1343
SE|233||ab|7|entity|C0229671|Serum|bdsu|||serum|||0|1000|1364|1369
SE|233||ab|7|entity|C0023884|Liver|bpoc|||liver|||0|875|1374|1379
SE|233||ab|7|entity|C0017040|Gamma-glutamyl transferase|aapp,enzy|||gamma-GT|||0|875|1380|1388
SE|233||ab|7|relation|0|0|C0017040|Gamma-glutamyl transferase|aapp,gngm,enzy|aapp|||gamma-GT|||0|875|1380|1388|MOD/HEAD|PART_OF||1374|1388|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|875|1374|1379

SE|233||ab|8|text|1414|1544|These data strongly suggest that the increase in serum gamma-GT activity may result from the induction of the enzyme in the liver.
SE|233||ab|8|entity|C1511726|Data|idcn|||data|||0|1000|1420|1424
SE|233||ab|8|entity|C0442805|Increase|ftcn|||increase|||0|1000|1451|1459
SE|233||ab|8|entity|C0229671|Serum|bdsu|||serum|||0|875|1463|1468
SE|233||ab|8|entity|C0017040|Gamma-glutamyl transferase|aapp,enzy|||gamma-GT|||0|875|1469|1477
SE|233||ab|8|entity|C0857127|Induction|topp|||induction|||0|1000|1507|1516
SE|233||ab|8|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|1524|1530
SE|233||ab|8|entity|C0023884|Liver|bpoc|||liver|||0|1000|1538|1543
SE|233||ab|8|relation|0|0|C0229671|Serum|bdsu|bdsu|||serum|||0|875|1463|1468|MOD/HEAD|LOCATION_OF||1463|1477|0|0|C0017040|Gamma-glutamyl transferase|aapp,gngm,enzy|aapp|||gamma-GT|||0|875|1469|1477
SE|233||ab|8|relation|1|1|C0023884|Liver|bpoc|bpoc|||liver|||0|1000|1538|1543|PREP|LOCATION_OF||1531|1533|5|1|C0014442|Enzymes|enzy,orch|orch|||enzyme|||0|1000|1524|1530
SE|233||ab|8|relation|3|1|C0017040|Gamma-glutamyl transferase|aapp,gngm,enzy|aapp|||gamma-GT|||0|875|1469|1477|NOM|STIMULATES||1507|1516|2|1|C0014442|Enzymes|enzy,orch|enzy|||enzyme|||0|1000|1524|1530


SE|234||ti|1|text|16|110|Changes in erythrocyte 2,3 diphosphoglycerate in women following short term maximal exercise.
SE|234||ti|1|entity|C0014792|Erythrocytes|cell|||erythrocyte|||0|861|27|38
SE|234||ti|1|entity|C0178597|diphosphoglycerate|carb|||diphosphoglycerate|||0|888|43|61
SE|234||ti|1|entity|C0043210|Woman|popg|||women|||0|1000|65|70
SE|234||ti|1|entity|C0443303|Short-term|tmco|||short term|||0|861|81|91
SE|234||ti|1|entity|C0205289|Maximal|qlco|||maximal|||0|861|92|99
SE|234||ti|1|entity|C0015259|Exercise|dora|||exercise|||0|861|100|108
SE|234||ti|1|relation|2|1|C0043210|Woman|popg,humn|humn|||women|||0|1000|65|70|PREP|LOCATION_OF||62|64|2|1|C0178597|diphosphoglycerate|carb|carb|||diphosphoglycerate|||0|888|43|61

SE|234||ab|1|text|116|264|15 untrained women were subjected to a walking treadmill test to determine the influence of maximal exercise upon synthesis of erythrocyte 2,3 DPG.
SE|234||ab|1|entity|C0043210|Woman|popg|||women|||0|827|129|134
SE|234||ab|1|entity|C0080331|Walking|dora|||walking|||0|901|155|162
SE|234||ab|1|entity|C0087110|Treadmill Test|diap|||treadmill test|||0|901|163|177
SE|234||ab|1|entity|C0205289|Maximal|qlco|||maximal|||0|888|208|215
SE|234||ab|1|entity|C0015259|Exercise|dora|||exercise|||0|888|216|224
SE|234||ab|1|entity|C0869032|Synthesis|phpr|||synthesis|||0|1000|230|239
SE|234||ab|1|entity|C0014792|Erythrocytes|cell|||erythrocyte|||0|861|243|254

SE|234||ab|2|text|264|546|Although there was a 9.8% increase in the 2,3 DPG content following exercise, there was a concomitant 9.4% increase in the hemoglobin level; therefore, when 2,3 DPG is expressed as a ratio to hemoglobin (See Article), there was no significant change as a result of exercise stress.
SE|234||ab|2|entity|C0442805|Increase|ftcn|||increase|||0|827|290|298
SE|234||ab|2|entity|C0015259|Exercise|dora|||exercise|||0|1000|332|340
SE|234||ab|2|entity|C1516780|Concomitant|qlco|||concomitant|||0|791|354|365
SE|234||ab|2|entity|C0442805|Increase|ftcn|||increase|||0|791|371|379
SE|234||ab|2|entity|C0019029|Hemoglobin concentration result|lbtr|||hemoglobin level|||0|1000|387|403
SE|234||ab|2|entity|C0456603|Ratio|inpr|||ratio|||0|1000|447|452
SE|234||ab|2|entity|C0019046|Hemoglobin|aapp,bacs|||hemoglobin|||0|1000|456|466
SE|234||ab|2|entity|C0750502|Significant|idcn|||significant|||0|888|495|506
SE|234||ab|2|entity|C0015259|Exercise|dora|||exercise|||0|888|529|537
SE|234||ab|2|entity|C0038435|Stress|fndg|||stress|||0|888|538|544

SE|234||ab|3|text|546|760|It was suggested that three additive factors produced during strenuous exercise; decreased pH; increased hemoglobin concentration; and increased CO2 production result in by-product inhibition of 2,3 DPG synthesis.
SE|234||ab|3|entity|C0205449|Three|qnco|||three|||0|840|568|573
SE|234||ab|3|entity|C0442796|Additive|qlco|||additive|||0|840|574|582
SE|234||ab|3|entity|C1521761|Factor|ftcn|||factors|||0|840|583|590
SE|234||ab|3|entity|C1514989|Strenuous Exercise|dora|||strenuous exercise|||0|1000|607|625
SE|234||ab|3|entity|C0205216|Decreased|qnco|||decreased|||0|888|627|636
SE|234||ab|3|entity|C0549448|Hemoglobin increased|lbtr|||increased hemoglobin|||0|901|641|661
SE|234||ab|3|entity|C0205217|Increased|qnco|||increased|||0|833|681|690
SE|234||ab|3|entity|C0007012|Carbon Dioxide|bacs,inch|||CO2|||0|833|691|694
SE|234||ab|3|entity|C0033268|production|ocac|||production|||0|833|695|705
SE|234||ab|3|entity|C1274040|result|ftcn|||result|||0|833|706|712
SE|234||ab|3|entity|C1514468|product|qnco|||product|||0|790|719|726
SE|234||ab|3|entity|C0869032|Synthesis|phpr|||synthesis|||0|802|749|758

SE|234||ab|4|text|760|889|It is concluded that 2,3 DPG does not provide a physiologic benefit in the adaptation of the oxygen transport system to exercise.
SE|234||ab|4|entity|C1518422|Not|ftcn|||not|||0|1000|794|797
SE|234||ab|4|entity|C0205463|Physiological|ftcn|||physiologic|||0|872|808|819
SE|234||ab|4|entity|C0814225|Benefits|qnco|||benefit|||0|872|820|827
SE|234||ab|4|entity|C0000934|Acclimatization|orgf|||adaptation|||0|1000|835|845
SE|234||ab|4|entity|C0597157|oxygen transport|ortf|||oxygen transport|||0|901|853|869
SE|234||ab|4|entity|C0449913|System|ftcn|||system|||0|901|870|876


SE|242||ti|1|text|16|101|Formation of fertilization acid by sea urchin eggs does not require specific cations.
SE|242||ti|1|entity|C1522492|Formation|ftcn|||Formation|||0|1000|16|25
SE|242||ti|1|entity|C0015914|Fertilization|orgf|||fertilization|||0|888|29|42
SE|242||ti|1|entity|C0001128|Acids|chem|||acid|||0|888|43|47
SE|242||ti|1|entity|C0036488|Sea Urchins|invt|||sea urchin|||0|901|51|61
SE|242||ti|1|entity|C0013710|Egg Food Product|food|||eggs|||0|901|62|66
SE|242||ti|1|entity|C1518422|Not|ftcn|||not|||0|1000|72|75
SE|242||ti|1|entity|C0007447|Cations|chvs|||cations|||0|861|93|100


SE|243||ti|1|text|16|82|Primary culture of parenchymal liver cells on collagen membranes.
SE|243||ti|1|entity|C0220814|Cultural|ftcn|||culture|||0|888|24|31
SE|243||ti|1|entity|C0023884|Liver|bpoc|||liver|||0|890|47|52
SE|243||ti|1|entity|C0682552|parenchymal cell|cell|||parenchymal liver cells|||0|890|35|58
SE|243||ti|1|entity|C0009325|Collagen|aapp,bacs,bodm|||collagen|||0|888|62|70
SE|243||ti|1|entity|C0025255|Tissue membrane|tisu|||membranes|||0|888|71|80
SE|243||ti|1|relation|0|0|C0682552|parenchymal cell|cell|cell|||parenchymal liver cells|||0|890|35|58|MOD/HEAD|PART_OF||47|58|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|890|47|52

SE|243||ti|2|text|82|125|Morphological and biochemical observations.
SE|243||ti|2|entity|C0543482|morphological|spco|||Morphological|||0|1000|82|95
SE|243||ti|2|entity|C0428132|Biochemical finding|lbtr|||biochemical observations|||0|983|100|124


SE|244||ti|1|text|16|109|Cell transformation in isolated striated muscle of hydromedusae independent of DNA synthesis.
SE|244||ti|1|entity|C0040682|cell transformation|celf|||Cell transformation|||0|1000|16|35
SE|244||ti|1|entity|C0205409|Isolated|ftcn|||isolated|||0|901|39|47
SE|244||ti|1|entity|C1331262|Muscle, Striated|tisu|||striated muscle|||0|901|48|63
SE|244||ti|1|entity|C1022743|Hydromedusa|rept|||hydromedusae|||0|966|67|79
SE|244||ti|1|entity|C0598312|DNA biosynthesis|genf|||DNA synthesis|||0|1000|95|108
SE|244||ti|1|relation|2|1|C1331262|Muscle, Striated|tisu|tisu|||striated muscle|||0|901|48|63|PREP|PART_OF||64|66|2|1|C1022743|Hydromedusa|rept|rept|||hydromedusae|||0|966|67|79


SE|245||ti|1|text|16|137|Induction of DNA synthesis by dichloroisoproterenol without initial rise of the cAMP level in the parotid gland of mouse.
SE|245||ti|1|entity|C0857127|Induction|topp|||Induction|||0|1000|16|25
SE|245||ti|1|entity|C0598312|DNA biosynthesis|genf|||DNA synthesis|||0|1000|29|42
SE|245||ti|1|entity|C0012075|dichloroisoproterenol|orch,phsu|||dichloroisoproterenol|||0|1000|46|67
SE|245||ti|1|entity|C0205265|Initially|tmco|||initial|||0|694|76|83
SE|245||ti|1|entity|||gngm|820|CAMP|cAMP|||0|1000|96|100
SE|245||ti|1|entity|C0030580|Parotid Gland|bpoc|||parotid gland|||0|1000|114|127
SE|245||ti|1|entity|C0025914|House mice|mamm|||mouse|||0|1000|131|136
SE|245||ti|1|relation|2|1|C0030580|Parotid Gland|bpoc|bpoc|||parotid gland|||0|1000|114|127|PREP|LOCATION_OF||107|109|5|1|||gngm,aapp|aapp|820|CAMP|cAMP|||0|1000|96|100
SE|245||ti|1|relation|6|1|C0030580|Parotid Gland|bpoc|bpoc|||parotid gland|||0|1000|114|127|PREP|PART_OF||128|130|1|1|C0025914|House mice|mamm|mamm|||mouse|||0|1000|131|136
SE|245||ti|1|relation|6|2|C0012075|dichloroisoproterenol|orch,phsu|orch|||dichloroisoproterenol|||0|1000|46|67|NOM|AUGMENTS||16|25|6|1|C0598312|DNA biosynthesis|genf|genf|||DNA synthesis|||0|1000|29|42


SE|246||ti|1|text|16|117|Cell density-dependent stimulation of glutamine synthetase activity in cultured mouse teratoma cells.
SE|246||ti|1|entity|C0162339|Cell Density|qnco|||Cell density|||0|861|16|28
SE|246||ti|1|entity|C1150667|glutamate-ammonia ligase activity|moft|||glutamine synthetase activity|||0|1000|54|83
SE|246||ti|1|entity|C0025914|House mice|mamm|||mouse|||0|861|96|101
SE|246||ti|1|entity|C0039538|Teratoma|neop|||teratoma|||0|861|102|110
SE|246||ti|1|entity|C0007585|Cell Culture Techniques|lbpr|||cultured mouse teratoma cells|||0|861|87|116


SE|247||ti|1|text|16|94|Polyadenylation of nascent RNA during the embryogenesis of Ilyanassa obsoleta.
SE|247||ti|1|entity|C0949765|Polyadenylation|moft|||Polyadenylation|||0|1000|16|31
SE|247||ti|1|entity|C0035668|RNA|bacs,nnon|||RNA|||0|861|43|46
SE|247||ti|1|entity|C0013936|Embryonic Development|ortf|||embryogenesis|||0|1000|58|71
SE|247||ti|1|entity|C0324003|Nassarius obsoletus|invt|||Ilyanassa obsoleta|||0|1000|75|93


SE|248||ti|1|text|16|116|The effect of environmental pH upon acid hydrolase activities of cultured human diploid fibroblasts.
SE|248||ti|1|entity|C1280500|Effect|qlco|||effect|||0|1000|20|26
SE|248||ti|1|entity|C0001128|Acids|chem|||acid|||0|890|52|56
SE|248||ti|1|entity|C1149632|hydrolase activity|moft|||hydrolase activities|||0|890|57|77
SE|248||ti|1|entity|C0010453|Anthropological Culture|idcn|||cultured|||0|815|81|89
SE|248||ti|1|entity|C0020114|Human|humn|||human|||0|815|90|95
SE|248||ti|1|entity|C0012568|Diploidy|orga|||diploid|||0|815|96|103
SE|248||ti|1|entity|C0016030|Fibroblasts|cell|||fibroblasts|||0|815|104|115


SE|249||ti|1|text|16|72|Enucleation of cells by density gradient centrifugation.
SE|249||ti|1|entity|C0014392|Enucleation procedure|topp|||Enucleation|||0|1000|16|27
SE|249||ti|1|entity|C0007634|Cells|cell|||cells|||0|1000|31|36
SE|249||ti|1|entity|C0007704|Centrifugation, Density Gradient|lbpr|||density gradient centrifugation|||0|1000|40|71
SE|249||ti|1|relation|1|1|C0007704|Centrifugation, Density Gradient|lbpr|lbpr|||density gradient centrifugation|||0|1000|40|71|PREP|METHOD_OF||37|39|2|2|C0014392|Enucleation procedure|topp|topp|||Enucleation|||0|1000|16|27


SE|252||ti|1|text|16|31|[Cryptorchism].
SE|252||ti|1|entity|C0010417|Cryptorchidism|cgab|||Cryptorchism|||0|1000|17|29


SE|253||ti|1|text|16|93|[Elements of scientific work organization in ambulance feldshers' functions].
SE|253||ti|1|entity|C0013879|Elements|elii|||Elements|||0|1000|17|25
SE|253||ti|1|entity|C0043227|Work|ocac|||work|||0|901|40|44
SE|253||ti|1|entity|C0920650|scientific organization|hcro|||scientific work organization|||0|901|29|57
SE|253||ti|1|entity|C0002422|Ambulances|mnob|||ambulance|||0|851|61|70
SE|253||ti|1|entity|C0015760|Feldshers|prog|||feldshers|||0|851|71|80
SE|253||ti|1|entity|C0542341|Function|ftcn|||functions|||0|851|82|91
SE|253||ti|1|relation|1|1|C0015760|Feldshers|prog,humn|humn|||feldshers|||0|851|71|80|PREP|LOCATION_OF||58|60|2|2|C0013879|Elements|elii|elii|||Elements|||0|1000|17|25


SE|254||ti|1|text|16|127|[Participation of feldshers and midwives in the secret and partisan activities during the great patriotic war].
SE|254||ti|1|entity|C0679823|participation|inbe|||Participation|||0|1000|17|30
SE|254||ti|1|entity|C0015760|Feldshers|prog|||feldshers|||0|1000|34|43
SE|254||ti|1|entity|C0026083|Midwife|prog|||midwives|||0|1000|48|56
SE|254||ti|1|entity|C0441655|Activities|acty|||activities|||0|861|84|94
SE|254||ti|1|entity|C1449759|World War I|acty|||great patriotic war|||0|913|106|125


SE|255||ti|1|text|16|113|[The organization of health education meetings, verbal reports, carnivals, reader's conferences].
SE|255||ti|1|entity|C0220885|organizational|qlco|||organization|||0|1000|21|33
SE|255||ti|1|entity|C0018701|Health education|hlca|||health education|||0|901|37|53
SE|255||ti|1|entity|C0556656|Meetings|hlca|||meetings|||0|901|54|62
SE|255||ti|1|entity|C0460109|Verbal report|inpr|||verbal reports|||0|983|64|78
SE|255||ti|1|entity|C1514743|Reader|prog|||reader's|||0|888|91|99
SE|255||ti|1|entity|C0086047|Conferences|hcpp|||conferences|||0|888|100|111


SE|256||ti|1|text|16|85|[Problems concerning the training of feldshers in foreign countries].
SE|256||ti|1|entity|C1546466|Problems|idcn|||Problems|||0|1000|17|25
SE|256||ti|1|entity|C0220931|Training|edac|||training|||0|1000|41|49
SE|256||ti|1|entity|C0015760|Feldshers|prog|||feldshers|||0|1000|53|62
SE|256||ti|1|entity|C0376327|International Aspects|idcn|||foreign|||0|888|66|73
SE|256||ti|1|entity|C0454664|Country|geoa|||countries|||0|888|74|83


SE|258||ti|1|text|16|87|Response to exogenous gonadotropins in the unresponsive ovary syndrome.
SE|258||ti|1|entity|C0871261|response|clna|||Response|||0|1000|16|24
SE|258||ti|1|entity|C0205228|Exogenous|ftcn|||exogenous|||0|888|28|37
SE|258||ti|1|entity|C0018061|Gonadotropins|aapp,horm,phsu|||gonadotropins|||0|888|38|51
SE|258||ti|1|entity|C0237284|Unresponsive|fndg|||unresponsive|||0|851|59|71
SE|258||ti|1|entity|C0029939|Ovary|bpoc|||ovary|||0|851|72|77
SE|258||ti|1|entity|C0039082|Syndrome|dsyn|||syndrome|||0|851|78|86
SE|258||ti|1|relation|0|0|C0029939|Ovary|bpoc|bpoc|||ovary|||0|851|72|77|MOD/HEAD|LOCATION_OF||72|86|0|0|C0039082|Syndrome|dsyn|dsyn|||syndrome|||0|851|78|86
SE|258||ti|1|relation|2|1|C0018061|Gonadotropins|aapp,gngm,horm,phsu|aapp|||gonadotropins|||0|888|38|51|PREP|ASSOCIATED_WITH||52|54|1|1|C0039082|Syndrome|dsyn|dsyn|||syndrome|||0|851|78|86


SE|259||ti|1|text|16|125|A comparative study of metal and plastic (Karman) cannulae for first trimester abortion by suction curettage.
SE|259||ti|1|entity|C0008972|Clinical Research|resa|||study|||0|861|30|35
SE|259||ti|1|entity|C0025552|Metals|inch|||metal|||0|1000|39|44
SE|259||ti|1|entity|C0032167|Plastics|sbst|||plastic|||0|1000|49|56
SE|259||ti|1|entity|C0520453|Cannula device|medd|||cannulae|||0|861|66|74
SE|259||ti|1|entity|C1279901|Firstly|qlco|||first|||0|802|79|84
SE|259||ti|1|entity|C0000811|Termination of pregnancy|topp|||abortion|||0|802|95|103
SE|259||ti|1|entity|C0042223|Vacuum Curettage|topp|||suction curettage|||0|1000|107|124
SE|259||ti|1|relation|1|1|C0042223|Vacuum Curettage|topp|topp|||suction curettage|||0|1000|107|124|PREP|METHOD_OF||104|106|5|1|C0000811|Termination of pregnancy|topp|topp|||abortion|||0|802|95|103
SE|259||ti|1|relation|2|1|C0000811|Termination of pregnancy|topp|topp|||abortion|||0|802|95|103|PREP|USES||75|78|4|1|C0520453|Cannula device|medd|medd|||cannulae|||0|861|66|74


SE|260||ti|1|text|16|68|Acute bacterial myositis following septic abortion.
SE|260||ti|1|entity|C0205178|acute|tmco|||Acute|||0|901|16|21
SE|260||ti|1|entity|C0263979|Purulent myositis|dsyn|||bacterial myositis|||0|901|22|40
SE|260||ti|1|entity|C0000817|Abortion, Septic|dsyn|||septic abortion|||0|1000|51|66
SE|260||ti|1|relation|1|1|C0000817|Abortion, Septic|dsyn|dsyn|||septic abortion|||0|1000|51|66|VERB|PRECEDES||41|50|1|1|C0263979|Purulent myositis|dsyn|dsyn|||bacterial myositis|||0|901|22|40

SE|260||ti|2|text|68|92|An unusual complication.
SE|260||ti|2|entity|C0009566|Complication|patf|||complication|||0|861|79|91


SE|261||ti|1|text|16|84|The binding of substrates and inhibitors to dihydrofolate reductase.
SE|261||ti|1|entity|C0243077|inhibitors|chvf|||inhibitors|||0|824|46|56
SE|261||ti|1|entity|C0039667|Dihydrofolate Reductase|aapp,enzy|||dihydrofolate reductase|||0|824|60|83


SE|262||ti|1|text|16|127|Euglena gracilis deoxyribonucleic acid polymerases: subcellular locations and variations during the cell cycle.
SE|262||ti|1|entity|C0015155|Euglena gracilis|alga,invt|||Euglena gracilis|||0|882|16|32
SE|262||ti|1|entity|C0012892|DNA-Directed DNA Polymerase|aapp,enzy|||deoxyribonucleic acid polymerases|||0|882|33|66
SE|262||ti|1|entity|C0450429|Location|spco|||locations|||0|861|80|89
SE|262||ti|1|entity|C0205419|Variant|qlco|||variations|||0|966|94|104
SE|262||ti|1|entity|C0007586|Cell Cycle|celf|||cell cycle|||0|1000|116|126
SE|262||ti|1|relation|0|0|C0012892|DNA-Directed DNA Polymerase|aapp,gngm,enzy|gngm|||deoxyribonucleic acid polymerases|||0|882|33|66|MOD/HEAD|PART_OF||16|66|0|0|C0015155|Euglena gracilis|alga,invt|alga|||Euglena gracilis|||0|882|16|32


SE|263||ti|1|text|16|55|Monomer complexes of polyadenylic acid.
SE|263||ti|1|entity|C0596973|monomer|chvs|||Monomer|||0|888|16|23
SE|263||ti|1|entity|C0439855|Complex|qlco|||complexes|||0|888|24|33
SE|263||ti|1|entity|C0085746|Adenine Polynucleotides|nnon|||polyadenylic acid|||0|966|37|54


SE|264||ti|1|text|16|94|5-Carbamoylmethyluridine: a new minor nucleoside of transfer ribonucleic acid.
SE|264||ti|1|entity|C0049092|5-carbamoylmethyluridine|nnon|||5-Carbamoylmethyluridine|||0|1000|16|40
SE|264||ti|1|entity|C0205314|New|tmco|||new|||0|851|44|47
SE|264||ti|1|entity|C0028621|Nucleosides|nnon|||nucleoside|||0|851|54|64
SE|264||ti|1|entity|C0035711|Transfer RNA|bacs,nnon|||transfer ribonucleic acid|||0|1000|68|93


SE|265||ti|1|text|16|89|The protective effects of cephaloridine on rat kidney lysosomes in vitro.
SE|265||ti|1|entity|C1280500|Effect|qlco|||effects|||0|844|31|38
SE|265||ti|1|entity|C0007727|Cephaloridine|antb,orch|||cephaloridine|||0|1000|42|55
SE|265||ti|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|851|59|62
SE|265||ti|1|entity|C0022646|Kidney|bpoc|||kidney|||0|851|63|69
SE|265||ti|1|entity|C0024369|Lysosomes|celc|||lysosomes|||0|851|70|79
SE|265||ti|1|entity|C1533691|in vitro|qlco|||in vitro|||0|1000|80|88
SE|265||ti|1|relation|0|0|C0024369|Lysosomes|celc|celc|||lysosomes|||0|851|70|79|MOD/HEAD|PART_OF||63|79|0|0|C0022646|Kidney|bpoc|bpoc|||kidney|||0|851|63|69
SE|265||ti|1|relation|3|1|C0007727|Cephaloridine|antb,orch|antb|||cephaloridine|||0|1000|42|55|NOM|AFFECTS||31|38|3|2|C0024369|Lysosomes|celc|celc|||lysosomes|||0|851|70|79


SE|266||ti|1|text|16|84|[In vitro studies on human ovarian contractility (author's transl)].
SE|266||ti|1|entity|C1533691|in vitro|qlco|||In vitro|||0|884|17|25
SE|266||ti|1|entity|C0008972|Clinical Research|resa|||studies|||0|884|26|33
SE|266||ti|1|entity|C0020114|Human|humn|||human|||0|818|37|42
SE|266||ti|1|entity|C0205065|Ovaro-|bpoc|||ovarian|||0|818|43|50
SE|266||ti|1|entity|C1140999|Contraction|patf|||contractility|||0|818|51|64
SE|266||ti|1|entity|C0221192|Author|idcn,prog|||author's|||0|694|66|74
SE|266||ti|1|relation|0|0|C0205065|Ovaro-|bpoc|bpoc|||ovarian|||0|818|43|50|MOD/HEAD|LOCATION_OF||43|64|0|0|C1140999|Contraction|patf|patf|||contractility|||0|818|51|64


SE|267||ti|1|text|16|77|[Studies on the energy for sperm motility (author's transl)].
SE|267||ti|1|entity|C0008972|Clinical Research|resa|||Studies|||0|966|17|24
SE|267||ti|1|entity|C0424589|Vitality|fndg|||energy|||0|1000|32|38
SE|267||ti|1|entity|C0037848|Sperm Motility|celf|||sperm motility|||0|1000|43|57
SE|267||ti|1|entity|C0221192|Author|idcn,prog|||author's|||0|694|59|67


SE|268||ti|1|text|16|108|Properties of urophysial proteins (urophysins) from the white sucker, Catostomus commersoni.
SE|268||ti|1|entity|C0871161|Property|qlco|||Properties|||0|966|16|26
SE|268||ti|1|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|861|41|49
SE|268||ti|1|entity|C0328264|Catostomus commersoni|fish|||white sucker|||0|1000|72|84
SE|268||ti|1|entity|C0328264|Catostomus commersoni|fish|||Catostomus commersoni|||0|1000|86|107


SE|269||ti|1|text|16|90|Glutamine synthetase in newborn mice homozygous for lethal albino alleles.
SE|269||ti|1|entity|C0017801|Glutamate-Ammonia Ligase|aapp,enzy|||Glutamine synthetase|||0|1000|16|36
SE|269||ti|1|entity|C0026809|Mus|mamm|||mice|||0|861|48|52
SE|269||ti|1|entity|C0001916|Albinism|cgab|||albino|||0|790|75|81
SE|269||ti|1|entity|C0002085|Alleles|gngm|||alleles|||0|790|82|89
SE|269||ti|1|relation|3|1|C0026809|Mus|mamm|mamm|||mice|||0|861|48|52|PREP|LOCATION_OF||37|39|1|1|C0017801|Glutamate-Ammonia Ligase|aapp,gngm,enzy|aapp|||Glutamine synthetase|||0|1000|16|36


SE|272||ti|1|text|16|114|[Extrabronchial effects of Bronchodilat in patients with asthma and chronic asthmatic bronchitis].
SE|272||ti|1|entity|C1280500|Effect|qlco|||effects|||0|827|32|39
SE|272||ti|1|entity|C0604799|bronchodilat|orch,phsu|||Bronchodilat|||0|1000|43|55
SE|272||ti|1|entity|C0030705|Patients|podg|||patients|||0|1000|59|67
SE|272||ti|1|entity|C0004096|Asthma|dsyn|||asthma|||0|1000|73|79
SE|272||ti|1|entity|C0264348|Chronic asthmatic bronchitis|dsyn|||chronic asthmatic bronchitis|||0|1000|84|112
SE|272||ti|1|relation|0|0|C0604799|bronchodilat|orch,phsu|phsu|||Bronchodilat|||0|1000|43|55|INFER|TREATS(INFER)||56|58|0|0|C0004096|Asthma|dsyn|dsyn|||asthma|||0|1000|73|79
SE|272||ti|1|relation|0|0|C0604799|bronchodilat|orch,phsu|phsu|||Bronchodilat|||0|1000|43|55|INFER|TREATS(INFER)||56|58|0|0|C0264348|Chronic asthmatic bronchitis|dsyn|dsyn|||chronic asthmatic bronchitis|||0|1000|84|112
SE|272||ti|1|relation|2|1|C0004096|Asthma|dsyn|dsyn|||asthma|||0|1000|73|79|PREP|PROCESS_OF||68|72|3|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|59|67
SE|272||ti|1|relation|2|1|C0264348|Chronic asthmatic bronchitis|dsyn|dsyn|||chronic asthmatic bronchitis|||0|1000|84|112|PREP|PROCESS_OF||68|72|3|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|59|67
SE|272||ti|1|relation|2|1|C0604799|bronchodilat|orch,phsu|phsu|||Bronchodilat|||0|1000|43|55|PREP|TREATS||56|58|3|1|C0030705|Patients|podg,humn|podg|||patients|||0|1000|59|67


SE|275||ti|1|text|16|63|[Allogenic bone marrow transplantation in men].
SE|275||ti|1|entity|C0149615|Allogeneic bone marrow transplantation|topp|||Allogenic bone marrow transplantation|||0|1000|17|54
SE|275||ti|1|entity|C0025266|Male population group|popg|||men|||0|1000|58|61
SE|275||ti|1|relation|1|1|C0149615|Allogeneic bone marrow transplantation|topp|topp|||Allogenic bone marrow transplantation|||0|1000|17|54|PREP|TREATS||55|57|1|1|C0025266|Male population group|popg,humn|popg|||men|||0|1000|58|61


SE|25462151||ti|1|text|21|71|Big biological data: challenges and opportunities.
SE|25462151||ti|1|entity|C0549177|Large|qnco|||Big|||0|851|21|24
SE|25462151||ti|1|entity|C0205460|biological|ftcn|||biological|||0|851|25|35
SE|25462151||ti|1|entity|C1511726|Data|idcn|||data|||0|851|36|40


SE|25462181||ti|1|text|21|83|Toxocara canis-associated visceral larva migrans of the liver.
SE|25462181||ti|1|entity|C0344046|Visceral larva migrans syndrome|dsyn|||Toxocara canis-associated visceral larva migrans|||0|884|21|69
SE|25462181||ti|1|entity|C0023884|Liver|bpoc|||liver|||0|1000|77|82
SE|25462181||ti|1|relation|1|1|C0023884|Liver|bpoc|bpoc|||liver|||0|1000|77|82|PREP|LOCATION_OF||70|72|1|1|C0344046|Visceral larva migrans syndrome|dsyn|dsyn|||Toxocara canis-associated visceral larva migrans|||0|884|21|69


SE|25462182||ti|1|text|21|74|B-type natriuretic peptide in infective endocarditis.
SE|25462182||ti|1|entity|C0054015|Brain natriuretic peptide|aapp,horm,phsu|||B-type natriuretic peptide|||0|1000|21|47
SE|25462182||ti|1|entity|C0014121|Bacterial Endocarditis|dsyn|||infective endocarditis|||0|1000|51|73
SE|25462182||ti|1|relation|1|1|C0054015|Brain natriuretic peptide|aapp,gngm,horm,phsu|aapp|||B-type natriuretic peptide|||0|1000|21|47|PREP|ASSOCIATED_WITH||48|50|1|1|C0014121|Bacterial Endocarditis|dsyn|dsyn|||infective endocarditis|||0|1000|51|73


SE|25462321||ti|1|text|21|96|[Outbreak of hepatitis A in a preschool--fresh seroprevalence data needed].
SE|25462321||ti|1|entity|C0012652|Disease Outbreaks|phpr|||Outbreak|||0|1000|22|30
SE|25462321||ti|1|entity|C0019159|Hepatitis A|dsyn|||hepatitis A|||0|1000|34|45
SE|25462321||ti|1|entity|C0443224|Fresh|qlco|||fresh|||0|851|62|67
SE|25462321||ti|1|entity|C0600367|Seroprevalence|resa|||seroprevalence|||0|851|68|82
SE|25462321||ti|1|entity|C1511726|Data|idcn|||data|||0|851|83|87


SE|25462432||ti|1|text|21|130|Response to the Editor: "Fractional exhaled nitric oxide-guided algorithm for children with allergic asthma".
SE|25462432||ti|1|entity|C0871261|response|clna|||Response|||0|1000|21|29
SE|25462432||ti|1|entity|C1264633|Fraction of|qnco|||Fractional|||0|928|46|56
SE|25462432||ti|1|entity|C0028128|Nitric Oxide|bacs,inch|||nitric oxide|||0|850|65|77
SE|25462432||ti|1|entity|C0181090|Professional guide|prog|||guided|||0|850|78|84
SE|25462432||ti|1|entity|C0002045|algorithm|inpr|||algorithm|||0|850|85|94
SE|25462432||ti|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|99|107
SE|25462432||ti|1|entity|C0155877|Extrinsic asthma NOS|dsyn|||allergic asthma|||0|1000|113|128
SE|25462432||ti|1|relation|1|1|C0155877|Extrinsic asthma NOS|dsyn|dsyn|||allergic asthma|||0|1000|113|128|PREP|PROCESS_OF||108|112|5|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|99|107


